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ABSTRACT 
A series of studies in rural Gambia established first-in-human evidence that peri-
conceptional environment, including maternal methyl-donor nutritional status, predicts 
offspring DNA methylation. Methyl donor status is largely determined by the complex 
interlinking pathways of one-carbon metabolism. Women’s methyl donor status 
(‘methylation potential’) is higher in the Gambian rainy season than in the dry 
season. Compared to infants conceived in the rainy season, those conceived in the dry 
season have decreased methylation at metastable epialleles (MEs). MEs are genomic loci 
whose methylation states are established in the very early embryo prior to gastrulation. Dry 
season conceptions are also associated with methylation patterns suggestive of a loss of 
imprinting at the VTRNA2-1 gene, a putative tumour suppressor and regulator of innate 
immunity. The long-term goal is to design an intervention that shifts the maternal 
metabolome to improve regulation of the infant epigenome by providing micronutrients in 
the ratio and quantity necessary for optimal one-carbon metabolism all year round. To 
achieve this we first require a proof-of-concept trial showing that a nutritional supplement 
can address nutritional imbalances and increase methylation potential in non-pregnant 
women. This step provides the overall rationale for this thesis.  
The research in this thesis contributes three key areas to existing knowledge of nutritional 
epigenetics in The Gambia. Firstly, it characterises seasonal differences in plasma nutritional 
biomarkers in a new dataset, validating the findings from previous studies and extending the 
consideration to new metabolites. Secondly, it explores how maternal nutritional predictors 
of infant DNA methylation may change between seasons, highlighting the importance of 
considering seasonality and underlying nutritional status in nutritional epigenetic research. 
Thirdly, it describes the design of a novel drink powder supplement, tailored to the target 
population by analysing negative nutritional predictors of homocysteine (designed to 
increase methylation potential). A clinical trial tested this new supplement alongside an 
existing multiple micronutrient tablet (UNIMMAP) amongst non-pregnant women in rural 
Gambia. Both interventions proved to be promising candidates for future epigenetic trials, 
acting on metabolic pathways to increase methylation potential.  
Whilst the explicit targeting of DNA methylation profiles by nutritional interventions remains 
premature, accumulating evidence supports a focus on nutrition-sensitive epigenetic 
mechanisms as potential contributors to the developmental origins of health and disease. 
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GLOSSARY OF KEY TERMS 
 
CpG site: Where a cytosine (5’ end) is found next to a guanine (3’ end) on 
a DNA strand along its linear sequence, hence ‘cytosine-
phosphate-guanine’ or CpG site.  
DNA methylation: The covalent bonding of a methyl (CH3) group to a nucleotide, 
most often at CpG sites where the cytosine base is methylated 
at the 5’ carbon position to form 5-methylcytosine. 
Differentially 
Methylated Region:  
Regions of the genome exhibiting different methylation states 
between groups of interest (i.e. between intervention arms in a 
trial, between groups experiencing different exposures in 
cohort studies etc.).  
Developmental 
Origins of Health and 
Disease:  
The hypothesis based on the work of David Barker that 
environmental exposures experienced early in life may 
influence future disease risk throughout the life course.  
Epigenetics: Modifications to the genome that may affect gene expression 
without altering the underlying nucleotide sequence. 
Mechanisms include DNA methylation, histone modifications 
and RNA-mediated effects. Epigenetic marks are mitotically 
heritable and can be influenced by environmental factors. 
Imprinted genes: A gene where only one allele is expressed and the other is 
silenced (‘monoallelic expression’).  They contain differentially 
methylated regions, where the silenced allele is generally 
hypermethylated. Imprinted genes are inherited and expressed 
in a parent-of-origin specific manner. If a gene is ‘paternally 
expressed’ it means the expressed allele comes from the father 
and the maternal allele is imprinted (‘silenced’). 
Metastable Epialleles: These are CpG sites whose non-genetically-determined 
methylation state varies between individuals, but where 
variation is correlated across tissues originating from all germ 
layers in a single individual – indicating that the marks must 
have been laid down in the first few hours after conception 
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before cell types start to specialize.  
Methylation 
potential: 
The extent to which methylation can occur e.g. through the 
provision of methyl donors and essential co-factors in one-
carbon metabolic pathways. 
One-carbon 
metabolism: 
The interlinking metabolic reactions of folate, homocysteine, 
methionine, choline, transsulfuration and transmethylation 
metabolic pathways. One-carbon units are activated and 
transferred to support numerous reactions, including those 
required for DNA synthesis, amino acid production and 
methylation.  
Periconceptional 
period: 
Often defined as the window 14 weeks before conception to 10 
weeks afterwards.  
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Chapter 1 Background to Thesis 
__________________________________________________________________________ 
 
Summary of Chapter  
 
In this chapter I briefly introduce the background to this thesis, summarising the work the 
research group I am attached to (the MRC International Nutrition Group) did prior to starting 
my thesis. I describe the rationale to my PhD, its aims and objectives and an overview of the 
structure of the PhD. I also state the extent to which I was involved in all aspects of the thesis, 
and provide details of the PhD timeline, publication outputs and funding received.  
 
The technical background is deliberately brief as this is provided in much greater detail in 
Chapter 3. Further details on the research leading up to this thesis are also provided in 
Chapter 2.   
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1.1  Introduction  
 
Why focus on epigenetics? 
The field of epigenetics is rapidly generating a great deal of interest, exploring how our very 
molecular make-up in the form of modifications to the genome can be altered by factors as 
diverse as ageing, disease, nutrition, stress, alcohol and exposure to pollutants(1). Epigenetic 
processes involve the interplay of DNA methylation, histone modifications and RNA-based 
mechanisms. They can result in changes to the genome that are mitotically heritable and can 
alter gene expression without changing the underlying DNA sequence(2).  
The fusion of sperm and egg to create a new human being involves highly intricate epigenetic 
processes requiring the erasure of methylation marks to create pluripotent cells, and then 
the re-establishment of specific methylation patterns as cells differentiate during early 
embryonic development(3). These processes use diverse metabolic pathways that are highly 
dependent upon the mother’s nutrition to provide the necessary methyl groups and 
essential coenzymes for methylation(4). The one-carbon metabolic pathways are most 
proximal to the DNA methylation reaction. Deficiencies in the key methyl donors of choline, 
betaine or folate, alongside deficiencies in vitamins B2, B6 and B12 that play essential co-
enzyme roles, may disrupt the metabolic pathways that are responsible for DNA methylation. 
Errors in this epigenetic reprogramming at periconception cause a range of pathologies with 
a high burden to human health(5). The most severe errors are embryonically lethal (causing 
infertility and later abortions) or can lead to severe developmental defects in the baby(6). 
Errors in imprinted genes (genes with parent-of-origin-specific expression) can affect fetal 
growth and brain development with major implications for long-term health(7). Finally there 
is evidence that early embryonic re-programming can capture information from the 
environment and ‘tune’ the offspring’s metabolic settings to optimise its fitness; suggesting 
it as a key mediator of the developmental origins of health and disease (DOHaD) 
paradigm(8,9).  
 
What has previous work from the MRC International Nutrition Group shown? 
In the lead-up to this PhD the MRC International Nutrition Group published a series of studies 
from rural Gambia that established(10), and then replicated(11), first-in-human evidence that 
periconceptional environment, including maternal methyl-donor nutritional status, predicts 
offspring DNA methylation. This recapitulates evidence previously available in experimental 
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animals(12). The group achieved this by combining a seasonal ‘experiment of nature’ (through 
which mothers consume different diets in the dry/harvest season compared to the 
wet/hungry season) with the study of so-called metastable epialleles (MEs). MEs are genomic 
regions in which methylation patterns are known to be established in the very early embryo, 
characterised by having a methylation state that varies between individuals, but where 
within an individual the variation is correlated across tissues originating from all germ 
layers(13). This indicates that the marks have been laid down in the first few days after 
conception before cell types start to specialize and therefore makes these genomic loci 
useful for studying periconceptional exposures associated with offspring methylation(10,11). 
The key learning from this previous body of work can be summarised as follows: 
 
 Women’s methyl donor status (‘methylation potential’) can be quantified by looking 
at plasma concentrations of one carbon biomarkers, such as folate, B2, B6, B12, 
betaine and choline. Higher concentrations of such methyl donors and coenzymes 
indicate a higher methylation potential.  
 The profile of plasma biomarkers in women of rural Gambia suggests a higher 
methylation potential in the rainy season than in the dry season(14).  
 Indeed, methylation levels at certain genomic loci (particularly MEs) were found to 
be higher in children conceived in the rainy season compared to those conceived in 
the dry season(11).  
 Some of the genetic loci demonstrating differential methylation by season of 
conception are known to influence health: 
o The first example is the imprinted gene VTRNA2-1; a cancer suppressor gene 
involved also in immune defences against viral infections(15). Imprinted 
genes should be hemi-methylated (i.e. the allele from one parent is 100% 
methylated and the other allele is unmethylated). The group instead found 
significant hypomethylation, suggestive of an excess of loss of imprinting, in 
dry season conceptions(15).  
o The group also showed that methylation of a critical region of the pro-opioid 
melanocortin gene (POMC) differs by season of conception. This locus is an 
ME. POMC methylation is associated with POMC expression and obesity 
traits in both children and adults(16,17).  
In summary, the evidence to date suggests women conceiving in the dry season have a one-
carbon metabolic profile that results in a lower maternal methylation potential. There is 
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preliminary evidence that this in turn affects methylation patterns in the fetal epigenome at 
loci implicated in a broad range of adverse birth and later life outcomes.  
1.2  PhD Rationale 
 
The observational data from my research group to date suggest that it may be possible to 
‘shift’ the periconceptional methyl donor metabolome in such a way as to significantly alter 
methylation at multiple loci, including at key phenotype-related MEs and imprinted regions. 
My overall PhD goal was to design and implement a proof-of-concept trial assessing whether 
a nutritional supplement could target one-carbon pathways to increase methylation 
potential in non-pregnant women by correcting nutritional imbalances. If successful, the 
supplement would be a candidate to test in larger pregnancy trials. 
Even without an explicit focus on epigenetics an understanding of seasonal one-carbon 
metabolome patterns and how to ensure women are not deficient in key related 
micronutrients is crucial for a wide range of health-related reasons(18). These include 
improving fertility (both male and female) and enabling normal oocyte maturation and 
embryogenesis(19,20); avoiding disruption of DNA synthesis and DNA stability(21,22); and 
mitigating risk factors for cardiovascular disease(23,24), cancer(22,25), neurological 
disorders(26,27), birth defects(28) and potentially pre-eclampsia(29). 
 
1.3  PhD Aim and Objectives 
 
Overall Aim:  To characterise Gambian seasonal variation in the maternal one-carbon 
metabolome and design a proof-of-concept pilot intervention to test 
whether a nutritional supplement can increase methylation potential in 
non-pregnant women. 
 
Specific objectives: 
a. Conduct a comprehensive literature review of human studies that investigate 
associations between maternal periconceptional nutritional exposures, the infant 
epigenome and later phenotypes.  
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b. Analyse an expanded set of maternal biomarkers (covering core one-carbon 
metabolites alongside new ones) in plasma obtained from the first antenatal visit of 
350 women across the year in West Kiang, The Gambia. Use Fourier series modelling 
to characterize how the maternal one-carbon metabolome varies across the year. 
Are there obvious micronutrient deficiencies in metabolites essential for one-carbon 
metabolism? Are there times of the year when women appear more vulnerable to 
these deficiencies?  
 
c. Interrogate existing data to explore whether the profile of maternal nutritional 
predictors of offspring methylation change between the rainy and dry season of The 
Gambia. This is to help answer the question whether the effect of a micronutrient 
supplement on DNA methylation would be consistent over the year. 
 
d. Using three datasets, ascertain which nutritional components are consistently 
associated with increased methylation potential in women of rural Gambia. 
 
e. Use the results from objectives b) to d) above to design a novel nutritional 
supplement to increase methylation potential and to decide which time of year is 
most suitable for a trial. 
 
f. Conduct a randomized controlled trial to test the effect of the novel supplement on 
increasing methylation potential (measured by reducing homocysteine 
concentration) in 300 non-pregnant Gambian women supplemented daily over 12 
weeks. 
 
The overall PhD framework is portrayed in Figure 1.1, split into a planning and 
implementation phase. Part A comprises objectives a) to d); Phase 2 comprises objectives e) 
and f).  
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Figure 1.1 PhD Conceptual framework 
 
1.4  PhD Outline 
The thesis is presented in a research paper style with additional linking chapters, submitted 
in accordance with London School of Hygiene and Tropical Medicine regulations. The 
prepared and published articles are included without adaptation and there is therefore some 
repetition between chapters on the study context. This has been minimised where possible. 
Where research papers included supplementary material for publication these have been 
included either at the end of the relevant chapter, or in the Annex section. The summary of 
each chapter indicates where all the relevant material can be found.  
 
The thesis contains nine chapters, which include two published papers and one prepared 
(unpublished) manuscript. A brief overview of each chapter follows.  
 
Chapter 1: An overview of the thesis structure, my involvement, collaborators and study 
timeline. 
 
Chapter 2: An introduction providing the context to the studies, detailing the locations, 
populations and datasets used.  
 
Chapter 3: A published research paper containing a literature review of candidate genes 
linking maternal nutrient exposure to offspring phenotypes via DNA methylation. 
 
Chapter 4: Here I explore how plasma nutritional metabolites in pregnant women co-vary 
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over the year. I employ longitudinal analysis to describe seasonal trends and to assess 
whether there are specific times of the year when women appear more vulnerable to 
micronutrient deficiencies.  
 
Chapter 5: A published research paper describing whether the association of maternal 
nutrition exposures with offspring DNA methylation is consistent over the year. To do this I 
stratify existing data on maternal biomarkers and offspring DNA methylation by season of 
conception and assess whether the profile of maternal nutritional predictors of offspring 
methylation remains constant or changes between the Gambian seasons. 
 
Chapter 6: I use three datasets to investigate which metabolites are associated 
with increasing methylation potential, estimated by the extent to which they decrease 
plasma homocysteine. I run multivariable linear regression models to assess which nutrients 
independently predict plasma homocysteine in the datasets. I select those that consistently 
demonstrate an inverse relationship with homocysteine as potential ingredients for a novel 
nutritional supplement. 
 
Chapter 7: I describe how I use the analyses from previous chapters to design a novel drink 
powder supplement tailored for West Kiang region of rural Gambia. I assess the chosen 
ingredients against existing dosage safety information, amounts given in previous trials and 
relevant plasma nutrient levels to establish final supplement doses well below upper safety 
limits.  
 
Chapter 8: A research paper (prepared for submission) describing a clinical trial in West Kiang 
region of Gambia. 298 women were recruited into the three-arm study comprising the novel 
drink powder arm, a commonly used multiple micronutrient supplement (UNIMMAP) arm, 
and a control arm. Women in the intervention arms took their supplement daily for 12 
weeks. Baseline, midline and endline blood samples were obtained from all participants to 
assess the effectiveness of the interventions on lowering plasma homocysteine.  
 
Chapter 9: A final discussion chapter to summarise the overall findings, strengths and 
weaknesses of the thesis by objective, and to reflect on future research priorities in the field 
of nutritional epigenetics.  
 
25 
 
1.5  Candidate’s Involvement 
The original idea for developing and testing a nutritional supplement as a future candidate 
for pregnancy trials with epigenetic outcomes came from Prof Andrew Prentice, Nutrition 
Theme Leader for MRC Unit The Gambia. He obtained the project funding and recruited me 
as a research assistant to develop and implement the aim. I was given free rein to develop 
and test the supplement as I saw fit, but had constant technical support and advice from Dr 
Matt Silver, my PhD supervisor, together with Prof Prentice.  
For Chapter 3, the literature review, I was responsible for coordinating the collaborative 
effort on the paper and produced the first draft of the paper. I include a detailed description 
of the input of co-authors at the beginning of the chapter. For Chapter 4 I organised the 
sample preparation, shipment and analysis of the plasma samples. I contributed ideas for 
the expanded biomarker list and visited the laboratory at the University of British Columbia 
(UBC) to learn more about the analyses. The analyses were overseen by Roger Dyer at UBC, 
who developed the assays for the mass spectrometry and who worked with Professor Rajavel 
Elango for the amino acid panel. I performed the longitudinal analyses of the biomarkers. For 
Chapter 5, Dr Matt Silver had the original idea of exploring seasonal interactions in nutritional 
predictors of methylation and provided me with the methylation data. I developed the 
statistical approach and drafted the first version of the paper, which was commented on by 
all co-authors and edited accordingly. Chapter 6 was my own work after double-checking my 
strategy with my supervisor. For Chapter 7 I decided on the ingredients and doses for the 
supplement myself, and wrote up the product safety information. However, I ran the final 
idea by my advisory committee (Prof Andrew Prentice, Dr Matt Silver, Prof Patrick Stover, Dr 
Sophie Moore), who checked they were happy with the rationale for the composition. I set 
up and managed the clinical trial summarised in Chapter 8, with the help of a hard-working 
field team in Keneba. I conducted all analyses and wrote the first draft of the paper. Chapter 
9 is my own work. 
Whilst I was given overall ownership of the direction and implementation of the contents of 
this thesis, this was, necessarily, a collaborative approach. I provide the names and roles of 
everyone involved as collaborators and field team members in Annex 1.1. 
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1.6  PhD Publications and additional outputs 
 
Published papers: 
 
 James P, Sajjadi S, Tomar AS, Saffari A, Fall CHD, Prentice AM, Shrestha S, Issarapu 
P, Yadav DK, Kaur L, et al. Candidate genes linking maternal nutrient exposure to 
offspring health via DNA methylation: a review of existing evidence in humans with 
specific focus on one-carbon metabolism. Int J Epidemiol. 2018; dyy153. 
https://doi.org/10.1093/ije/dyy153 (Chapter 3). 
 Philip T James,  Paula Dominguez-Salas,  Branwen J Hennig, Sophie E Moore,  Andrew 
M Prentice and  Matt J Silver. Maternal one-carbon metabolism and infant DNA 
methylation between contrasting seasonal environments: A case study from The 
Gambia. Current Developments in Nutrition. 2018; nzy082. 
https://doi.org/10.1093/cdn/nzy082 (Chapter 5).  
 
Manuscript in preparation:  
 
 Philip T James, Andrew M Prentice & Matt J Silver. Comparison of a novel drink 
powder and existing multiple micronutrient tablet in reducing plasma homocysteine 
in non-pregnant women in rural Gambia: a randomised controlled trial to identify 
future candidates for epigenetic trials. Am. J. Clin. Nutr. (targeted) (Chapter 8). 
 
Textbook chapter: 
 
 James P, Silver M, Prentice A. Epigenetics, Nutrition, and Infant Health. In: 
Karakochuk C, Whitfield K, Green T and Kraemer K eds. The Biology of the First 1,000 
Days. 2017. p. 335–54. CRC Press.  (Annex 3.5) 
 
Magazine article: 
 
 James P, Silver M, Prentice A. Epigenetics, Nutrition, and Infant Health. Sight and 
Life. 2015; 29(1): 35-38. (Annex 3.6) 
 
27 
 
Poster: 
 
 Maternal One-Carbon Biomarkers and the Infant Methylome: The Role of 
Seasonality Using a Case Study from The Gambia. FASEB. 2017; 31 (Supplement 1): 
Abstract 644.14. Presented at Epigenomics of Common Disease, October 2017, 
Wellcome Genome Campus, UK. (Developed into Chapter 5).  
 
Invited conference talks: 
 
 ‘Can what a mother eats at the time of conception influence the epigenome of her 
child?’  
o DOHaD 9th World Congress, November 2015, Cape Town, South Africa. 
o Rank Prize Funds Symposium on Preconception Nutrition and Lifelong 
Health, February 2016, Grasmere, UK. 
o Society for Nutrition, Education and Health Action (SNEHA) Conference, 
March 2016, Hyderabad, India.  
 
 ‘Next generation supplement design’, Micronutrient Forum Global Conference, 
October 2016. Sight and Life Elevator Pitch Finalist, Cancun, Mexico. 
 
 ‘Epigenetics, Nutrition and Infant Health’, IUNS 21st International Congress of 
Nutrition, October 2017, Buenos Aires, Argentina. 
 
There were also three papers I was involved with as part of my PhD training as a supervisor 
to MSc Students and lecturer on the Nutrition in Emergencies module at LSHTM. These are 
unrelated to the PhD topic.  
 
 Natasha Phillipa O’Sullivan, Natasha Lelijveld, Natasha Lelijveld, Alexandra 
Rutishauser-Perera and Philip T James. Follow-up between 6 and 24 months after 
discharge from treatment for severe acute malnutrition in children aged 6-59 
months: A systematic review. PLoS ONE. 2018; 13(8):e0202053. 
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 Lucas K, James P, Choh AC, Lee M, Czerwinski SA, Demerath EW, Johnson W. The 
positive association of infant weight gain with adulthood body mass index has 
strengthened over time in the Fels Longitudinal Study. Pediatr Obes. 2018; 13:476–
84.  
 
 Adnaan Ghanachi, Philip T James, Carla Cerami.  Guts, Germs and Iron: A Systematic 
Review of the Effect of Iron Supplementation and Fortification on Diarrhoea in 
Children Aged 4 to 59 Months. Current Developments in Nutrition. 2018 (submitted).  
 
1.7  PhD Timeframe 
The PhD took place from October 2015 to October 2018. An overview of the timeframe of 
key activities is provided in Annex 1.2.  
 
1.8  Funding  
The PhD was funded by (core funding MC-A760-5QX00) to MRC Unit The Gambia by the UK 
Medical Research Council (salary and travel costs) and the MRC grant for the ‘Impact of 
maternal diet on the epigenome’ (MC_EX_MR/M01424X/1) for all clinical trial-related costs.  
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Chapter 2 PhD setting and datasets used 
__________________________________________________________________________ 
 
Summary of Chapter  
 
This chapter provides a brief overview of the study setting. It provides the geographical 
context of the West Kiang region of The Gambia, where the datasets I use in this thesis 
originate, as well as where I conducted my fieldwork for the clinical trial described in Chapter 
8.   
 
It describes the detailed methodology for three datasets I refer to throughout the thesis. 
Two of the datasets were already established when I started the thesis, and one I established 
for this PhD.   
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2.1  PhD Setting: West Kiang, The Gambia 
The Republic of The Gambia in West Africa is the smallest African nation. It is surrounded by 
Senegal and has a population of 1.9 million people with a growth rate of 3.3% per annum(1). 
Data for this thesis comes from villages of West Kiang district of the Lower River Division, 
where MRC Keneba is located (Figure 2.1). This is an area of rural subsistence farming, 
predominantly made up of the sedentary Mandinka ethnic group. The Gambia experiences 
a rainy season from July to October (Figure 2.2a). This is a planting season with increased 
energy expenditure associated with agricultural work, and increased incidence of malarial 
and diarrhoeal diseases. Food stores from the harvest period run low in this season, hence it 
is also referred to as the ‘hungry’ season.  The cooler dry season (Figure 2.2b) covers the 
other months, with harvesting occurring particularly in February to April, leading to improved 
food security(2,3). Despite overall household food stores being more replete in the dry season, 
it is the rainy season that is associated with higher plasma levels of certain micronutrients 
central to one-carbon metabolism(4). The underlying reasons are yet to be confirmed, but 
hypotheses include increased availability of green leaves during the rains or the scarcity of 
staples forcing people to increase food diversity (e.g. through seeking bush foods). 
 
 
 
Figure 2.1 Location of MRC Keneba within West Kiang, The Gambia. Village circle sizes 
proportional to population. 
Source: Hennig BJ et al. Int J Epidemiol. 2017; 46(2): e13(5). Reproduced with permission. 
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Figure 2.2 The Gambian rainy (a) and dry (b) season in Keneba, West Kiang. Photo credit: 
Andrew Prentice. 
 
2.2  Datasets used in thesis 
Three datasets are referred to in this thesis. Two are from the original Methyl Donors and 
Epigenetics (MDEG) study, the ‘indicator group’ and the ‘main study group’ led by Paula 
Dominguez-Salas from 2009-2012(4,6,7).  These were established prior to me starting the PhD 
but I use them for additional analyses. The third, termed ‘MDEG-2’, forms a new dataset for 
this thesis and utilises stored samples from the Early Nutrition & Immune Development 
(ENID) Trial(8). I was involved in the sample selection and preparation, defined the biomarkers 
of interest and received training at the University of British Columbia laboratory on the 
principles of mass spectrometry used in many of the assays.  
Table 2.1 summarises the key characteristics of each dataset and where they have been used 
in this thesis. Fuller details on each dataset are provided below, along with a summary of the 
key findings generated from each.  
 
2.2.1  MDEG Indicator group 
This was an observational study that took place in West Kiang region between July 2009 and 
June 2010, and written up in Dominguez-Salas et al. (2013)(4). The overall aim was to 
document the dietary intake and plasma nutrition concentrations of a cohort of non-
pregnant women, with a focus on one-carbon related metabolites. This dataset therefore 
provided a reference for the seasonal variation in these metabolites over a year, hence 
referred to as the ‘indicator group’. 
Non-pregnant women between the ages of 18 and 45 years (mean age 31 years) were 
followed monthly for a year. Each month they provided a fasted 10 mL blood sample and 
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were observed by field workers for collection of a 48-hour weighed dietary intake. This thesis 
utilises the blood sample data. Blood samples were collected in the field into EDTA 
monovettes, transported on ice and fully processed within two hours at the MRC laboratory 
in Keneba. Samples were spun for 10 minutes at 2,750g and the plasma was removed, 
aliquoted and immediately stored at -80°C. A sample of the remaining red blood cells were 
removed, washed and also stored at -80°C. The original list of maternal one-carbon 
biomarkers analysed were folate, B12, holotranscobalamin (active B12), choline, betaine, 
dimethylglycine (DMG), methionine, s-adenosyl methionine (SAM), s-adenosyl 
homocysteine (SAH), homocysteine (Hcy), riboflavin (B2), cysteine, 4-pyridoxic acid (PA), 
pyridoxal (PL) and pyridoxal 5’-phosphate (PLP). Throughout this thesis this collection of 
biomarkers is termed the ‘core one-carbon biomarker’ set. 
 
Plasma samples were shipped to the Department of Pediatrics, University of British 
Columbia, Canada for analysis of the following one-carbon metabolites by liquid 
chromatography-tandem mass spectrometry: SAM, SAH, free choline, betaine, DMG, Hcy, 
methionine, cysteine and the B6 vitamers (PA, PL, PLP). Plasma B12, active B12 and folate 
were analysed at UBC using an AxSyM analyser (Abbot laboratories, Chicago, IL). Riboflavin 
(B2) concentrations were analysed in the washed red blood cells by erythrocyte glutathione 
reductase activation coefficient (EGRAC) assay at MRC Human Nutrition Research 
laboratories, Cambridge, UK.  
 
A sample size of 30 women per month was planned for, and to account for drop-out and 
those being excluded after becoming pregnant 62 women were recruited into the study. 
Overall between 22 and 30 blood draws were obtained each month throughout the year.  
 
Key findings from the Indicator group(4): 
 
 Over the year there were notable seasonal fluctuations in plasma concentrations of 
one-carbon metabolites, particularly, folate, choline, betaine, DMG, homocysteine 
and B6. 
 In the peak rainy season (July-October) compared to the peak dry season (February 
– April) there were higher concentrations of plasma folate, B2, betaine and 
SAM:SAH, and lower concentrations of B12, DMG, B6 and Hcy.  
 Overall this equated to a higher methylation potential in the rainy season. 
 For many metabolites dietary intake measurements demonstrated poor stability 
from one month to the next after adjusting for seasonality, and did not correlate well 
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with plasma concentrations. The recommendation was to use plasma concentrations 
going forwards.  
This thesis uses the Indicator group dataset to help identify nutritional predictors of 
homocysteine (Chapter 6), and to validate the seasonal trend findings described in Chapter 
4.  
2.2.2  MDEG main study group 
This dataset contains 167 mother-child pairs enrolled into the main MDEG cohort. Women 
of reproductive age (18-45 years) in West Kiang district were invited to participate and 
followed monthly. Those women conceiving in the peak of the rainy season (July-September 
2009) and the peak of the dry season (February – April 2010) were enrolled and continued 
to be followed monthly until delivery. Their offspring were then followed throughout infancy. 
Detailed methodology and the main study results have been previously published in 
Dominguez-Salas et al. (2014)(7).  Women provided a 10mL fasting venous blood sample at 
the point they reported their first missed menses (mean (SD) 8.6 ± 4 weeks gestation). The 
same set of core one-carbon biomarkers were analysed as described in the Indicator group, 
using the same laboratory analyses. The seasonal trends obtained from the Indicator group 
were then used to back-extrapolate the plasma concentrations to the time of conception. 
Infant DNA was obtained from a 3mL venepuncture taken between 2-8 months after 
delivery. In this main group study methylation at 6 MEs in the infant DNA were analysed. 
More recently two other published papers have also utilised the offspring genome-wide DNA 
methylation data, measured using the Illumina Infinium HumanMethytlation450 array (‘450k 
array’)(9,10). 
 
Key findings from the main study group(7): 
 
 Similar to findings in the Indicator group, the profile of plasma biomarkers back-
extrapolated to the time of conception showed a higher methylation potential in 
the peak rainy season compared to the peak dry season. 
 Mean methylation across the 6 MEs in the infant DNA was higher in the rainy 
season compared to the dry season, corresponding to the higher plasma 
methylation potential. 
 Periconceptional plasma B2 concentration was positively associated with infant 
DNA methylation whilst Hcy, B6 and cysteine were inversely associated. 
 
In this thesis the MDEG main study dataset is used to look at seasonal interactions in the 
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association between maternal nutritional predictors and infant DNA methylation in Chapter 
5. It is also used to help identify nutritional predictors of homocysteine (Chapter 6) and to 
validate the seasonal trend findings described in Chapter 4.  
2.2.3  MDEG-2 
This dataset was established to generate information on an expanded set of biomarkers 
compared to the previous two. Unlike the MDEG main study, which only had data from six 
months of the year, the MDEG-2 dataset was designed to capture year-round variation in 
maternal plasma biomarkers and to be able to associate these with offspring DNA at a later 
date. 
The dataset uses banked samples from the Early Nutrition & Immune Development (ENID) 
Trial (ISRCTN49285450) testing the effect of different nutritional supplements given to 
pregnant women on the immune development of their children. The trial provides a detailed 
bank of samples from multiple time-points across pregnancy and in infancy until 24 months 
of age. A subsample of 350 mother-child pairs from the ENID trial forms this MDEG-2 dataset. 
The ENID trial protocol has been previously described in detail(8). In brief, women were 
randomised to four intervention groups after a positive pregnancy test at their ‘booking’ visit 
(the first clinic visit when pregnancy was confirmed, at approximately 13 weeks gestation): 
iron-folate (Fe-Fol) tablets, multiple micronutrient (MMN) tablets, a lipid-based nutritional 
supplement (LNS) fortified with Fe-Fol and LNS fortified with MMN. Supplementation was 
taken daily from the booking visit until delivery. At the time of booking mothers provided a 
fasted sample of 10 mL venous blood; 7.5mL into lithium heparin monovettes and 2.6mL into  
an EDTA monovette. Samples were immediately placed on ice after the venepuncture and 
taken to the laboratory for processing within one hour. The monovettes were centrifuged at 
1800 RCFs for ten minutes at 4°C and the plasma drawn off into 2mL microtubes. The 
microtubes were immediately frozen at -70°C. The plasma samples experienced two freeze-
thaw cycles (one to sub-aliquot and one at the point of analysis).  Since maternal booking 
blood samples were taken before the interventions were started the trial design does not 
affect interpretation of the maternal plasma nutritional biomarkers. The first booking visit 
took place in January 2010 and final child was born in February 2014. 
In order to understand how the metabolome changes across the year 350 samples were 
purposively selected to represent an even distribution by month of booking. Within each 
month the women with the earliest gestational age at booking (assessed by ultrasound) were 
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selected to capture the metabolome closest to the periconceptional period.  
Chapter 4 details the plasma metabolites selected for analysis as part of the MDEG-2 dataset 
and their laboratory analyses. They include all the core one-carbon biomarkers looked at in 
the indicator group and MDEG main study, but also consider additional ones such as amino 
acids and inflammatory markers. As such the MDEG-2 set of metabolites are the termed the 
‘expanded biomarker’ collection.  
 
The MDEG-2 dataset is used for the seasonal trends analyses of the expanded biomarker 
collection in Chapter 4, and also to investigate nutritional predictors of homocysteine in 
Chapter 6.  
 
 
 
38 
 
Table 2.1 Summary of dataset characteristics used in thesis 
Dataset Study design Total N Dry Season N 
(February-April) 
Rainy Season N 
(July –September) 
Biomarkers measured Referred to in thesis 
MDEG 
Indicator 
group 
Non-pregnant women, ~30 
followed for one year, with 
repeated monthly blood 
samples(2).  
48 women 
with 288 
total 
observations 
34 women with 
79 observations 
28 women with 
63 observations 
Core group: Hcy, B2, PLP 
(B6), B12, folate, 
methionine, choline, 
betaine, DMG, cysteine 
Overview given: 
Section 2.2.1 
 
Also referred to:  
Chapters 4, 6 
MDEG 
Main 
Study 
 
 
Cross-sectional data comprising 
a baseline blood sample from 
pregnant women at first 
antenatal visit. Samples are 
taken from the peak of rainy 
and peak of dry season(4), 
spanning 6 months of the year. 
167 83 84 Core group, as above Overview given: 
Section 2.2.2 
 
Also referred to: 
Chapters 4, 5, 6 
MDEG-2  
 
 
Cross sectional data comprising 
a baseline blood sample from 
pregnant women at first 
antenatal visit. Samples 
selected from each month of 
year. 
350 87 100 Expanded group: Core 
group plus AGP, Asp, Thr, 
Ser, Glu, Gly, Ala, Val, Ile, 
Leu, Tyr, Phe, Lys, His, 
Arg, Pro 
Overview given: 
Section 2.2.3 
 
Also referred to: 
Chapters 4, 6 
 
 
Abbreviations: AGP, α-1 acid glycoprotein; Ala, alanine; Arg, arginine; Asp, aspartic acid; DMG, dimethylglycine; Glu, glutamic acid; Gly, glycine; Hcy, 
homocysteine; His, histidine; Ile, isoleucine; Leu, leucine; Lys, lysine;  MDEG, Methyl Donors and Epigenetics; Phe, phenylalanine; PLP, pyridoxal 5’-phosphate; 
Pro, proline; Ser, serine; Thr, threonine; Tyr, tyrosine; Val, valine.
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Chapter 3 Literature Review 
__________________________________________________________________________ 
 
Summary of Chapter 
Background: Mounting evidence suggests that nutritional exposures during pregnancy 
influence the fetal epigenome, and that these epigenetic changes can persist postnatally, 
with implications for disease risk across the lifecourse.  
Methods: We review human intergenerational studies using a three-part search strategy. 
Search 1 investigates associations between pre-conceptional or pregnancy nutritional 
exposures, focussing on one-carbon metabolism, and offspring DNA methylation. Search 2 
considers associations between offspring DNA methylation at genes found in the first 
search and growth-related, cardio-metabolic and cognitive outcomes. Search 3 isolates 
those studies explicitly linking maternal nutritional exposure to offspring phenotype via 
DNA methylation. Finally, we compile all candidate genes and regions of interest identified 
in the searches and describe their genomic locations, annotations and coverage on the 
Illumina Infinium Methylation beadchip arrays. 
Results: We summarise findings from the 34 studies found in the first search, the 31 
studies found in the second search and the eight studies found in the third search. We 
provide details of all regions of interest within 45 genes captured by this review.  
Conclusions: Many studies have investigated imprinted genes as priority loci, but with the 
adoption of microarray-based platforms other candidate genes and gene classes are now 
emerging. Despite a wealth of information, the current literature is characterised by 
heterogeneous exposures and outcomes, and mostly comprise observational associations 
that are frequently underpowered. The synthesis of current knowledge provided by this 
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review identifies research needs on the pathway to developing possible early-life 
interventions to optimise lifelong health. 
Notes 
I have inserted the published version. Where the paper refers to supplementary material and 
tables these can be found in Annexes 3.1 to 3.4. 
I published two other reviews for different audiences. Since these covered very similar 
material I have included them in the Annexes.  
 Annex 3.5: James P, Silver M, Prentice A. Epigenetics, Nutrition, and Infant Health. 
In: Karakochuk C, Whitfield K, Green T and Kraemer K eds. The Biology of the First 
1,000 Days. 2017. p. 335–54.  
 
This is a textbook chapter written for a readership of public health professionals 
and students in the medical and nutrition field. 
 
 Annex 3.6: James P, Silver M, Prentice A. Epigenetics, Nutrition, and Infant Health. 
2015; Sight and Life 29(1): 35-38.  
 
This is a magazine article for a readership of both academics, practitioners and 
students, and is written as a short primer. 
The review in this chapter was also used to identify candidate genes that were not included 
on the Infinium MethylationEPIC BeadChip array, and hence needed to be pyrosequenced, 
in the EMPHASIS project (Epigenetic Mechanisms linking Pre-conceptional nutrition and 
Health Assessed in India and Sub-Saharan Africa, ISRCTN14266771). The protocol paper for 
this project, for which I am a co-author, can found here: 
 
Chandak GR et al. Protocol for the EMPHASIS study; epigenetic mechanisms linking maternal 
pre-conceptional nutrition and children’s health in India and Sub-Saharan Africa. BMC 
Nutrition (2017) 3:81.  
 
https://bmcnutr.biomedcentral.com/articles/10.1186/s40795-017-0200-0  
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Abstract
Background: Mounting evidence suggests that nutritional exposures during pregnancy
influence the fetal epigenome, and that these epigenetic changes can persist postnatally,
with implications for disease risk across the life course.
Methods:We review human intergenerational studies using a three-part search strategy.
Search 1 investigates associations between preconceptional or pregnancy nutritional
exposures, focusing on one-carbon metabolism, and offspring DNA methylation. Search
2 considers associations between offspring DNA methylation at genes found in the first
search and growth-related, cardiometabolic and cognitive outcomes. Search 3 isolates
those studies explicitly linking maternal nutritional exposure to offspring phenotype via
DNA methylation. Finally, we compile all candidate genes and regions of interest identi-
fied in the searches and describe their genomic locations, annotations and coverage on
the Illumina Infinium Methylation beadchip arrays.
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Results:We summarize findings from the 34 studies found in the first search, the 31 stud-
ies found in the second search and the eight studies found in the third search. We pro-
vide details of all regions of interest within 45 genes captured by this review.
Conclusions: Many studies have investigated imprinted genes as priority loci, but with
the adoption of microarray-based platforms other candidate genes and gene classes are
now emerging. Despite a wealth of information, the current literature is characterized by
heterogeneous exposures and outcomes, and mostly comprise observational associa-
tions that are frequently underpowered. The synthesis of current knowledge provided by
this review identifies research needs on the pathway to developing possible early life
interventions to optimize lifelong health.
Key words: Epigenetics, DNA methylation, fetal programming, Developmental Origins of Health and Disease, one-
carbon metabolism, candidate genes, metastable epialleles, cognitive development, cardiometabolic outcomes,
growth
Introduction
Epigenetic modifications influence gene expression without al-
tering the nucleotide sequence, through the action of a diverse
array of molecular mechanisms including DNA methylation,
histone modifications and RNA-mediated effects.1 Epigenetic
processes have been implicated in the aetiology of a variety of
diseases,2 most prominently cancer3 and fetal growth disor-
ders.4 Epigenetic marks are mitotically heritable and can be
influenced by the environment,5 suggesting a potential mecha-
nism linking early life exposures to later phenotype,6,7 a no-
tion supported by animal studies.8–10 However, the extent to
which epigenetics plays a role in fetal programming in humans
remains relatively unexplored. In this review we collate evi-
dence from human intergenerational studies, exploring which
nutritional exposures during pregnancy may affect DNA
methylation in the offspring, and the possible impact of such
modifications on health and disease risk across the life course.
DNA methylation and gene expression
Many biological processes rely on DNA methylation, in-
cluding genomic imprinting, X-chromosome inactivation
and tissue-specific gene expression.11 DNA methylation
describes the addition of a methyl group to a cytosine base
at the 5’ carbon position to form 5-methylcytosine,
catalyzed by DNA methyltransferases (DNMTs). This
most commonly occurs at cytosine bases adjacent to gua-
nine, termed CpG (‘cytosine-phosphate-guanine’) sites.
Regions of high CpG density are known as ‘CpG islands’,
and approximately two-thirds of human genes contain
these in their promoter regions.12 DNA methylation has
been shown to influence transcriptional activity either by
blocking transcription factors binding to the DNA, or by
the recruitment of histone modifiers which promote a
closed chromatin structure and gene silencing.1 CpG meth-
ylation within promoters is typically associated with tran-
scriptional silencing,13 although not consistently, and the
effect of DNA methylation may vary depending on which
region within the gene is methylated.14 There is also in-
creasing evidence that DNA methylation and histone mod-
ifications work in concert with non-coding RNAs to
regulate gene expression.15 DNA methylation plays a role
in chromatin remodelling, as DNMT enzymes at CpG sites
can be physically linked to enzymes which bring about his-
tone methylation and de-acetylation.13 MicroRNAs
(miRNAs) affect gene expression through binding to mes-
senger RNAs (mRNAs) and repressing translation,16 in-
cluding mRNAs that control the expression of DNMTs
Key Messages
• The body of evidence linking maternal nutritional exposure to offspring phenotype via DNA methylation in humans is
rapidly growing yet currently remains complex and inconsistent.
• Candidate genes in the field of intergenerational nutritional epigenetics go beyond imprinted genes to include other
gene classes such as metastable epialleles.
• Going forwards, there is a continued need for adequately powered prospective cohort studies with repeated longitu-
dinal measurements and randomized nutritional interventions to track the full continuum from maternal exposure to
offspring epigenotype to later phenotype.
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and histone deacetylases.15 The transcription of some
miRNA classes can be influenced by CpG methylation and
histone modifications.16
Epigenetics, windows of plasticity and the
Developmental Origins of Health and Disease
The Developmental Origins of Health and Disease (DOHaD)
hypothesis posits that early life exposure to environmental
insults can increase the risk of later adverse health outcomes.7
David Barker’s early cohort studies showed that lower birth-
weight was associated with an increased risk of hypertension,
type 2 diabetes (T2D) and cardiovascular disease in later
life,17 findings that were widely replicated.18 Risk of disease
was further exacerbated by rapid childhood weight gain,
adult obesity and other lifestyle factors such as unhealthy
diets, smoking and lack of exercise.19,20 The Dutch Hunger
Winter studies showed that exposure to famine during preg-
nancy was associated with a wide range of phenotypes in the
adult offspring, including increased blood pressure,21
obesity22 and schizophrenia,23 effects that depended on the
timing of the exposure during pregnancy.22
Epigenetic processes are emerging as potential mecha-
nisms to explain these and other associations found in the
DOHaD literature. For example the ‘thrifty epigenome’
hypothesis proposes that in utero exposures can shape an
epigenetic signature, resulting in a phenotype that is
‘adapted’ to the early life environment but which may
prove to be ‘maladapted’ if the environment changes in
later life.24 Therefore famine exposure during pregnancy
could programme ‘thrifty epigenotypes’ that are adapted
to a nutritionally poor environment, but this may subse-
quently trigger metabolic disease if the adult environment
changes to one that is nutritionally abundant.
The periconceptional period is a time of rapid cell dif-
ferentiation and epigenetic remodelling, and may therefore
represent a critical window during which the developing
epigenome is sensitive to environmental influences.25 We
define the periconceptional window from 14 weeks pre-
ceding conception until 10 weeks after conception.26
Within 48 hours of fertilization, there is rapid erasure of
methylation marks to render the developing cells pluripo-
tent.11 After implantation, re-methylation occurs in a
tissue-specific manner, and continues throughout preg-
nancy, enabling differentiation of somatic cells. A second
wave of demethylation occurs in the primordial germ cells
as they migrate to the genital ridge.27 At this stage most pa-
rental imprints are erased, so that sex-specific imprints can
be laid down. In boys the prospermatogonia then undergo
re-methylation throughout gestation, whereas in girls the
oocytes continue to be re-methylated over the duration of
their maturation, with evidence of high activity as each egg
ripens before ovulation.27
Notable classes of loci that may be especially sensitive
to early environmental exposure include imprinted genes,
metastable epialleles (MEs) and transposable elements
(TEs).6 Imprinted genes exhibit monoallelic expression,
whereby only the maternally or paternally inherited allele
is expressed, with expression controlled by regulatory
regions whose methylation state is inherited in a parent of
origin-specific manner.28 MEs are genomic loci showing
variable methylation between individuals, but showing
high correlation in methylation status across tissues within
the same individual, indicating establishment of methyla-
tion state in the first few days after conception, preceding
gastrulation.29 MEs therefore help to pinpoint the timing
of an exposure influencing ME methylation to the pericon-
ceptional period.30,31 TEs are small, mobile sequences of
DNA that are thought to comprise 45% of the human ge-
nome.32 They can insert into new genomic locations and
become disruptive if transposed into a functional gene or
when increasing copy number. Whereas most TEs are si-
lenced epigenetically,33 some have variable methylation
patterns that have been shown to be influenced by nutri-
tion in mice.9 Their methylation states can alter neighbour-
ing gene expression, exemplified by the Agouti mouse
model detailed later.
Influence of nutrition on DNA methylation
A range of maternal exposures have been associated with
DNA methylation including nutrition, stress, infection,
pollutants, smoking, radiation, level of exercise and paren-
tal body composition.34–36 Animal studies suggest that the
epigenome is particularly sensitive to such environmental
factors in early life, notably during the prenatal and neona-
tal periods.9,25,37 Studies of the effects of early life nutri-
tion on DNA methylation have shown that maternal
under- or over-nutrition or differences in protein, fat, sugar
or micronutrient intake during gestation can induce epige-
netic and phenotypic changes in the offspring.8,38 Recent
studies have also shown that variations in paternal diet or
body composition might also induce long-term epigenetic
and phenotypic changes in the offspring.39 One-carbon
nutrients and metabolites are thought to be particularly
important in the periconceptional period and during em-
bryonic development.26 One-carbon metabolism (OCM)
pathways link the folate, methionine, homocysteine, trans-
sulphuration and transmethylation metabolic pathways to-
gether (Figure 1) . These are crucial for many biochemical
processes, including DNA methylation.
Nutrition plays a key role in OCM by providing sub-
strates (folate, methionine, choline and betaine) and essen-
tial co-factors (vitamins B12, B6 and B2). For example,
B12 is required by methionine synthase to methylate
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homocysteine, B6 is essential in the homocysteine trans-
sulphuration pathway, and both B6 and B2 are needed to
reduce dietary folate to methyltetrahydrofolate. A more
detailed overview of OCM and the role of nutrients in
these pathways is provided in Supplementary Material 1,
available as Supplementary data at IJE online.
The potential for maternal nutrition to both alter off-
spring DNA methylation and influence phenotype is fa-
mously illustrated by the Agouti mouse experiments. Two
groups of pregnant dams were fed diets that differed only in
nutrients essential to OCM (folic acid, choline, betaine and
B12). Increased levels of one-carbon nutrients increased
methylation in the isogenic pups at a retrotransposon locus
[Intracisternal A Particle (IAP), also an ME] upstream of the
Agouti gene. The degree of expression of the Agouti gene
depended on the level of IAP methylation, and this in turn
altered the pups’ fur colour, as well as their appetite, adipos-
ity and glucose tolerance in adulthood.6,9
Review methodology
We performed a narrative review of the literature in three
stages to form the thematic analysis in this paper. First we
searched for studies describing associations between pre-
conceptional or pregnancy nutritional exposures and DNA
methylation in offspring. We limited this search to human
studies that used an intergenerational design. We included
nutritional exposures in dietary or supplemental form re-
lated to OCM, or broader measures that could influence
availability of such nutrients (famine, seasonal diets and
macronutrients). We excluded paternal exposures and
nutrients not directly involved in OCM, and we only con-
sidered epigenetic studies focusing on DNA methylation.
Second, we searched for human studies linking infant
DNA methylation to a subset of phenotypic outcomes
(growth-related, cardiometabolic and cognitive), restrict-
ing the included studies to those describing methylation at
Figure 1. A simplified summary of one-carbon metabolism. BHMT, Betaine Homocysteine MethylTransferase; CBS, Cystathionine-Beta-Synthase;
CTH, Cystathionine Gamma-Lyase; DHFR, Dihydrofolate Reductase; dTMP, Deoxythymidine Monophosphate; dTTP, Deoxythymidine Triphosphate;
FAD, Flavin Adenine Dinucleotide; GNMT, Glycine N-MethylTransferase; MAT, Methionine AdenosylTransferase; MS, Methionine Synthase; MT,
Methyl Transferases; MTHFD, MethyleneTetraHydroFolate Dehydrogenase; MTHF, MethyleneTetraHydroFolate Reductase; SAHH, S-Adenosyl
Homocysteine Hydrolase; SHMT, Serine HydroxyMethylTransferase; TS, Thymidylate Synthase. Source: reproduced with permission from James
et al. Epigenetics, nutrition and infant health. In: Karakochuk C, Whitfield K, Green T, Kraemer K (eds). The Biology of the First 1000 Days. Boca Raton,
FL: CRC Press, 2017.
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genetic loci identified in the first search (‘nutrition-
sensitive’ loci). Third, we isolated those studies explicitly
linking maternal nutritional exposure to offspring pheno-
type via DNA methylation. Three authors (P.J., S.S.,
A.S.T.) performed the searches in PubMed and Google
Scholar, assessing titles and abstracts against the
inclusion criteria. Reference sections of included studies
and relevant review papers were also used to help confirm
that key studies had been included. Searches took place
from January to March 2017. Supplementary Material 2,
available as Supplementary data at IJE online, details the
strategy and gives an example of the search terms used in
PubMed.
Review of studies linking maternal
nutritional exposure to offspring DNA
methylation
We provide a broad overview of the associations found in
the literature between maternal nutritional exposure and off-
spring DNA methylation in Table 1. Below we briefly review
the associations by type of exposure, but refer the reader to
detailed information on the individual studies (n ¼ 34) in
Supplementary Table 1, available as Supplementary data at
IJE online, which includes information on the nutritional
exposures, timing of exposures, study design, DNA tissue,
age of offspring and associated genes. All gene names are de-
fined in Table 4 (see candidate gene data summary, below).
Table 1. Summary of associations between maternal one-carbon metabolites and broader nutritional exposures with offspring
DNA methylation
Timing of exposure Maternal exposurea Offspring DNA methylation association
("/#: increased/decreased methylation)
Periconception "B2 "PLAGL1 (ZAC1),40 "VTRNA2-141
"Betaine " DNMT1,42 "POMC,43 "RXRA44
Famine #IGF2,45 "#bIGF2,46 #INSIGF,46,47 "IL10,47 "GNASAS,47 "LEP,47
"ABCA1,47 "MEG3,47 "TACC1,48 "ZNF385A,48 #TMEM105,48
"PAX8,49 #ZFP57,4, #PRDM949
"Folates #STX11,50 #OTX2,50 #TFAP2A,50 #CYS1,50 #LEP,44 "RXRA44
"Folic acid "LEP,42 #H19,51 "IGF2,52#IGF244
"Multiple micronutrients #GNASAS,53 #MEG3,53 #IGF2R,53 #MEST53
Seasonality of one-carbon
metabolitesc
"POMC,43 "VTRNA2-1,41 "BOLA3,30 "FLJ20433,30 "PAX8,30
"SLITRK1,30 "ZFYVE28,30 "RBM4631
1st and 2nd trimester "B6 "MEG354
"Betaine # LEP42
"Carbohydrates #RXRA55
"Choline #DNMT142
Famine "FAM150B,48 "SLC38A2,48 "PPAP2C,48 #OSBPL5/MRGPRG,48
"TACC1,48 "ZNF385A,48 "PAX8,49 #ZFP57,49 #PRDM949
"Folates #PEG3,56 "NR3C1,57 #MEG3,56 #PLAGL1,56 "IGF2,56 #LEP,42
#DNMT142
"Folic acid #PEG3,58 "IGF2,58 #DNMT144
3rd trimester "B2 "PLAGL1 (ZAC1)40
"B12 #IGF259
"Choline "#d NR3C1,60 "#dCRH,60 "DNMT1,42,44
Famine #GNASAS,47 "TACC1,48 "ZNF385A,48 "PAX8,49 #ZFP57,49
#PRDM949
"Folates "DNMT1,44 #RXRA,42 "LASP1,61 "ACADM,61 "WNT9A,61
"FZD7,61 #ZFP57,61 #LY6E,61 #C21orf5661
"Folic acid "RXRA42
" Meat and fish intake "HSD262
" High sugar, high fat diet "IGF263
"Omega-3 PUFA #H19,64 "IGF2,6 mostly #associations in EWAS65
"Omega-6 PUFA #MIRLET7BHG66
aLike nutrients are shaded in the same colour during each time period.
bDifferent associations at different loci within gene.
cRainy season (higher concentration of most one-carbon metabolites) versus dry season.
dDifferent associations between different tissues.
EWAS, epigenome-wide association study; PUFA, polyunsaturated fatty acids.
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Folate
Associations between maternal folate exposure and the off-
spring methylome are inconsistent, with varying effects
according to the form of folate (dietary folates or folic acid
supplements)58 the timing of exposure,42,58 baseline mater-
nal folate status,50,61 underlying genotype,67 the genomic
region affected68 and individual CpG site.42
Periconceptional folic acid has been positively associ-
ated with offspring methylation at LEP,42 inversely associ-
ated with methylation at H19,51 and has demonstrated
both positive52 and inverse44 associations at IGF2. Not all
studies have found an effect of periconceptional folic acid
exposure.58 Supplementation started after 12 weeks of ges-
tation has been associated with increased offspring methyl-
ation at IGF2 and decreased methylation at PEG3.58 Folic
acid taken up to the end of the second trimester has been
inversely associated with DNMT1 methylation, but posi-
tively correlated at the same locus when the folic acid con-
sumption was extended into the third trimester.44
Data for dietary folate intakes (assessed using questionnaires
or plasma samples) are equally variable. Periconceptional folate
intake and offspring DNA methylation were inversely associ-
ated with the majority of differentially methylated CpGs in an
epigenome-wide screen, although this trend reversed in strati-
fied analysis among women with low intakes (<200 mg/day).50
Periconceptional intakes have also been inversely associated
with methylation at LEP and positively associated at RXRA.44
First trimester folate exposure has shown positive associations
with DNA methylation at IGF256 and NR3C1,57 and inverse
associations at MEG3, PLAGL1 and PEG3.56 For second tri-
mester folate exposure, studies have reported inverse associa-
tions at multiple differentially methylated CpG sites,68 and at
LEP and DNMT1.42 Third trimester folate exposure has
shown positive associations with methylation at DNMT1,44
and at LASP1, ACADM, WNT9A, C21orf56 and FZD7,61
but inverse associations atZFP57, LY6E and RXRA.42,61
B vitamins
Maternal serum B12 at first antenatal visit has been in-
versely associated with cord blood global methylation lev-
els,67 and inversely associated with offspring IGF2
methylation when exposure timing was at delivery.59 Some
studies have assessed joint effects of B vitamins. One study
assessed pre-pregnancy and third trimester maternal B2,
B3, B6, folate and B12 intake, and found a positive corre-
lation between maternal B2 and offspring methylation at
PLAGL1 (ZAC1) at both time points.40 Another study
found no associations between first trimester maternal
plasma B12 and B6 concentrations with offspring methyla-
tion at H19, PEG10/SGCE and PLAGL1, but there was a
positive trend in methylation at MEG3 across maternal B6
quartiles.54
Choline and betaine
To date there is one human intervention study investigating
the effect of supplementing mothers’ diets with choline
(480mg vs 930mg) in the third trimester on offspring DNA
methylation. The intervention increased methylation at
NR3C1 and CRH in fetal placental tissue but reduced methyl-
ation in cord blood. No effect was seen at GNAS-AS, IGF2,
IL10 or LEP.60 In observational studies, second trimester cho-
line intake has been inversely associated withDNMT1methyl-
ation in cord blood.42 Third trimester choline intake has been
positively associated with DNMT1 methylation in cord blood
and in infant buccal cells.42,44 Maternal periconceptional beta-
ine intake has been positively associated with cord blood
methylation at DNMT1, RXRA and POMC,42–44 and second
trimester intake inversely associated with LEP methylation.42
Polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) are thought to influ-
ence OCM by upregulating enzymes responsible for the
methylation of homocysteine to methionine and by directly
influencing demand for methyl groups via phosphatidylcho-
line (described in Supplementary Material 1, available as
Supplementary data at IJE online). There have been several
studies of PUFA supplementation in mothers. In one trial,
omega-3 PUFA supplementation in the second and third tri-
mesters showed no difference in the cord blood methylation
of various gene promoter sites, but the intervention in-
creased global methylation (LINE-1) in offspring of mothers
who smoked.69 It also decreased H19 methylation, and in-
creased IGF2 methylation in offspring of overweight moth-
ers.64 A more recent trial, also implemented in the second
and third trimesters, found omega-3 PUFA supplementation
was associated with 21 differentially methylated regions
(DMRs) at birth.65 These were predominantly hypomethy-
lated in the intervention group. However, not all omega-3
PUFA supplementations trials have demonstrated an effect
on methylation.70 Maternal plasma omega-6 PUFA concen-
trations in the third trimester have been inversely associated
with offspring MIRLET7BHG methylation.66
Broader nutrition measures: famine studies,
seasonal exposures, macronutrients
Several studies have used broader measures of maternal
nutritional exposure, such as famine, season of conception
and macronutrient intake. During the Dutch Famine of
1944, there was a large drop in all food intakes, with aver-
age energy intake reduced to 500–1000 kcal per day.71
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In follow-up studies of adults who were exposed to famine
in utero, exposure in early pregnancy (periconception and
up to 10 weeks of gestation) was associated with lower
methylation of INSIF and TMEM105, increased methyla-
tion at IL10, GNASAS, LEP, ABCA1, MEG3, TACC1
and ZNF385A, and both increased and decreased methyla-
tion at IGF2 depending on the loci within the gene.45–48
Not all these effects were seen in those exposed during late
gestation.45,48 In a candidate gene analysis of putative
metastable epialleles, offspring exposed to famine for at
least 7 months during gestation in Bangladesh had higher
methylation at PAX8 and lower methylation at PRDM9
and ZFP57, compared with unexposed controls.49
One study found an inverse association between mater-
nal second trimester carbohydrate intake and infant RXRA
methylation.55 Another study looked at the effect of a pre-
natal diet high in fat and sugar and found a positive associ-
ation with offspring IGF2 methylation.63 Higher
methylation at GR has been observed in infants of mothers
having higher meat/fish/vegetables and lower bread/potato
intake in late pregnancy (>20 weeks of gestation compared
with earlier in pregnancy) and increased infant methylation
at HSD2 has been associated with increased maternal meat
and fish intake in late pregnancy.62 In a pilot trial of peri-
conceptional multiple micronutrient supplementation
(UNIMMAP) for mothers, there were sex-specific effects
on infant methylation at IGF2R, GNASAS, MEG3 and
MEST.53 The difficulty of such studies, however, is that it
is not possible to know which nutrient deficits or imbalan-
ces caused the epigenetic effects. In The Gambia, where
season has marked effects on maternal diet and body
weight,72 children conceived in the rainy season had higher
methylation in peripheral blood lymphocytes at six MEs,
at VTRNA2–1 and at POMC compared with those con-
ceived in the dry season.31,41,43 This may reflect a role of
one-carbon-related nutrients; in the rainy season, maternal
periconceptional plasma showed higher concentrations of
folate, B2, methionine, betaine, S-adenosyl methionine
(SAM):S-adenosyl homocysteine (SAH) ratio and betai-
ne:dimethylglycine (DMG) ratio, and lower B12 and ho-
mocysteine, indicating higher methylation potential.
Aside from those considered above, the list of maternal
exposures associated with changes in infant DNA methyla-
tion continues to grow. These include further nutrition-
related exposures (e.g. dietary polyphenols,73 vitamin
D74,75 and vitamin A76) non-nutrition-related exposures
(e.g. maternal stress77 and toxin exposure78) and factors
that span the spectrum of nutrition and health-related con-
siderations (e.g. maternal hyperglycaemia,79 maternal
body mass index (BMI),80–82 intrauterine growth restric-
tion (IUGR),83–85 the microbiome86 and infection87). The
ongoing challenge is not only to identify relevant
exposures, but also to delineate the consequences for hu-
man health across the life course. It is to this latter point
that we now turn.
Review of studies linking
nutrition-associated DNA methylation
loci to health outcomes
In animal studies, nutritional exposures in pregnancy bring
about distinct phenotypic effects in offspring via epigenetic
mechanisms. Differential methylation of genes may induce
phenotypic variation by the modulation of gene expression
which may alter tissue structure, homeostatic control pro-
cesses and the activity of metabolic pathways.88 Often
cited examples include the effects of maternal methyl do-
nor supplementation on offspring coat colour and adipos-
ity in the Agouti mouse, and the development of the fertile
queen bee from genetically identical larvae by epigenetic si-
lencing of DNMT3, caused by preferential feeding of royal
jelly.9,89
In this section we focus on evidence provided by two
types of studies:
i. Those reporting associations between methylation at
the nutrition-sensitive epigenetic loci described above
and offspring phenotypes; these are summarized in
Table 2, with detailed information on all included stud-
ies (n ¼ 31) in Supplementary Table 2, available as
Supplementary data at IJE online;
ii. Those linking maternal nutrition exposure, infant DNA
methylation and offspring phenotypic effects in a single
study (n ¼ 8); these are summarized in Table 3.
We consider three broad categories of offspring pheno-
typic outcomes: growth and body composition, cardiome-
tabolic risk markers and cognitive function.
Growth and body composition
DNA methylation signatures in different tissues such as
cord and peripheral blood, placenta, subcutaneous and vis-
ceral adipose tissue and buccal cells have been associated
with growth outcomes such as size at birth (usually birth-
weight, with or without adjustment for gestational age),
child/adult adiposity and skeletal growth or bone size/qual-
ity (see Supplementary Table 2, available as Supplementary
data at IJE online).
Birth size: most studies investigating growth-related
phenotypes have analysed imprinted genes due to their
known role in fetal growth regulation.106 Chromosomal
region 11p15.5 contains two imprinting control regions
(ICRs): the H19/IGF2 (ICR1) and KCNQ1/CDKN1C
(ICR2) domains.107 Russell–Silver Syndrome (RSS, a
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disorder of impaired growth) is associated with hypomethy-
lation of ICR1 and hypermethylation of ICR2. Beckwith-
Wiedemann Syndrome (BWS, an over-growth disorder) is
associated with hypermethylation of ICR1 and hypomethy-
lation of ICR2.108 Some studies indicate that patients with
RSS and BWS exhibit abnormal methylation at multiple
Table 2. Summary of associations between methylation at nutrition-sensitive genetic loci and phenotypes
Direction of DNA methylation/locus Associated phenotype/direction Tissue analysed Age at methylation
measurement("/#: increased/decreased)
Birth size
"H19,56 "PLAGL1,56
#MEG3,56 #MIRLET7BHG,66
"IGF290
"Birthweight Cord blood Birth
"IGF2 DMR291 "Birthweight Placenta Birth
#IGF2,52 "HSD262 "Birthweight Peripheral blood 17 months,52 40 years62
"H19 ICR62 #Birth length Peripheral blood 40 years
"PLAGL140 "Estimated fetal weight at 32 weeks of
gestation
Cord blood Birth
"HSD262 #Neonatal ponderal index Peripheral blood 40 years
#IGF2 DMR0,83 "H1992 "Small for gestational age Cord blood Birth
"MEST,93 "LEP94 "Small for gestational age Placenta,93 cord blood94 Birth
#IGF2 DMR095 "Small for gestational age Peripheral blood 11 years
Anthropometric measures/adiposity
"PLAGL140 "Weight at age 1 year Cord blood Birth
"PLAGL140 "Body mass index (BMI) z-score at age 1 year Cord blood Birth
"IGF2 DMR291 "Height, head and thorax circumference at
birth
Placenta Birth
"POMC96 "Obesity at age 11 years Peripheral blood 11 years
"IGF2/H19 ICR97 #Early childhood head circumference Peripheral blood 1–10 years
"H19 ICR,62 "HSD262 "Weight in adulthood Peripheral blood 40 years
"H19 ICR,62 "HSD2,62
"NR3C1 exon 1C62
"Waist circumference in adulthood Peripheral blood 40 years
"POMC,43 "H19 ICR,62
"HSD2,62 "NR3C1
exon 1C,62 #LEP98
"BMI in adulthood Peripheral blood 48,43 40,62 34.798 years
"RXRA55 "Adiposity at age 9 years Cord blood Birth
#LEP99 "Obesity at age 10–15 years Saliva 10–15 years
#LEP100 "Obese subjects with insulin resistance at age
10-16 years
Peripheral blood 10–16 years
"IGF2/H19 ICR97 "Skinfold thickness and subcutaneous
adiposity at age 17 years
Peripheral blood 17 years
Skeletal growth and bone quality
#RXRA75 "Bone mineral content at age 4 years Cord blood Birth
Cardiometabolic outcomes
"LEP98 "Fasting low-density lipoproteincholesterol
levels in adulthood
Peripheral blood,
Subcutaneous adipose
tissue
34.7 years
"H19 ICR,62 # NR3C1 exon
1F,62 "HSD262
"Blood pressure in adulthood Peripheral blood 40 years
#LEP101 "High-density lipoprotein (HDL) profile Peripheral blood 17 months
"IGF2102 "Triglycerides (TG), "TG:HDL Peripheral blood 11.6 years
Cognitive outcomes
"IGF263 "Early onset conduct problem, attention-
deficit/hyperactivity disorder
Cord blood Birth
"NR3C1,103,104 #HSD2103,104 "Risk of being in a poorly regulated neurobe-
havioural profile
Placenta, Buccal cells Birth
"LEP105 "Lethargy and hypotonicity Placenta Birth
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gene loci.109 Differences in methylation at these loci have
also been associated with less extreme growth-related phe-
notypes. In a study of 50 French-Canadian mothers and
infants, 31% of variance in birthweight was attributed
jointly to differential IGF2/H19 methylation and genotype
of a particular IGF2/H19 polymorphism (rs2107425).91
The direction of association between methylation and birth-
weight, however, varies by study and tissue analysed.90,91
For example, hypomethylation at IGF2 DMRs have been
associated with both increased and decreased birth-
weight.52,83,90,95,110 Some studies have found no association
with birthweight.111 Further examples of the complex rela-
tionship between DNA methylation at various IGF2/H19
DMRs and infant growth phenotypes are detailed in
Supplementary Table 2, available as Supplementary data at
IJE online.
The paternally expressed imprinted gene MEST acts as
an inhibitor of human adipogenesis and is involved in skel-
etal muscle growth and development.112 In placenta, in-
creased methylation at the MEST transcription start site is
correlated with reduced gene expression and IUGR.93,113
Increased methylation at the paternally expressed
PLAGL1, which codes for a cell growth suppressor pro-
tein, is associated with higher birthweight and weight at 1
year of age.40
Some studies have associated other (non-imprinted)
genes with birth size. For example, small-for-gestational
age newborns had higher methylation at LEP in cord
blood than appropriate-for-gestational age infants.94
Methylation at CpGs within HSD11B2, which codes for
the enzyme responsible for catalyzing the conversion of
cortisol to inactive cortisone, has been inversely related to
newborn ponderal index in a cohort study.62
A small number of studies have investigated links be-
tween maternal nutrition, DNA methylation and newborn
size. One study found that higher maternal erythrocyte fo-
late levels in the first trimester were associated with de-
creased methylation in cord blood at MEG3, PLAGL1
and PEG3, and increased methylation at IGF2.56 Folate
concentration and methylation at five DMRs were posi-
tively associated with birthweight. The authors hypothe-
siszed that the association of folate with birthweight could
be mediated by differential methylation at MEG3, H19
and PLAGL1, with MEG3 contributing the strongest ef-
fect. Another cohort study found that higher maternal
plasma glucose and omega-6 PUFA concentrations in the
third trimester were associated with increased infant meth-
ylation at IGDCC4 and CACNA1G, and decreased meth-
ylation at MIRLET7BHG. These methylation patterns
were all associated with higher birthweight.66
Adiposity: a case-control study in Germany found that
obese adults (BMI>35 kg/m2) demonstrated lower
methylation at MEST than in controls (BMI<25 kg/m2),
and used a separate dataset to suggest that such outcomes
may be partially caused by intrauterine exposure to gesta-
tional diabetes mellitus.114 In obese boys from the USA, an
inverse association was reported between LEP methylation
in buccal DNA and BMI, waist circumference (as z-scores)
and percentage body fat.99 NR3C1 Exon 1 C methylation
has been positively associated with waist circumference
and BMI at age 40 years,62 and increased IGF2/H19 meth-
ylation has been associated with increased skinfold thick-
ness and subcutaneous adiposity at age 17 years.97
A number of studies have investigated maternal nutri-
tional exposure, DNA methylation and child adiposity.
POMC codes for melanocyte-stimulating hormone (MSH)
and is involved with leptin in the regulation of body
weight. POMC is an ME, and children conceived in the
dry season in The Gambia had lower DNA methylation at
a POMC variably methylated region (VMR) compared
with those conceived in the rainy season.43 POMC VMR
methylation influences POMC expression,96 and methyla-
tion at this locus in blood and MSH-positive neurons is as-
sociated with BMI and obesity in children and adults.43
Godfrey et al. (2011) found that lower carbohydrate intake
during early pregnancy was associated with increased um-
bilical cord tissue methylation at RXRA, which in turn
was associated with greater adiposity in the offspring at
9 years of age.55
Skeletal growth and bone quality: RXRA forms hetero-
dimers with vitamin D (and other nuclear) receptors, facili-
tating their role in the regulation of bone metabolism.115,116
Differential methylation of specific CpGs in RXRA in cord
blood DNA has been inversely associated with percentage
bone mineral content and bone mineral content adjusted for
body size, measured at age 4 years, and also with maternal
free 25(OH)-vitamin D index.75
Cardiometabolic outcomes
Maternal nutritional status during pregnancy and factors
influencing fetal growth have been implicated in the aetiol-
ogy of cardiometabolic outcomes such as dyslipidaemia,
hypertension, type 2 diabetes (T2D) and cardiovascular
disease later in life.117,118
Leptin has been studied extensively in the domain of
cardiometabolic outcomes, owing to its role in metabolism
and regulation of body weight.119 LEP methylation at a
specific CpG in blood and subcutaneous adipose tissue has
been positively associated with low-density lipoprotein
cholesterol levels in very obese (BMI>40 kg/m2) adults.98
In the same study, methylation at the LEP promoter was
inversely correlated with BMI.98 A different study found
an inverse relationship between LEP methylation in whole
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blood and high-density lipoprotein cholesterol levels in 17-
month-old infants.101 Furthermore, lower methylation in
CpGs near the LEP transcription start site has been ob-
served in adolescents with obesity and insulin resistance,
although not with obesity alone.100 IGF2 methylation has
also been related to lipid profile in obese children aged
11 years; those with intermediate methylation at the IGF2
P3 promoter had higher triglycerides (TG) and a higher
TG:high-density lipoprotein cholesterol ratio than those
with hypomethylation.102 HSD2 methylation has been
positively associated with systolic blood pressure,62 and
NR3C1 exon1F and H19 ICR methylation also show posi-
tive associations with both systolic and diastolic blood
pressures in adults.62 Note that adiposity and obesity
(reviewed above) are also important risk factors that,
alongside other markers, can signal increased risk of ad-
verse cardiometabolic outcomes.120
Cognitive outcomes
The glucocorticoid receptors modulate the action of gluco-
corticoids and are involved in brain development and func-
tion.121 NR3C1 and HSD11B2 genes regulate the action
of cortisol and have been well studied in relation to neuro-
behaviour. Increased methylation at the NR3C1 promoter
and decreased methylation in HSD11B2 in placental and
infant buccal cell DNA have been associated with a high-
risk neurobehavioural profile characterized by poor atten-
tion, high excitability, low quality of movement and signs
of stress.103,104 An increase in LEP methylation in placen-
tal DNA has been associated with an increased risk of leth-
argy and hypotonia among male infants.105 Increased
methylation at IGF2 in cord blood has been associated
with early onset persistent attention-deficit/ hyperactivity
disorder (ADHD) in children between 7 and 13 years of
age.63
Candidate gene data summary
In Table 4 we provide further details of the 45 ‘candidate
genes’ highlighted so far in this review. This includes infor-
mation on their genomic location, the studies that consid-
ered them, regions of interest (ROIs) analysed and the
coverage of ROIs on Illumina Infinium Methylation bead-
chip arrays.
Discussion
In this review we have described evidence in humans link-
ing maternal nutrition during pregnancy with DNA meth-
ylation in the offspring, and linking DNA methylation at
nutrition-sensitive loci to phenotypes at birth and
outcomes in later life. As with all reviews, publication bias
can mean that null findings may have been under-reported,
and studies that do report associations may sometimes rely
on post hoc subgroup analyses for significant findings.
There are also numerous challenges specific to both the de-
sign and interpretation of intergenerational nutritional epi-
genetics studies which we discuss in the following sections.
Measuring nutritional exposures
Methods for measuring maternal nutritional exposure
have limitations. For example, one of the most commonly
used methods for this purpose are food frequency question-
naires, which suffer from recall bias and have differing va-
lidity by micronutrient.123 Weighed records require
accurate, context-specific dietary databases and well-
trained data collectors, and may not accurately reflect nor-
mal eating habits.124 However, these two approaches have
the advantage of capturing food groups and combinations
of nutrients that more direct tissue nutritional biomarkers
can overlook.125 Plasma biomarkers are challenging to in-
terpret, given that they represent nutrient levels after ab-
sorption and through interaction with genotype, and are
not simple reflections of dietary intake. Concentrations do
not capture metabolite flux, and can be misleadingly low if
tissue uptake is rapid. Of particular relevance to maternal
gestational samples is the effect of haemodilution, which
can lower several biomarker concentrations.126 Maternal
plasma nutrient concentrations are assumed to reflect die-
tary intake, and to correlate with cord blood concentra-
tions and nutrient levels in fetal tissue, which may not be
the case. Whereas positive correlations between maternal
serum and cord blood serum are found for homocysteine,
betaine, folate and B12, cord blood levels are multiple
times higher, suggesting that these nutrients are homeo-
statically controlled to ensure fetal supply.127 In the con-
text of periconceptional studies, more research is needed
on which accessible tissues best represent the nutritional
milieu surrounding the developing embryo in the initial
days after fertilization. In the meantime, serum or plasma
levels, though imperfect, are likely to offer a more accurate
representation of fetal nutrient exposure than dietary in-
take methods.
Most of the attention on nutritional exposures has
focused on the provision of methyl groups and the necessary
co-factors for DNA methylation. However, the periconcep-
tional period is marked by an initial wave of demethylation
to erase parental epigenetic marks, before the process of
remethylation.27 It is therefore important to consider the
role nutrition could play in influencing demethylation.
In demethylation, 5-methylcytosine is sequentially oxidized
to 5-hydroxymethylcytosine and 5-formylcytosine (5fC)
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by 10-11 translocation (TET) dioxygenases that use vitamin
C (ascorbate) as a co-factor.128 5fC can then either be fur-
ther oxidized to 5-carboxylcytosine or converted to an
unmethylated cytosine by base excision repair. Adding vita-
min C to mouse or human embryonic stem cells in vitro
increases the activity of TET enzymes, resulting in active de-
methylation in the germline.129 However, to our knowledge
there have been no human in vivo studies exploring effects
of periconceptional vitamin C deficiency on offspring DNA
methylation.
Nutritional compounds do not act in isolation, and ide-
ally analyses should recognize this by considering their inter-
actions in metabolic pathways. For example, one-carbon
metabolism is governed by intricately controlled feedback
loops which help protect the flux of metabolites, through
key reactions over a range of nutrient and co-factor concen-
trations.130,131 This means that associations between indi-
vidual micronutrients and methylation (e.g. the commonly
analysed methyl donors folate and betaine) can disappear
after adjustment for other metabolites (e.g. SAM and DMG,
which can inhibit transmethylation reaction rates).
Advances in measurement technology that allow the mea-
surement of a greater range of nutritional biomarkers (e.g.
metabolomics), combined with more sophisticated analyti-
cal techniques,132,133 should enable a more nuanced under-
standing of the ways in which nutritional biomarkers
combine to jointly influence methylation.
Measuring DNA methylation
A single CpG site in a single cell is either methylated or
unmethylated, but measurements are typically made at the
tissue level where methylation is a quantitative measure
corresponding to the proportion of methylated cells.134
Accurate assessment of tissue-level DNA methylation pat-
terns presents a challenge, given the sensitivity of the meas-
urements to both technical and biological variation. The
advent of high-throughput, genome-wide microarray plat-
forms, such as the Illumina HumanMethylation 450 K and
EPIC arrays,135–137 has helped in this regard, first by help-
ing to standardize aspects of epigenome-wide association
study (EWAS) design, and second by reducing the cost of
genome-wide methylation assays required for adequately
powered large studies.
Microarray-based EWAS have a number of limitations.
First, by design, only a small proportion of the methylome
is interrogated. These platforms attempt to include CpGs
sites from all annotated genes, but the number of CpG sites
per gene is low and equal coverage is typically not given to
all genomic features and/or CpG contexts, with the focus
having traditionally been on sites in promoters and CpG
islands. Second, arrays provide no information onT
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sequence-level variation, which is known to influence
methylation status.138,139 Finally, bioinformatics and ana-
lytical expertise are required (as well as the necessary com-
putational resources) to process and model the data, and to
correct for batch and other technical effects, in order to
obtain reliable, high-quality methylation profiles.140 As an
alternative, true genome-wide approaches such as whole-
genome bisulphite sequencing (WGBS) are available which
interrogate all 28 million CpG sites in the methylome, al-
though this is currently prohibitively expensive for larger
samples. Targeted high-resolution platforms141,142 offer a
potential compromise between coverage and cost, but their
utility, convenience and cost-effectiveness for performing
EWAS remain to be established. Given the importance of
demethylation during periconceptional epigenetic remodel-
ling, it may also be important to consider the oxidized
forms of 5-methyl cytosine (e.g. 5-hydroxymethylcytosine)
which occur as intermediate products in the demethylation
pathway.143
Tissue specificity, confounding and stability of
methylation across the life course
The tissue-specific nature of DNA methylation presents a
major challenge for epigenetic association studies.134,144
The majority of studies reported in this review are con-
strained to accessible tissues such as cord blood that may
be unrelated to the phenotype of interest, and different tis-
sues may be sensitive to different environmental exposures.
In this case reference epigenomes from different tissues and
cell types in both healthy and diseased individuals145 may
inform the choice of tissue as well as providing data for
investigating the tissue specificity of identified signals.
Where exposure-related effects occur during early embry-
onic development, before gastrulation, methylation
changes may be concordant across multiple tissues,146 so
that methylation states in accessible tissues such as blood
and buccal cells may serve as a proxy for methylation in
the target tissue.
Furthermore, numerous biological factors may act as
potential confounders, for example age, sex, smoking sta-
tus and BMI. Tissue-specific methylation differences aris-
ing from cell type heterogeneity, notably in blood, can also
act as confounders,147 although there are well-established
methods that can be used to correct for this.147,148
DNA sequence polymorphisms are also known to influ-
ence DNA methylation status and may confound observed
associations.149 Heritability of DNA methylation is esti-
mated to be in the range of 18% to 37%.150,151 Consistent
with this, many studies have shown that methylation quan-
titative trait loci (mQTL)—genetic variants associated with
methylation differences at the population level—are
widespread. To account for this, ideally high-throughput
genotype data on the sample being studied should be
used149 but, if such data are unavailable, population-level
reference mQTL data can be informative.139
Finally, methylation changes associated with an early-
life exposure may change throughout the life course, with
implications for their utility as biomarkers of exposure or
predictors of later phenotype.152–154 Depending on the re-
search question, this may suggest the need to assess long-
term stability of methylation at specific loci, through the
collection of longitudinal samples.
Linking methylation changes to gene function
Many of the DNA methylation changes reported in studies
covered in this review are small, often within the margins
of error of the measuring technology, making it difficult to
draw conclusions on their functional relevance.155 Indeed,
relatively few methylation studies measure gene expres-
sion. The link between DNA methylation and expression is
complex, depending on genomic context (e.g. location
with gene bodies, promoters and enhancers).156 This could
in part explain seemingly contradictory findings from dif-
ferent studies measuring associations at the same gene.
Moreover, a change in methylation may influence tran-
scription factor binding and the induction of a specific sig-
nalling pathway in order to observe a change in gene
expression. To aid further understanding, future studies
should therefore consider measuring transcription factor
binding, markers of gene transcription (mRNA levels),
and/or translation (protein levels), to better map the poten-
tial effects of DNA methylation differences on gene
function.157
Capturing phenotypes
In this review we have focused on phenotypic outcomes
most commonly considered in the DOHaD context.
However, we do not wish to exclude the possibility that
there may be a broader range of phenotypes that are impli-
cated. For example, exposure to the Dutch Hunger Winter
famine during pregnancy has been associated with a wide
variety of offspring phenotypes, varying according to the
timing of famine exposure during gestation.45,47
Consideration of the ‘thrifty epigenotype’ hypothesis24
would suggest that famine-imposed epigenetic modifica-
tions in early life are adaptive where similar environment
conditions persist, but maladaptive otherwise. There could
therefore be a spectrum of phenotypes according to how
great the mismatch is between in utero and later life envi-
ronments. In the case of complex traits such as obesity, the
resultant phenotype may also be influenced by factors such
International Journal of Epidemiology, 2018, Vol. 0, No. 0 21
Downloaded from https://academic.oup.com/ije/advance-article-abstract/doi/10.1093/ije/dyy153/5075855
by guest
on 02 September 2018
as diet and lifestyle in conjunction with methylation differ-
ences and genotype of the individual.158
Causal inference
A major goal of nutritional epigenetic studies, also covered
in this review, is to assess the potential for epigenetic
marks to mediate links between nutritional exposures and
health outcomes. In this context, the use of prospective
study designs with randomization including negative con-
trols, and techniques such as mediation analysis based on
regression systems,159 structural equation modelling160 or
network-based techniques,161 parametric/semi-parametric
methods,162 or instrumental variable approaches such as
Mendelian randomization,80,163,164 can help to strengthen
causal inference. More broadly, triangulating findings
from diverse studies, each with their own strengths, limita-
tions, assumptions and opposing biases, will maximize the
potential for robust findings.165,166
Study design considerations
The literature in this area is dominated by observational
studies. This increases the risk of spurious associations due
to confounding or reverse causation,149 the latter being a
particular problem with methylation association studies
where the direction of causality can be hard to establish.
Added to this, effect sizes are generally modest, with
group-level differences in mean methylation typically less
than 10% and often in the region of 1–5% for many of the
exposures and phenotypes studied.155,167,168 This has
implications for the design of studies characterizing
genome-wide, population-level methylation differences, as
they need to be adequately powered to detect potentially
small effects after adjusting for multiple testing.169
Current interest in periconceptional nutrition has stimu-
lated a number of preconceptional nutrition trials.170–174
In these studies, supplementation before conception is nec-
essary to ensure that the conception period is covered and
that a maximal effect on maternal nutritional status at con-
ception is achieved. Nonetheless, accurately pinpointing
the timing of nutritional exposures to conception is
challenging.
Conclusions
The body of evidence linking maternal nutritional exposure
to offspring phenotype via DNA methylation in humans is
rapidly growing yet currently remains complex and incon-
sistent. It is characterized by heterogeneous exposures and
outcomes, and mainly observational associations that are
frequently under-powered. Existing evidence suggests that
the effect of nutritional exposures on DNA methylation
depends on the form of the nutritional component, the tim-
ing of exposure during periconception and pregnancy, the
underlying nutritional status of the mother, maternal and
offspring genotype and the specific loci under investigation.
The picture is more complex than methylation being deter-
mined simply by availability of methyl donors. Many stud-
ies have investigated imprinted genes as priority loci for
their vulnerability to nutritional exposures, but with the
adoption of microarray-based platforms, other candidate
genes and gene classes are emerging, for example metastable
epialleles.
The utility of this emerging evidence in terms of its
translation into effective interventions and therapies
remains an open question. Epigenetic marks like DNA
methylation may act as integrators of multiple exposures
and genetic risk factors, as well as molecular mediators of
the effect of exposures on phenotype. Where robust associ-
ations are established, DNA methylation can serve as a
proxy measure or biomarker of earlier nutritional expo-
sures.175 As mediators of the effect on later phenotype, nu-
tritionally sensitive DNA methylation changes can provide
a means to identify genes and pathways for targeted inter-
ventions. Whereas there is still much work to do in this
area, there are grounds for optimism that epigenomic
approaches will provide insights into the molecular basis
of the developmental origins of health and disease, which
could in turn lead to the development of next-generation
interventions.
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Chapter 4 Variation in plasma biomarker 
concentrations over the year in the Methyl Donors 
and Epigenetics-2 dataset  
__________________________________________________________________________ 
 
Summary of Chapter 
 
Background: In The Gambia previous studies have shown that plasma concentrations of one-
carbon biomarkers vary over the year, and that maternal concentrations of some of these at 
the time of conception predict infant DNA methylation at various genomic loci. 
 
Objective: The four objectives of this chapter were to describe the variation in 
concentrations of an expanded set of plasma biomarkers over the year, including amino 
acids; to assess the degree of replication of previous yearly trends; to check for new seasonal 
windows of nutritional vulnerability, and to provide a dataset ready for downstream 
nutrition-methylation analysis. 
 
Methods: Banked plasma samples from 350 pregnant women in their first trimester were 
analysed for 26 metabolites. Samples were purposively selected to span the whole year. All 
plasma biomarkers were pre-adjusted for inflammation, age, body mass index and 
gestational age, and were assessed for evidence of periodic variation over the year. Those 
demonstrating a periodic pattern were fitted using Fourier term linear regression models to 
visualise the periodic variation over the year. The amplitude of the periodic variation was 
calculated using the coefficient of cyclic variation (CCV). The timing of peaks and troughs of 
the trends were compared with data from previous studies.   
 
Results: All core one-carbon biomarkers apart from methionine and dimethylglycine (DMG) 
demonstrated a periodic pattern, along with six of the other amino acids. For the biomarkers 
showing evidence of periodic variation, the Fourier term regressions explained between 
2.3% to 10.1% of the variability. The magnitude of the periodic variation (CCV) varied from 
3.5% to 16.2%. Comparison of the peaks and troughs of biomarker trends with previous 
studies demonstrated good replication, with the exception of DMG. 
 
Conclusions: Fitted trends using Fourier term regression models explained relatively little of 
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the overall variation of biomarker concentrations. However, small fluctuations in individual 
biomarkers may combine to exert larger effects on methylation potential and DNA 
methylation, to be considered in future analyses. There is no clear-cut season of deficiency 
and adequacy, although a possible new window of nutritional vulnerability to consider is 
September to October.  
 
Notes 
 
Four documents in the Annexes provide additional details for this chapter: 
 
 An overview of how a systems biology approach can be used to consider the entirety 
of human metabolic pathways (Annex 4.1). 
 A detailed primer on how to use Fourier term regression modelling to represent 
periodic trends, and how such models are used to back-extrapolate data to the time 
of conception (Annex 4.2). 
 Details of all the plasma biomarkers assessed, with information on their role in one-
carbon metabolism, possible changes in concentration during pregnancy and 
storage, and their correlation with dietary intake data (Annex 4.3). 
 Annotated one-carbon metabolic pathway diagrams further justifying the rationale 
for biomarker choice and providing background on biochemistry (Annex 4.4).  
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4.1  Introduction 
 
In this chapter I explore the extent to which a broad range of nutritional plasma biomarkers 
in pregnant women from rural Gambia demonstrate a periodic variation over the year and 
whether they co-vary in the expected ways. This builds on previous work performed by 
Dominguez-Salas et al. (2013)(1) using the ‘Indicator group’, described in Chapter 2. In brief, 
the Indicator group study team followed approximately 30 non-pregnant women in West 
Kiang region for one year. Each month they took a fasted venepuncture sample and analysed 
plasma concentrations of one-carbon biomarkers. Regression models using Fourier terms 
were used to represent the periodic variation that the biomarkers displayed over the year. 
The Indicator group data were also used to assess whether there were differences in plasma 
concentrations of one-carbon biomarkers between the peak rainy (July-September) and peak 
dry (February-April) seasons, under the hypothesis that marked variation in dietary intake 
between the two seasons would influence nutrient status. The Indicator group findings 
suggested that one-carbon biomarkers did show evidence of periodic patterns, and that 
folate, betaine, B2 and the S-adenosyl methionine (SAM): S-adenosyl homocysteine (SAH) 
ratio were higher in the rainy season, suggesting a higher methylation potential.  
I investigate a subsample of 350 pregnant mothers enrolled into the ENID trial to form the 
‘MDEG-2’ dataset, introduced in Chapter 2. The plasma samples form a baseline that spans 
the whole year, enabling an analysis of periodic patterns across the year. A key difference, 
however, is that the MDEG-2 samples are cross-sectional (one time-point, 350 women), 
whereas the indicator group is composed of repeated measurements.  
I had four main aims forming the rationale of the analyses in this chapter:  
 
1. Expanding the set of plasma biomarkers to include amino acids 
Whilst the one-carbon metabolic pathways investigated in the Indicator group are 
the ones most proximal to DNA methylation, my collaborators and I wanted to 
broaden the investigation to other related pathways that may have been previously 
overlooked. We therefore included a panel of amino acids since several amino acids 
are thought to contribute one-carbon units(2), and in turn deficiencies in one-carbon-
related analytes may affect amino acid metabolism(3–5). Originally as part of this aim 
my collaborators and I had considered integrating as much plasma concentration 
information as resources enabled into a systems biology model that sought to 
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represent the whole human metabolome. I provide details of the original systems 
biology plans in Annex 4.1. The intention of this approach was to use a platform that 
could enable us to interrogate other metabolic pathways outside the core one-
carbon pathways.  Although this collaboration did not work out I chose to continue 
the exploration of the additional metabolites in the analyses described in this 
chapter, in the expectation they could still potentially identify pathways distal to the 
‘core’ one-carbon ones to consider.   
 
2. Replication of previous yearly trends  
Analysis of the MDEG-2 dataset provided an opportunity to assess the extent of 
replication of yearly trends seen in both the MDEG Indicator group and main study 
group. These studies have been introduced in Chapter 2 (summary in Table 2.1). As 
part of this aim I sought to determine the whether the MDEG-2 dataset, a cross-
sectional sample of women taken from throughout the year, would enable any 
periodic patterns to emerge, or whether there would be too much inter-individual 
variation for this.   
 
3. Defining seasonal windows of nutritional vulnerability 
I wanted to investigate in greater detail whether the ‘peak seasons’ used in previous 
studies (the Indicator group and MDEG main study(1,6)) were the best time points to 
consider, or whether there were other windows where women were particularly 
vulnerable to nutritional deficiencies. This might inform a suitable timeframe for the 
supplementation trial detailed in Chapter 8, as well as delineate specific windows for 
investigation in future studies using this dataset.  
 
4. Preparation for downstream nutrition-methylation analysis 
Finally, I aimed to provide a detailed description of the nutritional status of this 
subsample in preparation for future planned studies that will explore nutritional 
predictors of infant DNA methylation throughout the year (and not just in peak 
seasons as in the MDEG main study(6)). I intend to using the Fourier term regression 
models outlined in this chapter to be able to back-extrapolate the biomarker 
concentrations to the time of conception. I provide an example of how this will be 
done in Annex 4.2. This will enable continued exploration of periconceptional 
nutritional exposures and their association with offspring methylation. This chapter 
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will help establish where the equations come from for the back-extrapolation, and 
will also provide transparency on the strengths and weaknesses of the modelling 
approach.  
The role of nutritional components in one-carbon metabolic pathways has been reviewed in 
Chapter 3. However, Annex 4.3 provides a summary of the core one-carbon biomarkers with 
a reminder of their relevance, as well as detailing factors that may affect their plasma 
concentration (such as stage of pregnancy and storage). The one-carbon metabolic pathways 
are further explained in Annex 4.4, which provides annotated metabolic pathway diagrams 
highlighting the role of the chosen metabolites. These illustrate in more detail how the 
transmethylation, folate, methionine and transsulfuration pathways intersect and justify the 
choice of the additional metabolites included in the expanded biomarker set.  
4.2  Methods 
4.2.1  Sample population 
I used a subsample of banked plasma aliquots obtained from pregnant women in their first 
trimester enrolling onto the ENID Trial, described in Chapter 2. Women provided their blood 
samples on enrolment, referred to as their ‘booking’ visit. This was before they received any 
supplements from the ENID trial and formed the baseline measurements. I selected the 
subsample of 350 women aiming to obtain as equal a proportion of women per booking 
month as possible, and choosing the earliest gestational ages within each month of booking. 
Figure 4.1 shows the flow diagram for the purposive selection of the 350 women in the 
subsample from 688 eligible women enrolled into the ENID Trial. Gestational age was 
estimated by ultrasound by study midwives. The sample size was chosen on the basis that 
this provided approximately 30 women per month, which was the sample size of the 
Indicator group.  
4.2.2  Laboratory analyses 
The mothers’ data is comprised of nutritional biomarkers analysed from EDTA-treated 
plasma. The following biomarkers were measured: choline, betaine, dimethylglycine (DMG), 
homocysteine, folate, vitamin B12, B6 vitamers (4-pyridoxic acid (PA), pyridoxal (PL) and 
pyridoxal-5’-phosphate (PLP)), vitamin B2, α-1-acid glycoprotein (AGP), cysteine, 
methionine, serine, glycine, alanine, arginine, aspartic acid, glutamic acid, histidine, 
isoleucine, leucine, lysine, phenylalanine, proline, threonine, tryptophan, tyrosine and 
valine.  
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Figure 4.1 Flow diagram showing the number of women enrolled onto the ENID trial and 
subsequent subsampling for this MDEG-2 study. 
 
Vitamin B12 and folate were measured using an Abbott AxSYM autoanalyzer. Choline, 
betaine, DMG, homocysteine, folate, B6 vitamers (PA, PL, PLP) and vitamin B2 were 
measured using liquid chromatography-tandem mass spectrometry. The amino acids were 
analysed using a Hitachi L-8900 amino acid analyser. All of these biomarkers were measured 
at the Child and Family Research Institute at the University of British Columbia. The 
inflammatory marker AGP was measured using the Cobas Integra 400 plus autoanalyser at 
MRC The Gambia, Keneba field station. All intra- and inter-assay coefficients of variation are 
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presented in Supplementary Table 4.1. Of the B6 vitamers I chose to solely present PLP, since 
this is the active component used as a coenzyme in reactions relevant to one-carbon 
metabolism. 
The original plan was also to measure S-adenosyl methionine (SAM), S-adenosyl 
homocysteine (SAH), decarboxylated SAM (dc-SAM), formate and active B12 
(holotranscobalamin). This was not possible, either due to degradation of the samples (SAM, 
SAH and dc-SAM), insufficient plasma volume (active B12) or assay failure (formate). 
In the analyses the biomarkers that were measured both in the Indicator group and in this 
dataset are termed ‘core one-carbon biomarkers’ (choline, betaine, DMG, homocysteine, 
folate, vitamin B12, PLP, vitamin B2, cysteine and methionine). The new metabolites 
included in this dataset are referred to as the ‘other amino acids’ (serine, glycine, alanine, 
arginine, aspartic acid, glutamic acid, histidine, isoleucine, leucine, lysine, phenylalanine, 
proline, threonine, tryptophan, tyrosine and valine).  
4.2.3  Data preparation 
Outliers in the plasma biomarkers were defined as those having a z-score of <-6 or >6.  The 
number of exclusions made per biomarker, along with the justification, is summarised in 
Supplementary Table 4.1, including the number of samples that did not have sufficient 
plasma to assay.  
4.2.4  Statistical analyses 
I used Stata 15.1 (StataCorp LLC, USA) for all analyses. I assessed the normality of the 
biomarker data by performing a skewness-kurtosis test based on D’Agostino et al. (1990)(7) 
(using the command ‘sktest’ in Stata). Biomarkers were skewed to the right and were 
therefore log-transformed to better approximate a normal distribution. For the baseline 
table I summarised overall (12-month) geometric means and 95% confidence intervals. For 
comparison with the Indicator group I also summarised the portions of the subsample falling 
into the peak rainy (July-October) and peak dry (February-April) seasons. I compared the 
rainy and dry season subsamples using the Wilcoxon rank-sum test.  
I pre-adjusted the plasma biomarkers before use in regression models for four a priori 
confounders: inflammation, age, body mass index (BMI) and gestational age. This was done 
to remove known associations with biomarkers that might mask any underlying periodic 
variation. Inflammatory markers are often overlooked in one-carbon biomarker analyses, but 
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have been shown in previous studies to be inversely associated with concentrations of PLP(8). 
Age has the potential to influence nutrient status through influence on dietary intake, 
pathological and physiological changes(9–11). BMI has been associated with several nutrient 
concentrations, including one-carbon biomarkers, in previous studies(12,13).  Gestational age 
may have an influence on biomarker concentrations through physiological changes in 
pregnancy, for example, through haemodilution (see examples provided in Annex 4.3). As in 
Dominguez-Salas (2014)(6), I generated the first three orthogonal polynomials for gestational 
age. I then regressed the log-transformed biomarker against the gestational age polynomials, 
maternal age, maternal BMI and AGP (a measure of chronic inflammation). I added the 
regression residuals to the constant to obtain the adjusted variables to take forwards into 
Fourier term regressions.  
Periodic patterns are variations around a mean that can be modelled using Fourier terms 
(FTs) in linear regression models. These models introduce sine and cosine waves to represent 
the periodic / cyclical fluctuation of biomarker concentrations over the year.  In Annex 4.2 I 
provide a primer of how to generate the FTs, how to assess whether it is appropriate to 
model a periodic pattern or not, and if so, how to choose the number of pairs of FTs to 
include in the linear regression model. For those biomarkers demonstrating a periodic 
pattern I measured the magnitude by calculating the ‘coefficient of cyclic variation (CCV)’. 
This is determined by the square root of half the sum of the squared Fourier term 
coefficients(14). The CCV is a standardised statistic that enables us to directly compare the 
extent of periodic variation between biomarkers and between datasets, regardless of the 
original units of the biomarker concentrations.  
The biomarker data were visualised by plotting the exponentials of the individual pre-
adjusted data points along with their fitted periodic variation curves (the mean and 95% 
confidence intervals (CI) of the fitted predictions from the appropriate FT regression). If there 
was no evidence for a trend I simply plotted the mean (95% CI) of the adjusted biomarkers. 
Given the biomarkers have a variety of measurement units I also represented the periodic 
variations as change in percentage of the geometric mean in order to plot groups of 
metabolites on the same axis according to their metabolic pathways.  
I compared the trends with the Indicator group and the MDEG main study by checking the 
timing of the peaks and troughs of the trends over the year. The Indicator group trends are 
published in Figures 4E-G of Dominguez-Salas et al. (2013)(1). The MDEG main study trends 
for the two three-month peak season windows (before they were back-extrapolated to the 
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time of conception) are shown in Figure 1b and Supplementary Figure 1 of Dominguez-Salas 
et al. (2014)(6).  I also compared the CCVs with the Indicator group (these were not available 
for the MDEG main study since the data only covered ‘peak’ seasons comprising six months 
of the year). 
4.3  Results 
4.3.1  Sample population 
The proportion of women represented in the subsample per month of booking and their 
mean gestational age is shown in Figures 4.2 and 4.3 respectively. I also include a visual 
reminder of the definitions of the peak seasons, with peak dry season February to April and 
peak rainy season July to September. I was able to obtain data from each month of booking, 
although proportions were imbalanced, ranging from 6.0% in May to 10.9% in July. Mean 
(95% CI) gestational age per month of booking were within approximately two weeks of each 
other across the year, ranging from 11.2 (10.7, 11.7) weeks in July to 13.4 (12.0, 14.8) weeks 
in January.  
 
 
Figure 4.2 Proportion of women selected for the subsample per month of booking (n=350). 
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Figure 4.3 Mean (95% confidence interval) gestational age in weeks per month of booking 
(n=350). 
4.3.2  Baseline characteristics 
In Table 4.1 I summarise the overall geometric mean (95% CI) plasma biomarker 
concentrations, age, gestational age and BMI of the subsample. I also stratify these by peak 
season for comparison with Dominguez Sala et al. (2013)(1). Looking at the core one-carbon 
biomarkers, over 30% of the subsample had low B2, PLP and methionine status and 
approximately quarter of the subsample had low folate and betaine status. The subsample 
were relatively replete in B12, choline and cysteine and only 4% of the subsample were 
categorised as having hyperhomocysteinemia. Regarding the other amino acids the majority 
(>80%) of the population had geometric mean concentrations below the 10th percentile of a 
healthy population in Canada for arginine, histidine, leucine, lysine, tyrosine and valine. This 
proportion was between 60-80% for isoleucine, phenylalanine, proline, serine and threonine, 
whilst it approximately half the sample for alanine and glycine. The majority of the 
subsample (87.3%) showed no sign of chronic inflammation as measured by AGP. The 
women had a geometric mean (95% CI) age of 28.8 (28.1, 29.5) years and a geometric mean 
BMI of 20.8 (20.5-21.1) kg/m2. 
For the core one-carbon biomarkers where differences were detected between the peak 
seasons, homocysteine, PLP, B12, cysteine and DMG had higher concentrations in the peak 
dry season. Folate had a higher concentration in the peak rainy season. There was no 
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difference between peak season concentration of B2 and betaine. Amongst the other amino 
acids glycine was higher in the peak rainy season and histidine, leucine and lysine were higher 
in the peak dry season. There was no evidence of a difference amongst the remaining amino 
acids. There was also no evidence to suggest a difference in inflammation between the peak 
seasons. Women enrolled into the trial during the peak rainy season were slightly older (2.5 
years) than those enrolling in the peak dry season, but there was no evidence for a difference 
in gestational age nor BMI.  
4.3.3  Periodic patterns in biomarkers over the year 
Figures 4.4A-Y show the plasma biomarker values adjusted for age, gestational age, 
inflammation and BMI. Where there is evidence of a periodic pattern they are overlaid with 
the FT regression fitted curves, showing the mean and 95% CIs of the fitted values. Table 4.2 
provides further details of these models, presenting the number of pairs of FTs introduced 
into the regressions where there is evidence of a trend, the proportion of the variance 
explained by the model (R2 and adjusted R2), and the size of the periodic variation as 
determined by the CCV. I also compare whether the peaks and troughs of the core one-
carbon biomarkers coincide with those seen in previous studies. Figures 4.5A-D express the 
periodic co-variation of biomarkers in percentage of the geometric mean. Although the 
metabolic pathways overlap, I portray the folate, betaine and transsulfuration pathways 
separately and summarise the co-variation of the other amino acids displaying a trend.  
There was evidence of periodic variation for all of the core one-carbon biomarkers apart 
from methionine and DMG. The FTs explained between 2.2% (for B12) and 12.9% (for folate) 
of the variation in biomarker concentrations (adjusted R2). Six of the other 15 amino acids 
showed evidence of periodic patterns (glycine, histidine, leucine, lysine, proline and serine). 
The biomarker concentration variation explained by the models ranged from 2.3% (for 
serine) to 10.1% (for lysine). Comparing the magnitude of the periodic variation for 
biomarkers with a trend, measured by the CCV, shows that B2 had the greatest periodic 
variation (16.2%), followed by folate (15.1%). The smallest periodic variation was found 
amongst the amino acids histidine, leucine and serine, with CCVs of approximately 3.5%. 
In the folate pathway (Fig. 4.5A) homocysteine showed inverse periodic variation with folate, 
and to a slightly lesser extent, with B2. Peak folate /B2 and trough homocysteine were in 
June-July. The peak of B12 did not coincide with the other B vitamins, coming earlier in the 
year during April. In the betaine pathway (Fig. 4.5B) betaine and choline had peaks at 
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different times of the year, and these did not mirror homocysteine troughs, nor did DMG 
show evidence of any trend. In the transsulfuration pathway (Fig. 4.5C) PLP and cysteine 
periodic variations largely coincided with peaks in April-May and troughs in September-
October, although the amplitude of PLP was greater than that of cysteine. Homocysteine 
showed an inverse pattern to these, although with a lag of two months with its trough in 
July. Within the six other amino acids showing periodic variation (Fig. 4.5D), histidine and 
lysine had a similar pattern with peak concentration in May and lowest concentration in 
August-September. Proline and serine had similar trajectories to each other, although with 
a one-month lag and a more complex pattern due to each being fitted with three pairs of 
FTs. Leucine and glycine showed inverse associations, with peak leucine / trough glycine in 
March and trough leucine / peak glycine in September.  
4.3.4  Comparison with Indicator group and MDEG main study 
In the core one-carbon biomarkers there was a similar periodic pattern between the MDEG-
2 results and the previous Indicator group and MDEG main study cohort for homocysteine, 
folate, PLP and B12. Similar peaks but different troughs were found for B2 and betaine, and 
similar troughs but different peaks for choline and cysteine. Methionine and DMG showed 
different yearly patterns to past studies. The results suggested that neither methionine nor 
DMG showed evidence of a periodic pattern. In the previous studies although methionine 
had been fitted with Fourier terms the amplitude was very low, generating near-flat trends 
fairly similar to the current results. DMG differed the most out of the biomarkers, in past 
studies showing a periodic variation peaking in March and with a trough in July. Compared 
to the MDEG-2 findings the CCVs of the Indicator group were similar for B12, betaine and 
cysteine; smaller for B2, and larger for homocysteine, folate, PLP, choline, methionine and 
DMG.  
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Table 4.1 Baseline concentrations of nutritional biomarkers and characteristics of the sample population 
Variables 
12-month 
Cut-off for low / abnormal status; 
n (%) 
Dry season Rainy season 
P value* 
 N 
Geometric mean  
(95% CI) 
N 
Geometric mean 
(95% CI) 
N 
Geometric mean  
(95% CI) 
Core one-carbon biomarkers 
Homocysteine (µmol/L) 349 7.8  (7.5-8.0) >15µmol/L(15); 15 (4.3%)a 87 8.1 (7.7-8.5) 100 7.3 (6.8-7.8) 0.023 
Folate (nmol/L) 350 13.1 (12.5-13.7) <10nmol/L(16); 90 (25.7%) 87 11.5 (10.8-12.4) 100 13.8 (12.6-15.2) 0.006 
B2 (nmol/L) 347 13.5 (12.4-14.5) <10nmol/L(17)b; 136 (39.1%) 86 14.5 (12.3-17.1) 100 12.5 (10.8-14.4) 0.202 
PLP (nmol/L) 349 24.6 (23.5-25.8) <20nmol/L(18)c; 110 (31.5%) 87 28.4 (25.7-31.4) 100 23.1 (21.5-24.9) 0.001 
B12 (pmol/L) 350 
374.5  
(358.4-391.5) 
<221pmol/L(19); 33 (9.4%) 87 
402.5  
(368.7-439.3) 
100 
341.2  
(313.1- 372.0) 
0.005 
Choline (µmol/L) 348 7.3 (7.1-7.4) <5µmol/L(15)c; 9 (2.6%) 87 7.4 (7.1-7.7) 100 7.1 (6.8-7.3) 0.076 
Betaine (µmol/L) 350 20.3 (19.6-21.0) <16µmol/L(15)c; 85 (24.3%) 87 21.1 (19.7-22.5) 100 21.6 (20.2 -23.0) 0.676 
Methionine (µmol/L) 350 21.2 (20.8-21.6) <20µmol/L(20)d; 128 (36.6%) 87 21.5 (20.7-22.3) 100 21.1 (20.4-21.8) 0.490 
Cysteine (µmol/L) 350 
212.2 
(208.1-216.3) 
<36µmol/L(20)d; 0 (0%) 87 
224.5         
(216.8-232.4) 
100 
197.5         
(190.6-204.7) 
<0.001 
Dimethylglycine (µmol/L) 346 2.0 (1.9-2.2) Not establishede 85 2.3 (2.0-2.5) 99 1.9 (1.7-2.1) 0.024 
Other amino acids 
Alanine (µmol/L) 348 
236.7           
(231.1 -242.6) 
<240µmol/L(20)d; 172 (49.4%) 86 
233.6         
(223.1-244.7) 
98 
243.5         
(232.0-255.6) 
0.198 
Arginine (µmol/L) 346 51.0 (49.6-52.4) <68µmol/L(20)d; 303 (87.6%) 86 52.0 (49.3-54.8) 98 50.4 (47.6-53.3) 0.508 
Aspartate (µmol/L) 345 5.2 (5.0-5.4) <2µmol/L(20)d; 2 (0.6%) 86 5.3 (4.9-5.7) 98 5.0 (4.6-5.5) 0.706 
Glutamate (µmol/L) 344 53.0 (50.7-55.4) <11µmol/L(20)d; 0 (0%) 85 53.2 (48.9-58.0) 98 50.6 (46.9-54.6) 0.516 
Glycine (µmol/L) 346 
177.1  
(172.1-182.2) 
<183µmol/L(20)d; 189 (54.6%) 86 
159.6     
(151.9-167.8) 
98 
191.4    
(181.2-202.1) 
<0.001 
Histidine (µmol/L) 346 65.5 (64.6-66.4) <77µmol/L(20)d; 308 (89.0%) 86 67.8 (66.0-69.6) 98 62.5 (60.9-64.2) <0.001 
Isoleucine (µmol/L) 346 43.8 (43.0-44.6) <47µmol/L(20)d; 222 (64.1%) 86 44.7 (42.7-46.7) 98 43.1 (41.7-44.6) 0.443 
Leucine (µmol/L) 346 82.9 (81.5-84.4) <101µmol/L(20)d; 302 (86.8%) 86 85.2; (81.9-88.6) 98 79.0 (76.6-81.5) 0.008 
Lysine (µmol/L) 346 
108.3         
(106.2-110.4) 
<157µmol/L(20)d; 342 (98.3%) 86 
111.9         
(107.7-116.2) 
98 
101.5        
(97.7-105.5) 
<0.001 
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Variables 
12-month 
Cut-off for low / abnormal status; 
n (%) 
Dry season Rainy season 
P value* 
 N 
Geometric mean  
(95% CI) 
N 
Geometric mean 
(95% CI) 
N 
Geometric mean  
(95% CI) 
Phenylalanine (µmol/L) 346 45.1 (44.5-45.7) <47µmol/L(20)d; 231 (66.8%) 86 45.7 (44.2-47.1) 98 45.8 (44.7-47.0) 0.601 
Proline (µmol/L) 345 
103.4    
(100.7-106.1) 
<113µmol/L(20)d; 231 (67.0%) 86 
101.8          
(97.2-106.6) 
98 
109.4         
(103.6-115.4) 
0.062 
Serine (µmol/L) 346 92.5 (90.7-94.3) <101µmol/L(20)d; 245 (70.8%) 86 94.5 (91.1-98.1) 98 94.1 (90.9-97.3) 0.978 
Threonine (µmol/L) 346 
98.3  
(96.1-100.7) 
<104µmol/L(20)d; 209 (60.4%) 86 
97.1  
(92.2-102.3) 
98 
101.7  
(97.2-106.4) 
0.334 
Tyrosine (µmol/L) 346 38.4 (37.6-39.1) <46µmol/L(20)d; 288 (83.2%) 86 38.4 (36.9-40.0) 98 39.1 (37.6-40.6) 0.564 
Valine (µmol/L) 346 
150.9  
(148.6-153.2) 
<178µmol/L(20)d; 300 (86.7%) 86 
151.8         
(146.7-157.1) 
98 
147.1         
(142.9-151.5) 
0.192 
Inflammatory markers 
AGP (g/L) 346 0.74 (0.70-0.78) >1g/L(21)f; 44 (12.7%) 83 0.71 (0.64-0.80) 100 0.72 (0.68-0.76) 0.872 
Other variables 
Age (years) 350 28.8 (28.1-29.5) - 87 27.1 (25.8-28.5) 100 29.7 (28.4-31.0) 0.016 
BMI (kg/m2) 350 20.8 (20.5-21.1) - 87 20.3 (19.8-20.8) 100 20.7 (20.1-21.4) 0.431 
Gestational age (weeks) 350 11.6 (11.4-11.9) - 87 11.6 (11.2-12.0) 100 11.4 (11.0- 11.8) 0.320 
 
Abbreviations: CI, confidence interval; PLP, pyridoxal 5’-phopshate; AGP, Alpha-1-acid glycoprotein; BMI, body mass index. 
*P value from Wilcoxon rank-sum test comparing the peak dry (February-April) and rainy (July-October) season samples, for comparison with Dominguez-
Salas et al. (2013)(1). Results <0.05 in bold.  
aDenotes hyperhomocysteinemia. 
bThere are no clearly defined plasma cut-offs for riboflavin deficiency (normally erythrocyte riboflavin is used). This cut-off represents the 5th percentile of 
healthy controls in the European Prospective Investigation into Cancer and Nutrition study(17).  
cThere are no clearly defined plasma cut-offs for deficiency. The suggested cut-offs indicate below the normal range and can be considered ‘low status’. 
dThe amino acids cut-offs represent the 10th percentile of a healthy population age > 16years in Canada(20). Note these cut-offs do not necessarily represent 
low status nor deficiency. 
eBy way of comparison, in US, Nordic, Asian and Australian populations plasma dimethylglycine geometric mean ranges from 3.7-5.0µmol/L(22). 
fIndicates chronic inflammation.
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Figure 4.4A-Y: Plasma metabolite concentrations over the year, adjusted for age, gestational age, 
inflammation and BMI, showing individual data points and mean (95% CI) concentrations. Those 
with evidence of periodic variation show the fit obtained from the Fourier term linear regression 
models. 
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Table 4.2 Information on periodic variation fit for biomarkers in MDEG-2 and comparison with Indicator group and MDEG main study cohort. 
Biomarker Evidence 
for 
periodic 
variation?a 
No. of 
pairs of 
Fourier 
terms 
N R2 Adj. R2 CCV (%) 
(95% CI)b 
Timing of peaks and 
troughs 
Similar peak and 
trough months in 
Indicator group?c 
Similar peak and trough 
months in MDEG1 main 
study?d 
Core one-carbon biomarkers  
Homocysteine Yes 2 349 0.0390 0.0281 5.8  
(2.8, 8.9) 
Peaks: Apr & Oct 
Troughs: Jan & July 
Yes – same timing 
Larger CCV: 10.2  
(7.9-12.5)% 
Similar Peak: Apr &Sept 
Trough: June 
Folate Yes 3 350 0.1443 0.1293 15.1  
(11.2, 
19.0) 
Peak: June / July & 
Nov 
Trough: Sep & Jan-
Apr 
Yes – same timing 
Larger CCV: 23.8  
(20.5-26.5)% 
Yes – same timing 
B2e Yes 2 347 0.0481 0.0369 16.2  
(8.5, 23.8) 
Peak: June 
Trough: Oct 
Similar peak but trough 
in Feb. Lower CCV: 9.0  
(7.6-10.4)% 
Similar peak. Trough not 
covered in window.  
PLPf Yes 2 349 0.1190 0.1087 14.6  
(10.4, 
18.8) 
Peak: May 
Trough: Sep 
Yes – same timing 
Larger CCV: 26.2  
(22.4-30.0)% 
Yes – same timing 
B12 Yes 1 350 0.0278 0.0222 6.7  
(2.5, 10.9) 
Peak: Mar/Apr 
Trough: Sep/Oct 
Yes – same timing 
Similar CCV: 3.5  
(1.9-5.1)% 
Similar peak, 
indiscernible trough 
Choline Yes 2 348 0.0533 0.0423 4.9  
(2.7, 7.1) 
Peaks: Feb & Aug 
Troughs: May & Oct 
Similar trough in May 
but peak is Dec.  
Higher CCV: 11.1  
(8.9-13.4)% 
Similar troughs  
Peak not covered in 
window 
Betaine Yes 2 350 0.0385 0.0274 6.0  
(2.8, 9.2) 
Peaks: Mar & Sep 
Troughs: June & Dec 
Similar peak in Sep but 
not in Mar. One trough 
in Feb. Similar CCV: 9.8  
(7.6-12.0)% 
 
Yes – same timing 
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Biomarker Evidence 
for 
periodic 
variation?a 
No. of 
pairs of 
Fourier 
terms 
N R2 Adj. R2 CCV (%) 
(95% CI)b 
Timing of peaks and 
troughs 
Similar peak and 
trough months in 
Indicator group?c 
Similar peak and trough 
months in MDEG1 main 
study?d 
Methionine No - 350 - - - N/A Similar very flat trend, 
possible peak Aug & 
Mar, possible trough 
Dec. CCV of 3.9  
(2.0-5.8)% 
Similar flat trend 
Cysteine Yes 1 350 0.0895 0.0842 5.3  
(3.5, 7.0) 
Peak: Mar/Apr 
Trough: Oct 
Flat trend. Similar 
trough but possible 
peak Jun/Jul. Similar 
CCV: 4.1 (3.0-5.2)% 
Flat trend, no discernible 
peaks and troughs 
DMG No - 346 - - - N/A No – peak in Mar and 
trough in Jul. CCV 16.3 
(13.4-19.3)%. 
Trough also in Jul, peak 
not covered in window 
Other amino acids  
Alanine No - 346 - - - N/A N/A N/A 
Arginine No - 346 - - - N/A N/A N/A 
Aspartate No - 345 - - - N/A N/A N/A 
Glutamate No - 344 - - - N/A N/A N/A 
Glycine Yes 1 346 0.0767 0.0713 7.0  
(4.4, 9.6) 
Peak: Sep 
Trough: Mar 
N/A N/A 
Histidine Yes 2 346 0.0818 0.0703 3.6  
(2.3, 5.0) 
Peak: May 
Trough: Sep 
N/A N/A 
Isoleucine No - 346 - - - N/A N/A N/A 
Leucine Yes 1 346 0.0547 0.0492 3.5  
(2.0, 5.0) 
Peak: Feb/Mar 
Trough: Aug/Sep 
N/A N/A 
Lysine Yes 3 346 0.1163 0.1007 6.2  
(4.4, 8.1) 
Peak: May/Jun 
Trough: Aug-Nov 
N/A N/A 
Phenylalanine No - 346 - - - N/A N/A N/A 
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Biomarker Evidence 
for 
periodic 
variation?a 
No. of 
pairs of 
Fourier 
terms 
N R2 Adj. R2 CCV (%) 
(95% CI)b 
Timing of peaks and 
troughs 
Similar peak and 
trough months in 
Indicator group?c 
Similar peak and trough 
months in MDEG1 main 
study?d 
Proline Yes 3 346 0.0729 0.0564 6.1  
(7.3, 9.5) 
Peaks: Apr & Sep 
Trough: Feb & Jun 
N/A N/A 
Serine Yes 3 346 0.0401 0.0232 3.6  
(1.7, 5.4) 
Peaks: Mar & Aug 
Troughs: Jan & Jun 
N/A N/A 
Threonine No - 346 - - - N/A N/A N/A 
Tyrosine No - 346 - -  N/A N/A N/A 
Valine No - 346 - -  N/A N/A N/A 
 
Abbreviations: Adj., adjusted; CCV, coefficient of cyclic variation; CI, confidence interval; DMG, dimethylglycine; PLP, pyridoxal-5’-phosphate. 
aLikelihood ratio test comparing model with Fourier terms against null model. P<0.05 interpreted as evidence for periodic variation, with successive pairs of 
Fourier terms being added based on further likelihood ratio tests. See Annex 4.2 for further details.  
bCalculated as the square root of half the sum of the squared Fourier term coefficients(14).  
cVisual comparison of timing of peaks and troughs of periodic patterns from 12-month trend Dominguez-Salas et al. (2013)(1).  
dVisual comparison of timing of peaks and troughs of periodic patterns from 6-month window in Dominguez-Salas et al. (2014)(6). 
eNote in MDEG-2 this is plasma B2 whilst in the Indicator group and MDEG main study this is 1/EGRAC coefficient from a red blood cell assay.  
fMDEG-2 plots PLP, the active biomarker. The Indicator group and MDEG main study plot total B6. However, in additional material Dominguez-Salas (2012) 
shows how the B6 vitamers are highly correlated in their seasonal trends(23). 
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Figure 4.5A-D: Summary diagrams showing covariation of metabolites by metabolic pathway. All metabolites adjusted for age, gestational 
age, BMI and inflammation. Periodic patterns are fitted from Fourier term linear regression models (mean and 95% CI bars). 
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4.4  Discussion  
I have explored the extent to which plasma biomarker concentrations of one-carbon 
metabolism and amino acids display periodic patterns over the year in a cross-sectional 
population of 350 women enrolled onto the ENID trial. All core one-carbon biomarkers apart 
from methionine and DMG demonstrated periodic variation, along with six of the other 
amino acids. The Fourier term regression models fitted to these biomarkers helped capture 
their covariation in different metabolic pathways, and helped quantify the extent to which 
periodic variation explained overall variation in the biomarkers. Timing of periodic peaks and 
troughs, as well as the amplitude of the periodic variations, varied greatly between the 
biomarkers. 
4.4.1  Covariation in biomarkers by metabolic pathways 
The covariation of biomarkers in the folate pathway largely followed what was expected 
from folate metabolism. Dietary folates and folic acid are reduced to form tetrahydrofolate 
(THF), which in turn is reduced to methylene-THF and then to 5-methyl-THF. B2 is required 
in this final reduction step since it is a precursor to flavin adenine dinucleotide, which is a 
cofactor for the enzyme 5-methyl tetrahydrofolate reductase to reduce methylene-THF to 
methyl-THF(24). Methyl-THF donates its methyl group to homocysteine under the action of 
the enzyme methionine synthase, which requires cobalamin (vitamin B12) as a co-factor(25). 
This final step converts homocysteine into methionine. These reactions explain why as folate 
and B2 increase so homocysteine decreases. We would also expect homocysteine to 
decrease as B12 increases, however, B12 has a modest periodic variation (CCV of 6.7%) 
compared to the larger periodic variations of folate and B2 (CCVs of 16.2% and 15.1% 
respectively). Furthermore, the women are more replete in B12 compared to folate or B2, 
suggesting that B12 status is not low enough to majorly disrupt homocysteine metabolism.  
Covariation of the biomarkers in the betaine pathway do not follow exactly what is expected. 
Betaine is formed through the oxidation of choline(26,27), hence I expected to see very similar 
trends in variation of choline and betaine. The lack of synchronicity here may be because 
rates of conversion to betaine are dependent on the relative metabolic demand in 
comparison with other products that choline can form, such as acetylcholine, 
phosphocholine and phosphatidylcholine. Furthermore choline and betaine are found in 
different food products (e.g. wheat bran, wheat germ, spinach, beets for betaine and red 
meat, poultry, milk, eggs and fish for choline(28)), which may follow different seasonal dietary 
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intake patterns(1). I expected homocysteine to decrease as choline and betaine increase 
because the methyl group from betaine can be donated to homocysteine via betaine-
homocysteine methyl transferase(29), forming an alternative pathway for the remethylation 
of homocysteine independent from the B12-dependent pathway described above. Given 
DMG is a product of the reaction just described I would have expected DMG to increase as 
homocysteine decreases if the betaine pathway is being relied on to re-methylate 
homocysteine. The absence of such a relationship could be because the folate/B12 pathway 
is taking prominence, or potentially because plasma does not adequately reflect the betaine 
remethylation pathway, which occurs more in the kidney and liver.  
In the transsulfuration pathway homocysteine is irreversibly degraded to cystathionine and 
then to cysteine(30). Both of the enzymes involved in these steps require PLP as a cofactor. 
Whilst homocysteine does demonstrate an inverse pattern to PLP, they are not synchronised 
exactly and the peak of PLP comes two months before the trough of homocysteine. Similarly, 
although cysteine shows a similar pattern to homocysteine (as would be expected since it is 
a product of homocysteine metabolism), the corresponding peaks and troughs of the 
periodic patterns are about two months apart. Knowledge of the reactions involved in the 
transsulfuration pathway therefore help provide hypotheses as to the nature of covariation 
to expect, but do not fully explain what is actually found.   
Covariation of the amino acids is not easy to interpret. Natural groupings to explore are a) 
serine, glycine and cysteine, b) histidine and tryptophan, c) tyrosine and phenylalanine and 
d) glutamate, proline and arginine.  
Serine can be used to form both glycine and cysteine. Regarding glycine formation, serine 
donates a 1-carbon unit at the stage of converting THF to methylene-THF through the action 
of serine hydroxymethyltransferase and PLP(31). In the process serine is converted to glycine, 
a reaction that is reversible. Regarding cysteine, serine donates its carbon skeleton in the 
transsulfuration pathway, where it is condensed with homocysteine to form cystathionine, 
which is then hydrolysed to form cysteine. However, there was not a pattern of covariation 
between serine and glycine, nor serine and cysteine. This may be because all three are 
classified as non-essential amino acids and therefore can be produced endogenously as per 
requirements. I also expected glycine to show correlations with folate, since it can be formed 
from carbon dioxide, ammonium and methylene-THF. In the reverse reaction in the glycine 
cleavage system in the mitochondria, the catabolism of glycine generates methylene-THF 
(with the involvement of THF), which is then used as a carbon donor in the one-carbon 
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pathways(32). Identifying these interrelationships would have required a more specific folate 
assay that provides a breakdown of the different forms of THF. The assay used primarily 
measured the amount of 5-methyl-THF, given this is the dominant form of THF circulating in 
plasma.  
The catabolism of amino acids tryptophan and histidine produces formate(2,33). Formate is 
produced in the mitochondria and then released into the cytosol, forming formyl-THF by 
condensation with THF. Formyl-THF can then either be used in purine synthesis or be 
interconverted into other THF oxidation states as part of folate metabolism(34).  
Unfortunately the assay used for formate measurement failed, but otherwise may have 
provided the missing link to better interpret covariation between these metabolites.  
The other amino acids, whilst important for health in numerous ways(35,36), are less clearly 
related to one-carbon metabolism. I expected tyrosine and phenylalanine to co-vary, 
because tyrosine is formed from phenylalanine (an essential amino acid) under the action of 
phenylalanine hydroxylase. There was no evidence for a periodic pattern in phenylalanine, 
however. Similarly, I expected glutamate, proline and arginine to co-vary since glutamate is 
used as the precursor for the formation of proline and arginine(37). However, these three 
amino acids are non-essential and therefore may better reflect metabolic demands rather 
than true periodic variations. Finally, leucine and lysine, both essential amino acids, had their 
lowest concentrations in August-September. Whilst both are needed for numerous functions 
(e.g. regulation of protein turnover, antiviral activity, protein methylation(35)), potential links 
with one-carbon metabolism are not well documented.  
4.4.2  Comparison with previous studies  
Comparing the timings of the troughs and peaks of the core one-carbon metabolites 
between this study and the Indicator group and the MDEG main group, there was generally 
a good replication of trends, with the exception of DMG. Only four biomarkers had an 
identical matching trend, however, and there are many possible reasons for this. The 
Indicator group was composed of non-pregnant women whereas the MDEG-2 and MDEG 
main study cohorts were comprised of pregnant women, mostly in their first trimester. 
Furthermore, I presented MDEG-2 periodic patterns adjusted for BMI, age, inflammation and 
gestational age for reasons outlined above (section 4.2.3), but the MDEG main study trends 
used unadjusted values. In the MDEG-2 data homocysteine, cysteine and B12 were all 
positively associated with inflammation (data not shown). Gestational age was positively 
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associated with homocysteine, cysteine and choline, and inversely associated with 
methionine, betaine, folate, PLP and B2. BMI was inversely associated with B12 and PLP and 
age was inversely associated with methionine and PLP. It is possible these confounders may 
partially explain some of the discrepancies found between the datasets.  
The MDEG main study and MDEG-2 datasets are comprised of cross-sectional samples, and 
therefore will contain greater inter-individual variation than the Indicator group, which 
aimed to follow the same women all year (although replacements were made as some 
Indicator group participants withdrew due to becoming pregnant, reaching menopause, self-
withdrawal, or moving away from the study area). The reduced inter-individual variation in 
the Indicator group may help explain why most of the CCVs were larger than in the MDEG-2 
data.   
Broadly, however, the comparison was useful in suggesting that despite the limitations of 
the subsample being composed of cross-sectional data, it was still able to capture similar 
periodic patterns found in the Indicator group, composed of longitudinal data. This suggests 
that intra-individual variation over the year is greater than inter-individual variation, and 
gives additional confidence that the existing MDEG-2 data can be used to assess potential 
timings for a supplementation trial (see below). It also suggests that once matching infant 
DNA methylation data becomes available for the subsample then this dataset will be helpful 
for looking at the nutritional predictors of methylation.  Annex 4.2 provides an example of 
how the Fourier term regression models from this chapter will be used to back-extrapolate 
the biomarker concentrations to the time of conception, for example, so that the research 
group can further interrogate periconceptional predictors of methylation to build on 
previous work in Dominguez-Salas et al. (2014)(6). 
4.4.3  Fit of the periodic patterns from Fourier term regression models 
Obtaining evidence for a periodic pattern does not guarantee that the trend provides a 
strong overall fit for the data, nor that there are clear seasonal differences. Obtaining a 
p<0.05 in the likelihood ratio test comparing the null model with the model with one pair of 
Fourier terms simply suggests that the Fourier term model fits better than having no terms. 
Whilst some biomarkers clearly show non-overlapping confidence intervals between peaks 
and troughs over the year (e.g. folate, PLP, cysteine), many demonstrate more subtle 
variation. Furthermore, for some biomarkers the extent of the periodic variation does not 
become apparent until all biomarkers are compared on the same scale (such as the 
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percentage of geometric mean graphs or the analysis of the CCVs). For example, looking at 
the B2 graph on its original scale of nmol/L (Fig. 4.4C) the periodic pattern appears fairly flat 
and the adjusted R2 is only 3.7%. This is because, as with many of the biomarkers, the original 
distribution is right-tailed, meaning that the y-axis scale needs to be expanded to capture 
these high concentrations. However, looking instead at variation around the geometric mean 
(Fig. 4.6A), alongside calculating a CCV of 16.2%, shows the underlying periodic variation is 
much stronger than first thought. Fulford (2014)(14) explains that relying on R2 estimates to 
explain the fit of periodic models can be problematic when imprecision in the biomarker 
estimates accounts for much of the variability (see laboratory CVs in Supplementary Table 
4.1). That said, given the measurement imprecision and inter-individual variation it is 
encouraging that underlying periodic patterns can still be detected at all, including some 
biomarkers with a relatively high adjusted R2 value of over 10% (folate, PLP, lysine).  
The CCV places observation of periodic variation on a uniform scale that enables comparison 
cross-biomarker and cross-dataset. Observing the CCVs then, folate, B2, PLP in particular 
would seem to have a stronger periodic variation than consideration of the adjusted R2 alone 
would indicate. Many of the biomarkers had both a low R2 and a low CCV (e.g. homocysteine, 
B12, choline, histidine, leucine, proline, serine). In these cases it may be important to 
consider that small variations in individual biomarkers may combine to create much larger 
impacts e.g. on methyl donor supply and methylation potential, when viewed at the 
metabolic pathway or even metabolome level.  
4.4.4  Peak seasonal windows 
Previous analyses have used the peak rainy and dry seasonal windows for comparison(1,6). 
The current MDEG-2 analyses enable a reflection on whether these windows are the most 
appropriate ones to consider when defining windows of vulnerability to micronutrient 
deficiencies, or lower methylation potential, for example. Clearly, biomarker variation over 
the year does not fall neatly into the peak rainy and dry seasons, and restricting analyses to 
these windows could miss seasonal differences at other time points. For example, comparing 
peak rainy and dry season concentrations for B2, choline and betaine suggests there is no 
difference (Table 4.1), yet Fourier term regression does justify a seasonal trend, and viewing 
variation over the whole year shows the peaks and troughs of their trends falling at periods 
outside the peak seasons.  
A potential new window to consider is September to October, which is the end of the rainy 
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season and the start of the dry season. Here there are troughs for B2, folate, B12, choline, 
cysteine, PLP, lysine, histidine and leucine. There is not the same clear alignment of peak 
concentrations, but June may be another window to consider, when there are higher levels 
of folate, B2, PLP, lysine and histidine.  
4.4.5  Limitations 
There were a few planned metabolites that were not able to be measured. As discussed 
above, one of these was formate. Formate (CHO2-) is a very small molecule and it is possible 
that the Sigma-Aldrich ELISA-based assay I attempted to use was simply unable to detect the 
low levels of formate in this population (speculatively, formate assays may be better at 
capturing abnormally high levels to help diagnose methanol poisoning). I had also planned 
to measure S-adenosyl methionine (SAM) and S-adenosyl homocysteine (SAH) to investigate 
a more direct measure of methylation potential. However, these metabolites had degraded 
either with processing or storage time (with SAM converting into SAH) and were no longer 
reliable estimates. Despite not having SAM and SAH, homocysteine is a very useful measure 
of methylation potential (see Chapter 6 for a discussion on this). I had also wanted to 
measure decarboxylated SAM to see whether there might be an indication at certain times 
of the year that SAM was being used preferentially in the polyamine pathway over the 
transmethylation pathway.  
In these analyses the additional metabolites considered in comparison to the Indicator group 
were the amino acids. As described above, their periodic variation was generally not as 
profound as for the core one one-carbon biomarkers, and the interpretation of their 
covariation is complex. Including information on amino acids other than those thought to 
influence one-carbon metabolism (methionine, cysteine, serine, glycine, tryptophan and 
histidine) may risk making the picture unnecessarily complex. However, as discussed in the 
introduction, the original aim was to collect as much metabolite information as possible to 
feed into a systems biology model, which then may have helped identify metabolic pathways 
more distal to core one-carbon ones that we might want to consider. The overall amino acid 
information may yet still be prove to be important when interpreting offspring DNA 
methylation data, when it comes in.  
Performing longitudinal analyses on data made up of cross-sectional measurements 
throughout the year will be susceptible to much greater variability and reduced precision 
compared to repeated measurements in the same individual. However, the comparison of 
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the general shapes of the periodic patterns with the Indicator group was helpful in 
confirming the validity of this approach in the MDEG-2 dataset. These biomarker trends will 
be used to assess associations with infant DNA methylation data across the whole year when 
the offspring data is available. The Indicator group followed 30 women across the year and 
was a time- and resource-intensive approach that would not have been possible with the 
sample size used in the MDEG-2 dataset.  
The dates of enrolment of women in the subsample onto the ENID trial ranged from February 
2010 to July 2013. Over this period the onset of Ramadan was 11th August in 2010 and 20th 
July in 2012. It is possible that trends over the months of July and August therefore may show 
a ‘Ramadan effect’ brought on by the effects on fasting and increased intake of certain foods 
to break the fast. However, this window does not appear to coincide with any major peaks 
and troughs of the periodic patterns. Nonetheless, until nutritional status is assessed in a 
year where Ramadan lies outside of the July-August window it remains difficult to 
disentangle the relative contribution of Ramadan food intake practices versus more 
consistent underlying seasonal trends.    
Plasma concentrations are imperfect measures of nutrient status for many reasons (see 
section 9.3.1 for more details), and these need to be considered at the time of interpretation. 
Annex 4.3 details some of these factors for the core set of one-carbon-related biomarkers 
where information is available, including the relationship between dietary intake and plasma 
concentration, known changes throughout pregnancy, and issues related to storage and 
free-thaw cycles. 
 
4.5  Conclusion 
The periodic patterns obtained from this dataset, composed of cross-sectional data, 
generally replicated the trends seen for core one-carbon biomarkers in the longitudinal 
dataset of the Indicator group. Fitted periodic patterns using Fourier term regression models 
explained relatively little of the overall variation of the biomarker concentrations, mostly less 
than 10%. However, a closer inspection of the trends using the variation about the geometric 
mean and the CCV showed that some metabolites did show significant periodic variation, 
especially for folate, B2 and PLP. Small fluctuations in individual biomarkers may combine to 
exert larger effects on methylation potential, which should be explored more formally when 
matching infant DNA methylation data becomes available. The inclusion of additional amino 
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acid measurements in the expanded biomarker set did not provide easily interpretable 
information to further our understanding of the covariation of core one-carbon biomarkers. 
However, this may be a limitation of using plasma concentration data in the absence of 
kinetic data, which makes it difficult to explore the complicated dynamics of metabolism 
(including circular pathways and allosteric inhibition, for example). It may also be because 
some of the other crucial metabolites that help link the amino acid pools to the one-carbon 
pathways, such as formate, were not measured.  
Looking at the overall picture of covariation of the metabolites there is no clear-cut season 
of deficiency and adequacy. The shape of the periodic patterns greatly differ, and the peaks 
and troughs of each biomarker rarely perfectly coincide. However, there does seem to be a 
rationale for exploring a new window of September-to-October for when infant methylation 
data is available, as this seems to be a period when several biomarkers are at (or near) their 
nadirs. The analyses in this chapter are helpful not only to validate previous findings of 
seasonal fluctuations in one-carbon biomarkers, but also in laying the groundwork for future 
analyses that will match this data with offspring DNA methylation data.    
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Supplemental Table 4.1: Laboratory information and outlier justifications 
 
Biomarker Assay type Intra-assay 
CV% 
Inter-assay 
CV% 
Outliers 
excluded 
Outlier 
Justification 
Insufficient 
plasma 
Total included in 
analysis 
Homocysteine LC-MS 3.9 4.1 1 55.1µmol/L (11.1 z-scores) 0 349 
Folate Abbott Architect i1000  <4.0 <4.7 0 N/A 0 350 
B2 LC-MS 1.3 7.4 2 >188nmol/L (>9.1 z-scores) 1 347 
PLP LC-MS 3.5 4.7 0 N/A 1 349 
B12 Abbott Architect i1000  <5.6 <6.8 0 N/A 0 350 
Choline LC-MS 2.5 3.4 2 >23.7µmol/L (>8 z-scores) 0 348 
Betaine LC-MS 2.2 3.9 0 N/A 0 350 
Methionine LC-MS 4.1 3.9 0 N/A 0 350 
Cysteine LC-MS 2.6 2.9 0 N/A 0 350 
DMG LC-MS 2.4 3.6 4 >14.6µmol/L (>6.5 z-scores) 0 346 
Alanine Hitachi L-8900    5.8  0 N/A 4 346 
Arginine Hitachi L-8900    3.6  0 N/A 4 346 
Aspartate Hitachi L-8900    27.5  1 20.8µmol/L (7.0 z-scores) 4 345 
Glutamate Hitachi L-8900    12.0  2 >273.3µmol/L (>6.3 z-scores) 4 344 
Glycine Hitachi L-8900    4.4  0 N/A 4 346 
Histidine Hitachi L-8900    4.2  0 N/A 4 346 
Isoleucine Hitachi L-8900    4.9  0 N/A 4 346 
Leucine Hitachi L-8900    4.0  0 N/A 4 346 
Lysine Hitachi L-8900    3.6  0 N/A 4 346 
Phenylalanine Hitachi L-8900    7.4  0 N/A 4 346 
Proline Hitachi L-8900    4.0 1 711µmol/L (14.1 z-scores) 4 345 
Serine Hitachi L-8900    2.8  0 N/A 4 346 
Threonine Hitachi L-8900    3.1  0 N/A 4 346 
Tyrosine Hitachi L-8900    5.8  0 N/A 4 346 
Valine Hitachi L-8900  3.1 0 N/A 4 346 
AGP Cobas Integra 400plus <16.0 <10.2 0 N/A 4 346 
 
Abbreviations: AGP, Alpha-1-acid glycoprotein; CV, coefficient of variation; DMG, dimethylglycine; LC-MS, liquid chromatography mass spectrometry; PLP, pyrodixol-5’-
phosphate. 
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Chapter 5 Maternal one-carbon metabolism and 
infant DNA methylation between contrasting seasonal 
environments: A case study from The Gambia 
__________________________________________________________________________ 
 
Summary of chapter 
 
Background: The periconceptional period is a time in which environmentally-induced 
changes to the epigenome could have significant consequences for offspring health. 
Metastable epialleles (MEs) are genomic loci demonstrating inter-individual variation in DNA 
methylation with intra-individual cross-tissue correlation, suggesting that methylation states 
are established in the very early embryo prior to gastrulation. In our previous Gambian 
studies we have shown that ME methylation states in the offspring are predicted by maternal 
levels of certain nutritional biomarkers around the time of conception.  
 
Objective: We assess whether the profile of maternal biomarker predictors of offspring 
methylation differs between rainy and dry seasons in a population of rural Gambians, using 
a larger set of 50 recently identified MEs.   
 
Methods: We measured 1-carbon biomarkers in maternal plasma back-extrapolated to 
conception, and cytosine-phosphate-guanine (CpG) methylation at 50 ME loci in their 
infants’ blood at mean age 3.3 months (N=120 mother-child pairs). We tested for 
interactions between seasonality and effects of biomarker concentrations on mean ME 
methylation z-score. We used backwards stepwise linear regression to select the profile of 
nutritional predictors of methylation in each season, and repeated this analysis with 
biomarker principal components (PCs) to capture biomarker co-variation. 
 
Results: We found preliminary evidence of seasonal differences in biomarker-methylation 
associations for folate, choline and homocysteine (interaction p values ≤0.03). Furthermore, 
in stratified analyses biomarker predictors of methylation changed between seasons. In the 
dry season B2 and methionine were positive predictors. In the rainy season, however, 
choline and B6 were positive predictors, and folate and B12 were negative ones. PC1 
captured co-variation in the folate metabolism cycle and predicted methylation in dry season 
conceptions. PC2 represented the betaine remethylation pathway and predicted rainy 
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season methylation.   
 
Conclusions: Underlying nutritional status may modify the association between nutritional 
biomarkers and methylation, and should be considered in future studies.  
 
Notes 
The chapter contains the final proofs sent to me before final publication. The narrative will 
not change from the version included here. 
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ABSTRACT
Background: The periconceptional period is a time in which environmentally induced changes to
the epigenome could have significant consequences for offspring health. Metastable epialleles
(MEs) are genomic loci demonstrating interindividual variation in DNA methylation with
intraindividual crosstissue correlation, suggesting that methylation states are established in the
very early embryo before gastrulation. In our previous Gambian studies, we have shown that ME
methylation states in the offspring are predicted by maternal concentrations of certain nutritional
biomarkers around the time of conception.
Objective: We aimed to assess whether the profile of maternal biomarker predictors of offspring
methylation differs between rainy and dry seasons in a population of rural Gambians, using a
larger set of 50 recently identified MEs.
Methods: We measured 1-carbon biomarkers in maternal plasma back-extrapolated to
conception, and cytosine-phosphate-guanine (CpG) methylation at 50 ME loci in their infants’
blood at a mean age of 3.3 mo (n = 120 mother-child pairs). We tested for interactions between
seasonality and effects of biomarker concentrations on mean ME methylation z score. We used
backward stepwise linear regression to select the profile of nutritional predictors of methylation
in each season and repeated this analysis with biomarker principal components (PCs) to capture
biomarker covariation.
Results: We found preliminary evidence of seasonal differences in biomarker-methylation
associations for folate, choline, and homocysteine (interaction P values ≤0.03). Furthermore, in
stratified analyses, biomarker predictors of methylation changed between seasons. In the dry
season, vitamin B-2 and methionine were positive predictors. In the rainy season, however,
choline and vitamin B-6 were positive predictors, and folate and vitamin B-12 were negative
predictors. PC1 captured covariation in the folate metabolism cycle and predicted methylation in
dry season conceptions. PC2 represented the betaine remethylation pathway and predicted rainy
season methylation.
Conclusions: Underlying nutritional status may modify the association between nutritional
biomarkers and methylation, and should be considered in future studies. Curr Dev Nutr
2018;0:nzy082.
Introduction
The Developmental Origins of Health and Disease (DOHaD) hypothesis suggests that early-life
environmental exposures affect lifelong health and disease risk (1–4). For example, exposure
to the Dutch Hunger Winter famine in 1944–1945 across different stages of prepregnancy
and pregnancy has been associated with lower birthweight (5), increased adult blood pressure
1
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and obesity (6–8), and increased risk of schizophrenia (9). One plausible
mechanism for these associations is through epigenetic modifications
to the genome (10–12). Epigenetic processes encompass mitotically
heritable changes to the genome that can alter gene expression without
changing the underlying DNA sequence (13), and include DNA
methylation (predominantly at cytosine-phosphate-guanine (CpG)
sites), histone modifications, and RNA-based mechanisms (14).
Times of increased cell turnover, such as during fetal development,
may be particularly susceptible to epigenetic errors or to adaptive
modifications designed to capture early environmental cues (15, 16).
Early embryonic development is a period of complex epigenetic
remodeling and cell differentiation (17–19), and thus represents a
critical window in which changes to the epigenetic program could have
significant consequences for offspring health (20).
Metastable epialleles (MEs) are genomic loci whose (nongenetically
determined) methylation state varies between individuals, but in whom
variation is correlated across tissues originating from all 3 germ layers
in a single individual (16, 21). This suggests the establishment of
stochastic methylation states in the first few days after conception
before separation into germ layers around gastrulation.MEmethylation
therefore provides a useful measure for studying the potential influence
of the periconceptional environment on selected regions of the
offspring epigenome (22, 23). ME methylation status in humans has
been associated with obesity, immune function, and certain cancers
(24–26).
A variety of nutritional and other environmental factors can impact
the infant epigenome in utero through maternal exposure (20, 27, 28),
including 1-carbon metabolites in the periconceptional period and
during embryonic development (29). One-carbon metabolism refers
to the interlinking reactions of the folate, choline, methionine, ho-
mocysteine, transsulfuration and transmethylation metabolic pathways
(30, 31). DNA methylation is one of the numerous transmethylation
reactions made possible by the donation of a methyl group from S-
adenosylmethionine (SAM), forming S-adenosyl homocysteine (SAH)
in the process (32). The SAM:SAH ratio has therefore been used as a
proxy indicator of methylation potential (33). The 1-carbon pathways
that enable transmethylation to occur rely on nutritional inputs in
the form of methyl donors (e.g., folate, choline, betaine) and essential
cofactors (e.g., vitamins B-2, B-6, and B-12) (30, 34). Nutritional status
of themother can therefore influenceDNAmethylation, and this ismost
clearly exemplified in animal models. In Agouti mouse experiments,
pregnant dams fed a diet rich in vitamin B-12, folic acid, choline, and
betaine gave birth to pups exhibiting increased methylation at the locus
influencing the expression of the Agouti gene compared with controls.
This resulted in changes to offspring fur color, appetite, adiposity, and
glucose tolerance (27, 35). In humans, there is also evidence linking
maternal nutrition to offspring DNA methylation, explored either as
individual micronutrients or as proxy measures of nutrition such as
famine and seasonality (36, 37). Although there is also much evidence
linking DNA methylation to later phenotype (12, 38), studies fully
exploring the continuum ofmaternal nutrient exposure, offspring DNA
methylation, and later phenotype are relatively rare (39).
In a series of studies in rural Gambia, we have been able to
exploit a seasonal “natural experiment,” whereby a cycling pattern
of rainy and dry seasons imposes strikingly different environmental,
especially nutritional, exposures on the population.We have shown that
plasma collected in nonpregnant women of child-bearing age contains
higher concentrations of methyl donors and has a higher methylation
potential in the peak rainy season (July to September) than in the
peak dry season (February to April) (40). Furthermore, we found that
seasonal differences in maternal periconceptional nutritional status
are associated with offspring methylation at multiple MEs. Increased
concentrations of vitamin B-2 and decreased concentrations of vitamin
B-6, homocysteine, and cysteine predicted increased offspring mean
methylation across 6MEs (23), whereas offspring conceived in the rainy
season had consistently higher concentrations of ME methylation in
peripheral blood monocytes than those conceived in the dry season
(22–26). However, our previous analyses did not explicitly test for
an interaction with season for the associations between biomarker
predictors and methylation.
Here, by exploring nutrient-season interactions, we extended our
previous analyses to investigate whether the profile of maternal
nutritional predictors of ME methylation varies between rainy and
dry seasons. In doing so, we used a recently identified larger set of
MEs associated with Gambian season of conception (SoC)-associated
MEs (26) and explored in greater detail how covariation in the
nutritional biomarkers can be captured in a principal components (PCs)
model.
Methods
This paper utilizes data from 2 parallel studies: the Methyl Donors and
Epigenetics (MDEG) study (23) and the Early Nutrition & Immune
Development (ENID) Trial (41), both conducted in the rural West
Kiang region of The Gambia.
Study population: The MDEG study
The MDEG study investigated the effects of periconceptional maternal
biomarkers on infant DNA methylation at 6 candidate MEs (23).
Women of reproductive age (18–45 y) were invited to participate
and were followed monthly until pregnancy confirmation. Consenting
women who conceived in the peak of the rainy season (July to Septem-
ber 2009) and the peak of the dry season (February to April 2010) were
enrolled. Women provided a 10-mL fasting venous blood sample at the
point they reported their first missed menses [mean (SD) 8.6± 4 weeks
of gestation]. The following maternal 1-carbon biomarkers were ana-
lyzed: plasma folate, vitamin B-12, active vitamin B-12, choline, betaine,
dimethylglycine (DMG), methionine, SAM, SAH, homocysteine (Hcy),
cysteine, 4-pyridoxic acid (PA), pyridoxal (PL), pyridoxal-5ʹ-phosphate
(PLP), and erythrocyte riboflavin (vitamin B-2), as described previously
(23). All biomarkers were back-extrapolated to the time of conception
using seasonal trends from a cohort of 30 nonpregnant women from the
same district, who provided fasted venous blood samples every month
for a year, as previously detailed (40). Infant DNA was obtained from a
3-mL venepuncture taken 2–8 mo after delivery. In this analysis, we use
a subset of 120 infants for whom we had analyzed genome-wide DNA
methylation data (Gene Expression Omnibus accession GSE59592),
obtained using the Illumina Infinium HumanMethytlation450 array
(“450k array”) (25, 42).
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Selection of season of conception-associated ME loci from
the ENID study
ME loci were identified using data from the ENID trial. Participants
in ENID partially overlap with those in the MDEG study, although in
the analysis described here, individuals from MDEG and ENID form
distinct, nonoverlapping groups. n = 50 SoC-associated ME loci were
identified as the intersection between loci identified in a recent screen
for MEs on the 450k array and 2171 CpGs showing SoC-associated
differential methylation using 450k data from 128 ENID blood samples
from infants aged 24 mo (26). Selection of loci demonstrating both
metastability and sensitivity to the periconceptional environment, each
in independent samples, strengthens evidence that they are established
in the early embryo (16, 25, 26).We provide details on the locations and
genomic context of the 50 CpGs used in this analysis in Supplementary
Table 1. Our use of ENID samples to identify SoC-associated MEs
in this analysis carries a number of advantages. First, it offers an
opportunity to validate observations of increased rainy SoC ME
methylation across independent ENID and MDEG 450k methylation
datasets. Second, annual patterns of Gambian seasonality mean that
potential confounding due to the relation between SoC and season of
sample collection is different between ENID (median age of collection
24 mo) and MDEG (median age 3 mo) cohorts, enabling more robust
inference (43). Third, SoC effects identified using ENID infant 24 mo
DNA are by definition more persistent than those identified in younger
MDEG samples, making them potentially more robust candidates for
use as biomarkers or mediators of later health outcomes.
Statistical analyses
Outcome: infant DNAmethylation at 50 CpGs. The 50 SoC-associated
ME loci on the 450k array identified using ENID methylation data (see
above) were carried forward for use as candidates in the current analysis
with 450k methylation data from 120 infants in the MDEG dataset, for
whichwe hadmatchingmaternal plasma biomarker concentration data.
DNAmethylation β values were adjusted for batch effects (25). CpG
methylation across the 50 ME loci was highly correlated (Cronbach’s
α test reliability coefficient of 0.908). We therefore derived a univariate
measure ofMEmethylation by convertingmethylation at eachCpG into
a z score [(individual observation – CpG mean)/CpG SD] and taking
the mean of the methylation z scores across all 50 CpGs as our primary
outcome measure.
Exposure variables: nutritional biomarkers. After removing variables
demonstrating colinearity, the final list of nutritional exposure vari-
ables was: folate, active vitamin B-12, vitamin B-2, choline, betaine,
DMG, SAM:SAH, Hcy, methionine, PLP, and cysteine. All nutritional
biomarkers were treated as continuous variables. All biomarkers were
log-transformed to improve normality, apart from SAM:SAH, which
was left untransformed, and standardized before analyses.
In order to capture covariation of the 1-carbon biomarkers, we
also conducted a PC analysis. Four PCs had an eigenvalue >1 and
underwent orthogonal varimax rotation. We generated individual PC
scores based on these loadings and used the resulting 4 PC variables in
subsequent regression analyses.
Baseline characteristics. Because this study uses a subsample of 120
mother-child pairs from the original sample (n = 166) (23), we report
the baseline characteristics again by SoC. Means (for continuous,
normal data) were compared using Student’s t test; medians (of non-
normal data) were compared using the Wilcoxon rank-sum test; and
proportions were compared using a chi-squared test or Fisher exact test
(for categories with sparse data).
Associations between nutritional exposures and infant DNA methy-
lation: crude analyses. To validate the findings from the original
MDEG study using this larger set of MEs, we ran linear regression
models to assess the crude association between maternal nutritional
exposures and SoC with infant mean methylation z score. To assess
the hypothesis that the profile of nutritional predictors might change
between seasons, we then included season as an interaction term in
the association between the nutritional exposures and methylation,
assessing the interaction using the likelihood ratio test.
Primary objective: Predictors of methylation by SoC. Given that
the interaction tests justified stratifying the data by SoC, we then
explored the predictors of methylation in each season separately
using multivariable linear regression. We used an automatic backward
stepwise approach for variable selection, using a P value of >0.2 as
the criterion for removal from the model. Each regression model was
run twice; first, using the individual 1-carbon biomarkers as exposures
(“biomarker model”) and second using the 4 PCs model.
All regression model residuals were checked for normality and
met the assumptions of linear regression models. All models included
11 a priori confounders: maternal age, BMI, and gestational age at
time of sample collection; infant sex and infant age at time of sample
collection; and 5 methylation-derived white blood cell counts (25). All
of these have previously been associated with methylation (44–47). We
report likelihood ratio test results comparing the full model against the
baseline model including a priori confounders only. Stata 14.0 (Stata
Corporation) was used for all statistical analyses.
Ethical considerations
Ethical approvals for the ENID trial and MDEG study were given by
The Gambia Government/MRC Joint Ethics Committee (SCC1126v2
and SCC1151, respectively). Consent was gained by signature or thumb
print from mothers for their own participation and that of their child.
All data were anonymized before analyses.
Results
Four PCs with an eigenvalue >1 explained 65.0% of the total variation
seen in the 11 biomarkers (SupplementaryTable 2). After rotation, PC1
was associated positively with folate and SAM:SAH, and inversely with
Hcy. PC2 was strongly correlated positively with choline and betaine,
and inversely with active vitamin B-12. PC3 was positively correlated
with the amino acids methionine and cysteine, and PC4 was strongly
correlated with PLP and active vitamin B-12. These 4 PCs explained
more than half the variability of all biomarkers apart fromactive vitamin
B-12 andB-2, which still had 54.3% and 60.0%unexplained respectively.
Figure 1 shows the correlation between the 1-carbon biomarkers and
the PC loadings as a heat map.
Baseline maternal and infant characteristics are summarized in
Table 1, detailed for the overall sample and by SoC. There was no
difference in maternal age, gestational age, maternal BMI, or infant sex
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FIGURE 1 Heat map showing correlation between 1-carbon
biomarkers and PCs after orthogonal rotation. ∗All
log-transformed, standardized variables, apart from SAM:SAH,
which is standardized but untransformed. †Cells shaded green for
positive correlations and red for inverse correlations. Intensity of
shading is proportional to strength of correlation. B12, vitamin
B-12; B2, vitamin B-2; PC, principal component; PLP,
pyridoxal-5ʹ-phosphate; SAH, S-adenosyl homocysteine; SAM,
S-adenosyl methionine.
by SoC. Infants conceived in the dry season were ∼0.5 mo younger at
their DNA blood draw than were those conceived in the rainy season.
Women conceiving in the rainy season had higher concentrations
of folate, vitamin B-2, betaine, cysteine, and SAM:SAH, and lower
concentrations of DMG, PLP, and Hcy than did those conceiving in
the dry season. There were higher scores for PC1 and PC3, and lower
scores for PC4 in the rainy season. We provide a detailed breakdown of
the nutritional status of the population, stratified by season, in Table 2.
Almost all women were deficient in vitamin B-2, >40% had low PLP
status, ∼30% and 20% had low concentrations of betaine and choline
respectively, 13% were folate-deficient, and participants were replete in
methionine and cysteine. There was evidence to suggest that a greater
proportion of women were folate-deficient in the dry season and that a
higher proportion had low PLP concentrations in the rainy season.
The crude association between mean total CpG methylation (z
scores) and each exposure (SoC, nutritional biomarkers and PCs) is
shown in Table 3. Total mean methylation across the 50 CpG sites was
0.26 z scores higher in the rainy season than in the dry season (95% CI:
0.07, 0.45; P = 0.008). The SAM:SAH ratio was positively associated
with methylation, and there was weak evidence to suggest that Hcy was
inversely associated. Among the PCs, only PC1was positively associated
with methylation.
To justify stratified analyses, we first tested whether there was
any interaction between the effect of the exposure on total mean
methylation by SoC (Table 3). There was some evidence of an
interaction with SoC for plasma folate, choline, and homocysteine
(P value for interaction = 0.019, 0.030, and 0.030, respectively). There
was no evidence of an interaction with season for any of the other
biomarkers, and overall effect sizes remained small. For the PCs, only
PC1 showed a different pattern of association with methylation by
season (P value for interaction = 0.002).
TABLE 1 Maternal and infant characteristics, overall and stratified by season of conception1
Total Dry season Rainy season
Variable n Statistic n Statistic n Statistic P2
Folate, nmol/L 117 15.4 (14.3–16.6) 59 12.6 (11.6–13.7) 58 18.9 (17.0–20.9) <0.001
Active B12, pmol/L 118 73.7 (68.1–79.8) 59 79.2 (71.4–87.8) 59 68.6 (60.7–77.6) 0.077
B2, 1/EGRAC 113 0.45 (0.43–0.48) 57 0.41 (0.38–0.44) 56 0.51 (0.47–0.55) <0.001
Choline, µmol/L 117 6.6 (6.2–6.70) 59 6.9 (6.3–7.5) 58 6.3 (5.9–6.8) 0.109
Betaine, µmol/L 118 18.8 (17.6–20.1) 59 17.5 (15.7–19.4) 59 20.2 (18.6–21.9) 0.033
Dimethylglycine, µmol/L 118 2.2 (1.9–2.4) 59 2.9 (2.5–3.3) 59 1.6 (1.4–1.8) <0.001
SAM:SAH ratio 118 7.7 (7.2–8.2) 59 6.5 (6.0–7.1) 59 9.1 (8.4–9.7) <0.001
Homocysteine, µmol/L 118 6.7 (6.3–7.2) 59 7.4 (6.8–8.1) 59 6.1 (5.7–6.6) <0.001
Methionine, µmol/L 118 24.4 (23.5–25.3) 59 22.9 (21.8–24.1) 59 26.0 (24.7–27.3) <0.001
Pyridoxal phosphate, nmol/L 118 21.9 (20.2–23.7) 59 23.7 (20.9–27.0) 59 20.1 (18.4–22.1) 0.041
Cysteine, µmol/L 118 197.3 (192.9–201.9) 59 192.6 (186.8–198.5) 59 202.2 (195.6–209.0) 0.032
PC1 111 0.00 ± 1.58 57 −0.89 ± 1.24 54 0.94 ± 1.36 <0.001
PC2 111 0.00 ± 1.34 57 −0.03 ± 1.46 54 0.04 ± 1.21 0.788
PC3 111 0.00 ± 1.26 57 −0.52 ± 1.14 54 0.55 ± 1.15 <0.001
PC4 111 0.00 ± 1.13 57 0.35 ± 1.18 54 −0.37 ± 0.95 <0.001
Maternal age, y 117 29.2 ± 6.7 58 28.2 ± 6.1 59 30.3 ± 7.2 0.089
Gestational age, d 120 60.7 ± 28.5 60 63.8 ± 27.8 60 57.6 ± 28.9 0.237
BMI, kg/m2 120 60 60 0.866
Underweight 16.7 ± 20 15.0 ± 9 18.3 ± 11
Normal 72.5 ± 87 73.3 ± 44 71.7 ± 43
Overweight 10.8 ± 13 11.7 ± 7 10.0 ± 6
Infant sex, % (n) 120 60 60 0.534
Female 48.3 (58) 51.7 (31) 45.0 (27)
Male 51.7 (62) 48.3 (29) 55.0 (33)
Infant age, mo 112 3.3 [3.11–3.77] 55 3.2 [3.07–3.21] 57 3.7 [3.31–4.0] <0.001
1Values are geometric means (95% CIs) for maternal biomarkers; medians [IQRs] for infant age; means ± SDs for PCs, maternal age, gestational age, and BMI; and % (n)
for infant sex. B12, vitamin B-12; B2, vitamin B-2; EGRAC, erythrocyte glutathione reductase activity coefficient; PC, principal component; SAH, S-adenosyl homocysteine;
SAM, S-adenosyl methionine.
2Testing difference by season: Wilcoxon rank-sum test for nonnormal data, Student’s t-test for normal data, chi-squared test for proportion.
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TABLE 2 Maternal plasma biomarker status, overall and stratified by season of conception1
Overall (both seasons) Dry season Rainy season
Variables Cutoff for low/abnormal status n below cutoff % n % n % P2
Homocysteine >15 µmol/L (48) 2/118 1.7 2/59 3.4 0/59 0.0 0.496
Folate <10 nmol/L (49) 15/117 12.8 12/59 20.3 3/58 5.2 0.024
B2 <0.77 (1/EGRAC) (50) 109/113 96.5 57/57 100.0 52/56 92.9 0.057
PLP <20 nmol/L (51)3 50/118 42.4 19/59 32.2 31/59 52.5 0.025
Active B12 <37 pmol/L (52) 6/118 5.1 1/59 1.7 5/59 8.5 0.207
Choline <5 µmol/L (48)3 24/117 20.5 12/59 20.3 12/58 20.7 0.963
Betaine <16 µmol/L (48)3 35/118 29.7 22/59 37.3 13/59 22.0 0.070
Methionine <20 µmol/L (53)4 19/118 16.1 12/59 20.3 7/59 11.9 0.210
Cysteine <36 µmol/L (53)4 0/118 0.0 0/59 0.0 0/59 0.0 —
1B12, vitamin B-12; B2, vitamin B-2; EGRAC, erythrocyte glutathione reductase activity coefficient; PLP, pyridoxal-5′-phosphate.
2Test for seasonal difference in biomarker status. P values from chi-squared test, or Fisher’s exact test (if any numerator <5).
3There are no clearly defined plasma cutoffs for deficiency. The suggested cutoffs indicate below the normal range and can be considered “low status.”
4The amino acid cutoffs represent the 10th percentile of a healthy population age >16 y in Canada (53). Note that these cutoffs do not necessarily represent low status
or deficiency.
In stratified analyses using backward stepwise regression, Hcy,
vitaminB-2,methionine, and SAM:SAHwere retained in the dry season
multivariable biomarker model (Table 4). Of these selected variables,
methionine was the strongest positive predictor of methylation,
followed by SAM:SAH.Hcywas associatedwith decreasingmethylation
as in crude analyses, as was vitamin B-2. The full model explained
27.0% of total variance in methylation (adjusted R2, model P = 0.001).
In the dry season, PC model PC1 was the only covariate retained,
and the model explained 18.7% of methylation variance (model
P = 0.009).
In the rainy season biomarkermodel, a different profile of predictors
was retained. SAM:SAH, choline, and PLP were associated with
increasing methylation, whereas folate and active vitamin B-12 were
associated with decreasing methylation (Table 5). The rainy season
model explained 9.4% of methylation variance (adjusted R2, model
P= 0.004). In the rainy season PCmodel, PC2 was positively associated
with methylation. PC1 and PC3 were also retained and showed weak
inverse associations. The model, however, fitted poorly.
A graphical summary of the associations between predictors of
methylation retained in the multivariable models by SoC is shown in
Figure 2. This figure simplifies the above results by focusing on the PC
associations, showing the switch of positive predictors of methylation
from the folate pathway in the dry season to the choline/betaine
pathway in the rainy season.
Discussion
This study extends our understanding of previously reported asso-
ciations between 1-carbon biomarkers in mothers at the time of
conception and DNA methylation at MEs in their infants. We have
validated previous findings of increased methylation at MEs for rainy
season conceptions, but found that maternal plasma biomarkers back-
extrapolated to the time of conception generally demonstrate little
individual effect on infant ME methylation, whether in crude analyses
or in multivariable predictive models. There was some preliminary
evidence to suggest an interaction between SoC and the association of
maternal 1-carbon biomarkers with infant methylation.
PCs and metabolic pathways
The PC approach is useful for exploring covariation in biomarkers
and their joint influence on methylation, although their biological
interpretation can be difficult. However, our findings suggested the
strongest loadings of each PC mapped onto different metabolic
pathways. The major loadings for PC1 are involved in the folate
metabolism cycle. The major form of folate in plasma is 5-methyl-
tetrahydrofolate (54), which donates its methyl group to Hcy via
methylene tetrahydrofolate reductase using vitamin vitamin B-12 as a
coenzyme (55). The remethylation of Hcy forms methionine, which
is then used to form SAM, thus explaining why the SAM:SAH ratio
loading is also positively correlated with this PC along with folate.
The inverse correlation of Hcy is expected because it is held in
equilibriumwith SAH, a buildup of which can impede the SAM to SAH
reaction via product inhibition of methyltransferases (56). In contrast,
PC2 loadings are positively associated with the betaine remethylation
pathway. Choline is the precursor to betaine, which is formed via a
2-step oxidation reaction (57). Betaine donates its methyl group to
homocysteine, catalyzed by betaine-homocysteine methyl transferase
(57). Methionine and cysteine provide the major loadings for PC3.
This could represent the transsulfuration pathway, because methionine
provides the sulfur atom for cysteine synthesis, via the irreversible
degradation of Hcy (31). It could also reflect that methionine and
cysteine are dietary components found in similar food sources. The PC4
primary loading comes from PLP, which is particularly involved in 1-
carbon metabolism as a coenzyme in the transsulfuration pathway, as
well as being required to reduce THF to methylene-THF (31).
Crude analyses between SoC, 1-carbon related exposures,
and methylation
Using an expanded set of 50 ME CpGs associated with SoC in samples
from older infants (26), we validated our previous finding (23) of
increased ME methylation in rainy season conceptions in the younger
cohort analyzed here. Biomarker concentrations differed by season
in ways that have been previously described (23), forming a profile
with higher methylation potential in the rainy season than in the dry
season. In the original MDEG study, we found that periconceptional
concentrations of vitamin B-2 were positively associated with offspring
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TABLE 3 Crude association between exposures and total mean CpG methylation z score, overall and stratified by season using
linear regression1
Overall (both seasons) Stratified analysis by season
Variable2 n Coefficient (95% CI)3 P4 Season Coefficient (95% CI)3 P4 P interaction5
Season6 109 0.26 (0.07, 0.45) 0.008
Log folate 108 0.02 (−0.07, 0.11) 0.623 Dry 0.10 (−0.06, 0.26) 0.237 0.019
Rainy −0.14 (−0.26, −0.01) 0.034
Log active B12 109 −0.08 (−0.17, 0.02) 0.102 Dry −0.04 (−0.18, 0.09) 0.549 0.758
Rainy −0.07 (−0.18, 0.05) 0.264
Log B2 105 0.04 (−0.05, 0.14) 0.347 Dry −0.01 (−0.16, 0.14) 0.916 0.986
Rainy −0.01 (−0.14, 0.13) 0.924
Log choline 108 0.02 (−0.07, 0.11) 0.642 Dry −0.02 (−0.13, 0.09) 0.705 0.030
Rainy 0.16 (0.02, 0.3) 0.023
Log betaine 109 0.05 (−0.04, 0.14) 0.236 Dry 0.02 (−0.09, 0.13) 0.661 0.661
Rainy 0.06 (−0.08, 0.2) 0.397
Log dimethylglycine 109 −0.03 (−0.12, 0.06) 0.496 Dry −0.01 (−0.15, 0.12) 0.869 0.227
Rainy 0.10 (−0.05, 0.26) 0.175
SAM:SAH ratio 109 0.12 (0.03, 0.20) 0.010 Dry 0.16 (0.02, 0.31) 0.029 0.086
Rainy 0.00 (−0.14, 0.14) 0.986
Log homocysteine 109 −0.09 (−0.18, 0.00) 0.054 Dry −0.13 (−0.25, −0.01) 0.039 0.030
Rainy 0.06 (−0.08, 0.21) 0.389
Log methionine 109 0.05 (−0.04, 0.15) 0.277 Dry 0.09 (−0.03, 0.22) 0.132 0.062
Rainy −0.07 (−0.21, 0.07) 0.341
Log PLP 109 0.05 (−0.04, 0.15) 0.277 Dry 0.00 (−0.11, 0.11) 0.999 0.762
Rainy −0.03 (−0.18, 0.13) 0.727
Log cysteine 109 −0.05 (−0.14, 0.04) 0.303 Dry −0.06 (−0.19, 0.07) 0.352 0.955
Rainy −0.06 (−0.18, 0.07) 0.371
PC1 103 0.06 (0.00, 0.12) 0.037 Dry 0.13 (0.03, 0.22) 0.015 0.002
Rainy −0.07 (−0.16, 0.02) 0.139
PC2 103 0.04 (−0.03, 0.11) 0.299 Dry 0.01 (−0.07, 0.10) 0.763 0.255
Rainy 0.09 (−0.02, 0.19) 0.123
PC3 103 0.00 (−0.09, 0.08) 0.909 Dry −0.02 (−0.13, 0.09) 0.762 0.399
Rainy −0.08 (−0.21, 0.04) 0.191
PC4 103 −0.06 (−0.14, 0.02) 0.126 Dry −0.03 (−0.13, 0.08) 0.628 0.837
Rainy −0.04 (−0.18, 0.09) 0.533
1B12, vitamin B-12; B2, vitamin B-2; CpG, cytosine-phosphate-guanine; PC, principal component; PLP, pyridoxal-5′-phosphate; SAH, S-adenosyl homocysteine; SAM,
S-adenosyl methionine.
2All 1-carbon biomarkers log-transformed and standardized, apart from SAM:SAH (standardized only).
3Adjusted for maternal BMI at time of bled, gestational age at time of bleed, maternal age, infant sex, infant age, white blood cell composition.
4Two-tailed t-test for coefficient slope.
5Likelihood ratio test comparing models with and without interaction term.
6Season is coded 0 = dry 1 = rainy.
methylation and Hcy, whereas vitamin B-6 and cysteine were inversely
associated (23). In these current analyses, we found the same association
with Hcy, but not with vitamin B-2, vitamin B-6, or cysteine. Instead,
in crude analyses, we found that SAM:SAH was positively associated
with methylation, in line with the expected effect of these intermediary
metabolites on methylation potential (33). The differences between the
current and previous analyses could reflect the reduced sample size
in this updated analysis (due to the smaller number of samples with
Illumina 450k array data), additional adjustment covariates used, or
the larger panel of MEs used to derive a univariate methylation score
in the current study. The associations reported here help explain why
there is evidence of a crude association between PC1 and methylation.
Homocysteine has been associated with decreased methylation in
several cross-sectional studies (58). Taken in isolation, folate did not
show any association with methylation in this study, and this has also
been the case in other studies (59–61). However, folate did load strongly
onto PC1, which showed a positive association with methylation in the
dry seasonmodel. Increasedmaternal periconceptional folate status has
been associated with increased methylation in infants at a differentially
methylated region ofRXRA (62).However, this pattern is not consistent,
and inverse associations between fetal periconceptional folate exposure
andmethylation have also been found at STX11,OTX2,TFAP2A,CYS1,
and LEP (39, 62, 63).
Predictors of methylation by SoC from multivariable
analyses
In the dry season, the predictors broadly indicate that increasing
methylation potential (increasing SAM:SAH and decreasing Hcy,
most likely through the folate pathway looking at the PC1 loadings)
contributes to higher levels of DNAmethylation. However, in the rainy
season, when there is higher plasma folate and lower plasmaHcy than in
the dry season, the folate pathway unexpectedly switches to an inverse
association, and we can hypothesize that the betaine remethylation
pathway takes prominence. Although these simple regression models
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TABLE 4 Multivariable linear regression: predictors of methylation (dry season)1
Biomarker model PC model
Variable2 Coefficient (95% CI)3 P4 Variable Coefficient (95% CI)3 P4
Log homocysteine −0.16 (−0.31, −0.01) 0.040 PC1 0.15 (0.03, 0.26) 0.012
Log methionine 0.17 (0.04, 0.30) 0.011
Log B2 −0.10 (−0.25, 0.06) 0.214
SAM:SAH ratio 0.13 (−0.05, 0.31) 0.164
n — 52 52
Overall model P5 — 0.001 0.009
R-squared — 0.471 0.362
Adjusted R-squared — 0.270 0.187
1B2, vitamin B-2; PC, principal component; SAH, S-adenosyl homocysteine; SAM, S-adenosyl methionine.
2All 1-carbon biomarkers log-transformed and standardized, apart from SAM:SAH (standardized only).
3Adjusted for maternal BMI at time of bleed, gestational age at time of bleed, maternal age, infant sex, infant age, white blood cell composition.
4Two-tailed t test for coefficient slope.
5Likelihood ratio test comparing the final model with the model only including a priori confounders.
cannot address the specific molecular mechanisms involved, we can
speculate on a few different possibilities. In the rainy season, we
could be seeing the effect of feedback loops attenuating the influence
of increased plasma folate. One-carbon metabolism is governed by
intricately controlled feedback loops, which help protect the flux of
metabolites through key reactions over a range of nutrient and cofactor
concentrations (64, 65). Alternatively, it could be that the rainy season
folatemetabolism is at saturation, and the system can then only enhance
SAM:SAH through the betaine remethylation pathway. This highlights
the complexity of 1-carbon metabolism in human populations and
suggests that the potential for effectmodifiers, for example season in our
Gambian setting, should be considered when modeling methyl donor
pathways. Given the exploratory nature of our analyses and the small
effect sizes reported, our findings need to be replicated in confirmatory
studies.
Limitations
There are a number of unmeasured exposures thatmay follow a seasonal
pattern and could contribute to differences in offspring methylation,
thus confounding our results. These include other nutrition-related
exposures [e.g., vitamin A (66), vitamin D (67, 68), and dietary
polyphenols (69)], as well as other potential exposures such as maternal
stress (70), toxin exposure (71), intrauterine growth restriction (72–74),
maternal hyperglycemia (75), infection (76), and seasonal differences in
the microbiome (77). Future nutritional intervention studies will help
establish whether there is a causal association between differences in
diet, nutritional biomarkers, and methylation.
Linear regression models rest on certain assumptions and have
a number of limitations. For example, when modeling the effects
of nutritional factors, minimum detection thresholds and saturation
effects will introduce nonlinear effects that cannot be captured by linear
regression. Stepwise regressions allow large numbers of predictors to be
evaluated, but have been criticized for producing inflated coefficients,
and for the fact that after the strongest predictor has been considered,
there is little additional explanatory power for any correlated predictor
(78). They are also known to be relatively unstable in that small changes
in the data can cause one variable to be selected over another, which can
then alter subsequent variable selection (79). It is therefore possible that
some of the differences we see between the seasons are related to model
instability rather than reflecting real changes. This point is exacerbated
by the fact that our sample size was small, meaning stratified analyses by
seasonmay not have had adequate power to distinguish true differences.
TABLE 5 Multivariable linear regression: predictors of methylation (rainy season)1
Biomarker model PC model
Variable2 Coefficient (95% CI)3 P4 Variable Coefficient (95% CI)4 P4
Log folate −0.20 (−0.35, −0.06) 0.008 PC1 −0.06 (−0.16, 0.03) 0.188
Log active B12 −0.08 (−0.20, 0.04) 0.201 PC2 0.09 (−0.01, 0.20) 0.080
Log PLP 0.11 (−0.08, 0.30) 0.236 PC3 −0.08 (−0.20, 0.04) 0.169
Log choline 0.18 (0.03, 0.32) 0.018
SAM:SAH ratio 0.14 (−0.02, 0.30) 0.093
n — 51 51
Overall model P5 — 0.004 0.052
R-squared — 0.366 0.243
Adjusted R-squared — 0.094 −0.023
1B12, vitamin B-12; PC, principal component; PLP, pyridoxal-5′-phosphate; SAH, S-adenosyl homocysteine; SAM, S-adenosyl methionine.
2All 1-carbon biomarkers log-transformed and standardized, apart from SAM:SAH (standardized only).
3Adjusted for maternal BMI at time of bleed, gestational age at time of bleed, maternal age, infant sex, infant age white blood cell composition.
4Two-tailed t-test for coefficient slope.
5Likelihood ratio test comparing the final model with the model only including a priori confounders. PC, principal component.
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FIGURE 2 Simplified summaries of metabolic pathways acting as positive (green) and negative (red) predictors of methylation by season
of conception, drawn from the retained principal-component coefficients in the multivariate models. Photos show Keneba, West Kiang
district, The Gambia. Photo credit: Andrew Prentice. BET, betaine; B12, vitamin B-12; B2, vitamin B-2; CHOL, choline; CYS, cysteine; DHF,
dihydrofolate; DMG, dimethyl glycine; Hcy, homocysteine; MET, methionine; methylene-THF, N5,10-methylene tetrahydrofolate;
methyl-THF, N5-methyl tetrahydrofolate; PLP, pyridoxal-5ʹ-phosphate; SAH, S-adenosyl homocysteine; SAM, S-adenosyl methionine; THF,
tetrahydrofolate; X, acceptor.
The use of PCs gives some further insight into the joint ef-
fect of correlated biomarkers, offering an analysis strategy that lies
conceptually between the consideration of biomarkers in isolation,
and more sophisticated approaches that attempt to model the full
complexity of metabolic networks. PC regression models are, however,
hard to interpret. There are other models that are designed to help
generate an understanding of how 1-carbon pathways interact (often
in nonlinear ways), for example by estimating fluxes of metabolites
through the pathways under given scenarios, andwithin specific cellular
compartments (50, 80–82). Although these models are mathematically
sophisticated, many are based on kinetic data that can be difficult to
obtain at the population level. Furthermore, there is a need to generate
models that can integrate plasma concentration data, themost common
and accessible type of experimental data used for human in vivo studies.
A promising way forward is within the field of systems biology, an
integrative discipline that analyses complex datasets to help generate
hypotheses, which can be experimentally validated and used to improve
computer modeling in an iterative fashion (83). However, despite the
limitations of the linear regression models we used, they can still play a
role in hypothesis generation.
Conclusions
Before this study, we had observed that methylation at 6 MEs is higher
among infants conceived in the rainy season than in those conceived
in the dry season, and this trend has been seen again in a larger set
of 50 MEs in the current analysis. However, we had not previously
investigated whether the same combination of methyl donors and
cofactors were consistently associated with methylation, or whether
there was an interaction with season. In this current analysis, we find
preliminary evidence to suggest that the rainy and dry seasons in The
Gambia have a different set of maternal nutritional predictors of infant
methylation. However, larger sample sizes and more sophisticated ways
of modeling the complex nonlinear interrelations of metabolites are
needed to further our understanding of what might trigger a switch
between different methylation pathways at the molecular level.
Although there is still much work to do to complete our under-
standing of underlying mechanisms, our findings highlight potential
considerations for future study design. If underlying nutritional status
(partially captured in this study by the observed seasonal variations
in plasma biomarker concentrations) influences the predictors of
DNA methylation, then this would be applicable to populations with
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heterogeneous patterns of dietary intake, whether seasonally driven
or otherwise. This suggests that studies would benefit from collecting
detailed information on nutritional status to assess if underlying
nutritional status acts as an effect modifier. In observational studies,
this informationmayhelp to explain contradicting associations between
nutrition and other environmental exposures and DNA methylation
or, in the case of trials, between nutritional interventions and DNA
methylation. Such considerationsmight also inform the timing of future
studies if there are seasonal dietary intake variations, or the targeting
of subgroups in the context of populations with broad variation
in nutritional status. In summary, the underlying nutritional status
could be an essential piece of information to help disentangle the
often complex and contradictory findings from nutritional epigenetics
studies.
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Supplementary Table 5.1: Location and genomic context of the 50 CpGs used in analyses* 
 
CpG ID Chromo-
some 
Position Gene name (UCSC) Gene region feature 
category (UCSC) 
Relationship to 
Canonical CpG Island† 
Enhancer 
element 
cg08787039 1 182921857 C1orf14 Body Island   
cg15025200 1 152161237     North Shore   
cg18388270 1 149212246         
cg17598339 2 170624727     Island Yes 
cg00817731 3 46759475 PRSS50 TSS200 Island   
cg01788113 3 46759472 PRSS50 TSS200 Island   
cg02834909 3 46759438 PRSS50 TSS200 Island   
cg16975614 3 105601834         
cg19668234 3 46759449 PRSS50 TSS200 Island   
cg20814179 4 940893 TMEM175 5'UTR Island   
cg23206463 5 561769     North Shore   
cg02735058 6 16181250         
cg09894276 6 169977394 WDR27 Body Island   
cg10218546 6 32729823 HLA-DQB2 Body Island   
cg15189031 6 34499314 PACSIN1 Body Island   
cg18609891 6 32729647 HLA-DQB2 Body Island   
cg23414861 6 74064064 DPPA5 TSS200 Island   
cg08767820 7 51539583       Yes 
cg10614809 7 51539190       Yes 
cg14329783 7 75779857     Island   
cg06565641 8 141359674 TRAPPC9;TRAPPC9 Body;Body South Shore Yes 
cg07092985 8 55533887 RP1 Body Island   
cg07234876 8 600039     Island   
cg23958373 8 599963     Island   
cg06159404 10 43846376     Island   
cg01794156 11 397077 PKP3 Body Island   
cg05940452 11 118842484 FOXR1;FOXR1 5'UTR;1stExon Island   
cg23188684 11 67383651     Island Yes 
cg11258452 12 119594454 SRRM4 Body South Shelf   
cg23887609 12 130822674 PIWIL1;PIWIL1 1stExon;5'UTR Island   
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CpG ID Chromo-
some 
Position Gene name (UCSC) Gene region feature 
category (UCSC) 
Relationship to 
Canonical CpG Island† 
Enhancer 
element 
cg24229701 12 130821962 PIWIL1 TSS1500 North Shore   
cg24838063 12 130822603 PIWIL1 TSS200 Island   
cg26677194 12 130822605 PIWIL1 TSS200 Island   
cg14089267 13 23412409     Island   
cg14395298 13 23412250     Island   
cg25576711 14 24780557 LTB4R2;LTB4R2;LTB4R2CI
DEB;CIDEB;LTB4R 
Body;1stExon;Body; 
1stExon;5'UTR;TSS200 
Island   
cg26310551 14 24780540 LTB4R2;LTB4R2;LTB4R2CI
DEB;CIDEB;LTB4R 
Body;1stExon;Body; 
1stExon;5'UTR;TSS200 
Island   
cg01232511 16 2867446 PRSS21;PRSS21; 
PRSS21 
Body;Body;Body Island   
cg08288433 17 20799511 CCDC144NL TSS200 Island   
cg13590055 18 77917647 LOC100130522;LOC10013
0522;PARD6G 
Body;Body;3'UTR Island   
cg21237861 18 77918142 PARD6G;LOC100130522;L
OC100130522 
Body;Body;Body Island   
cg26211724 18 57636670     Island   
cg02452966 19 39056216 RYR1;RYR1 Body;Body Island   
cg05345154 19 2250901 AMH Body Island   
cg15035382 19 40728255 CNTD2 3'UTR Island   
cg17434634 19 49522954     Island Yes 
cg19605788 19 40729386 CNTD2 Body Island Yes 
cg19712189 19 33210851 TDRD12;TDRD12 5'UTR;1stExon Island   
cg24923931 19 40904691 PRX;PRX Body;Body Island   
cg13403462 20 32256071 NECAB3;NECAB3;C20orf13
4;C20orf134 
Body;Body;1stExon;3'UTR South Shore   
 
*All details from Infinium HumanMethylation450K Manifest File v1.2 using coordinates from Genome Build 37. 
†Shores - 0-2 kb from CpG island; Shelves - 2-4 kb from CpG island. 
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Supplementary Table 5.2: Principal components explaining variation in 11 biomarkers of 
1-carbon metabolism 
 
Principal 
Component (PC) 
Eigenvalue Proportion of 
variance explained 
Cumulative proportion of 
variance explained 
PC1 2.70 0.25 0.25 
PC2 1.99 0.18 0.43 
PC3 1.40 0.13 0.55 
PC4 1.06 0.10 0.65 
PC5 0.93 0.08 0.74 
PC6 0.78 0.07 0.81 
PC7 0.73 0.07 0.87 
PC8 0.47 0.04 0.92 
PC9 0.40 0.04 0.95 
PC10 0.33 0.03 0.98 
PC11 0.21 0.02 1.00 
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Chapter 6 Nutritional predictors of plasma 
homocysteine in three datasets from West Kiang 
region, The Gambia. 
__________________________________________________________________________ 
 
Summary of Chapter 
 
Background: In rural Gambia dry season plasma homocysteine concentrations are higher 
than in the rainy season amongst women of reproductive age. Previous studies have 
suggested that children born to women conceiving in the dry season have patterns of DNA 
methylation suggestive of loss of regular imprinting. Furthermore, maternal homocysteine is 
inversely associated with DNA methylation at several genomic loci. The hypothesis is that a 
pre-conception supplement lowering homocysteine will help enable epigenetic processes to 
function unhindered during fetal development. This chapter identifies potential ingredients 
for a novel homocysteine-lowering supplement, tailoring the design to the requirements of 
the population in West Kiang, rural Gambia.  
 
Methods: Linear regression models from three datasets from rural Gambia are used to 
identify nutritional predictors of homocysteine in plasma. Recognising that predictive models 
can be unstable in their variable selection, three regression approaches are adopted (two-
step approach, backwards stepwise and Lasso) to obtain a qualitative overview of the most 
consistent patterns of predictors of homocysteine. Predictive equations for homocysteine 
from each dataset are tested in the other two datasets in order to understand how 
generalizable the results are.  
 
Results: Four predictors were consistently inversely associated with homocysteine across the 
datasets and regression approaches: folate, B12, B2 and betaine. Cysteine and 
dimethylglycine were consistently positively associated with homocysteine. The patterns for 
choline and B6 were inconsistent, either not being retained as predictors in the models or 
being retained with conflicting directions of association with homocysteine. Predictive 
equations for homocysteine performed well cross-dataset (all adjusted R2>0.39). 
 
Conclusions: The analyses result in the selection of four nutritional inputs to consider at the 
supplement design stage: betaine, vitamin B12, vitamin B2 and folate. These findings are 
generalizable to different cohorts from the same region in The Gambia.  
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6.1  Introduction 
Prior work from the MRC International Nutrition Group is summarised in Chapter 2. In brief, 
the existing evidence suggests that women conceiving in the dry season have a profile of 
nutrients related to one-carbon metabolism that correspond to a lower methylation 
potential compared to those conceiving in the rainy season. In turn, offspring conceived in 
the dry season display DNA methylation patterns suggestive of loss of imprinting at the 
VTRNA2-1 gene(1). Our group’s long-term goal is therefore to design a periconceptional 
nutritional intervention for women that improves the regulation of the infant epigenome by 
providing micronutrients in the quantity necessary for optimal one-carbon metabolism all 
year round. To achieve this we first require a proof-of-concept trial showing that a nutritional 
supplement can optimise the metabolome in non-pregnant women by correcting nutritional 
imbalances and increasing the methylation potential by reducing homocysteine. Should the 
supplement work it could be a promising candidate for future pregnancy trials investigating 
offspring epigenetic outcomes.  
The primary end point in the proof-of-concept trial is to reduce plasma homocysteine (Hcy), 
since maternal plasma Hcy is strongly inversely associated with the ratio of S-adenosyl 
methionine (SAM) to S-adensosyl homocysteine (SAH)(2), a measure of methylation 
potential(3), and inversely associated with infant methylation at ME loci (as shown in Chapter 
5 and Dominguez-Salas et al. 2014(4)). The hypothesis here is that reducing homocysteine will 
help improve the methylation potential and enable one-carbon metabolic pathways to 
function unhindered.  
Whilst the ratio of SAM:SAH is the most common and direct measure of methylation 
potential, there are a number of reasons why investigating plasma Hcy is preferable. Firstly, 
plasma Hcy is stable in EDTA at room temperature for 8 days and at -25°C for 29 years(5). This 
is in contrast to SAM, which rapidly converts into SAH and is strongly affected by freeze-thaw 
cycles. For example, unpublished data from the University of British Columbia suggests that 
the concentration of SAH after the second freeze-thaw cycle is 16.7% higher than after the 
first free-thaw cycle (details in Annex 4.3). Investigating Hcy is therefore more reliable, 
particularly when using stored samples. Secondly, Hcy assays are cheaper and more 
commonly available than those for SAM and SAH. Thirdly, there is already a wealth of existing 
evidence to show how nutritional interventions have been successful in reducing 
homocysteine through targeting one-carbon metabolic pathways(6–8).  
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In the target population, women of reproductive age of West Kiang district, there were three 
available datasets of plasma metabolites involved in one-carbon metabolism (MDEG main 
study, Indicator group, MDEG-2). In this chapter I investigate the nutritional biomarker 
predictors of homocysteine in these three datasets with the aim of identifying the 
micronutrients consistently demonstrating inverse associations with homocysteine as 
candidates to take forwards into the supplement design stage. These analyses therefore 
provide an opportunity to tailor the supplement more specifically to the population in rural 
Gambia rather than rely on a more generic formula. 
6.2  Methods 
The three datasets had different characteristics, for example, varying in which months of the 
year were captured, pregnant versus non-pregnant participants and different years of data 
collection. Comparing predictors of homocysteine across these three different datasets was 
intended to improve the generalisability of results. Full details of the three datasets are 
presented in Chapter 2 (an overview of each) and Chapter 4 (details on MDEG-2).  
6.2.1  Selection of 1-carbon biomarkers as potential predictors 
I assessed the original list of biomarkers in each dataset for multicollinearity by inspecting 
the variance inflation factors. Amongst the B6 vitamers I dropped pyridoxic acid and 
pyridoxal from all datasets since they were highly correlated with pyridoxal-5’-phospahte 
(PLP), which is the main functional marker of vitamin B6. Since the active B12 data was 
missing in the MDEG-2 dataset (see Chapter 4) I used plasma total B12 from all datasets 
instead. As previously mentioned, SAM and SAH from the MDEG-2 dataset had degraded 
over storage time and/or freeze-thaw processing and were unusable. I dropped them from 
the list of potential predictors for that reason, and also because I wanted to prioritise the 
biomarkers that could be considered for a supplement rather than the intermediary 
metabolites. For the MDEG main study and the Indicator group the final list of potential 
predictors was therefore: B2, PLP, B12, cysteine, methionine, dimethylglycine (DMG), folate, 
choline and betaine. MDEG-2 used the same list but also included the amino acid panel.  
Cysteine and DMG are the products of metabolic reactions involving homocysteine. Cysteine 
is formed in the transsulfuration pathway after Hcy is irreversibly degraded, and DMG is 
formed during the remethylation pathway involving betaine as the methyl donor. As such, 
they are not so useful for consideration of supplementation design and so I also repeated all 
analyses excluding these two metabolites. Although methionine is also a product of Hcy 
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remethylation it sits in a direct circular pathway that regenerates Hcy via SAM (see Annex 
4.4 figure B), and therefore methionine was kept in all models. 
6.2.2  Predictive models: three approaches 
Since regression models are not always stable in their variable selection (see discussion in 
Chapter 5) I wanted to compare three different methods of linear regression modelling: a 
two-step approach, backwards stepwise and least angle regression using Lasso (‘least 
absolute shrinkage and selection operator’). The aim was to obtain a qualitative overview in 
order to identify consistent patterns of predictors of homocysteine in different datasets 
using different variable selection approaches.   
Log Hcy was used as the dependent variable in all the models. All potential nutritional 
predictors were standardised and log-transformed before entry into the models as 
independent variables. All effect sizes therefore represent the change in log Hcy for a one SD 
increase in the log-transformed independent variable. Some a priori confounders were 
forced into all models, and these varied according to the information available for each 
dataset (age for Indicator group; age, BMI and gestational age for MDEG main study; age, 
BMI, gestational age and inflammation using α-1-acid glycoprotein (AGP) for MDEG-2). The 
Indicator group dataset contained repeated measures on the same individual. Both the 
Breusch-Pagan test (for random effects versus ordinary least squares regression, p<0.001) 
and the Hausman test (for fixed versus random effects, p=0.24), confirmed the use of 
random effects. This longitudinal dataset, however, could only use the two-step approach, 
which was the only method allowing for the modelling of random effects. The MDEG main 
study and MDEG-2 datasets, being cross-sectional, could use all three modelling approaches.  
In the two-step approach log Hcy was regressed against the nutritional predictors in 
univariable linear regression. Any variables with p<0.1 were then taken forwards to a 
multivariable linear regression model. In the final results I report any retained independent 
variables with p<0.05. The Wald test was used for the statistical tests in this approach. In the 
backwards stepwise approach I used automatic selection with p>0.2 as the criteria for 
removal from the model. Again, in the final results I only report the retained independent 
variables with p<0.05 using the Wald test. In the Lasso model the number of variables 
retained in the final model corresponds to the lowest Cp statistic found. No individual p 
values are reported and the output contains the coefficients only. Given it was not possible 
to force confounders into the Lasso models I pre-adjusted log Hcy by regressing it against the 
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confounders prior to model entry. 
I ran the three models using all the data available (‘combined season’ model), but then also 
stratified the models by peak of the dry season (February – April) and the peak of the rainy 
season (July – September). This was because the aim was to implement the supplementation 
trial in the dry season since, as mentioned previously, this is the time of year associated with 
lower methylation potential and possible loss of imprinting at VTRNA 2-1. Table 6.1 
summarises the different datasets used, detailing the list of potential nutritional predictors, 
the confounders, the type of statistical models used and the sample sizes.  
6.2.3  Generalisability of predictors across datasets 
For supplement design considerations it can be useful to know how generalizable results are 
from one dataset to another by assessing how well the predictors of homocysteine in one 
cohort work in other datasets. To do this I generated predictive equations for homocysteine 
in each of the three datasets and then tested how well these equations worked when applied 
to the other two datasets. I considered the set of plasma nutritional biomarkers that were 
common across all three datasets: betaine, choline, DMG, B12, B2, folate, methionine, 
cysteine and PLP.  To obtain the predictive linear equations I ran a multivariable linear 
regression with log Hcy as the outcome and the plasma biomarkers all entered as exposures. 
The constant and the coefficients from this regression model provided the equation for 
predicted Hcy, and I recorded how well this model predicted actual Hcy within the same 
dataset. Then I applied the predictive equation to the other datasets to generate the new 
predicted Hcy variable, and regressed this against actual Hcy to assess its predictive power 
(‘cross-dataset’ prediction). In all these cross-dataset predictive models the predictors were 
all log-transformed and standardised.  All models were adjusted for age. Two additional 
variables, BMI and gestational age, were considered when comparing MDEG main study and 
MDEG-2 datasets (the Indicator group did not have this information). All regression models 
performed using the Indicator group dataset used random effects to account for the 
longitudinal data design. When describing model fit in the MDEG main study and MDEG-2 
datasets the adjusted R2 is reported.  
Supplementary Material 6.1 provides a more detailed example of the methodology I 
followed to generate the equations for these cross-dataset predictions.  
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Table 6.1 Summary of datasets and models used 
Dataset Total N Dry Season N Rainy Season 
N 
Biomarkers included in 
model 
A priori 
confounders 
forced into all 
models 
Models used Notes 
Indicator 
group 
48 women 
with 288 total 
observations 
34 women 
with 79 
observations 
28 women 
with 63 
observations 
Hcy, B2, PLP, B12, folate, 
methionine, choline, 
betaine, DMG, cysteine 
Age Linear 
regression with 
random effects. 
2-step approach 
only 
Non-pregnant 
women, roughly 30 
followed for one 
year, longitudinal 
study with monthly 
blood samples(2).  
MDEG 
main 
study 
 
 
167 83 84 Hcy, B2, PLP, B12, folate, 
methionine, choline, 
betaine, DMG, cysteine 
Maternal age, 
BMI, gestational 
age 
Ordinary linear 
regression. 2-
step, backwards 
stepwise and 
Lasso 
Cross-sectional data, 
pregnant women 
selected from peak 
of rainy and peak of 
dry season(4). 
MDEG-2  
 
 
350 87 100 Hcy, B2, PLP, B12, folate, 
methionine, choline, 
betaine, DMG, cysteine, 
Asp, Thr, Ser, Glu, Gly, 
Ala, Val, Ile, Leu, Tyr, 
Phe, Lys, His, Arg, Pro 
Maternal age, 
BMI, gestational 
age, 
inflammation 
(AGP) 
Ordinary linear 
regression. 2-
step, backwards 
stepwise and 
Lasso 
Cross sectional data, 
pregnant women 
selected from each 
month of year. 
 
Abbreviations: Hcy, homocysteine; PLP, pyridoxal 5’-phosphate; DMG, dimethylglycine; BMI, body mass index; Asp, aspartic acid; Thr, threonine; Ser, serine; 
Glu, glutamic acid; Gly, glycine; Ala, alanine; Val, valine; Ile, isoleucine; Leu, leucine; Tyr, tyrosine; Phe, phenylalanine; Lys, lysine; His, histidine; Arg, arginine; 
Pro, proline. 
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6.3  Results 
Tables 6.2, 6.3 and 6.4 detail the predictors of Hcy retained in final multivariable models in 
the MDEG main study, MDEG-2 and Indicator group datasets respectively. A summary of the 
retained coefficients in all models is provided in Figure 6.1.  
There were four predictors consistently inversely associated with Hcy in most model 
approaches and seasons: folate, B2, B12 and betaine. Of these folate had the strongest effect 
sizes, particularly in the dry season. Cysteine was positively associated with Hcy in all models. 
DMG was also positively associated with Hcy in the combined and dry season models.  
The pattern for choline and PLP was inconsistent. In several models they were not retained 
as predictors, and where they did feature the direction of the association varied. Choline was 
inversely associated with Hcy in the MDEG-2 Lasso dry and rainy season models, yet was 
positively associated in the MDEG main study Lasso models in all seasons.  PLP was positively 
associated with Hcy in the MDEG-2 dataset but showed different directions of association by 
season in the MDEG main study dataset.  
The amino acids were only measured in the MDEG-2 dataset. Glycine was a positive predictor 
of Hcy in the combined models but was not retained when models were stratified by season. 
None of the other amino acids showed a consistent pattern, and when they were retained 
in the final models they had small effect sizes.  
When the analyses were repeated with the by-products DMG and cysteine removed from 
the models (Supplementary Tables 6.1-6.3, Supplementary Figure 6.1) the underlying 
patterns were largely similar. Folate, B2, B12 and betaine, where they were retained in the 
models, remained negative predictors of Hcy. The positive association between PLP and Hcy 
became stronger, but the associations between choline and Hcy became weaker (although 
still demonstrating both positive and inverse directions).  For the amino acids glycine 
remained a positive predictor of Hcy in the MDEG-2 combined season models, however, this 
time proline was also identified as a positive predictor and alanine as a negative predictor.  
Table 6.5 summarises how well the set of nutritional biomarkers common to all three 
datasets predicted homocysteine within their own dataset. For example, in the MDEG main 
study dataset the predicted Hcy using the equation from nine biomarkers plus age explained 
57.4% of the variation of actual homocysteine. In the MDEG-2 dataset predicted Hcy using 
these ten predictors explained 52.5% of the variance of actual Hcy. In both cases adding the 
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two extra co-variates of BMI and gestational age improved the adjusted R2 only modestly 
(<1%). In the Indicator group the predicted Hcy performed better at explaining the variance 
of actual Hcy within each subject (47.8%) compared to between subjects (35.1%).  
Table 6.6 summarises how well the predictive equations worked cross-dataset. The Indicator 
group equation predicted 54.4% of the variance of Hcy in the MDEG main study, which was 
only 3% less than the MDEG main study’s own set of predictors. It performed almost as well 
in MDEG-2, explaining just 7.4% less than the original set of predictors. For predicting Hcy in 
the Indicator group, the MDEG main study and MDEG-2 equations predicted similar levels of 
within-group and overall variance. They achieved very close to the performance using the 
Indicator group’s own set of predictors (difference of <2%). The cross dataset comparisons 
between the MDEG main study and MDEG-2 did not perform quite so well, explaining 
between 14-18.4% less variance than the same-dataset predictions. However, even in the 
worst performing comparison (MDEG-2 predictive model from 12 variables tested in the 
MDEG main study) the overall variance explained was 39.6%, which is still considerable. 
Whilst adding the two extra variables (gestational age and BMI) slightly improved model fit 
when prediction occurred within the same dataset, in cross-dataset comparisons these two 
extra variables actually decreased model fit by around 3%.  
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Table 6.2 Nutritional Biomarker Independent Predictors of Homocysteine in MDEG Main Study Dataset 
Seasonal 
Model 
Statistical 
approach* 
N R2 Positive predictorsƗ 
(β, 95%CI, p value) 
Negative predictorsƗ 
(β, 95%CI, p value) 
Combined 
Seasons 
 
2-step 150 0.582 Cysteine  
DMG  
0.14 (0.10, 0.18), p<0.001 
0.05 (0.01, 0.09), p=0.015 
Folate  
B2  
-0.12 (-0.16, -0.09), p<0.001 
-0.05 (-0.08, -0.01), p=0.009 
Backwards 
Stepwise 
149 0.610 Cysteine  0.16 (0.12, 0.20), p<0.001 Folate  
B2  
B12  
-0.14 (-0.17, -0.10), p<0.001 
-0.04 (-0.07, 0.00), p=0.029 
-0.05 (-0.09, -0.02), p=0.005 
Lasso 152 0.422 Cysteine  
DMG  
Choline  
Methionine 
0.14 
0.04 
0.04 
0.02 
Folate  
Betaine  
B2  
B12 
PLP  
-0.11 
-0.08 
-0.04 
-0.03 
-0.01 
Dry season 
 
(Feb-Apr) 
2-step 79 0.575 Cysteine  0.16 (0.10, 0.22), p<0.001 Folate  
B2  
-0.17 (-0.23, -0.11), p<0.001 
-0.07 (-0.13, -0.01), p=0.018 
Backwards 
Stepwise 
79 0.542 Cysteine  0.16 (0.10, 0.23), p<0.001 Folate  -0.18 (-0.24, -0.12), p<0.001 
Lasso 80 0.423 Cysteine  
DMG  
Choline  
Methionine  
 
0.13 
0.05 
0.06 
0.03 
Folate  
B2  
B12  
Betaine  
PLP 
-0.11 
-0.06 
-0.02 
-0.11 
-0.02 
Rainy season 
 
(Jul-Oct) 
2-step 77 0.622 Cysteine  0.13 (0.08, 0.17), p<0.001 None  
Backwards 
stepwise 
70 0.732 Cysteine  0.17 (0.12, 0.21), p<0.001 Folate  
B12  
-0.10 (-0.14, -0.06), p<0.001 
-0.05 (-0.09, -0.01), p=0.010 
Lasso 72 0.504 Cysteine  
Choline  
DMG  
PLP  
0.14 
0.04 
0.03 
0.03 
Folate 
Betaine  
B2  
B12  
-0.09 
-0.05 
-0.02 
-0.04 
*Lasso model fitted to variables demonstrating the smallest Cp value. Note no confidence intervals are reported for Lasso models.  
ƗPredictors are adjusted for maternal age, gestational and BMI. Only variables with a final p<0.05 reported.  
ǂβ Coefficients represent the change in log homocysteine for a one SD increase in the log-transformed independent variable. 
Abbreviations: CI, confidence interval; DMG, dimethylglycine; PLP, pyridoxal 5’-phosphate 
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Table 6.3 Nutritional Biomarker Independent Predictors of homocysteine in MDEG-2 Dataset 
Seasonal 
Model 
Statistical 
approach* 
N R2 Positive predictorsƗ 
(β, 95%CI, p value) 
Negative predictorsƗ 
(β, 95%CI, p value) 
Year-round 
 
2-step 339 0.588 Cysteine 
Glycine 
DMG 
0.21 (0.18, 0.24), p<0.001 
0.05 (0.02, 0.08), p<0.001 
0.03 (0.01, 0.06), p=0.019 
Folate 
B12 
Betaine 
-0.10 (-0.13, -0.08), p<0.001 
-0.10, (-0.13, -0.08), p<0.001 
-0.07 (-0.10, -0.04), p<0.001 
Backwards 
Stepwise 
338 0.610 Cysteine 
Glycine  
DMG  
Proline  
PLP  
Aspartate  
0.2 (0.18, 0.23), p<0.001 
0.06 (0.04, 0.09), p<0.001 
0.04 (0.01, 0.06), p=0.004 
0.04 (0.01, 0.07), p=0.009 
0.04 (0.00, 0.07), p=0.027 
0.03 (0.00, 0.06), p=0.046 
Folate 
B12  
Betaine  
B2  
-0.10 (-0.13, -0.08), p<0.001 
-0.10 (-0.12, -0.07), p<0.001 
-0.07 (-0.10, -0.04), p<0.001 
-0.05 (-0.07, -0.02), p<0.001 
 
Lasso 342 0.540 Cysteine  
Glycine  
PLP 
DMG  
Proline  
Glutamate  
Aspartate  
Isoleucine  
Serine  
0.18 
0.06 
0.04 
0.03 
0.03 
0.02 
0.02 
0.01 
0.01 
Folate  
B12  
Betaine  
B2  
Tyrosine  
Threonine  
Alanine  
Methionine  
-0.09 
-0.08 
-0.06 
-0.04 
-0.02 
-0.02 
-0.01 
-0.01 
Dry season 
 
(Feb-Apr) 
2-step 82 0.470 Cysteine  0.18 (0.13, 0.23), p<0.001 B12 
Betaine  
-0.08 (-0.13, -0.03), p=0.001 
-0.07 (-0.12, -0.03), p=0.003 
Backwards 
Stepwise 
81 0.624 Cysteine  
PLP 
Aspartate  
 
0.18 (0.13, 0.23), p<0.001 
0.05 (0.01, 0.10), p=0.021 
0.05 (0.00, 0.10), p=0.042 
Betaine  
Folate  
B12  
B2 
Threonine  
-0.08 (-0.13, -0.04), p<0.001 
-0.08 (-0.13, -0.02), p=0.008 
-0.07 (-0.12, -0.03), p=0.003 
-0.05 (-0.10, -0.01), p=0.013  
-0.04 (-0.08, 0.00), p=0.045 
Lasso 85 0.572 Cysteine  
PLP 
Proline  
Serine 
0.16 
0.07 
0.04 
0.03 
Betaine  
Folate  
B12  
Choline 
-0.06 
-0.06 
-0.06 
-0.04 
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Seasonal 
Model 
Statistical 
approach* 
N R2 Positive predictorsƗ 
(β, 95%CI, p value) 
Negative predictorsƗ 
(β, 95%CI, p value) 
Glycine  
Aspartate  
DMG  
0.02 
0.02 
0.01 
B2 
Threonine  
-0.03 
-0.03 
Rainy season 
 
(Jul-Oct) 
2-step 98 0.636 Cysteine  
 
0.23 (0.17, 0.29), p<0.001 B12  
Folate  
B2  
-0.09 (-0.14, -0.04), p<0.001 
-0.08 (-0.12, -0.03), p=0.001 
-0.06 (-0.11, -0.01), p=0.022 
Backwards 
stepwise 
98 0.700 Cysteine  
Valine  
Proline  
Aspartate  
 
0.24 (0.18, 0.29), p<0.001 
0.11 (0.03, 0.19), p=0.005 
0.07 (0.01, 0.13), p=0.028 
0.04, p=0.022 
Leucine  
B12  
Folate  
Alanine  
B2  
-0.10 (-0.19, -0.01), p=0.035 
-0.08, (-0.12, -0.04), p<0.001 
-0.07 (-0.11, -0.03), p=0.002 
-0.07 (-0.12, -0.01), p=0.028 
-0.05 (-0.10, 0.00), p=0.036 
Lasso 98 0.529 Cysteine  
Glutamate  
Proline  
Aspartate  
Valine  
 
0.18 
0.03 
0.02 
0.01 
0.01 
B12  
Folate  
B2  
Betaine  
Tyrosine  
Histidine  
Choline  
-0.06 
-0.06 
-0.04 
-0.02 
-0.02 
-0.01 
-0.01 
 
*Lasso model fitted to variables demonstrating the smallest Cp value. Note no confidence intervals are reported for Lasso models.  
ƗPredictors are adjusted for maternal age, BMI, gestational age and inflammation (AGP). Only variables with a final p<0.05 reported.  
ǂβ Coefficients represent the change in log homocysteine for a one SD increase in the log-transformed independent variable. 
Abbreviations: AGP, Alpha-1-acid glycoprotein; CI, confidence interval; DMG, dimethylglycine; PLP, pyridoxal 5’-phosphate
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Table 6.4 Nutritional Biomarker Independent Predictors of homocysteine in the Indicator group dataset 
Seasonal Model No. 
observations 
No. women Overall R2* Positive predictorsƗ 
(βǂ, 95% CI, p value) 
Negative predictorsƗ 
(βǂ, 95% CI, p value) 
Combined seasons 288 48 0.306 Cysteine  
DMG  
0.14 (0.11, 0.17), p<0.001 
0.08 (0.04, 0.12), p<0.001 
Folate 
Betaine  
-0.11 (-0.13, -0.08), p<0.001 
-0.05 (-0.08, -0.02), p=0.003 
Dry (Feb-Apr) 79 34 0.295 Cysteine  0.17 (0.12, 0.21), p<0.001 Folate  -0.15 (-0.22, -0.08), p<0.001 
Rainy (Jul-Oct) 63 28 0.549 Cysteine  0.16 (0.11, 0.22), p<0.001 Folate 
B12 
B2  
-0.13 (-0.18, -0.07), p<0.001 
-0.09 (-0.16, -0.02), p=0.009 
-0.09 (-0.17, -0.01), p=0.026 
 
*Two-step linear regression using random effects 
Ɨ Predictors are those variables retained in the multivariable model with p<0.05, adjusted for age. 
ǂβ Coefficients represent the change in log homocysteine for a one SD increase in the log-transformed independent variable. 
Abbreviations: CI, confidence interval; DMG, dimethylglycine 
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Figure 6.1 Summary of retained coefficients of multivariable linear regression models in three datasets, by season*. 
 
*Note: Coefficients represent change in log homocysteine 
for each SD increase in the log-transformed independent 
variable. Only variables with p<0.05 shown. Those inversely 
associated with homocysteine are shaded in green, and 
those positively associated are shaded in red.  
 
Abbreviations: DMG, dimethylglycine; MDEG1, MDEG main 
study 
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Table 6.5 Performance of predictors of homocysteine within their own dataset 
Dataset  Variables used  Regress actual against predicted* 
N Root 
MSE 
R2 Adj 
R2 
p 
MDEG 
main 
study 
Bet, chol, DMG, B12, fol, met, cys, B2, 
PLP, age (10) 
152 0.203 0.602 0.574 <0.001 
MDEG 
main 
study 
Bet, chol, DMG, B12, fol, met, cys, B2, 
PLP, age, BMI, gestational age (12) 
149 0.202 0.614 0.580 <0.001 
Indicator 
group 
Bet, chol, DMG, B12, fol, met, cys, B2, 
PLP, age (10) 
288 
Obs,  
48 
women 
 0.478 
(within) 
0.351 
(between) 
0.359 
(overall) 
 <0.001 
MDEG-2 Bet, chol, DMG, B12, fol, met, cys, B2, 
PLP, age (10) 
346 0.238 0.539 0.525 <0.001 
MDEG-2  Bet, chol, DMG, B12, fol, met, cys, B2, 
PLP, age, BMI, gestational age (12) 
346 0.236 0.547 0.531 <0.001 
 
*Results from a univariable linear regression with actual log homocysteine as the dependent variable 
and predicted log homocysteine as the independent variable.  
 
Abbreviations: Bet, betaine; chol, choline, DMG, dimethylglycine; fol, folate; met, methionine; cys, 
cysteine, PLP, pyridoxal 5’-phosphate; MSE, mean square error; Adj, adjusted; Obs, observations. 
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Table 6.6 Performance predictors of homocysteine cross-dataset 
Original 
Dataset  
Test dataset Variables used  Regress actual against predicted* Difference in R2 compared to 
same dataset prediction (Table 
6.5) 
N Root 
MSE 
R2 Adj R2 p 
MDEG 
main 
study 
Indicator  Bet, chol, DMG, B12, fol, met, cys, 
B2, PLP age (10) 
288 Obs, 
48 women 
 0.421 (within) 
0.414 (between) 
0.387 (overall) 
 <0.001 -0.057 (within) 
0.063 (between) 
0.028 
(overall) 
MDEG 
main 
study 
MDEG-2 Bet, chol, DMG, B12, fol, met, cys, 
B2, PLP age (10) 
346 0.263 0.418 0.417 <0.001 -0.121 
MDEG 
main 
study 
MDEG-2 Bet, chol, DMG, B12, fol, met, cys, 
B2, PLP age, BMI, gestational age 
(12) 
346 0.269 0.383 0.391 <0.001 -0.164 
Indicator 
group 
MDEG main 
study 
Bet, chol, DMG, B12, fol, met, cys, 
B2, PLP age (10) 
152 0.210 0.546 0.544 <0.001 -0.056 
Indicator 
group 
MDEG-2 Bet, chol, DMG, B12, fol, met, cys, 
B2, PLP age (10) 
346 0.256 0.452 0.451 <0.001 -0.087 
MDEG-2 Indicator 
group 
Bet, chol, DMG, B12, fol, met, cys, 
B2, PLP age (10) 
288 Obs 48 
women 
 0.401 (within) 
0.305 (between) 
0.350 (overall) 
 <0.001 -0.077 (within) 
-0.046 (between) 
-0.009 (overall) 
MDEG-2 MDEG main 
study 
Bet, chol, DMG, B12, fol, met, cys, 
B2, PLP age (10) 
152 0.236 0.431 0.427 <0.001 -0.171 
MDEG-2 MDEG main 
study 
Bet, chol, DMG, B12, fol, met, cys, 
B2, PLP age, BMI, gestational age 
(12) 
149 0.243 0.400 0.396 <0.001 -0.214 
 
*Results from a univariable linear regression with actual log homocysteine as the dependent variable and predicted log homocysteine as the independent variable.  
Abbreviations: Bet, betaine; chol, choline, DMG, dimethylglycine; fol, folate; met, methionine; cys, cysteine, PLP, pyridoxal 5’-phosphate; MSE, mean square error; Adj, 
adjusted; Obs, observations. 
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6.4  Discussion 
In order to assess which nutritional components could be considered for a supplement to 
reduce plasma homocysteine I analysed three different datasets using three different linear 
regression approaches to see which nutritional biomarkers were consistently inversely 
associated with Hcy. This approach built up an overview of the most reliable predictors of 
homocysteine. Folate, B12, B2 and betaine were the most consistent negative predictors of 
Hcy. Predictive equations for Hcy generated in one dataset worked well in the other datasets, 
indicating that results from these models could be generalizable to different cohorts from 
the same region in The Gambia.  
6.4.1  Negative predictors of homocysteine 
The findings that plasma folate, B12, B2 and betaine were inversely associated with Hcy are 
consistent with the literature(10–13). Supplementation with these components have been 
successful in previous trials with the aim of reducing homocysteine(6,14–17).  
Hcy can be metabolised via a process involving remethylation or through the transsulfuration 
pathway.  In the former, Hcy accepts a methyl group to form methionine(18), which can then 
in turn be condensed with ATP to form S-adenosyl methionine, a methyl donor involved in 
numerous transmethylation reactions.  The remethylation of Hcy to methionine uses two 
distinct pathways. The major one is the vitamin B12- dependent reaction involving folate 
metabolic pathways(19), chiefly the donation of a methyl group from N5-methyl 
tetrahydrofolate (‘methyl-THF’). The alternative pathway for the methylation of Hcy, 
predominantly used in the liver and kidneys, uses the methyl group from betaine, a product 
formed through the oxidation of choline(20,21). In the transsulfuration pathway Hcy is 
metabolised through its irreversible degradation to cystathionine and cysteine, requiring PLP 
(vitamin B6)(19). Annex 4.4 provides more details on the context of these pathways.  
Dietary folates and folic acid therefore contribute to the removal of homocysteine via 
methyl-THF. They are first reduced to form tetrahydrofolate (THF), which is in turn is reduced 
to methylene-THF, then to methyl-THF. This is the form that donates its methyl group to Hcy 
using vitamin B12. In human plasma and the cytosol the predominant form of vitamin B12 is 
methylcobalamin(22). This is the form that is used as a coenzyme for methionine synthase, 
the enzyme responsible for adding the methyl group from 5-methyl-THF to Hcy to form 
methionine. The cobalt atom in the methylcobalamin cycles between different oxidation 
states in the reaction catalysed by methionine synthase. Firstly cob(I)alamin accepts the 
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methyl group from 5-methyl-THF to form methylcob(I)alamin and THF. Methylcob(I)alamin 
then transfers the methyl group to homocysteine to form methionine, and generating 
cob(I)alamin again. Every 100-2000 cycles the cob(I)alamin is oxidised to cob(II)alamin (it 
loses an electron)(23,24). This is oxidation state is catalytically inactive and the compound 
needs to be reduced back to the +1 oxidation state. In humans methionine synthase 
reductase catalyses the reaction whereby the cob(II)abalamin is firstly reduced to 
cob(I)alamin and then  SAM provides a methyl donor to regenerate methylcob(I)alamin(23,24). 
The above metabolic descriptions explain why folate, betaine and B12 are required to recycle 
Hcy. In order to understand where B2 fits in we need to re-visit the step where dietary folates 
are converted to methylene-THF. B2 is required as a precursor to flavin mononucleotide 
(FMN), a reaction catalysed by riboflavin kinase. FMN is converted to flavin adenine 
dinucleotide (FAD) by FAD synthase(25,26). FAD is a cofactor required by 
methylenetetrahydrofolate reductase (MTHFR) to reduce methylene-THF to methyl-THF(3).  
Threonine was retained as a negative predictor of Hcy in some models, as was alanine in the 
analyses excluding cysteine and DMG. The relationship between plasma Hcy and amino acids 
is not well documented in the literature. However, in a study investigating plasma 
metabolites in healthy controls no association between Hcy and amino acids was found(27). 
Without further justification from the literature it is not possible to say whether these are 
genuine or chance findings of associations, especially as amino acids were only measured in 
one of the datasets.    
6.4.2  Positive predictors of homocysteine 
Cysteine was the strongest positive predictor of Hcy, which was to be expected given that 
Hcy can be converted into cystathionine by Cystathionine β-synthase (CBS) and then onto 
cysteine by Cystathionine γ-lyase(19). The positive association of DMG with homocysteine can 
be explained by the reaction catalysed by betaine-homocysteine methyltransferase (BHMT), 
which methylates Hcy using a methyl group from betaine and in the process forms DMG(28). 
Thus describing cysteine and DMG as ‘positive predictors’ can be misleading since they are 
by-products of Hcy catabolism, and this is the reason the analyses were repeated without 
these two metabolites.  
There were no strong associations between methionine and Hcy, most likely explained by its 
position on a circular metabolic pathway and therefore it can be viewed as both a substrate 
for Hcy production and as a by-product of Hcy catabolism. It can be seen as a substrate for 
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Hcy production since it is condensed with ATP to form SAM, which is then demethylated to 
SAH, which in turn is hydrolysed to form Hcy and adenosine(19,29).  Methionine can also be 
viewed as the product resulting from Hcy catabolism through Hcy remethylation using the 
methyl group from 5-methyl-THF or betaine. Linear regression models are not designed to 
model such circular pathways and therefore it is perhaps not surprising that no clear 
associations between methionine and Hcy can be identified. We might only expect 
homocysteine to significantly rise in response to a methionine load (e.g. straight after a 
protein-rich meal), whereas the samples in these datasets are fasted blood samples.  
Given that choline is oxidised to betaine(30), and that in the datasets betaine is strongly 
inversely associated with Hcy, an inverse association between choline and homocysteine was 
expected. Whilst this was the case in the MDEG-2 dataset, in the MDEG main study choline 
had a positive association with Hcy. Despite seeming counter intuitive, this positive 
association has been found previously in pregnant women(10). Molloy et al. (2005) 
hypothesise that increased fetal requirements for choline during pregnancy upregulates 
choline production via phosphatidylcholine (PC) synthesis(10). To produce one molecule of PC 
using the PEMT pathway three methyl groups from SAM are required. Once SAM donates its 
methyl group it forms SAH, which is hydrolysed to Hcy(31), thereby increasing Hcy 
concentrations.  It is therefore unlikely that choline is associated with increased Hcy in a 
causal relationship per se, but that the association is due to the physiological adaptation in 
pregnancy to increased endogenous production of choline. This remains speculative since 
we cannot distinguish between dietary and endogenous sources of choline in the plasma 
samples, nor was the direction of the association between choline and Hcy consistent within 
the datasets. 
Vitamin B6 (in the active form of PLP) is required to reduce THF to methylene-THF, and is 
also a cofactor in the transsulfuration pathway converting homocysteine to cysteine(19). It 
was therefore expected to be a negative predictor, considering its role in pathways 
responsible for Hcy’s remethylation and transsulfuration. Indeed, B6 has been inversely 
associated with Hcy in previous studies(12,32,33). However, there are also several studies 
showing that PLP has no effect on fasting Hcy levels(11,34,35). It is more likely that the effect of 
PLP will be seen in reducing Hcy after a methionine load(19). It is biologically very unlikely that 
PLP would cause an increase in plasma Hcy, and its retention in some of the models as a 
positive predictor is not easily explained.  
The positive association between glycine and Hcy could be explained by the reaction 
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catalysed by glycine N-methyltransferase (GNMT). In this reaction glycine accepts a methyl 
group from SAM to form SAH and sarcosine. This reaction occurs especially when SAM 
concentrations are high(17). The production of SAH from this reaction would therefore 
contribute to higher Hcy through the hydrolysis of SAH to Hcy. Surprisingly, serine was not 
retained in many models at all, and where it was retained the effect size was very small. 
Given that serine is used in the transsulfuration pathway to catabolise Hcy, and also used as 
a 1-carbon donor at the stage of converting THF to methylene-THF through the action of 
serine hydroxymethyltransferase and PLP(36), it may have been expected to have an inverse 
association with Hcy.  
6.4.3  Predictive power and generalisability of predictors 
In the two cross-sectional datasets (MDEG main study and MDEG-2) the set of predictors 
explained well over half the variability of plasma Hcy, with the predictors working slightly 
less well in the longitudinal dataset (Indicator group). However, the predictors were still able 
to explain over a third of the variability of Hcy in the Indicator group. The predictors also 
performed well in cross-dataset comparisons. This is particularly encouraging given that the 
predictive model from the MDEG main study dataset, derived from only 6 months of data, 
was still able to predict Hcy in datasets including year-round data (MDEG-2 and the Indicator 
group). Taken together these results affirmed the notion that nutritional predictors of Hcy 
are generalizable between different cohorts from West Kiang region, and can therefore be 
taken forwards as fairly robust predictors of Hcy when it comes to supplement design 
considerations.  
The unexplained variability in plasma Hcy could perhaps be partially explained by the effect 
of SNPs in enzymes involved in one-carbon metabolism (e.g. MTHFR, CBS) on homocysteine 
levels. The notion that relevant SNPs influence plasma Hcy levels has been well documented 
in other populations(37–43). However, the effect of these genetic variants on total plasma Hcy 
variability is likely to be less significant than the nutritional biomarker predictors, with the 
former often explaining less than 6% of total Hcy variability(37,42). There are also several other 
potential predictors of Hcy which were not measured (e.g. fat-free mass, renal function, 
estradiol and creatinine concentrations, caffeine consumption, smoking, alcohol intake 
etc.(12,35)). The overall aim of these analyses was to identify nutritional inputs that could be 
modified through a supplement, rather than an exercise in identifying all potential predictors 
of Hcy. The high proportion of Hcy variability explained by the profile of nutritional predictors 
provided confidence that a nutritional approach to modifying Hcy should work well in the 
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target population.  
6.4.4  Limitations 
All linear regression approaches have their own set of limitations in the way they select and 
report the effect of a sub-set of explanatory variables. These limitations have been explored 
in Chapter 5 and elsewhere in detail(44–47). The potential differences that the type of linear 
regression approach can make to variable selection was the main reason that three different 
approaches were compared. In a traditional research study on predictors of homocysteine 
this would clearly be open to criticisms of multiple testing and an incoherent statistical 
approach. However, for a supplement design aim it was useful to assess to what extent 
similar trends emerged across multiple datasets and linear regression approaches that could 
help identify consistent negative predictors of Hcy.  
The datasets carry the limitations of utilising cross-sectional plasma information. Whilst 
useful for identifying predictors of Hcy they cannot go much further in guiding the doses of 
ingredients to include in a supplement, nor what the expected effect of a supplement might 
be on plasma Hcy. To achieve this would require the integration of dietary intake data and 
kinetic data to be used in more formal pharmacodynamics approaches, which go beyond the 
scope of this PhD. A plasma sample taken at one point in time can provide clues as to what 
some of the underlying determinants of plasma Hcy are, but without further clinical tests it 
can be difficult to disentangle the components. For example, a high Hcy concentration could 
be due to increased transmethylation, decreased transsulfuration, decreased remethylation, 
decreased uptake of Hcy by the kidney, genetic defects in key enzymes, or a combination of 
these factors(19,29,48).  Thus the utility of these analyses is constrained to selection of potential 
ingredients to take forwards to the supplement design stage. The outputs of this analysis 
may therefore be seen as more qualitative in nature rather than quantitative, but they still 
help to design a supplement that is better tailored to the West Kiang population rather than 
rely solely on a generic, commercially available supplement.   
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6.5  Conclusion 
In the context of West Kiang, the four nutritional biomarkers consistently inversely 
associated with plasma Hcy were betaine, B12, B2 and folate. These findings were consistent 
with the literature. Vitamin B6 and choline, contrary to expectations, were positively 
associated with Hcy and therefore dropped from the list of potential supplement ingredients. 
Betaine, B12, B2 and folate were taken forwards into the supplement design stage, which is 
explored in more detail in the following chapter.  
 
6.6  References 
1.  Silver MJ, Kessler NJ, Hennig BJ, et al. (2015) Independent genomewide screens 
identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to 
periconceptional environment. Genome Biol. 16, 118. 
2.  Dominguez-Salas P, Moore SE, Cole D, et al. (2013) DNA methylation potential: 
dietary intake and blood concentrations of one-carbon metabolites and cofactors in 
rural African women. Am. J. Clin. Nutr. 97, 1217–27. 
3.  Mason JB (2003) Biomarkers of Nutrient Exposure and Status in One-Carbon (Methyl) 
Metabolism. J. Nutr. 133, 941S–947. 
4.  Dominguez-Salas P, Moore SE, Baker MS, et al. (2014) Maternal nutrition at 
conception modulates DNA methylation of human metastable epialleles. Nat. 
Commun. 5, 3746.  
5.  Hustad S, Eussen S, Midttun Ø, et al. (2012) Kinetic modeling of storage effects on 
biomarkers related to B vitamin status and one-carbon metabolism. Clin. Chem. 58, 
402–10. 
6.  Homocysteine Lowering Trialists’ Collaboration. (1998) Lowering blood homocysteine 
with folic acid based supplements: meta-analysis of randomised trials. BMJ 316, 894–
8. 
7.  Huang T, Zheng J, Chen Y, et al. (2011) High consumption of Ω-3 polyunsaturated fatty 
acids decrease plasma homocysteine: a meta-analysis of randomized, placebo-
controlled trials. Nutrition 27, 863–7. 
8.  McRae MP (2013) Betaine supplementation decreases plasma homocysteine in 
healthy adult participants: a meta-analysis. J. Chiropr. Med. 12, 20–25. 
9.  Moore SE, Fulford AJ, Darboe MK, et al. (2012) A randomized trial to investigate the 
effects of pre-natal and infant nutritional supplementation on infant immune 
development in rural Gambia: the ENID trial: Early Nutrition and Immune 
Development. BMC Pregnancy Childbirth 12, 107.  
10.  Molloy AM, Mills JL, Cox C, et al. (2005) Choline and homocysteine interrelations in 
umbilical cord and maternal plasma at delivery. Am. J. Clin. Nutr. 82, 836–42. 
 146 
 
11.  Holm PI, Ueland PM, Vollset SE, et al. (2005) Betaine and folate status as cooperative 
determinants of plasma homocysteine in humans. Arterioscler. Thromb. Vasc. Biol. 
25, 379–85.  
12.  Jacques PF, Bostom AG, Wilson PW, et al. (2001) Determinants of plasma total 
homocysteine concentration in the Framingham Offspring cohort. Am. J. Clin. Nutr. 
73, 613–621.  
13.  van Beynum IM, den Heijer M, Thomas CM, et al. (2005) Total homocysteine and its 
predictors in Dutch children. Am. J. Clin. Nutr. 81, 1110–1116. 
14.  Steenge GR, Verhoef P & Katan MB (2003) Betaine supplementation lowers plasma 
homocysteine in healthy men and women. J. Nutr. 133, 1291–5. 
15.  Olthof MR, van Vliet T, Verhoef P, et al. (2005) Effect of homocysteine-lowering 
nutrients on blood lipids: results from four randomised, placebo-controlled studies in 
healthy humans. PLoS Med. 2, e135  
16.  Dawson SL, Bowe SJ & Crowe TC (2016) A combination of omega-3 fatty acids, folic 
acid and B-group vitamins is superior at lowering homocysteine than omega-3 alone: 
A meta-analysis. Nutr. Res. 36, 499–508. 
17.  Olthof MR & Verhoef P (2005) Effects of betaine intake on plasma homocysteine 
concentrations and consequences for health. Curr. Drug Metab. 6, 15–22. 
18.  Robinson JL & Bertolo RF (2016) The Pediatric Methionine Requirement Should 
Incorporate Remethylation Potential and Transmethylation Demands. Adv. Nutr. 7, 
523–34. 
19.  Selhub J (1999) Homocysteine metabolism. Annu. Rev. Nutr. 19, 217–46.  
20.  Velzing-Aarts F V, Holm PI, Fokkema MR, et al. (2005) Plasma choline and betaine and 
their relation to plasma homocysteine in normal pregnancy. Am. J. Clin. Nutr. 81, 
1383–9. 
21.  McKeever MP, Weir DG, Molloy A, et al. (1991) Betaine-homocysteine 
methyltransferase: organ distribution in man, pig and rat and subcellular distribution 
in the rat. Clin. Sci. 81, 551–6. 
22.  Green R & Miller JW (2007) Vitamin B12. In Handbook of Vitamins, 4th ed. [ZempleniJ, 
Rucker R, McCormick D, et al., editors]. Boca Ralton, FL: Taylor & Francis Group. 
23.  Ragsdale SW (2008) Catalysis of methyl group transfers involving tetrahydrofolate 
and B(12). Vitam. Horm. 79, 293–324. 
24.  Banerjee R V & Matthews RG (1990) Cobalamin-dependent methionine synthase. 
FASEB J. 4, 1450–9. 
25.  Hustad S, McKinley MC, McNulty H, et al. (2002) Riboflavin, Flavin Mononucleotide, 
and Flavin Adenine Dinucleotide in Human Plasma and Erythrocytes at Baseline and 
after Low-Dose Riboflavin Supplementation. Clin. Chem. 48, 1571–1577. 
26.  Hustad S, Schneede J & Ueland PM (2013) Madame Curie Bioscience Database 
 147 
 
[Internet]. In Madame Curie Biosci. Database [Internet]. Austin (TX): Landes 
Bioscience. 
27.  Hong SY, Yang DH & Chang SK (1998) The relationship between plasma homocysteine 
and amino acid concentrations in patients with end-stage renal disease. J. Ren. Nutr. 
8, 34–9. 
28.  Ueland PM, Holm PI & Hustad S (2005) Betaine: a key modulator of one-carbon 
metabolism and homocysteine status. Clin. Chem. Lab. Med. 43, 1069–75. 
29.  Stipanuk MH (2004) Sulfur amino acid metabolism: pathways for production and 
removal of homocysteine and cysteine. Annu. Rev. Nutr. 24, 539–77. 
30.  Ueland PM (2011) Choline and betaine in health and disease. J. Inherit. Metab. Dis. 
34, 3–15. 
31.  Pajares MA & Pérez-Sala D (2006) Betaine homocysteine S-methyltransferase: just a 
regulator of homocysteine metabolism? Cell. Mol. Life Sci. 63, 2792–803. 
32.  Selhub J, Jacques PF, Wilson PW, et al. (1993) Vitamin status and intake as primary 
determinants of homocysteinemia in an elderly population. JAMA 270, 2693–8. 
33.  Siri PW, Verhoef P & Kok FJ (1998) Vitamins B6, B12, and folate: association with 
plasma total homocysteine and risk of coronary atherosclerosis. J. Am. Coll. Nutr. 17, 
435–41.  
34.  Andersson A, Brattström L, Israelsson B, et al. (1992) Plasma homocysteine before 
and after methionine loading with regard to age, gender, and menopausal status. Eur. 
J. Clin. Invest. 22, 79–87. 
35.  Dierkes J, Jeckel A, Ambrosch A, et al. (2001) Factors explaining the difference of total 
homocysteine between men and women in the European Investigation Into Cancer 
and Nutrition Potsdam study. Metabolism. 50, 640–5.  
36.  Davis SR, Stacpoole PW, Williamson J, et al. (2004) Tracer-derived total and folate-
dependent homocysteine remethylation and synthesis rates in humans indicate that 
serine is the main one-carbon donor. Am. J. Physiol. Endocrinol. Metab. 286, E272-9. 
37.  van Meurs JB, Pare G, Schwartz SM, et al. (2013) Common genetic loci influencing 
plasma homocysteine concentrations and their effect on risk of coronary artery 
disease. Am. J. Clin. Nutr. 98, 668–676. 
38.  Cotlarciuc I, Malik R, Holliday EG, et al. (2014) Effect of genetic variants associated 
with plasma homocysteine levels on stroke risk. Stroke 45, 1920–4.  
39.  Zhu Y, Zhu R-X, He Z-Y, et al. (2015) Association of MTHFR C677T with total 
homocysteine plasma levels and susceptibility to Parkinson’s disease: a meta-
analysis. Neurol. Sci. 36, 945–951.  
40.  Nienaber-Rousseau C, Ellis SM, Moss SJ, et al. (2013) Gene–environment and gene–
gene interactions of specific MTHFR, MTR and CBS gene variants in relation to 
homocysteine in black South Africans. Gene 530, 113–118. 
 148 
 
41.  STEFANO V, DEKOU V, NICAUD V, et al. (1998) Linkage disequilibrium at the 
cystathionine beta synthase (CBS) locus and the association between genetic 
variation at the CBS locus and plasma levels of homocysteine. Ann. Hum. Genet. 62, 
481–490. 
42.  Dekou V, Gudnason V, Hawe E, et al. (2001) Gene-environment and gene-gene 
interaction in the determination of plasma homocysteine levels in healthy middle-
aged men. Thromb. Haemost. 85, 67–74. 
43.  Williams SR, Yang Q, Chen F, et al. (2014) Genome-Wide Meta-Analysis of 
Homocysteine and Methionine Metabolism Identifies Five One Carbon Metabolism 
Loci and a Novel Association of ALDH1L1 with Ischemic Stroke. PLoS Genet. 10, 
e1004214  
44.  George EI (2000) The Variable Selection Problem. J. Am. Stat. Assoc. 95, 1304–1308. 
45.  Greenland S (1989) Modeling and variable selection in epidemiologic analysis. Am. J. 
Public Health 79, 340–9. 
46.  Walter S & Tiemeier H (2009) Variable selection: current practice in epidemiological 
studies. Eur. J. Epidemiol. 24, 733–736. 
47.  Morozova O, Levina O, Uusküla A, et al. (2015) Comparison of subset selection 
methods in linear regression in the context of health-related quality of life and 
substance abuse in Russia. BMC Med. Res. Methodol. 15, 71. 
48.  Hoffer LJ (2004) Homocysteine remethylation and trans-sulfuration. Metabolism. 53, 
1480–3.  
 
 
  
 149 
 
Supplementary Material 6.1:  Generating the cross-dataset predictive models for 
homocysteine 
 
Example using the MDEG main study dataset: 
 
Step 1: Perform a linear regression with log-transformed homocysteine as the outcome and 
all predictor variables and a priori confounders as explanatory variables. Note all explanatory 
variables are log-transformed and standardised prior to model entry.  
 
Log 
Homocysteine 
Coef. Std. Err. t P>t [95% 
Conf. 
Interval] 
Betaine -.0225277 .0273018 -0.83 0.411 -.0765188 .0314633 
Choline .0270422 .0204959 1.32 0.189 -.0134897 .0675741 
Dimethylglycine .0428009 .0202828 2.11 0.037 .0026903 .0829115 
B12 -.049664 .018733 -2.65 0.009 -.0867097 -.0126183 
Folate -.1267153 .0194482 -6.52 0.000 -.1651752 -.0882553 
Methionine .0142125 .0198103 0.72 0.474 -.0249635 .0533885 
Cysteine .1642254 .0206111 7.97 0.000 .1234657 .2049851 
B2 -.0391662 .017476 -2.24 0.027 -.073726 -.0046064 
Pyridoxal 5’-
phophate 
-.0154349 .0195357 -0.79 0.431 -.0540679 .023198 
Age .056085 .0187471 2.99 0.003 .0190113 .0931586 
Body Mass Index -.014398 .0182335 -0.79 0.431 -.0504558 .0216599 
Gestational Age -.039648 .0255307 -1.55 0.123 -.0901366 .0108405 
Constant 1.928049 .0166372 115.89 0.000 1.895147 1.96095 
 
Step 2: Obtain the predictive equation from the constant and coefficients from step 1 
Predicted log Hcy =  1.928049 -0.0225277*betaine + 0.0270422*choline + 0.0428009*DMG  
-0.049664 *B12  - 0.1267153*folate + 0.0142125*methionine + 0.1642254*cysteine -
0.0391662*B2 - 0.0154349*PLP + 0.056085*age - 0.014398*BMI - 0.039648*gestational age 
 
Step 3: In a new dataset (e.g. MDEG-2) generate the predicted homocysteine values by 
applying the equation from step 2 to the log transformed, standardised explanatory 
variables. 
 
Step 4: Regress the actual homocysteine in the new dataset against the predicted 
homocysteine to assess how well the equation performs.    
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S1 Table 6.1: Nutritional Biomarker Independent Predictors of Homocysteine without Cysteine & Dimethylglycine in MDEG Main Study  
 
Seasonal 
Model 
Statistical 
approach* 
N R2 Positive predictorsƗ 
(β, 95%CI, p value) 
Negative predictorsƗ 
(β, 95%CI, p value) 
Combined 
Seasons 
 
2-step 150 0.386 None  Folate  
B2  
-0.09 (-0.13, -0.05), p<0.001 
-0.06 (-0.10, -0.02), p=0.006 
Backwards 
Stepwise 
149 0.391 None  Folate  
B2  
-0.10 (-0.15, -0.06), p<0.001 
-0.06 (-0.10, -0.02), p=0.007 
Lasso  149 0.161 Methionine  
Choline  
0.01 
0.01 
Folate  
B2 
-0.07 
-0.04 
Dry season 
 
(Feb-Apr) 
2-step 79 0.397 None  Folate -0.16, (-0.23, -0.09), p<0.001 
Backwards 
Stepwise 
79 0.414 None  Folate  
B2  
-0.16 (-0.23, -0.09), p<0.001 
-0.07 (-0.14, -0.01), p=0.032 
Lasso 79 0.216 None  Folate  
B2  
-0.1 
-0.03 
Rainy season 
 
(Jul-Oct) 
2-step 77 0.439 None  None  
Backwards 
stepwise 
70 0.481 None  None  
Lasso 70 0.085 Choline  0.03 Folate  
B2  
-0.02 
-0.01 
 
*Lasso model fitted to variables demonstrating the smallest Cp value. Note no confidence intervals are reported for Lasso models.  
ƗPredictors are adjusted for maternal age, gestational and BMI. Only variables with a final p<0.05 reported.  
ǂβ Coefficients represent the change in log homocysteine for a one SD increase in the log-transformed independent variable. 
Abbreviations: CI, confidence interval 
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S1 Table 6.2: Nutritional Biomarker Independent Predictors of Homocysteine without Cysteine & Dimethyl glycine in MDEG-2 Study  
 
Seasonal 
Model 
Statistical 
approach* 
N R2 Positive predictorsƗ 
(β, 95%CI, p value) 
Negative predictorsƗ 
(β, 95%CI, p value) 
Year-round 
 
2-step 341 0.309 PLP 
Glycine  
 
0.09 (0.05, 0.13), p<0.001 
0.06 (0.03, 0.10), p<0.001 
Folate 
Betaine  
B12  
-0.1 (-0.14, -0.07), p<0.001 
-0.07 (-0.11, -0.04), p<0.001 
-0.06 (-0.10, -0.03), p<0.001 
Backwards 
Stepwise 
340 0.359 PLP 
Glycine  
Proline  
Aspartate  
 
0.12 (0.08, 0.16), p<0.001 
0.08 (0.05, 0.12), p<0.001 
0.06 (0.03, 0.10), p<0.001 
0.04 (0.01, 0.08), p=0.015 
Folate 
Alanine  
Betaine  
B12  
B2  
-0.10 (-0.14, -0.07), p<0.001 
-0.09 (-0.13, -0.06), p<0.001 
-0.08 (-0.12, -0.05), p<0.001 
-0.07 (-0.10, -0.04) p<0.001 
-0.03 (-0.07, 0.00), p<0.037 
Lasso 344 0.297 PLP 
Glycine  
Proline  
Aspartate  
Choline  
Glutamate 
Valine 
Histidine 
Arginine 
Serine 
Phenylalanine 
0.10 
0.08 
0.05 
0.03 
0.02 
0.01 
0.01 
0.01 
0.01 
0.01 
0.01 
Folate  
Alanine  
Betaine  
B12  
B2  
Tyrosine  
Threonine 
-0.10 
-0.07 
-0.07 
-0.06 
-0.03 
-0.02 
-0.01 
Dry season 
 
(Feb-Apr) 
2-step 82 0.119 None  None  
Backwards 
Stepwise 
82 0.402 PLP 
Proline  
 
0.11 (0.05, 0.17), p<0.001 
0.11 (0.03, 0.19), p=0.005 
 
Betaine  
Alanine  
Folate  
B2  
-0.10 (-0.16, -0.04), p<0.001 
-0.09 (-0.16, -0.02), p=0.009 
-0.08 (-0.15, 0.00), p=0.039 
-0.06 (-0.11, 0.00), p= 0.033 
Lasso 85 0.280 PLP 
Proline  
Serine  
0.09 
0.05 
0.02 
Betaine  
B12  
B2  
-0.04 
-0.03 
-0.03 
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Seasonal 
Model 
Statistical 
approach* 
N R2 Positive predictorsƗ 
(β, 95%CI, p value) 
Negative predictorsƗ 
(β, 95%CI, p value) 
 Choline  
Threonine  
Folate  
-0.02 
-0.02 
-0.01 
Rainy season 
 
(Jul-Oct) 
2-step 98 0.382 None  B2  -0.07 (-0.13, 0.00), p=0.038 
Backwards 
stepwise 
98 0.480 Valine  
PLP  
Proline  
0.12 (0.02, 0.23), p=0.02 
0.10 (0.02, 0.18), p=0.013 
0.09 (0.01, 0.17), p=0.027 
Alanine 
Betaine  
 
-0.11 (-0.19, -0.03), p=0.006 
-0.08 (-0.15, -0.01), p=0.019 
Lasso 98 0.216 Glutamate  
PLP  
 
0.05 
0.03 
Betaine  
B2  
B12  
Folate  
 
-0.06 
-0.03 
-0.02 
-0.02 
 
*Lasso model fitted to variables demonstrating the smallest Cp value. Note no confidence intervals are reported for Lasso models.  
ƗPredictors are adjusted for maternal age, BMI, gestational age and inflammation (AGP). Only variables with a final p<0.05 reported.  
ǂβ Coefficients represent the change in log homocysteine for a one SD increase in the log-transformed independent variable. 
Abbreviations: AGP, Alpha-1-acid glycoprotein; CI, confidence interval; PLP, pyridoxal 5’-phosphate 
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S1 Table 6.3: Nutritional Biomarker Independent Predictors of Homocysteine without Cysteine & Dimethylglycine in the Indicator group 
 
Seasonal Model No. 
observations 
No. women Overall 
R2* 
Positive predictorsƗ 
(βǂ, 95% CI, p value) 
Negative predictorsƗ 
(βǂ, 95% CI, p value) 
Combined seasons 288 48 0.226 Methionine  
 
0.05 (0.02, 0.07), p<0.001 Folate  
Betaine  
B2  
-0.08 (-0.11, -0.05), p<0.001 
-0.06 (-0.10, -0.02), p=0.002 
-0.04 (-0.08, 0.00), p=0.042 
Dry (Feb-Apr) 79 34 0.188 None  None  
Rainy (Jul-Oct) 63 28 0.264 None  Folate 
B12  
-0.09 (-0.15, -0.02), p=0.006 
-0.09 (-0.17, 0.00), p=0.046 
*Two-step linear regression using random effects 
Ɨ Predictors are those variables retained in the multivariable model with p<0.05, adjusted for age. 
ǂβ Coefficients represent the change in log homocysteine for a one SD increase in the log-transformed independent variable. 
Abbreviations: CI, confidence interval 
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Supplementary Figure 6.1: Summary of retained coefficients of multivariable linear regression models without cysteine & DMG in three datasets*. 
 
Biomarker MDEG2 MDEG2 MDEG2 MDEG1 MDEG1 MDEG1 Indicator MDEG2 MDEG2 MDEG2 MDEG1 MDEG1 MDEG1 Indicator
2-step Stepwise LASSO 2-step Stepwise LASSO 2-step 2-step Stepwise LASSO 2-step Stepwise LASSO 2-step
Folate -0.1 -0.1 -0.1 -0.09 -0.1 -0.07 -0.08 -0.08 -0.01 -0.16 -0.16 -0.1
B2 -0.03 -0.03 -0.06 -0.06 -0.04 -0.04 -0.06 -0.07 -0.07 -0.03
Choline 0.02 -0.02
B12 -0.06 -0.06 -0.03
PLP 0.09 0.12 0.1 0.11 0.09
Betaine -0.07 -0.08 -0.07 -0.06 -0.1 -0.04
Glycine 0.06 0.08 0.08
Glutamate
Proline 0.06 0.05 0.11 0.05
Aspartate 0.04 0.03
Tyrosine -0.02
Alanine -0.09 -0.07 -0.09
Serine 0.02
Threonine -0.02
Methionine 0.05
Valine
Biomarker MDEG2 MDEG2 MDEG2 MDEG1 MDEG1 MDEG1 Indicator
2-step Stepwise LASSO 2-step Stepwise LASSO 2-step
Folate -0.02 -0.02 -0.09
B2 -0.07 -0.03 -0.01
Choline 0.03
B12 -0.02 -0.09
PLP 0.1 0.03
Betaine -0.08 -0.06
Glycine
Glutamate 0.05
Proline 0.09
Aspartate
Tyrosine
Alanine -0.11
Serine
Threonine
Methionine
Valine 0.12
Combined seasons Dry season
Rainy season 
*Note: Coefficients represent change in log homocysteine 
for each SD increase in the log-transformed independent 
variable. Only variables with p<0.05 shown. Those inversely 
associated with homocysteine are shaded in green, and 
those positively associated are shaded in red.  
 
Abbreviations: DMG, dimethylglycine; MDEG1, MDEG main 
study 
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Chapter 7 Design of the MDEG-2 Methyl Donor 
Supplement 
__________________________________________________________________________ 
 
Summary of Chapter  
 
In this chapter I summarise the development of the novel drink powder supplement designed 
for the clinical trial. This includes: 
 
 An overview of the product characteristics of the new drink powder supplement. 
 A section focussing especially on betaine, since this is the first known time betaine 
has been used in a supplement in The Gambia. 
 A section overviewing the use of folic acid, vitamin B2 and vitamin B12, the other 
supplement ingredients that have been used several times before.  
Previous trials that have used the supplement ingredients in interventions, especially 
pregnancy trials where possible, have been summarised in the chapter, with more detailed 
information on each trial provided in Annex 7.1.  
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7.1  Introduction 
7.1.1  Supplement design rationale 
Section 6.1 summarises the rationale for developing a novel nutritional supplement, 
explaining the  long-term goal of shifting the maternal metabolome to optimise regulation 
of the infant epigenome by providing micronutrients in the ratio and quantity necessary for 
optimal one-carbon metabolism all year round. That section also gives the reasons why in 
the trial of the novel supplement amongst non-pregnant women the primary objective is to 
reduce plasma homocysteine. The hypothesis is that reducing homocysteine will help 
improve the methylation potential and enable one-carbon metabolic pathways to function 
unhindered.  
7.1.2  Summary of research leading to design 
Information presented in Chapters 4, 5 and 6 helped provide the ground work for the design 
of a novel nutritional supplement, called the ‘MDEG-2 Methyl Donor Supplement’. Chapter 
4 presented analysis from a sub-sample of women from West Kiang enrolled into the ENID 
trial (n=350).  Geometric mean (95% CI) homocysteine concentration is higher in the peak 
dry season (February – April) compared to the peak rainy season (July-September) [8.06 
(7.65, 8.50) µmol/L vs. 7.31 (6.82, 7.84) µmol/L; p=0.023]. These results corroborate 
longitudinal data from previous studies demonstrating similar observations in seasonal 
homocysteine concentrations(1,2). The rationale was therefore to design a supplement for 
this pilot study that could decrease dry season homocysteine plasma concentrations to at 
least those found in the rainy season, if not lower. Chapter 4 also showed that over a quarter 
of women had a low plasma folate concentration (<10nmol/L), 39% of women had a low 
plasma B2 concentration (<10nmol/L), 9.4% had a low B12 concentration (<221 pmol/L) and 
a quarter had a betaine concentration below the normal range (<16µmol/L). Figure 7.1 
presents a summary of the seasonal trends for the biomarkers of interest using the data 
presented in Chapter 4.  
Recommendations from Chapter 5 suggested that future supplementation studies for 
epigenetic outcomes would need to consider the underlying nutritional status of the 
participants, because the maternal nutritional predictors of offspring DNA methylation vary 
between the dry and rainy seasons. Although the clinical trial described in Chapter 8 does 
not look at epigenetic outcomes, the plan was to conduct the study in the dry season as this 
is the period associated with lower maternal methylation potential.  
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Chapter 6 provided the analyses from three separate datasets from West Kiang to determine 
the consistent nutritional predictors of decreased plasma homocysteine. These were folate, 
B2, B12 and betaine, and provided the final list of components for supplement consideration. 
There is already a lot of evidence suggesting similar nutritional interventions have been 
successful in reducing homocysteine(3–5). Whilst the ingredients comprising this supplement 
have been widely used before (see review below), this is the first time to our knowledge this 
specific combination and dosage of micronutrients have been used. The final supplement 
composition is described in section 7.2 below.  
 
 
Figure 7.1: Summary of seasonal trends of folate, homocysteine, B2, B12 and betaine in 
first trimester pregnancy in West Kiang (N=350). Data presented in Chapter 4. 
 
7.1.3  MDEG-2 Methyl Donor Supplement development  
Literature reviews and data analysis for supplement ingredients took place from September 
2016 to June 2017. Supplement design was finalised on 7th July 2017 following a final meeting 
between the PhD candidate and Prof Andrew Prentice (Nutrition theme leader, MRC 
Gambia), Dr Matt Silver (Senior Investigator Scientist, MRC Gambia), Prof Patrick Stover 
(external advisor, Cornell University), Dr Martha Field (external advisor, Cornell University) 
and Dr Sophie Moore (external advisor, Kings College London). The Joint Gambian 
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government / MRC Gambia Scientific Coordination Committee approved the clinical trial 
protocol for submission to the Ethics Committee on 11th October 2017. Full ethical approval 
was granted by the Joint Gambian government / MRC Gambia Ethics Committee on 11th 
December, 2017. Production of the supplement was started by Kendy Ltd. on 11th December, 
2017. Import authorisation from the Medicines Control Agency in The Gambia was granted 
on 9th February 2018, and the supplements arrived in The Gambia ready for the trial 
described in Chapter 8 on 19th February, 2018.  
The following sections provide a summary of the overall product characteristics of the 
MDEG-2 methyl donor supplement, followed by a section explicitly focussing on the 
characteristics of betaine, since this is the component that has not previously been used in 
nutritional supplements in The Gambia. The chapter finishes with a brief review of the use 
of vitamins B12, B2 and folic acid. 
 
7.2  Overall characteristics of the MDEG-2 Methyl Donor Supplement  
The novel supplement is a white, crystalline powdered, water-soluble nutritional supplement 
provided in daily dose sachets of net weight 4011mg. It is designed to be taken orally after 
being fully dissolved in 200ml of water. The dosage for adults 16 years and older is one sachet 
(4011mg) per day for 12 weeks. The supplement has been designed to reduce plasma 
homocysteine concentrations. In the planned clinical trial the hypothesis is it will reduce 
plasma homocysteine by at least 1µmol/L over 12 weeks of daily supplementation.  
Table 7.1 details the product formulation. Given the poor nutritional status of women of 
West Kiang in B2, B12 and folate (Table 4.1) the dose is twice the dietary reference intake of 
these components (explored in more detail in section 7.4). The dose of betaine is 4g per day 
(justified in section 7.3).  In order to ensure each sachet contains the appropriate quantity of 
the active ingredients a correction for overage is considered. Vitamin B2 uses a conversion 
factor of 1.4286 to ensure the appropriate amount of active ingredient is incorporated 
(2.80mg x 1.4286 x 10% overage = 4.40mg). Vitamin B12 is obtained from 0.1% titrated 
powder (5.2µg x 1000 x 10% overage = 5.70mg). The calculation for folic acid is more straight 
forwards (800µg x 12.5% overage = 0.9mg) and for the pure betaine powder no overage is 
necessary due to the large volume (4g). There are no excipients in the supplement. 
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Table 7.1 MDEG-2 Methyl Donor Supplement active ingredients 
Active 
Ingredients 
Generic Name Anatomical 
Therapeutic 
Chemical code* 
Quantity of 
pure active 
substance 
Total quantity 
of chemical 
compound 
(mg) 
Vitamin B2 Riboflavin 5-
phosphate 
A11HA04 2.80mg 4.40 
Vitamin B9 Folic Acid B03BB01 800µg 0.90 
Vitamin B12 Cyanocobalamin B03BA01 5.2 µg 5.70 
Betaine Betaine A16AA06 4g 4000.00 
TOTAL WEIGHT 4011.0 mg 
 
* The Anatomical Therapeutic Chemical classification system is designated by the WHO Collaborating 
Centre for Drug Statistics Methodology: https://www.whocc.no/atc/structure_and_principles/  
 
7.2.1  Potential drug interactions 
Folic acid can decrease the effectiveness of the drugs used to prevent seizures:  Fosphenytoin 
(Cerebyx), Phenobarbital (Luminal), Phenytoin (Dilantin), Primidone (Mysoline). It can also 
decrease the effectiveness of certain drugs for cancer treatment: Adrucil (Fluorouracil), 
Xeloda (capecitabine) and Methotrexate (MTX, Rheumatrex). Patients at risk of seizure or 
undergoing cancer treatment should not receive this supplement. Folic acid, in high doses, 
can reduce the effectiveness of antifolate antimalarials (such as Fansidar)(6). The risk of this 
is low in the study population given folate status is low to start with and the supplement 
contains a low dose of folic acid, however, women taking antifolate antimalarials should be 
closely monitored for any signs of malaria.  
7.2.2  Fertility 
There is not yet epidemiological data on use of this supplement in pregnancy and lactation 
given it is the first time of usage. However, folic acid, B12 and B2 are commonly administered 
in pregnancy at the doses contained in this supplement. There have been no documented 
adverse effects of betaine given in pregnancy, although data is limited. Animal reproduction 
studies have not been conducted. Administering this supplement during pregnancy is 
compatible with good maternal and fetal outcomes based on available literature(7,8). There is 
currently a lack of data on whether betaine anhydrous is excreted in human milk. 
Supplementation of lactating women should be done with careful monitoring until more data 
is available. No data is available on effects of the supplement on fertility. 
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7.2.3  Undesirable effects 
Riboflavin may cause urine to be more yellow in colour. Betaine may increase plasma levels 
of methionine. There are no reported cases of overdose for any of the supplement 
ingredients. 
7.2.4  Pharmacological properties 
The supplement reduces levels of homocysteine by tackling the two pathways of methylating 
homocysteine to methionine. Chapter 6 describes the mechanisms by which plasma 
homocysteine can be decreased in detail. In brief, one way in which this can happen is by 
accepting a methyl group to form methionine(9), using two distinct pathways. The major one 
is the vitamin B12- dependent reaction involving folate metabolic pathways(10), chiefly the 
donation of a methyl group from N5-methyl tetrahydrofolate. An alternative pathway, 
predominantly used in the liver and kidneys, uses the methyl group from betaine, a product 
formed through the oxidation of choline(11,12). Homocysteine can also be removed through 
its irreversible degradation to cystathionine and cysteine in the transsulfuration pathway 
requiring vitamin B6(10).  
7.2.5  Production, shipping and storage 
The supplement is manufactured and packed by Kendy Ltd., 101 Sofia Street, 1320 Bankya, 
Bulgaria for MRC Unit The Gambia, Atlantic Boulevard, Faraja, The Gambia. It is packed into 
sachets containing one daily dose (4011mg). The supplement is shipped in boxes of 60 
sachets. It should be stored in a dry place below 25˚C. Expiry of the unopened supplement is 
two years after the date of manufacture. 
Kendy Ltd. received its Good Manufacturing Practice certification from the Bulgarian Drug 
Agency (BG/GMP/2016/090). The Certificate of Analysis for the supplement was supplied by 
the Kendy Ltd.  quality control manager (No. 1034/18.12.2017).  
7.3  Characteristics of betaine 
Table 7.2 provides some of the physical, chemical and pharmaceutical properties of the 
betaine dose used in the supplement. 
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Table 7.2 Overview of key properties of betaine 
Daily dose: 4g 
PubChem CID:   247 
Chemical formula: C5H11NO2 
Physical properties: Solid, molecular weight 117.148 g/mol, sweet taste, water-
soluble(13) 
Synonyms:   Glycine betaine, trimethylglycine, betaine anhydrous, Cystadane® 
Pharmaceutical 
properties: 
Methylation agent used to lowers homocysteine, to increase low 
plasma methionine and S-adenosyl methionine (SAM) in patients 
with MTHFR deficiency, to treat homocystinuria(14). 
Handling hazards: The betaine will be pre-packaged in the supplement sachets, so 
no direct handling will be necessary. In the event of accidental 
spillage most companies (169/193) declare no hazards(15). The 
remaining companies suggest avoiding contact with eyes and 
prolonged contact with skin due to irritant properties. 
 
7.3.1  Metabolism and toxicology 
Betaine can be directly sourced from the diet (e.g. wheat bran, wheat germ, spinach, 
beets(16)). Intake from food is estimated at 0.5-2 g/d(17). It can also be formed endogenously 
from choline. Choline can be synthesised or obtained from the diet (good sources include 
red meat, poultry, milk, eggs and fish(16)). A two-step oxidation reaction converts it to 
betaine(7), a process occurring mainly in the liver and kidneys(18). Betaine can donate its 
methyl group to homocysteine via betaine-homocysteine methyl transferase (BHMT)(7). 
Betaine is absorbed into the enterocytes from the ileum and then released into the portal 
circulation, where it is transported to the liver(18). Bioavailability of ingested betaine is 
thought to be almost 100%(19).  When betaine is metabolised its methyl group is transferred 
to homocysteine via BHMT, enabling the formation of methionine from homocysteine(7).  In 
losing its methyl group betaine is converted to dimethylglycine(7). Urinary excretion of 
betaine is variable and appears to be under homeostatic control(7).  
In a toxicology study of male and female Sprague-Dawley rats (n=50), 0, 1, 2, and 5% betaine 
(corresponding to 0-7143mg/kg) was added to a maintenance chow and the rats were 
followed for up to 90 days. No toxicity occurred(20). It is reported that doses equal to or 
greater than 10,000 mg/kg in rats frequently caused death(21).  For human use, the 
manufacturers of Cystadane® (oral betaine anhydrous powder) state that whilst long-term 
carcinogenicity and reproductive toxicity studies have not been conducted, a ‘standard 
battery of genotoxicity test reveals no specific hazard for humans’(14). Betaine is categorised 
for hepatotoxicity as likelihood score E by the US National Library of Medicine, which 
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corresponds to an ‘unlikely cause of clinically apparent liver injury’ and that ‘despite 
extensive use, there is no evidence that the drug has caused liver injury’(22).  
7.3.2  Effects in humans 
Betaine is a natural food product, but has been used therapeutically in humans to reduce 
homocysteine. Table 7.3 summarises betaine supplementation intervention trials in humans.  
 
Table 7.3 Summary of trials assessing effect of oral betaine on homocysteine 
Reference Betaine 
daily dose 
Duration of 
trial  
Participants Results Serious 
adverse 
events? 
Schwab et al. 
(2002)(23) 
6g 12 weeks N=42, mean age = 
44 years, healthy 
adults 
Reduction of 
Hcy by 
1µmol/l 
No 
Steenge et al. 
(2003)(24) 
6g 6 weeks  N=24, mean age = 
44.5 years, healthy 
adults 
Reduction of 
Hcy by 
1.8µmol/l 
No 
Olthof et al. 
(2003)(25) 
6g 6 weeks  N=38, healthy 
adults 
Reduction of 
Hcy by 
2.2µmol/l 
No 
Olthof et al. 
(2006)(26) 
6g 6 weeks  N=39, mean age = 
59 years, healthy 
adults 
Reduction of 
Hcy by 
1.2µmol/l 
No 
Schwab et al. 
(2011)(27) 
4g 24 weeks N=63, mean age = 
27 years, healthy 
adults 
No significant 
reduction of 
Hcy.  
No 
 
In a meta-analysis of the studies included the Table 7.3 the authors concluded that 
‘supplementation of betaine at 4 to 6 g/d significantly lowers plasma homocysteine 
concentration in healthy adults by 1.23 μmol/L or 11.8% of baseline values’(5). 
There were no serious adverse effects in any of the trials listed in Table 7.3. In larger doses 
of 6g/day three small studies have reported a small rise of 10mg/dL low-density lipoprotein 
cholesterol, however, this effect has not been consistently seen in trials and is not considered 
to be a clinically significant side effect(5).  
The Summary of Product Characteristics documentation for Cystadane® contains 
information on side effects. Cystadane® is used to treat homocystinuria and is recommended 
in a dose of 100mg/kg/day. For a 60kg adult this would be 6g total per day. Documented side 
effects for Cystadane® are provided in Table 7.4. Note that the side-effects of brain oedema 
and blood methionine increases in Table 7.4 are restricted to patients with CBS deficiency. 
In all cases symptoms were reversed and complete recovery attained after stopping 
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treatment(14). The UK National Institute for Health and Care Excellence (NICE) report all side-
effects related to oral betaine as uncommon(28). No cases of overdose have been reported 
and no drug interaction studies have been performed.  
 
Table 7.4 Side-effects for Cystadane® 
Side-effect category Frequency* 
Metabolism and nutrition disorders Uncommon: anorexia 
Psychiatric disorders Uncommon: agitation, irritability 
Nervous system disorders Uncommon: brain oedema 
Gastrointestinal disorders Uncommon: diarrhoea, glossitis, nausea, 
stomach discomfort, vomiting 
Skin and subcutaneous tissue disorders Uncommon: hair loss, hives, skin odour 
abnormal 
Renal and urinary disorders Uncommon: urinary incontinence 
Investigations Very common: blood methionine 
increased 
 
*Frequency: ‘uncommon’ (≥ 1/1,000 to < 1/100); very common (≥1/10) 
Source: Cystadane® Summary of Product Characteristics(14) 
 
7.3.3 Overall summary of safety of betaine in humans 
Betaine anhydrous is Generally Recognised As Safe (GRAS) and so is exempted from the usual 
Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements. This 
means there are no official upper limits to its consumption. However, the UK National 
Institute for Health and Care Excellence advise a maximum of 20g per day(28). With the 
proposed dosage of 4g/day there are no foreseen adverse effects related to the consumption 
of this supplement ingredient.  
7.4  Characteristics of Vitamins B2, B12 and Folic Acid  
Some of the physical, chemical and pharmaceutical properties of the B vitamins used in the 
supplement are shown in Table 7.5. All three vitamins can be found naturally in certain foods. 
Folate is found in green leafy vegetables, liver and wholegrain cereals. Vitamin B2 is found in 
milk, eggs, yeast and liver. Vitamin B12 is found in liver, meat and dairy foods.  
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Table 7.5 Overview of properties of folic acid, B12 and B2 
 Vitamin B2(29) Vitamin B12(30) Folic Acid(31) 
Daily dose:  2.80mg 5.2 µg 800µg 
PubChem CID:  493570 5311498 6037 
Chemical formula:  C17H20N4O6 C63H88CoN14O14P C19H19N7O6 
Molecular Weight: 376.369 g/mol 1355.388 g/mol 441.404 g/mol 
Physical properties:  Water-soluble, yellow 
crystalline powder, 
solid, bitter 
Water-soluble, red 
crystalline powder, 
solid, tasteless 
Low water solubility, 
yellow crystalline 
powder, tasteless 
Synonyms:  Riboflavin 5-
phosphate, 
lactoflavin, riboflavin, 
Vitamin G, 
lactoflavine 
Cyanocobalamin, 
cobalamin, 68-19-9, 
crystamine, anacobin 
59-30-3; folate, 
pteroylglutamic acid, 
Vitamin M, Folacin 
Pharmaceutical 
properties:  
Co-enzyme role in 
energy production 
and 1-carbon 
metabolism 
Hematopoiesis, 
neural metabolism, 
DNA and RNA 
production, 
macronutrient 
metabolism and 1-
carbon metabolism 
 
Hematopoiesis, one-
carbon donor, purine 
& pyrimidine 
synthesis 
Handling hazards:  No hazard No hazard (34/35 
companies). 1 
company suggests 
avoid eye and skin 
contact (irritant) 
Avoid eye and skin 
contact (irritant) 
 
7.4.1  Metabolism and toxicology 
Homocysteine concentrations can be lowered through one of two major pathways as 
described above. Firstly, the transsulfuration pathway causes its irreversible degradation 
when metabolising it to cysteine. Secondly, the methylation of homocysteine forms 
methionine, and is the pathway that this supplement targets.  
Dietary folates and folic acid are reduced to form tetrahydrofolate (THF), which is a scaffold 
upon which one-carbon units can be attached and activated. THF in turn is reduced to 
methylene-THF, then to 5-methyl-THF, which donates its methyl group to homocysteine 
using vitamin B12(32). The different forms of THF are interconvertible, except the methyl-THF 
form. In the absence of sufficient B12 to utilise the methyl group from methyl-THF in 
homocysteine methylation (a process which re-generates THF), methyl-THF can accumulate 
at the expense of other THF forms. This is termed the ‘folate trap’ or ‘methyl trap’ and means 
pathways dependent on other forms of THF (e.g. purine synthesis and the thymidylate 
pathway) can become impaired(33).  
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Riboflavin is combined with ATP to form two important coenzymes:  flavin mononucleotide 
(FMN) in a reaction catalysed by riboflavin kinase, and flavin-adenine dinucleotide (FAD), 
which is formed from FMN using FAD synthase(34,35). FAD is a cofactor required for MTHFR to 
reduce methylene-THF to methyl-THF(36). Vitamin B12 is a cofactor in the methylation of 
homocysteine by 5-methyl-THF. In human plasma and the cytosol the predominant form is 
methylcobalamin(37). The B12 (in methyl, adenosyl or cyano (synthetic) form) is transported 
in plasma bound to two proteins: haptocorrin or transcobalamin. The binding of B12 to 
transcobalamin forms holotranscobalamin, and this is the only form taken into cells. Once in 
the cell lysosome the transcobalamin is degraded and the B12 used for intracellular 
metabolism. If the B12 is in 5’-deoxyadenosylcobalamin form it is used as a coenzyme for 
methylmalonyl CoA mutase. If it is in the methylcobalamin form it is used as a coenzyme for 
methionine synthase.  
Riboflavin (Vitamin B2) is mainly absorbed in the small intestine by active or facilitated 
transport when at low levels and by passive diffusion at high levels(38). Some is also absorbed 
in the colon(39). It is mainly transported in the plasma attached to proteins such as 
immunoglobulins(38). Vitamin B12 is bound to Intrinsic Factor (IF) and absorbed in the ileum. 
The IF-B12 complex is taken into the intestinal enterocytes by receptor-mediated 
endocytosis(37). In the enterocyte B12 is released from IF and is transported in plasma bound 
to transcobalamin or haptocorrin(37). Folic acid is a synthetic version of folate, which does not 
occur naturally. It is fully oxidised and requires a two-step reduction process to get it to the 
active THF form. To be taken up and transported THF needs to be in monoglutamate form. 
Monoglutamate-THF is absorbed in the duodenum and jejenum by Slc46a1 (a proton-
coupled transporter). It enters the circulation and is taken into cells by folate receptors 1&2 
and by Slc19a1 reduced folate carrier. The circulating form in plasma is free or bound to 
albumin or other proteins.  
Riboflavin intake in excess of requirements is excreted in urine(39). Vitamin B12 is stored in 
the liver and mainly secreted in bile. Excess can be excreted in urine(30). Excess folic acid is 
excreted in urine(31). 
In animal studies riboflavin has proved toxic in doses of 50mg/kg in mice(29). For vitamin B12 
1.5-3 mg/kg body weight have caused convulsions then cardiac or respiratory failure in 
mice(30).  In humans there is no reported toxicity for riboflavin, B12 and folic acid given in oral 
doses.  
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7.4.2  Effects in humans 
Folic acid, B12 and B2 are common supplements provided in research studies and public 
health campaigns. Table 7.6 summarises the previous doses given in different countries in 
supplementation trials for a variety of health outcomes. It shows how the doses provided in 
the MDEG-2 methyl donor supplement have been already been commonly utilised. Further 
information of each of the studies included in this table is provided in Annex 7.1, which 
details the trial population, location, doses, primary outcomes and whether any side effects 
were reported.  
 
Table 7.6 Overview of previous doses given of folic acid, B2 and B12 
Ingredient 
Recommended daily 
intakes and 
biomarker levels 
Amount in 
MDEG2 Methyl 
Donor 
Supplement  
Amounts given in 
previous trials 
Folate given as folic acid UK Recommended 
Daily Allowance 
(RDA): 200 µg/d  
Pregnancy + 100 
µg/d(40) 
 
USA  Dietary 
Reference Intake 
(DRI): 400 µg/d in 
pregnancy(41) 
 
 
 
 
800 µg/d 
 
(2x Dietary 
Reference Intake 
[DRI]) 
200 µg/d(42) 
215 µg/d(43) 
300 µg/d(44) 
350 µg/d(45) 
400 µg/d(46–60) 
500 µg/d(61) 
600 µg/d(62) 
800 µg/d(24,46,63–65) 
Increments between 50–
800µg/d(66) 
150-2500 µg/d(67) 
2500 µg/d(68) 
4000 µg/d (69) 
2800 µg/wk(70) 
Vitamin B12 given as 
cyanocobalamin 
UK RDA : 1.5µg/d(40) 
 
USA RDA: 2.6 µg/d in 
pregnancy(41) 
 
 
 
5.2 µg/d 
 
(2x DRI) 
2.0 µg/d(43) 
2.2 µg/d(51) 
2.6 µg /d(47–49,54–60,62) 
3 µg/d(45) 
4 µg/d(65,71) 
5.2 µg/d(52) 
6 µg/d(53) 
20  µg/d(72) 
50 µg/d(64) 
400 µg/d(63,68) 
Riboflavin (vitamin B2) 
given as Riboflavin-5'-
phosphate 
UK  RDA for adult 
women:  
1.1mg/d, +0.3mg in 
pregnancy(40) 
 
USA RDA: 1.4 mg/d in 
pregnancy(41) 
 
 
2.8 mg/d 
 
(2x DRI) 
1.4 mg/d(47–49,55–58,60,62) 
1.5mg/d(69) 
1.6 mg/d(42,71) 
1.8 mg/d(54,65) 
1.9 mg/d(43,59) 
2 mg/d(53) 
2.8 mg/d(52) 
5 mg/d(44) 
15 mg/d(45) 
20 mg/d(64) 
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There are no reported serious adverse effects to taking riboflavin supplements(73), however, 
some individuals may find their urine is more yellow in colour than normal. There are no 
documented significant adverse effects of taking B12 supplement, even at doses several 
hundred times what is contained in this supplement(73). There are no documented significant 
adverse effects of taking folic acid supplements at this dose.  
7.4.3  Overall summary of safety in humans 
Supplement doses for folic acid, B2 and B12 are proposed at twice the Dietary Reference 
Intake (DRI) set for the United States of America(41) in order to correct the micronutrient 
deficiencies in the dry season.  
 
Folic acid (proposed supplement 800 µg/d, 2xDRI):  
The proposed supplement dose has been used before in several large trials(63–65), and is well 
below the amount expected to cause adverse effects. The Expert Group on Vitamins & 
Minerals (2003) states that  “in the general population a supplemental dose of 1 mg/day 
(equivalent to 0.017 mg/kg bw/day in a 60 kg adult) would not be expected to cause adverse 
effects”(74). The European Agency for Food Safety (2006) states that the Lowest observed-
adverse-effect level (LOAEL) is 5 mg per day(73), and current US government advice for 
women who have previously had a baby with a birth defect is to take up to 4000 µg/d(75). 
Side effects have only been documented with doses in excess of 1mg/day.  
 
Riboflavin (B2) (proposed supplement 2.8 mg/d, 2xDRI): 
Riboflavin is Generally Recognised As Safe (GRAS), even when given in doses up to 14 times 
what is contained in the supplement(76). GRAS Report 114 on Riboflavin states that “there is 
no evidence in the available information on riboflavin or riboflavin-5'-phosphate that 
demonstrates or suggest reasonable grounds to suspect, a hazard to the public when they 
are used at levels that are now current or that might reasonably be expected in the 
future”(76). The Expert Group on Vitamins & Minerals (2003) also concur, stating that 
“supplemental intakes of 40 mg riboflavin/day (equivalent to 0.67 mg/kg bw for a 60 kg 
adult) would be unlikely to result in adverse effects. This is in addition to riboflavin provided 
by the diet”(74).  
 
Cyanocobalamin (B12) (proposed supplement 5.2 µg/d, 2xDRI): 
The GRAS Report 104 on Cyanocobalamin states that “there is no evidence in the available 
information on vitamin B12 that demonstrates, or suggests reasonable grounds to suspect, 
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a hazard to the public when it is used at levels that are now current and in the manner now 
practiced, or that might reasonably be expected in the future”(76). The Expert Group on 
Vitamins & Minerals (2003) states that “it is generally accepted that ingested vitamin B12 
(cobalamin) has a very low toxicity in humans…supplemental 2.0 mg cyanocobalamin/day 
should not produce any adverse effects and this intake can be used for guidance 
purposes”(74).  
7.5  Overall conclusion on usage of MDEG-2 Methyl Donor Supplement  
The ingredients included in this supplement are extremely unlikely to result in any adverse 
events when taken at the correct dosage of one sachet per day. There are many existing 
commercial formulations that contain doses several hundred to several thousand times 
more than the MDEG-2 methyl donor supplement (e.g. Bluebonnet Nutrition Homocysteine 
Formula, Thorne Methyl Guard Plus, Biocare Methyl Multinutrient). Considering the research 
project will be delivered under observed supplementation, and provided against the 
backdrop of micronutrient deficiencies associated with the Gambian dry season, it is 
considered a safe nutritional supplement tailored to the requirements of the target 
population.   
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Chapter 8 Comparison of a novel drink powder and 
existing multiple micronutrient tablet (UNIMMAP) in 
reducing plasma homocysteine in non-pregnant 
women in rural Gambia: a randomised controlled trial 
to identify future candidates for epigenetic trials. 
_____________________________________________  
 
Summary of Chapter  
 
Background: Maternal periconceptional nutritional status is associated with infant DNA 
methylation profiles. DNA methylation relies on nutritional inputs for one-carbon metabolic 
pathways, including efficient recycling of homocysteine. This proof-of-concept trial in non-
pregnant women tests the effectiveness of a supplement designed to improve one-carbon-
related nutrient status and assess its potential future use in pregnancy trials. 
Objective: To assess the effectiveness of a novel drink powder on reducing plasma 
homocysteine in non-pregnant women in rural Gambia.  
Methods: We designed a novel drink powder based on determinants of plasma 
homocysteine in the target population.  We conducted a 3-arm, unblinded, randomized, 
controlled trial. Non-pregnant women of reproductive age were randomized in a 1:1:1 
allocation ratio to 12 weeks of daily supplementation of either a) a novel drink powder (4g 
betaine, 800µg folic acid, 5.2µg vitamin B12 and 2.8mg vitamin B2), b) a multiple 
micronutrient tablet (UNIMMAP) containing 15 micronutrients at the dietary recommended 
intake or c) no intervention. Supplementation was observed daily. Fasted venepuncture 
samples were collected at baseline, midline and endline to measure plasma homocysteine. 
We used linear regression models to determine the difference in homocysteine between 
pairs of trial arms at midline (week 5) and endline (week 12), adjusted for baseline 
homocysteine, age and body mass index. 
Results: 298 eligible women were enrolled and randomised. Compliance was >97.8% for 
both interventions. At endline, compared to the controls, the drink powder and UNIMMAP 
reduced mean plasma homocysteine by 23.6% and 15.5% respectively (both p<0.001). 
Compared to UNIMMAP, the drink powder reduced mean homocysteine by 8.8% (p=0.025). 
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The effects were stronger at midline. 
Conclusions: The trial confirms that dietary supplements can influence metabolic pathways 
that we have shown in previous studies to predict offspring DNA methylation. Both 
supplements reduced homocysteine effectively and remain potential candidates for future 
epigenetic trials in pregnancy in rural Gambia. 
 
Notes 
 
The chapter is written in a journal article format, ready for a further round of co-author 
review before submission. I also plan to submit a condensed version of Chapter 6 as 
supplementary material to explain how the supplement was designed, along with the 
CONSORT checklist once the article is finalised.   
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8.1  Introduction 
Epigenetic processes describe changes to the genome that can alter gene expression without 
changing the underlying DNA sequence(1). One mechanism is DNA methylation of cytosine 
bases, and there is evidence that this can be influenced by a variety of environmental factors, 
including maternal nutritional status(2). Epigenetic modifications therefore provide a 
plausible mechanism linking early life environmental insults with increased risk of adverse 
health outcomes throughout the lifecourse(3). The in utero period, especially the very first 
few days after conception, is a period of exceptionally rapid cell differentiation and complex 
epigenetic remodelling(4) and represents a window in which epigenetic modifications and 
errors could have significant consequences for the health of the child(5). Of the factors that 
may affect the infant epigenome in utero through maternal exposure, nutritional one-
carbon-related metabolites are of particular interest(2,6,7). One carbon metabolism 
encompasses the metabolic pathways crucial for the provision of methyl groups required for 
DNA methylation. These pathways involve folate, methionine, serine, glycine, choline and 
betaine in methyl group donation, and vitamins B2, B12 and B6 as essential coenzymes.  
Our previous research in The Gambia has explored the interplay of seasonality, maternal 
nutritional status and offspring DNA methylation. In the Gambian rainy season women have 
increased plasma concentrations of key one-carbon metabolites compared to the dry 
season, corresponding to an increased methylation potential(8). Indeed, offspring of women 
conceiving in the peak rainy season demonstrate increased DNA methylation at genomic loci 
where methylation is established in the very early embryo(9–11). Furthermore, concentrations 
of several methyl donor metabolites in mothers predict the offspring’s methylation at these 
loci(9). Recent work suggests that decreased methylation potential in the dry season may lead 
to suboptimal outcomes, as evidenced by methylation patterns suggestive of a loss of regular 
imprinting at the non-coding RNA gene VTRNA2-1(12). These observations raise the question 
whether a nutritional intervention can shift the maternal metabolome to optimise regulation 
of the infant epigenome by providing micronutrients in the ratio and quantity necessary for 
optimal one carbon metabolism all year round, for example by increasing methyl donor 
provision in the dry season.  
As a prequel to possible future studies of a pre-conceptional intervention we conducted a 
proof-of-concept randomised controlled trial in non-pregnant women with homocysteine as 
the primary outcome. Homocysteine is strongly inversely associated with the ratio of S-
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adenosyl methionine (SAM): S-adensoyl homocysteine (SAH)(8), a measure of methylation 
potential(13). Homocysteine can be hydrolysed to SAH, which acts as an allosteric inhibitor of 
the SAM to SAH (transmethylation) reaction(14,15). Therefore by reducing dry season 
concentrations of homocysteine we hope to improve methylation potential. 
We compared the effectiveness of a novel drink powder containing betaine and B vitamins 
against the United Nations Multiple Micronutrient Preparation (UNIMMAP). 
 
8.2  Subjects and methods 
8.2.1  Trial outline 
We conducted a 3-arm, parallel assignment, unblinded, randomized, controlled trial with 298 
women. Non-pregnant, non-lactating, healthy women of reproductive age from the West 
Kiang region of The Gambia were randomized in a 1:1:1 allocation ratio to 12 weeks of daily 
supplementation of either a) a novel betaine and B vitamins drink powder supplement (‘drink 
powder’), b) an existing available micronutrient tablet (UNIMMAP) or c) no intervention 
(control). All participants were invited for midline and endline visits for anthropometric 
measurements and to provide a venepuncture sample. The trial was registered at 
Clinicaltrials.gov (NCT03431597). The supplementation phase of the trial took place from 
March to June 2018, in the Gambian dry season. 
Our primary objective was to assess the effect of the drink powder on plasma homocysteine 
after 12 weeks of daily supplementation versus the control group. Our secondary objectives 
were to look at this comparison at midline, and to compare the effectiveness of the drink 
powder versus the UNIMMAP tablet at midline and endline.  
8.2.2  Participants 
Study participants came from 21 villages of the West Kiang region. A list of potentially eligible 
women within West Kiang was generated using the Medical Research Council Gambia 
(MRCG) Keneba Health and Demographic Surveillance System database(16). At the screening 
stage a team of ten field workers visited women at their homes to explain the study and 
eligibility criteria, and to invite them to join the study by providing informed consent. 
Women were eligible at the screening stage if they were pre-menopausal aged 18-45 years, 
non-pregnant to their knowledge, non-lactating (at least 9 months post-partum), had no plan 
to conceive in the ensuing 3 months, no plans to travel, and with no current illness or chronic 
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health problems (cardiovascular disease, renal disease, thyroid disease or cancer). Women 
were excluded if they were currently taking B vitamin or multivitamin supplements or taking 
medication for prevention of seizures (e.g. Carbamazepine). Women with high blood 
pressure were excluded only when there was an additional history of stroke or heart attack. 
8.2.3  Sample size 
Unpublished year-round homocysteine data from a recent trial in the same region(17) 
indicated that women have a mean (SD) plasma homocysteine concentration of 8.06 µmol/L 
(±2.5) in the peak dry season of February to April. We wanted to detect a minimum change 
in plasma homocysteine of 1µmol/L, which would bring it under mean rainy season 
concentration (7.31µmol/L). This required 99 women per arm to give 80% power (two 
sample t-test, alpha = 0.05), which we increased to 125 to allow for 20% attrition.  
8.2.4  Study design  
Women who provided informed consent at the screening stage were invited to come for the 
baseline visit at MRCG Keneba field station. They provided a urine sample for the study 
nurses to conduct a rapid pregnancy test, and were then formally enrolled onto the trial if 
they had a confirmed negative pregnancy test result.   
Randomisation 
Study participants were randomized to the drink powder, UNIMMAP tablet or control arm in 
a 1:1:1 ratio according to a computer generated randomization scheme. A list of study IDs 
was generated in advance by the Keneba database manager. In advance of the baseline study 
the MRC statistician pre-assigned one of the three trial arms (‘drink powder’, ‘tablet’, 
‘control’) to each participant’s study ID in a 1:1:1 ratio using block randomisation. A block 
size of 15 was used. The sub-investigator printed the study ID and group allocation onto a 
piece of paper and sealed in an envelope. The envelopes were arranged in consecutive order 
of participant 1 to 375, and kept for the baseline visit. The sealed envelopes were not an 
attempt to keep the group allocation blind, since this was an unblinded trial. However, they 
helped ensure only one person received a study ID and corresponding group allocation at a 
time upon enrolment, overseen by the field coordinator. 
 
Study visits 
At the baseline visit all enrolled women had their weight (Seca scale ±0.1kg), height (Seca 
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stadiometer ± 0.1cm) and blood pressure (Omron) measured. Each measurement was taken 
in triplicate and the average used. The study nurses collected a fasted venepuncture sample 
from the participants into 9mL EDTA monovettes, which were kept on ice. The samples were 
processed by the laboratory in Keneba within one hour of collection. Samples were spun 
using an Eppendorf 5810R centrifuge at 1800 rcf for 10 minutes at 4ºC to separate the 
plasma. Plasma aliquots were then immediately stored at -70°C until analysis. 
Participants were invited back for a midline visit at week 5 and an endline visit at week 12. 
The midline visit was programmed at week 5 rather than week 6 to ensure samples were 
collected before the start of Ramadan. The exact same procedures were repeated as for 
baseline. If women were pregnant at midline they were given the choice of whether to 
continue in the study or not. Although supplements were safe for pregnancy the information 
was recorded to be able to account for any effects of hemodilution at the analysis stage. 
There were no changes to the originally planned methods after trial commencement. 
Design of the novel betaine and B vitamins drink powder 
To design the supplement we analysed three separate datasets containing plasma nutrient 
concentrations from women in West Kiang. We ran multivariable linear regression models 
to assess which nutrients independently predicted plasma homocysteine. We selected those 
which consistently demonstrated an inverse relationship with homocysteine as candidates 
for the supplement. The chosen supplement ingredients were then carefully assessed against 
existing dosage safety information, doses given in previous trials and current plasma nutrient 
levels to establish final supplement doses well below upper safety limits. 
Supplement composition and supplementation schedule  
Table 8.1 details the composition of the two intervention products. The drink powder 
contained 4g of anhydrous betaine with two times the Dietary Reference Intake (DRI) of folic 
acid, vitamin B12 and vitamin B2 (manufactured by Kendy Ltd., Bulgaria, sourcing betaine 
from Danisco, Finland). The UNIMMAP tablet contained 15 micronutrients at the DRI 
(manufactured by DSM Nutritional Products, South Africa). 
Those participants who were randomised to the intervention arms at baseline started their 
supplementation the next day in their home villages. The supplements were supplied to 
participants on a daily basis by Village Assistants (VAs). VAs were employees of MRCG living 
in the villages they were supervising. The participants visited their VA on a daily basis. The 
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VAs dissolved the drink powder into 200mL of water, and participants were given the option 
to add sugar to taste in case it was too bitter.  UNIMMAP was provided in capsule form, to 
be taken with water. The VAs observed consumption of the supplements.  
Once a week field assistants delivered weekly packs of supplements to the VAs to administer 
to the participants in their village. The weekly pack included a tally sheet for the VA to record 
any adverse events experienced by the participants daily. They also included seven small 
coloured cards that were given to the participants, who were asked to give in a card every 
time they visited the VA in order to measure compliance. Each week the field assistants 
would compile a report on the adverse events from the tally sheets and record compliance, 
measured by counting the number of cards a participant had returned that week and cross-
checking with the number of remaining supplements in the pack. After the 12 weeks of 
supplementation the participants continued to be monitored for a further three weeks to 
capture any delayed adverse events.  
 
Table 8.1 Composition of interventional products, per daily dose. 
 
Abbreviations: RE, retinol equivalent; UNIMMAP, Daily United Nations Multiple 
Micronutrient Preparation supplement. 
Novel drink powder UNIMMAP tablet 
Ingredient Amount in 
supplement 
Ingredient Amount in 
supplement 
Folate as folic acid 800µg  Folic Acid 400µg 
Vitamin B12 as 
cyanocobalamin 
5.2µg  Vitamin B12 2.6µg 
Riboflavin (vitamin B2) as 
Riboflavin-5'-phosphate 
2.8mg  Riboflavin 1.4mg 
Betaine as anhydrous 
betaine 
4g  - - 
- - Vitamin A 800µg RE 
- - Vitamin D 5µg 
- - Vitamin E 10mg 
- - Thiamine 1.4mg 
- - Niacin 18mg 
- - Vitamin B6 1.9mg 
- - Vitamin C 70mg 
- - Zinc 15mg 
- - Iron 30mg 
- - Iodine 150µg 
- - Selenium 65µg 
- - Copper 2mg 
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8.2.5  Laboratory methods 
We analysed the concentration of plasma homocysteine in samples from baseline, midline 
and endline visits at the MRCG Keneba laboratory using the COBAS INTEGRA® 400 Plus 
analyzer. All samples were analysed in one batch on completion of endline. All samples 
experienced one cycle of freeze-thaw. Inter-assay coefficients of variation (CVs) were <4.0% 
and intra-assay CVs were <5.1%. 
8.2.6  Blinding 
Due to the different characteristics of the drink powder and the tablet, the participants, field 
assistants and the VAs were not blinded to group allocation. The laboratory technician 
analysing the plasma homocysteine was blinded to group allocation.  
8.2.7  Ethical considerations 
The trial received ethics approval from The Gambia Government / MRC Joint Ethics 
Committee (reference SCC 1575v1.2). All participants provided informed consent by 
signature if literate, otherwise by thumb print in the presence of an impartial witness if 
illiterate. The MRCG Clinical Trials Support Office conducted four monitoring trips to ensure 
the trial was implemented according to the international standards of Good Clinical Practice. 
All procedures were in accordance with the Helsinki Declaration of 1975 as revised in 1983. 
8.2.8  Statistical Analysis 
We summarized compliance as a percentage of the total number of cards received for each 
participant over the trial duration. We summarized adverse events by calculating the 
proportion of participants that had self-reported any adverse event at any point over the 
trial duration. We compared baseline medians of continuous variables between the three 
trial arms using the Kruskal-Wallis test. We used the Wilcoxon rank-sum test to compare 
medians of percentage compliance between the two intervention arms, and the chi-squared 
test for proportions of participants reporting morbidities (with the Fisher’s exact test for any 
numerator <5). 
We used analysis of covariance (ANCOVA) regression models to assess the effectiveness of 
the supplements at lowering homocysteine at midline and endline. We first assessed the 
homocysteine variables for normality using the Shapiro-Wilk test. Variables were right-
skewed, but satisfied normality assumptions after log-transformation. We then performed 
the ANCOVA analyses, consisting of linear regression models comparing the difference in log 
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homocysteine between two trial arms at midline or endline, adjusted for baseline 
homocysteine, age and body mass index (BMI). The β coefficient provided an estimate of the 
ratio of geometric mean homocysteine concentration, which we also chose to present as 
percentage change in the geometric mean using the formula (eβ-1)*100. We analysed the 
data using a complete case analysis, and also performed a sensitivity analysis restricted to 
non-pregnant, fasted, compliant (>80% compliance) individuals. All analyses were performed 
in Stata 15.1 (StataCorp 2017, Texas, USA).  
8.3  Results 
The participant flow diagram is shown in Figure 8.1. Of the 511 women initially approached 
for the trial, 298 eligible women were enrolled and randomised to the drink powder, 
UNIMMAP and control arms. Although only 10 women officially withdrew over the study 
timeframe (9 before midline and 1 before endline), on the days of the study visits there were 
many absentees. 104 did not attend the baseline visit and were not enrolled. At midline there 
were 16 absentees and 45 at endline, despite those in the supplement arms continuing with 
the intervention in their villages. There were 298, 273 and 243 plasma samples available for 
homocysteine analysis at baseline, midline and endline respectively. Of these, one (in the 
UNIMMAP arm at midline) had a homocysteine reading below the detection limit.  
Baseline characteristics for the enrolled participants are provided in Table 8.2. There was no 
difference in age, BMI, homocysteine concentration, blood pressure and pulse of 
participants between trial arms.  
The unadjusted homocysteine concentration results by time point are shown in Table 8.3 
and Figure 8.2. In the drink powder arm, mean homocysteine concentration decreased by 
2.67µmol/L and 2.32µmol/L compared to baseline at midline and endline respectively. A 
similar, though attenuated, pattern was observed in the UNIMMAP arm, where midline and 
endline mean homocysteine concentrations were 1.28µmol/L and 1.22µmol/L lower than 
baseline respectively.  
Table 8.4 provides the results of the pairwise comparisons between trial arms at endline and 
midline, adjusted for age, BMI and baseline homocysteine. Compared to the controls the 
drink powder reduced mean plasma homocysteine by 24.1% and UNIMMAP reduced it by 
16.4% (both p<0.001) after 12 weeks of daily supplementation. Comparing the two 
intervention arms, the drink powder reduced mean homocysteine by 9.2% more than 
UNIMMAP (p=0.025). 
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Figure 8.1 Participant flow diagram 
 
Abbreviations: UNIMMAP, Daily United Nations Multiple Micronutrient Preparation 
supplement. 
 
  
 187 
 
Table 8.2 Baseline characteristics 
Variable Control (N=100) 
Median (IQR) 
Drink powder 
(N=93) 
Median (IQR) 
UNIMMAP 
(N=105) 
Median (IQR) 
P 
value* 
Age (years) 28.5 (22.1, 38.7) 30.7 (21.7, 39.7) 26 (20.2, 38.8) 0.57 
BMI (kg/m2) 21.3 (18.6, 25.3) 21.9 (19.6, 26.3) 21.0 (19.0, 23.5) 0.81 
Homocysteine 
(µmol/L) 
9.7 (7.9, 12.3) 10.4 (7.6, 14.1) 10.2 (7.2, 12.7) 0.27 
Systolic BP (mmHg) 114 (105, 124) 114 (107, 122) 114 (105, 122) 0.30 
Diastolic BP (mmHg) 70 (63, 77) 70 (65, 77) 69 (62, 75) 0.30 
Pulse  
(beats per min) 
72 (65, 79) 71 (63, 81) 72 (66, 77) 0.96 
 
* Kruskal-Wallis test for comparing medians 
Abbreviations: BMI, body mass index; BP, blood pressure; IQR, interquartile range; 
UNIMMAP: Daily United Nations Multiple Micronutrient Preparation supplement. 
 
 
Table 8.3 Unadjusted plasma homocysteine (µmol/L) by time point 
 
Baseline Midline Endline 
Study arm N Geometric 
mean  
(95% CI) 
N Geometric 
mean  
(95% CI) 
N Geometric 
mean  
(95% CI) 
Control  100 10.00  
(9.28, 10.78) 
93 11.50  
(10.62, 12.46) 
82 10.18  
(9.54, 10.87) 
UNIMMAP  105 9.83  
(9.10, 10.62) 
91 8.55  
(8.02, 9.12) 
84 8.61  
(8.14, 9.12) 
Drink powder 93 10.59  
(9.67, 11.60) 
88 7.90  
(7.33, 8.51) 
77 8.27  
(7.66, 8.92) 
 
  
Abbreviations: CI, confidence interval; UNIMMAP, Daily United Nations Multiple 
Micronutrient Preparation supplement. 
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Figure 8.2 Geometric mean homocysteine over time by trial arm 
Abbreviations: UNIMMAP, Daily United Nations Multiple Micronutrient Preparation 
supplement. 
 
Effects at midline were more pronounced, where the drink powder reduced mean plasma 
homocysteine by 35.8% compared to the controls, and UNIMMAP reduced homocysteine by 
22.5%. The drink powder reduced mean homocysteine 15.9% more than UNIMMAP (all p 
values <0.001).  
We performed a sensitivity analysis excluding any participants who became pregnant during 
the study period, who gave a non-fasted blood sample or had compliance <80%. At midline 
8 participants were found to be pregnant and decided to continue with the study (2/93 
(2.15%) in control arm, 0 in drink powder arm and 6/92 (6.52%) in UNIMMAP arm). At endline 
a total of 20 women were pregnant (4/82 (4.88%) in control arm, 7/77 (9.09%) in drink 
powder arm and 8/84 (9.53%) in UNIMMAP arm). At midline one person reported they had 
not fasted before venepuncture (in the UNIMMAP arm). At endline 16 participants had not 
fasted (1 in control arm, 6 in drink powder arm, 9 in UNIMMAP arm). The trial results 
excluding pregnant, non-fasted and non-compliant individuals are provided in 
Supplementary Table 8.1. Effect sizes and p values are almost identical to those described 
in the intention-to-treat analysis above. 
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In this trial supplementation was observed daily and compliance was extremely high in both 
intervention arms, at 97.8% for UNIMMAP and 98.8% for the drink powder (Table 8.5). The 
compliance was higher than the proportion of women reporting for the endline study visit 
(Figure 8.1) because some women continued to take their supplements at home even though 
they did not attend the endline visit. There was no difference between self-reported adverse 
events (AEs) between the intervention arms. Table 8.5 describes the proportion of 
participants who reported an adverse event to their village assistant on at least one day over 
the 12-week period. The most common AEs described for the two interventions were 
abdominal pain, nausea and dizziness, followed by urine discoloration and fever. The 
frequency of these AEs, however, was low. Mean AE duration across the trial was less than 
half a day per person, and the maximum number of days an individual reported a given AE 
was 19 days for abdominal pain (additional details in Supplementary Table 8.2). There were 
two serious adverse events reported over the trial duration (one miscarriage in week 9 and 
one stroke in week 10), both in the drink powder arm. The Trial Safety Monitor and Medical 
Expert judged both events as highly unlikely to have been caused by the supplement, and 
both participants resumed participation in the trial after the events.  
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Table 8.4 Multivariable regression results showing percentage difference in geometric mean plasma homocysteine between trial arms 
  
 
 
 
 
 
 
 
 
 
* β represents difference in log homocysteine at time point between trial arms, adjusted for baseline homocysteine, age and body mass index at time point. 
**Calculated from (eβ-1)*100 
Abbreviations: CI, confidence interval; UNIMMAP, Daily United Nations Multiple Micronutrient Preparation supplement. 
 
Trial arms Time point N β (95% CI)* % difference in geometric 
means** 
P value 
Drink powder vs. control 12 weeks 159 -0.27 (-0.35, -0.19) -23.6 (-29.5, -17.1) <0.001 
UNIMMAP vs. control 12 weeks 166 -0.17 (-0.24, -0.10) -15.5 (-21.2, -9.4) <0.001 
Drink powder vs. UNIMMAP 12 weeks 161 -0.09 (-0.17, -0.01) -8.8  (-15.8, -1.2) 0.025 
Drink powder vs. control 5 weeks 181 -0.43 (-0.51, -0.36) -35.1 (-39.7, -30.2) <0.001 
UNIMMAP vs. control 5 weeks 184 -0.26 (-0.33, -0.20) -23.1 (-28.1, -17.8) <0.001 
Drink powder vs. UNIMMAP 5 weeks 179 -0.15 (-0.22, -0.09) -14.3 (-20.0, -8.2) <0.001 
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Table 8.5 Compliance and self-reported morbidity (condition ever experienced over trial) 
 UNIMMAP 
 
Drink Powder 
 
P value* 
% Compliance (Median IQR) 97.8 (91.0, 100.0) 98.8 (91.6, 100.0) 0.23 
Nausea (N %) 17/104 (16.4) 8/93 (8.6) 0.10 
Dizziness (N %) 14/104 (13.5) 12/93 (12.9) 0.91 
Urine discolouration (N %) 4/104 (3.9) 8/93 (8.6) 0.23 
Abdominal pain (N %) 19/104 (18.3) 13/93 (14.0) 0.41 
Fever (N %) 4/104 (3.9) 6/93 (6.5) 0.52 
 
*Wilcoxon rank-sum test of medians for percentage compliance, chi-squared test for 
morbidity (with Fisher’s exact test for any numerator <5) 
Abbreviations: UNIMMAP, Daily United Nations Multiple Micronutrient Preparation 
supplement. 
 
8.4  Discussion  
In this trial both supplements were highly effective in reducing homocysteine after twelve 
weeks of daily supplementation, with the strongest effect sizes apparent after five weeks. 
There was strong evidence to suggest the drink powder was more effective than UNIMMAP 
at midline, and that this advantage was maintained, although weaker, at endline. Trial 
compliance was high and self-reported adverse events were low throughout the trial, and 
neither varied by intervention arm. The trial confirms an important proof-of-principle that 
dietary supplements can influence metabolic pathways that we have shown in previous 
observational studies to predict offspring methylation levels(9,12,18). 
Nutritional supplements comprising various combinations of folic acid, B vitamins and methyl 
donors such as betaine have been successful in lowering plasma homocysteine in multiple 
trials(19–23). However, despite a call over ten years ago for more supplementation studies 
looking at the combined effect of B vitamins with betaine(24), there still remain very few. A 
meta-analysis of twelve folic acid supplementation trials (with or without additional B 
vitamins) showed that folic acid supplementation between 1-3 months of supplementation 
reduced homocysteine by 25% (similar across all doses from 0.5-5mg)(23). The UNIMMAP 
multivitamin tablet, which contains one DRI of folic acid, B12, B2 and B6 amongst other 
ingredients, demonstrated similar effectiveness in our trial.  
The drink powder contained double the amount of folic acid, B12 and B2 compared to 
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UNIMMAP, alongside the addition of betaine, components that may explain its comparative 
effectiveness.  Doubling the B vitamin dosage may not greatly contribute towards increased 
homocysteine-reduction properties: previous studies suggest that dose of folic acid does not 
greatly matter(23), that additional B12 also has a disputed effect(23,25), and that B2 
supplementation is only effective amongst those with the rare MTHFR 677 TT genotype(26,27).  
In contrast, in a meta-analysis 4-6g of daily betaine supplementation for 6-12 weeks 
decreases plasma homocysteine by 1.23 μmol/L, corresponding to a 11.8% reduction of 
mean baseline values(28). We can therefore speculate that the betaine in the drink powder 
has an additive effect compared to the action of folic acid and B vitamins in UNIMMAP. The 
results also suggest that the vitamin B6 in UNIMMAP is not required to reduce homocysteine 
in this population, supporting findings from previous trials, including those involving 
participants with low B6 status(23,29,30). It appears that tailoring the drink powder design to 
the nutritional profile of the local population using plasma determinants of homocysteine 
worked well, and could be a viable approach for future supplement design. 
The performance of both interventions surpassed our expectations. Given many of the 
previous folic acid supplementation trials have been performed in patients with 
hyperhomocysteinemia, those with increased risk of cardiovascular events and amongst 
more elderly participants(23), we had envisaged a more modest reduction of around 1µmol/L 
in our healthy, relatively young population. The heightened effectiveness of the 
interventions at midline may be a seasonal effect, driven by higher plasma homocysteine in 
the controls. A previous longitudinal study of one-carbon biomarkers in non-pregnant 
women in Gambia also showed that maximum plasma homocysteine concentration and 
minimum folate concentration occurred in late March-early April(8), the timing of our midline. 
The trial design involving daily observed supplementation, akin to an efficacy rather than 
effectiveness trial, could also be a factor in the degree of success. 
Although the drink powder reduced homocysteine more quickly than UNIMMAP at midline, 
by endline the differences were less pronounced. We have a particular interest in the 
potential for a micronutrient supplement to influence the establishment of DNA methylation 
marks in the very early embryo(9,11). The sensitive periconceptional period may extend back 
beyond the three months required for the most active phase of oocyte maturation(6), and 
there is increasing awareness that interventions should cover longer periods than this to 
account for unknown timing of conception(31). Therefore factors such as cost-effectiveness 
and long-term acceptability become relevant considerations for candidate supplements 
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alongside speed of action. The high compliance rates in both arms suggests that both 
interventions were acceptable in the village community settings. The low reported morbidity 
also reinforces the low-risk nature of these supplements. UNIMMAP has been provided in 
pre-conception and pregnancy trials in numerous settings(32–40). Of the trials that reported 
morbidity the majority found there to be no difference between UNIMMAP and control 
arms. Given the drink powder arm in our trial reported similar levels of adverse events to the 
UNIMMAP arm we have assurance that both are well tolerated, further supported by the 
fact that no participant withdrew from the trial on account of adverse effects.  
Lowering homocysteine and providing one-carbon related nutrients are essential for a range 
of biological processes related to fertility and embryo development, and epigenetic 
mechanisms are just one of several aspects to consider at periconception(6,41,42). Future 
supplement designs may therefore want to consider adding other nutrients essential for 
optimal fetal development that were beyond the scope of this proof-of-concept trial. 
Choline, for example, not only acts as a metabolic precursor to betaine, but as an essential 
component of lipids, lipoproteins and neurotransmitters(43,44). However, the interrelated 
nature of metabolic pathways may mean the provision of supplemental folic acid and betaine 
is sufficient to reduce the demand for choline for transmethylation and therefore spare it for 
other important functions(45–47). Further research is required to determine the extent of such 
compensatory mechanisms and the implication for supplement design.  
Our trial had several limitations. We used homocysteine as an integrated indicator of B 
vitamin status and methylation potential but, had resources allowed, we would have liked 
to quantify the effects of the two supplements on micronutrient status. The study visits had 
a number of no-shows due to travel and exam-sitting commitments, particularly at the 
baseline visit. Unfortunately, we were unable to extend the midline or endline visits due to 
the need to avoid the month of Ramadan, when venepuncture sample collection was not 
viable. Whilst this meant we did not achieve our intended sample size of 99 women per arm 
we were fortunate that the effect sizes of the intervention were much greater than expected.  
Finally, we did not collect information on genetic polymorphisms that may have affected 
homocysteine metabolism(48).  
In conclusion, both supplements worked to reduce homocysteine concentrations from those 
seen in the dry season to below those in the rainy season, and therefore met the trial 
objective. It is premature to speculate whether the improvements on homocysteine 
reduction offered by the drink powder would be of epigenetic significance in future trials. As 
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such, they both remain potential candidates for future epigenetic trials in pregnancy in the 
rural Gambian setting. This is contingent on future research confirming causal links between 
maternal nutrient exposure, offspring methylation and phenotypic effect, which is an area 
of continued investigation.  
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Supplementary Table 8.1: Multivariable regression results showing percentage difference in geometric mean plasma homocysteine between trial arms, 
constricted to fasted, non-pregnant, compliant participants 
 
  
 
 
 
 
 
 
 
* β represents difference in log homocysteine at time point between trial arms, adjusted for baseline homocysteine, age and body mass index at time point. 
**Fasted and non-pregnant at time point, and above 80% compliance at time point 
Ɨ Calculated from (eβ-1)*100 
 
 
 
  
Trial arms Timepoint N* β (95% CI)** % difference in geometric 
means Ɨ 
P value 
Drink powder vs. control 12 weeks 141 -0.28 (-0.36, -0.19) -24.1 (-30.1, -17.4) <0.001 
UNIMMAP vs. control 12 weeks 143 -0.18 (-0.25, -0.1) -16.4 (-22.5, -9.9) <0.001 
Drink powder vs. UNIMMAP 12 weeks 130 -0.10 (-0.18, -0.01) -9.2 (-16.7, -1.1) 0.028 
Drink powder vs. control 5 weeks 176 -0.44 (-0.52, -0.37) -35.8 (-40.4, -30.8) <0.001 
UNIMMAP vs. control 5 weeks 168 -0.26 (-0.33, -0.18) -22.5 (-27.9, -16.8) <0.001 
Drink powder vs. UNIMMAP 5 weeks 162 -0.17 (-0.25, -0.1) -15.9 (-21.9, -9.4) <0.001 
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Supplementary Table 8.2: Additional details on morbidity  
 
 UNIMMAP Drink Powder 
Adverse Event N Mean 
(days) 
Median 
(days) 
Min 
(days) 
Max 
(days) 
N Mean 
(days) 
Median 
(days) 
Min 
(days) 
Max 
(days) 
Nausea  104 0.26 0 0 5 93 0.21 0 0 7 
Dizziness  104 0.37 0 0 10 93 0.30 0 0 6 
Urine discolouration  104 0.05 0 0 2 93 0.37 0 0 8 
Abdominal pain  104 0.58 0 0 19 93 0.46 0 0 14 
Fever  104 0.07 0 0 2 93 0.18 0 0 7 
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Chapter 9 Discussion 
__________________________________________________________________________ 
 
Summary of chapter 
 
In this chapter I summarise the main findings, strengths and weaknesses of the PhD by 
objective. I then expand on some questions that recurred for me during the PhD period. 
These include exploring what plasma biomarkers represent and their appropriateness as a 
proxy measure of the periconceptional nutritional environment. To help with the latter point 
I draw on research from Assisted Reproductive Technology. I then give an overview of some 
of the additional exposures we could consider measuring in The Gambia to further our 
understanding of why seasonality has such an influence on DNA methylation. I finish with 
suggestions on the way forwards for nutritional epigenetic research in the field of public 
health nutrition.  
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9.1  Summary of PhD findings, strengths and weaknesses by objective 
9.1.1  Objective a): A literature review of human studies that investigate associations 
between maternal periconceptional nutritional exposures, the infant epigenome and 
later phenotypes.  
 
There is considerable interest in the extent to which diseases in later life may have been 
programmed through environmental exposures in very early life, and if so, whether there is 
the potential for interventions at periconception and in pregnancy to mitigate these effects. 
Chapter 3 set out the context of nutritional epigenetics within the Developmental Origins of 
Health and Disease (DOHaD) paradigm. This reviewed what we know to date about how 
nutritional exposures at periconception and throughout pregnancy influence infant DNA 
methylation patterns, and in turn whether these epigenetic signatures are further associated 
with later risk of disease. The literature summarised there painted a complex, heterogeneous 
picture, showing whilst there is a rapidly building evidence base that maternal nutritional 
exposures are associated with infant methylation, the patterns are far from consistent. There 
is also a growing, although often separate, evidence base that DNA methylation marks in 
infancy, particularly at imprinted genes and metastable epialleles, are associated with 
adverse phenotypes in the cognitive, growth and cardiometabolic domains. The review 
highlighted the lack of studies that have been able to link maternal exposure through to 
offspring phenotype via DNA methylation as a mediating mechanism. Recommendations 
therefore included more research on the nature of the exposures as well as the confounders, 
and, where possible, the implementation of randomised trials to help determine causality 
when linking early exposures to offspring methylation.  
 
Strengths 
 The review had a unique focus on identifying research drawing together exposure-
methylation-phenotype associations in a single study.  
 The genes that featured in the literature searches were summarised with genomic 
locations, annotations, and coverage on existing commonly used DNA methylation 
platforms (Illumina 450k / EPIC Arrays). The intention was that this would provide a 
useful resource for researchers in nutritional and epigenetic epidemiology looking to 
design a targeted methylation analysis, as well as for those wanting to target specific 
genes and pathways in future interventions.  
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 The overview of candidate genes highlighted gene classes of interest to consider 
alongside imprinted genes, such as metastable epialleles (MEs).   
 
Weaknesses 
 Heterogeneity in the type, measurement and timing of nutritional exposures, 
alongside variation in the genetic loci investigated by study, meant that a 
systematic literature review and meta-analysis was not possible.  
 The review was restricted to DNA methylation and nutrients involved in one-
carbon metabolism to allow a feasible scope. Other environmental, including 
nutritional exposures, were therefore excluded. The nutritional effects on 
histone modifications and micro RNAs were not investigated, but are important 
mechanisms to consider in future research. 
 
9.1.2  Objective b): Analyse an expanded set of maternal biomarkers and characterize 
how the maternal one-carbon metabolome varies across the year 
 
Chapter 4 presented the analyses of the seasonal trends of core one-carbon biomarkers 
(folate, B2, B6, B12, betaine, choline, homocysteine, dimethylglycine (DMG), methionine, 
cysteine) and a panel of amino acids in plasma. The dataset contained 350 plasma samples 
of women in their first trimester of pregnancy, purposively sampled to cover the whole year. 
Apart from methionine and DMG all the core one-carbon biomarkers and six amino acids 
demonstrated a seasonal variation in plasma concentrations. The seasonal trends were 
modelled using Fourier term (FT) linear regression models. The FT models explained between 
2.2% and 12.9% of the variation in biomarker concentrations. The coefficient of cyclic 
variation, a measure of the magnitude of the periodic variation for biomarkers with a 
seasonal trend, showed that B2 had the greatest seasonal variation (16.2%). This was 
followed by folate (15.1%) and decreased to approximately 3.5% amongst the amino acids 
histidine, leucine and serine. Timing of the seasonal peaks and troughs, as well as the 
amplitude of the seasonal differences, varied greatly between the biomarkers. Co-variation 
between many of the biomarkers could be explained based on the biochemistry involved in 
one-carbon metabolism. However, it was not possible to fully explain all the co-variation 
seen, which could reflect the complexities of interpreting plasma concentrations (explored 
in section 9.3.1 below).  
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Strengths  
 This dataset contained the first year-round information on one-carbon metabolites 
in pregnant women in The Gambia. Previous datasets had either been in non-
pregnant women, or only captured 6 months of the year. 
 The analysis was an ideal opportunity to consolidate prior knowledge from two 
previous datasets, and expand the focus beyond core one-carbon metabolites. The 
seasonal trends across the three datasets generally showed a consistent pattern. 
This confirmed that methylation potential was lower in the dry season, when 
homocysteine concentrations were higher.  
 The dataset was comprised of cross-sectional samples taken from different women 
across the whole year. This meant the dataset was vulnerable to higher inter-
individual variation compared to datasets composed of repeated measures in the 
same women across the year (e.g. as in the Indicator group dataset). However, the 
very similar trends with the Indicator group justified the utility of this dataset to 
investigate seasonal trends.   
 The analyses suggested a potential new seasonal window of interest at the end of 
the rainy season, in September and October, when several biomarkers were at their 
lowest concentrations.  
 The analyses considered a greater number of potential confounders compared to 
previous studies, being able to adjust the seasonal trends for BMI, inflammation, age 
and gestational age. 
Weaknesses 
 The introduction of FTs to model seasonal trends risks oversimplifying seasonal 
patterns, where not all variation may fit a sinusoidal wave pattern. However, they 
do enable a standardised way of comparing the amplitude of variation between 
biomarkers and across datasets.  
 The intermediary metabolites S-adenosyl methionine (SAM), S-adenosyl 
homocysteine (SAH) and formate were planned but not measured due to assay 
difficulties. These would have provided an additional level of detail on methylation 
potential using the SAM:SAH ratio, and on an important source of 1-carbons via 
formate. Future planned studies using SAM:SAH should ensure storage and freeze-
thaw cycles are kept to a minimum. 
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9.1.3  Objective c): Explore whether the profile of maternal nutritional predictors of 
offspring methylation changes between the rainy and dry season of The Gambia.  
Chapter 5 analysed the association of maternal nutrient plasma concentrations in the MDEG 
cohort, back-extrapolated to the time of conception, with offspring DNA methylation at 
mean age 3.3 months. In the offspring DNA a new, larger set of genomic loci were 
investigated. These were 50 CpG loci that were MEs and exhibited differential methylation 
by season of conception. Unlike previous analyses, in this analysis season was introduced as 
a potential effect modifier to explore whether the profile of nutritional predictors of 
methylation differed between the Gambian rainy and dry seasons. There was preliminary 
evidence of seasonal differences in biomarker-methylation associations for folate, choline 
and homocysteine.  During the dry season plasma biomarkers associated with the folate 
remethylation pathway predicted DNA methylation. In the rainy season the profile of 
predictors appeared to switch to a set more aligned to the betaine remethylation pathway. 
Speculatively this was due to the differences in the underlying nutritional status of women 
between the seasons. Differences in dietary intake patterns and underlying nutritional status 
may need to be considered as potential effect modifiers in the relationship between 
exposures and methylation in all contexts, not just in rural Gambia. The effect of a nutritional 
intervention, for example, may therefore be dependent on the time of year of 
implementation and the nutritional status of the population being targeted.  
 
Strengths 
 The investigation of season as an effect modifier was a novel approach in this 
analysis, intended to further our understanding of how seasonality influences DNA 
methylation through differences in nutrition exposures.   
 The use of a larger set of MEs confirmed and strengthened previous findings that 
offspring conceived in the rainy season have higher levels of ME methylation than 
offspring conceived in the dry season.  
 The analyses used principal components to capture some of the co-variation 
between biomarkers and their joint influence on methylation. This approach was 
helpful in considering the role of metabolic pathways rather than considering 
biomarkers individually.  
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Weaknesses 
 A relatively small sample size, combined with the instability of regression models in 
variable selection, meant that the findings from this analysis should be viewed as 
hypothesis-generating, requiring further validation in datasets explicitly powered to 
test seasonal interactions. 
 Linear regression models cannot capture the complexity of metabolism, for example, 
the non-linear patterns and allosteric regulation of reactions. Models incorporating 
kinetic data may help interrogate some of the molecular mechanisms underpinning 
the apparent switch of methylation predictors between the seasons.   
 A number of unmeasured seasonal exposures could also influence methylation 
patterns, and several of these are considered in section 9.4 below.  
 
9.1.4:  Objective d): Determine which nutritional components are consistently 
associated with increased methylation potential in women of rural Gambia 
 
In Chapter 6 three datasets (two cross-sectional and one longitudinal) were used to 
investigate the nutritional exposures that were consistently inversely associated with plasma 
homocysteine in the West Kiang population. The purpose was to identify potential 
ingredients for a supplement using the hypothesis that reducing homocysteine would help 
improve methylation potential and enable one-carbon metabolic pathways to function 
unhindered. Three regression approaches were used to obtain a qualitative overview of the 
patterns of predictors of homocysteine in the different datasets using different variable 
selection approaches.  To assess how generalizable results were from one dataset to another, 
an important consideration when designing a supplement, the predictive equation for 
homocysteine in one dataset was applied to the other two datasets to quantify its predictive 
power.  
Folate, B12, B2 and betaine were the most consistent negative predictors of plasma 
homocysteine. Cysteine, DMG, choline and vitamin B6 were positive predictors of 
homocysteine. The association of the negative predictors, along with cysteine and DMG, 
could be explained through an understanding of homocysteine metabolism. The positive 
associations of B6 and choline with homocysteine were not expected, although similar 
associations have also been found in other studies. In the two cross-sectional datasets the 
set of predictors explained over half the variability of plasma homocysteine, and over a third 
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of the variability in the longitudinal dataset. The predictors performed well in cross-dataset 
comparisons. Overall the results confirmed that nutritional predictors of homocysteine are 
generalizable between different cohorts from West Kiang region, and therefore represent 
robust predictors of homocysteine for supplement design considerations.  
Strengths 
 The combination of using three datasets, three variable selection approaches and 
cross-dataset predictive power enabled the identification of robust negative 
predictors of homocysteine. 
 Identifying plasma predictors of homocysteine represented a simple approach to 
tailor a supplement design to a target population. This approach could be replicated 
in different contexts.  
Weaknesses 
 Identifying predictors of plasma homocysteine is useful for supplement ingredient 
selection but does not provide information on the dose of the component to 
consider. 
 Dietary inputs in the form of a supplement may not necessarily act in the same way 
as plasma determinants of homocysteine. The complex relationships between 
dietary intake and plasma concentrations are explored further in section 9.3.1.  
 
9.1.5   Objective e) Use the results from objectives b) to d) to design a novel nutritional 
supplement to increase methylation potential and to decide which time of year is most 
suitable for a trial. 
 
Chapter 7 described the design of a novel drink powder supplement using the four negative 
predictors of plasma homocysteine identified in Chapter 6. The drink powder contained folic 
acid, B2 and B12 at twice the dietary reference intake (DRI), and betaine at 4g per day. The 
decision to double the DRI of folic acid and the B vitamins came from the analysis in Chapter 
4, which showed that over a quarter of women had a low plasma folate concentration, 39% 
of women had a low plasma B2 concentration, and 9.4% had a low B12 concentration. The 
supplement therefore not only had to provide the daily allowances for maintenance of good 
health, but to correct micronutrient deficiencies as well. Much of Chapter 7 was dedicated 
to exploring the safety of the drink powder supplement. Previous doses of the supplement 
ingredients provided in previous trials, particularly pregnancy trials where possible, were 
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recorded along with summaries of documents assessing safety. Overall it was concluded that 
the suggested drink powder was a low-risk formulation, extremely unlikely to result in any 
adverse events when taken at the correct dosage of one sachet per day. 
Chapter 5 suggested that the timing of future interventions matters and should be carefully 
considered in study design. Information from Chapter 4, alongside previous research, helped 
confirm that the timing of the supplementation trial should be in the dry season. The 
longitudinal analysis in Chapter 4 suggested that mean plasma homocysteine concentration 
was higher in the peak dry season (February – April) compared to the peak rainy season (July-
September), a pattern also seen in previous studies. A higher homocysteine concentration is 
associated with a lower methylation potential in the dry season, and indeed, the MRC 
Gambia research group had previously found methylation patterns suggestive of loss of 
imprinting at the VTRNA 2-1 gene in offspring conceived during the dry season(1).  The clinical 
trial described in Chapter 8 did not intend to look at epigenetic outcomes. However, 
conducting it in the dry season was important to give the best indication of how the 
supplement might perform in future epigenetic trials aimed at increasing maternal 
methylation potential in the dry season and optimising offspring methylation patterns.  
Strengths 
 The novel drink powder design contains, as far as is known, a unique ingredient and 
dosage combination designed to lower homocysteine. Betaine, folic acid and B 
vitamins have been used in previous homocysteine-lowering trials, but have not 
previously been combined into the same supplement in The Gambia. 
 The comprehensive review of previous dosages provided in trials, alongside the 
review of existing safety information, provided reassurance that the supplement 
design was safe. 
Weaknesses 
 Not all previous clinical trials published information on adverse events, therefore it 
was not possible to completely exclude the possibility of unrecorded side effects. 
 There was not as much safety information on betaine compared to folic acid and 
the B vitamins. Previous betaine trials had been conducted in non-pregnant adults. 
Therefore manufacturer information for a betaine powder supplement 
(Cystadane®) was particularly relied upon rather than information from pregnancy 
trials, which would have been preferable.  
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9.1.6  Objective f): Conduct a randomized controlled trial to test the effect of the novel 
supplement on increasing methylation potential via reducing homocysteine. 
 
Chapter 8 described a 3-arm randomised controlled trial conducted amongst 298 non-
pregnant, healthy women of rural Gambia. The effectiveness of the novel drink powder in 
reducing plasma homocysteine was tested in a proof-of-concept trial, against a control arm 
and an arm receiving the UNIMMAP multiple micronutrient tablet. The rationale was that a 
supplement reducing homocysteine would increase methylation potential and therefore be 
a suitable candidate for future epigenetic trials if it was safe and well accepted. Compared 
to the control arm the drink powder reduced mean plasma homocysteine by 24.1% and 
UNIMMAP by 16.4% (both p<0.001) after 12 weeks of daily supplementation. These effects 
exceeded expectations. The drink powder was more effective than UNIMMAP, reducing 
mean homocysteine by a further 9.2% (p=0.025), which could be attributed to the addition 
of betaine. 
 
Both interventions brought dry season homocysteine concentrations to below those found 
in the rainy season, and therefore met the trial aim. Both supplements therefore remain 
candidates for future pregnancy trials looking at infant epigenetic outcomes.  Only after such 
trials will it be possible to verify whether the additional effectiveness of the drink powder 
provides any advantage over UNIMMAP in terms of influence on infant DNA methylation. 
The drink powder works more quickly and effectively than UNIMMAP to reduce plasma 
homocysteine. However, UNIMMAP has the advantage of having previously been used in 
several large pregnancy trials, and may therefore be easier to justify to ethics committees. 
Also, being a tablet, UNIMMAP may be logistically easier to administer than the drink 
powder.    
 
Strengths 
 This is the first time a nutritional supplement has been designed and tested in The 
Gambia with the specific aim of acting on metabolic pathways shown in previous 
observational studies to predict offspring methylation levels.  
 The trial results confirmed that using plasma concentration data to tailor the design 
of a homocysteine-lowering supplement to the target population is an effective 
strategy.  
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 Trial compliance was high (>97%) and self-reported adverse events were low 
throughout the trial, and neither varied by intervention arm. This confirmed that 
both supplements were safe and well accepted by the participants. 
 
Weaknesses 
 The trial would have benefitted from qualitative research investigating participants’ 
attitudes to the two interventions to provide further information on future 
acceptability and sustainability.  
 The Gambian government recently changed regulations so that food supplements 
were categorised as medicines, and therefore the same regulations as for full drug 
trials needed to be met.  This meant trial set-up took longer than expected and the 
trial finished at the end of the dry season in June, when plasma homocysteine levels 
are approaching their lowest concentration (Chapter 4). Running the trial earlier in 
the dry season, when homocysteine concentrations are higher, may have resulted in 
an even stronger effect of the interventions.  
 
9.2  Unanswered questions 
 
This final chapter offers space to reflect on some unresolved issues in the hope they might 
be useful considerations for researchers going forwards. The main recurring questions that 
surfaced during the thesis included: 
 
 We use plasma nutrient concentrations in the analyses. What exactly do these 
plasma concentrations represent? 
 Is plasma the best proxy we have for the nutritional environment surrounding the 
oocyte as it matures and the embryo in the first days after fertilization? 
 Assisted Reproductive Technologies have been developing pre-implantation 
embryos in vitro for decades. What can we learn from this field about the optimal 
nutritional environment required at periconception? 
 We know that differences in one-carbon metabolites do not fully account for the 
effect of seasonality on DNA methylation. What are some of the other potential 
exposures to explore in future research? 
 Is there really a need to focus on molecular mechanisms within the field of public 
health nutrition? 
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 Should future interventions focus exclusively on epigenetic outcomes? Are we ready 
for such interventions, and if not, why not? 
 
These questions are addressed in three broad sections below. 
 
9.3  Plasma biomarkers and the search for the optimal nutritional 
environment for the maturing oocyte and the early embryo 
 
Given many studies, including the ones presented in this thesis, use plasma nutrient 
concentrations, I first ask how well these represent dietary intake. Practical interventions in 
the public health nutrition field are likely to involve dietary advice or supplements, and 
therefore a thorough understanding of the relationship between dietary intake and plasma 
concentrations is important.  I then explore the extent to which plasma nutrient 
concentrations represent the nutritional environment experienced by the early embryo. I 
define this in two main stages: firstly, the nutritional content of the follicular fluid in which 
the oocyte matures before ovulation, and secondly, the nutrients available in the uterine 
tract environment supporting the embryo in the first few days prior to implantation and 
gastrulation. Together these topics help consolidate what we know about the 
periconceptional nutritional environment, the degree to which dietary intake may influence 
it and what knowledge gaps remain.   
9.3.1  The relationship between dietary intake and plasma concentrations 
Biomarkers of nutritional status can reflect different time-scales, from the short-term to the 
long-term. Plasma nutrient concentrations generally represent short-term dietary intake 
over recent hours(2), or can sometimes reflect intake over previous days if the subject has 
fasted overnight(3).  Other tissues, such as hair follicles and adipose, can provide an insight 
about intake in the previous months or years(4,5). The appropriateness of the tissue sample 
depends on the extent to which the nutrient is stored there and to what extent any stores 
reflect nutrient intake. For example, plasma folate is often used as a measure of recent intake 
but red blood cell folate is more appropriate for an average of the status in the previous 60 
days (the average half-life of an erthyrocyte)(2).  
For population studies that require samples from many people at multiple time points, 
accessibility and acceptability become key issues alongside biological appropriateness. 
Venepunctures and the assessment of nutritional status using either red blood cell or plasma 
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concentrations therefore represent a relatively feasible option. However, multiple 
considerations are required before making assertions about how the plasma concentrations 
reflect dietary intake and nutrient status. Many reviews have addressed some of the issues 
to consider(3,4,6–8), from which the following points are summarised. 
Firstly, the degree to which plasma concentrations and dietary intake can be correlated 
depends on the accuracy of intake data. There is frequent under-reporting of energy intake 
in dietary recalls, alongside the difficulties of being able to recall accurate information on 
meal composition and portion size. Even when directly measuring intake through observed, 
weighed records, there is the possibility of participants changing their normal eating habits 
under assessment conditions. Secondly, there are the factors that affect nutrient 
concentration in food before consumption, such as preparation style, cooking time, light 
exposure and storage conditions.  Thirdly, after ingestion factors affecting nutrient 
absorption come into play. These include genetic considerations, homeostatic control, 
nutrient-nutrient interactions, underlying nutritional status, gut transit times, fibre and 
phytate content, and the influence of microbiota. Furthermore, smoking, alcohol intake, 
physical activity levels, disease, the interaction of medications and levels of inflammation 
can also affect nutrient absorption. Finally, plasma concentrations can be affected by 
laboratory issues such as length of storage, number of freeze-thaw cycles, processing time, 
potential contamination and differing stability according to the anti-coagulant used. The 
different laboratory assays chosen for analyses have specific levels of precision, limits of 
detection and intra-assay, inter-assay and inter-laboratory variation. Considering all the 
above factors it is unsurprising that using plasma biomarkers to assess nutritional exposures 
so often generates variable or sometimes counter-intuitive results.  
9.3.2  Is plasma a useful proxy for the nutritional environment of the early embryo? 
The above section has summarised many of the considerations required in order to relate 
diet to plasma concentrations. The next steps are to ask where the nutrients come from that 
sustain methylation processes at periconception, and the extent to which maternal plasma 
reflects the available nutrient stores. Whilst the vast majority of transmethylation reactions 
occur in the liver(9,10), we are particularly interested in two phases relevant to periconception: 
the maturation of the oocyte in the ovarian follicular fluid prior to ovulation (which provides 
the oocyte nutrient stores) and the uterine tract environment in the first few days post-
fertilization prior to implantation and gastrulation. Both the maternal oocyte stores and the 
nutritional environment of the early embryo are therefore essential to consider for 
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understanding optimal periconceptional nutrition(11).  
Follicular fluid 
Follicular fluid obtains its nutrients from plasma(12,13), hence maternal plasma concentration 
may actually be a very appropriate proxy for the environment in which the oocyte is 
developing. There is limited information on the exact nature of the follicular fluid. However, 
homocysteine and folate have been shown to have a similar concentration in both serum 
and ovarian follicular fluid, whereas methionine concentration is higher in serum than 
follicular fluid(14). Lower homocysteine in the follicular fluid is associated with improved 
oocyte maturity and embryo quality in Assisted Reproductive Therapy(15). A mouse study 
tested the effect of an in vitro culture low in methyl donors (low methionine, folic acid, B12, 
choline, B6) on the maturation of ooctytes. The low methyl donor culture led to decreased 
follicular development and reduced methylation at MEST compared to controls, but no 
difference in methylation at SNPRN, IGF2R and H19(16). Furthermore, folic acid 
supplementation in humans does appear to influence follicular fluid homocysteine and folate 
concentrations(17). Considering the oocyte goes through a period of intense maturation 
within the follicular fluid in the 14 weeks prior to ovulation(18), combined with the suggestion 
that supplies of nutrients in the ooplasm fuel the oocyte post-ovulation and when it is 
fertilized(18,19), the follicular fluid is of great importance in determining the nutritional 
environment of the pre-implantation embryo.  
Whilst in our Gambian studies we have back-extrapolated the plasma samples of mothers to 
the time of conception, perhaps this is only capturing part of the story, more appropriate to 
the environment of the uterine tract at conception. This may not necessarily, however, be 
reflecting the three months prior to ovulation where the maternal nutritional environment 
affects the follicular fluid and oocyte cytoplasm composition, influencing the concentration 
of metabolites required for the initial cell divisions in the pre-implantation embryo(18,19). The 
metabolic substrates and enzymes in the early embryo prior to maternal-to-zygotic transition 
(MZT), being prior to zygote gene activation, have to be provided by the maternal oocyte 
storage pools(11,20). In humans the MZT is at the eight-cell stage around 2-3 days post-
fertilisation(21). In future studies it may also therefore be worth assessing the average 
nutrient concentration of the three months prior to conception to see if this sheds any more 
light on the relative contribution of the oocyte development phase to DNA methylation 
patterns in the early embryo.  
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Uterine tract environment 
The extent to which plasma nutrient concentrations reflect uterine tract concentrations is 
not well defined. The fact that previous Gambian studies using plasma nutrient 
concentrations back-extrapolated to the time of conception (Chapter 5 and Dominguez-Salas 
et al. 2014(22)) have been associated with infant DNA patterns suggests that maternal plasma 
may still be a good enough proxy. Indeed, considering the complexities involved in 
interpreting plasma concentration data outlined in section 9.3.1, alongside the modelling 
assumptions involved in back-extrapolation (see Annex 4.2. for more details), we would 
expect the various imprecisions to tend towards a null result rather than producing biased 
estimates. Yet the associations between plasma concentrations at conception and infant 
DNA methylation remain significant and follow expected directions of association. However, 
formal studies assessing correlations between plasma and uterine environment are very few. 
For example, one study characterising the amino acid profile in human uterine fluid found 
that although branched chain amino acids reflected dietary intake, the uterine 
concentrations did not correlate with serum concentrations(23). To the best of my knowledge 
there is no literature investigating the correlations of one-carbon metabolites between 
human serum and uterine fluid.  
Given the dearth of information on this topic it is helpful to turn to findings from Assisted 
Reproductive Technology, since there have now been decades of research into developing 
an embryo in vitro prior to introducing the pre-implantation embryo into the uterus at the 
day 3-5 mark.  
9.3.3  What can Assisted Reproductive Technologies teach us about the uterine 
environment? 
Over 6 million babies have now been born using practices of Assisted Reproductive 
Technology (ART)(24).  The culture used to surround the early embryo during in vitro 
fertilization (IVF) can therefore tell us a lot about the nutritional environment required to 
sustain a viable embryo. From the outset, it should be noted that the IVF cultures do not 
necessarily represent the optimum environment. Indeed, there is an increasing recognition 
of the potential aberrant DNA methylation that can occur in ART at the pre-implantation 
stage. There is accumulating evidence that DNA methylation differences between offspring 
from ART compared with those naturally conceived affect loci at imprinted genes and 
MEs(11,19,24,25), with some suggesting this could be due to perturbations in the folate and 
methionine cycles(19,26). Recent reviews document how children born using ART have 
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increased risk of low birthweight, congenital anomalies and conditions related to imprinting 
disorders compared to those conceived spontaneously(24,27). There may also be an increased 
risk of adverse cardio-metabolic phenotypes(28). However, despite the increased risks, the 
incidence of these adverse phenotypes is still very low(19,27). It is debated whether these 
phenotypes are determined by aberrant DNA methylation dynamics during the in vitro 
window of the first 3-5 days before implantation, or whether they are a reflection of parental 
characteristics seeking ART (e.g. they may be older, be infertile etc.) or the increased 
incidence of multiple births associated with ART(19,28). However, there is preliminary research 
comparing offspring conceived using ART with those born naturally to sub-fertile women 
suggesting that that ART does have an increased risk of low birthweight and prematurity, 
reviewed in Canovas et al. (2017)(24).  
Given the above, what could be the differences between the ART cultures versus the human 
uterine tract secretions? We know from recent studies that the type of embryo culture 
medium is associated with pregnancy and perinatal outcomes(29), although high-quality data 
is lacking and it is therefore difficult to determine precisely which components are causing 
the effects(19,30). IVF cultures were originally modelled on genital tract secretions of various 
mammals in the early 1970s, reviewed in Ménézo et al. 2013(11). It is difficult to obtain the 
specific methyl donor content of commercially available culture mediums, though reviews 
suggest they vary by manufacturer(26,31). Although some culture components are listed by 
companies, many are not, and the concentrations are often unspecified due to commercial 
sensitivity(11).  
Human embryonic stem cells (hESC) have been used as models to generate insights into pre-
implantation embryo metabolism. A study by Steele et al. (2005) examined which one-
carbon metabolic enzymes are expressed by hESC in an attempt to better understand the 
dynamics of one-carbon pathways in the early embryo(26). All key one-carbon enzymes were 
expressed, albeit it with a low expression of betaine homocysteine methyltransferase-2 
(BHMT2). When the experiments introduced methotrexate (a folate inhibitor) to the cell 
culture to deplete folate concentrations the intracellular (cytosolic) concentration of 
homocysteine increased by 63% and methionine decreased, further emphasising the 
necessity of folate in the culture. The authors speculated that since the one-carbon 
metabolic enzymes were expressed in hESC there was a rationale for believing that maternal 
diet or culture medium could influence methylation potential through one-carbon pathways 
in the preimplantation embryo. 
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Since the research described above in the hESC cell lines, more has been discovered about 
the human pre-implantation embryo directly, building on evidence from bovine oocyte and 
preimplantation studies(32,33). Whilst most one-carbon metabolic enzymes do seem to be 
expressed(34), the transsulfuration pathway (catalysed by cystathionine beta synthase) is 
absent in the very early human embryo until the maternal to zygotic transition(11,20). This is 
why folate and B vitamins are particularly essential for the developing embryo, to avoid 
build-up of homocysteine in the absence of the transsulfuration pathway (which can 
decrease methylation potential) by recycling it to methionine(11). 
Further research is needed to better define the nutritional environment of the uterine tract 
and how well plasma concentrations mirror this. It is also not yet clearly defined what the 
influence of maternal nutrition is during the oocyte development phase (affecting the oocyte 
intracellular stores) relative to the environment of the uterine tract (i.e. the extracellular 
nutritional resources for the pre-implantation embryo). However, research from population-
based intergenerational nutritional epigenetic studies and from the ART field both point to 
the possibility that perturbations in one-carbon metabolites during the periconceptional 
period have the potential to influence methylation potential and methylation patterns in the 
developing embryo. Improved synergy between these fields of research may help to further 
understanding of what is happening at the molecular level and how these findings might 
eventually influence population–level interventions.  
9.4  Towards a rural Gambian ‘exposome’ 
In our Gambian studies plasma differences in one-carbon metabolites do not fully account 
for the effect of season on offspring methylation. There remain a number of other 
unmeasured seasonal exposures that may act as confounders or effect modifiers of the 
associations we have seen to date. The totality of all the different environmental exposures 
that can be experienced across the lifecourse has been termed the ‘exposome’(35,36).  
Studying the exposome in greater detail could help define what other components 
contribute to the seasonal influence on DNA methylation. One example of ongoing research 
utilising such an approach is the Human Early-Life Exposome (HELIX) project, a consortium 
of six European birth cohorts, which seeks to characterize early-life non-genetic exposures 
from a range of environmental factors and therefore provide a wealth of information on the 
‘early-life exposome’ from conception onwards(37). The project is ongoing and may prove 
useful in highlighting candidate exposures to consider in The Gambia.  
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9.4.1  The role of metabolomics  
Within the exposome nutrition exposures are often considered using a metabolomics 
approach, which investigates the entire set of metabolites present in a given tissue(38). This 
approach may help identify metabolic pathways associated with DNA methylation that lie 
more distal to the core one-carbon biomarkers we have explored to date. We will need to 
adopt sophisticated ways to analyse metabolomics datasets with their multiple, correlated 
exposures and possible interactions. Statistical approaches will need to take account of 
multiple testing yet still have the flexibility to be useful for hypothesis generation. A review 
of some different statistical techniques is provided by Barrera-Gomez et al. (2017)(39). An 
important limitation to be aware of in metabolomics is the accuracy and reproducibility of 
the laboratory assays used. Whilst techniques are constantly improving, there is a possibility 
for misclassification of some metabolites(40). In non-targeted approaches measuring 
hundreds of metabolites it is not possible to adopt the same use of internal and external 
standards as in a smaller, targeted approach. This is important to consider for Gambian 
studies where the differences we find in certain nutrient concentrations between the 
seasons are small and therefore require assays with a high degree of precision.  
As previously discussed, it can be challenging to correlate dietary intake data with plasma 
nutrient concentrations. However, in the long-term we would want to consider nutritional 
interventions that are food-based in the interests of acceptability and sustainability. There is 
a developing field of metabolomics research that may help in this regard, using ‘multi-
metabolite biomarker models’, reviewed in Garcia-Aloy et al. (2017)(6). These map profiles of 
metabolites onto certain foods, and may be able to help identify dietary patterns in a more 
objective way than traditional questionnaires and recalls. Accurate panels of biomarkers 
have been developed that mirror the intake of certain food and drink, such as for cocoa, 
bread, wine and coffee(6). Metabolomic profiling in 24h urine has been used to differentiate 
dietary patterns in a controlled feeding setting (distinguishing between four different 
diets)(41). There are also preliminary investigations into combining dietary intake data from 
questionnaires with the biomarker panels to predict certain phenotypes of interest with 
greater sensitivity(42). 
Such approaches are in the early days of development but could offer an interesting strategy 
for helping to determine whether there are certain foods responsible for the differing one-
carbon biomarker concentrations we find in the different Gambian seasons. The 
development of biomarker profiles for the Gambian diet would be an intensive and 
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expensive undertaking, so one approach may be to select a shortlist of the foods most likely 
to differ between the seasons based on the current dietary intake information we have from 
the Gambia. Dominguez-Salas et al. (2013)(43) considered the correlation between intake of 
individual nutrients and their plasma concentrations but did not extend this to a food group 
analysis. Some preliminary hypotheses to test include whether the mango season towards 
the end of the dry season contributes to the peak in plasma folate, and whether betaine 
concentrations may be associated with timing of Ramadan due to the potentially increased 
intake of bread when breaking the fast.  
9.4.2  Additional exposures to consider 
Annex 9.1 provides a summary of the literature on exposures that may be promising 
candidates for future research in The Gambia. These include the microbiome, additional 
nutritional exposures such as polyunsaturated fatty acids and vitamin C, oxidative stress, 
inflammation and infection, toxin exposure and the consideration of paternal influences.  
9.5  The future of nutritional epigenetic work in public health nutrition 
9.5.1  The search for epigenetically-mediated phenotypic effects 
There is a concerted effort to investigate whether the alterations to DNA methylation 
associated with  periconceptional nutrition and other exposures result in tangible phenotypic 
outcomes. The review in Chapter 3 highlighted some of the challenges in assessing causality 
in methylation-phenotype associations and the research still required. As an overall 
motivation to continue the Gambian epigenetic research, despite the difficulty in defining 
concrete phenotypes at present, it can be helpful to re-visit one of the original inspirations 
to investigate molecular mechanisms. In rural Gambia there remains a striking, and as yet 
still unexplained, observation that children born in the rainy season are six times more likely 
to die between age 15-65 years than those born in the dry season(44,45).  Given the mortality 
curves diverge in puberty, and that there is no difference in the clinical diagnosis of 
premature death (the majority are infection-related), it appears these different mortality 
risks may be due to a programmed effect.  Epigenetic mechanisms remain a leading 
candidate to explore.  
Although the current evidence base for exposure-methylation-phenotype studies is sparse, 
this is changing. There are several ongoing preconception nutrition interventions, reviewed 
in Barker et al. (2018)(46), that will be generating  data within the next few years on offspring 
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phenotypes, with the ability to investigate epigenetic mechanisms.  One particular 
consortium of interest, for example, is the Pregnancy and Childhood Epigenetics (PACE) 
group. This compromises 39 studies with 29,000 samples to date(47) with a promising breadth 
of research into phenotypes to come.  
Within The Gambia we have ongoing studies that will also contribute to this research gap. 
The EMPHASIS study, described in Fall et al. (2017)(48), is following up children aged 5-9 years 
who were conceived during preconception nutritional intervention trials in The Gambia and 
India. The Gambia trial used UNIMMAP whilst the Indian intervention was a food-based 
supplement. The phenotypes of interest are cognitive, cardiometabolic, growth and body 
composition outcomes. Another current study is a cohort investigating the observations 
arising from previous literature on how the POMC gene displays differential methylation by 
season of conception in Gambian infants, and how in separate German case-control studies 
these methylation differences are associated with obesity at age 11 and in adulthood(49,50). 
The cohort study will examine three different life stages: 0-2 years, mid-childhood and 
adulthood to assess the effects of POMC methylation on weight regulation and energy 
balance over a wide range of ages in a single study. Some of the children now being followed 
up in mid-childhood (age 5-9 years) were born to mothers included in the MDEG-2 dataset 
(Chapter 4), hence the data on maternal one-carbon biomarkers and amino acids will be 
utilized to explore nutritional predictors of POMC methylation. 
In The Gambia given season of conception affects methylation at a variety of genetic loci, 
notably MEs, it may be necessary to jointly consider a wide range of potential phenotypes 
that could be affected (both beneficial and adverse). This is different to the conventional 
epigenome-wide association study (EWAS) approach where each study tends to focus on a 
single, well-defined phenotype.  
 
9.5.2  The way forwards: are nutritional epigenetic trials premature? 
Intervention trials that target changes in DNA methylation as the primary outcome in 
intergenerational settings require that certain criteria be met. Firstly, that there is sufficient 
evidence the maternal nutritional intervention has the potential to affect offspring 
methylation. Secondly, that these nutrition-associated methylation changes are causally 
associated with beneficial phenotypic outcomes. Whilst the scientific community is not yet 
in a position to be able to fully meet these criteria, as discussed in the previous section the 
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next few years will generate an unprecedented level of evidence to evaluate the options. 
Existing knowledge gaps include exploring whether increased methylation potential is always 
beneficial. Increased methylation at one genetic locus may be beneficial whilst at another it 
could be detrimental. At present there is no blueprint of the methylation patterns that 
constitute the ‘optimum’ methylome. As part of this, further research is also required on 
how DNA methylation influences gene expression, either directly or via interaction with 
histone modifications and micro RNAs. 
Not all public health nutrition practitioners are accustomed to, nor convinced of the need of, 
studying the molecular as part of informing population-level interventions. Indeed, it is 
important to step back and reflect on the extent to which we need to know the mechanisms 
at work to be able to improve health outcomes. There is very strong evidence, for example, 
that neural tube defects are preventable through preconceptional folic acid, which is now 
recommended worldwide and has led to mandatory food fortification in many countries(51). 
The mechanism for why folic acid is protective is still undefined, although some studies 
suggest epigenetics could play a role(52,53). Using this example it could be argued that the 
knowledge of providing folic acid at preconception is enough, and understanding the 
underpinning mechanism is now of secondary importance. Unfortunately, similar solutions 
have not been discovered for all adverse phenotypes of interest. For example, meta-analyses 
of the effect of multiple micronutrient supplementation during pregnancy (often missing the 
periconceptional period) on birth outcomes have shown generally disappointing results, with 
only modest improvements in birthweight and very limited impact on other outcomes such 
as pre-term births, miscarriages, still births and perinatal mortality(54–57). Continued 
investigations into mechanisms that might link maternal nutrition to offspring phenotype are 
therefore of critical importance to further guide the timing and composition of interventions, 
and to ensure research funding is directed towards interventions that work. 
Whilst ongoing research is undoubtedly required to build the evidence base to safely and 
effectively target epigenetic outcomes through nutritional interventions, there is still enough 
evidence to suggest that epigenetic mechanisms be considered as secondary outcome 
measures for planned preconception trials. This would apply not only to food fortification 
and supplementation trials, but also to the cash transfer and behavioural change 
preconception interventions that are being advocated for in a recent conceptual model laid 
out in The Lancet to improve maternal nutrition and infant outcomes(46). Collecting 
information on offspring DNA methylation would enable these mechanisms to be further 
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explored, even if the primary outcomes are targeting other pathways. This recommendation 
has time and resource implications, and therefore would need to be considered at the 
project planning stage.  
 
9.6  Conclusion  
The research in this thesis has contributed three key components to our existing knowledge 
of nutritional epigenetics in The Gambia. Firstly, it has further characterised some of the 
seasonal differences in plasma nutritional biomarkers, validating the findings from previous 
studies and extending the consideration to biomarkers outside the core one-carbon 
metabolism subset. Secondly, it has highlighted the importance of considering seasonality 
and nutrient status as potential effect modifiers for maternal nutritional predictors of infant 
methylation. Thirdly, it has identified a novel nutritional supplement and the existing 
UNIMMAP tablet as promising candidates for future epigenetic trials acting on metabolic 
pathways to increase methylation potential. Whilst the explicit targeting of DNA methylation 
profiles by nutritional interventions remains premature, accumulating evidence continues to 
support the focus on epigenetic mechanisms as important considerations in understanding 
the developmental origins of health and disease.   
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ANNEX 3.1  Supplementary Material 1:   Additional information on the 
role of nutritional factors within one-carbon metabolism 
 
An overview of one-carbon metabolism 
S-adenosyl methionine (SAM) is the methyl donor for hundreds of transmethylation 
reactions(1), and its importance in epigenetics stems from its ability to methylate cytosine 
bases and histones. The loss of a methyl group from SAM forms S-adenosyl homocysteine 
(SAH), a build-up of which can reduce methylation rates through allosteric inhibition(2). The 
SAM:SAH ratio can be used as a proxy indicator of methylation potential(3). SAH is further 
hydrolysed to homocysteine (Hcy)(4) and, since this reaction is reversible, Hcy needs to be 
removed from the system to maintain favourable methylation conditions. Hcy can be 
methylated to form methionine or be irreversibly degraded in the transsulfuration pathway. 
In the case of methionine formation, Hcy can either receive the methyl group from N5-methyl 
tetrahydrofolate (‘methyl-THF’), produced through the reduction of dietary folates and folic 
acid, or from betaine in the liver and kidneys, a product formed through the oxidation of 
choline. Methionine can then be condensed with ATP to form SAM and complete the cycle. 
Genetic variants in one-carbon enzymes can also affect the flow of metabolites through 
these pathways(5). 
The role of individual nutrients 
Folate: Dietary folates and folic acid are reduced to form tetrahydrofolate (THF), which is a 
scaffold upon which one-carbon units can be attached and activated. THF in turn is reduced 
to methylene-THF, then to 5-methyl-THF, which donates its methyl group to homocysteine 
using vitamin B12(6). 
B vitamins: Several B vitamins act as cofactors in one-carbon pathways (B12, B2, B6). Vitamin 
B12 is a cofactor in the methylation of homocysteine by 5-methyl-THF. Vitamin B6 (in the 
active form of pyridoxal-5’-phosphate; PLP) is required to reduce THF to methylene-THF, and 
is also a cofactor in the transsulfuration pathway converting homocysteine to cysteine(7). B2 
is required as a precursor to FAD, which is a cofactor for MTHFR to reduce methylene-THF to 
methyl-THF(3). The different forms of THF are interconvertible, except the methyl-THF form. 
In the absence of sufficient B12 to utilise the methyl group from methyl-THF in homocysteine 
methylation (a process which re-generates THF), methyl-THF can accumulate at the expense 
of other THF forms. This is termed the ‘folate trap’ or ‘methyl trap’ and means pathways 
dependent on other forms of THF (e.g. purine synthesis and the thymidylate pathway) can 
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become impaired(8).  
Choline can be synthesised endogenously or obtained from the diet (good sources include 
red meat, poultry, milk, eggs and fish(9)). A two-step oxidation reaction converts it to 
betaine(10), which can donate its methyl group to homocysteine via betaine-homocysteine 
methyl transferase (BHMT)(10). Betaine can also be directly sourced from the diet (e.g. wheat 
bran, wheat germ, spinach, beets(9)). 
Polyunsaturated fatty acids (PUFAs) influence the 1-carbon pathway through two 
mechanisms. Firstly, ω-3 PUFAs upregulate enzymes responsible for the methylation of 
homocysteine to methionine(11,12). Secondly, the availability of PUFAs can influence methyl 
balance via phosphatidylcholine (PC). PC is used in the production of very low density 
lipoproteins (VLDLPs), bile and surfactants. It is formed via two main pathways: the cytidine 
diphosphocholine (CDP)–choline (‘Kennedy’) pathway and the PEMT pathway, which 
converts phosphatidylethanolamine (PE) to PC (Fig. 1). PC differs in composition according 
to the pathway of its formation; the former incorporates more saturated fatty acids and the 
latter more PUFAs, such as arachidonic acid (AA) and docosahexaenoic acid (DHA)(13). In the 
PEMT pathway the conversion of a molecule of PE to PC requires three methyl groups from 
SAM. In rodent studies imbalances in methyl donor supply and the coenzymes involved in 1-
carbon metabolism affect PEMT activity, manifested in disturbances to tissue levels of 
PUFAs(12,14), since the PEMT pathway is the major way phospholipids are transported from 
the liver to the plasma and other tissues(15,16). These effects have been most pronounced in 
pregnant dams consuming a diets designed to resemble a rural Indian intake, with excess 
folic acid and restricted vitamin B12 lowering offspring placental and brain DHA, as well as 
lowering placental global methylation(17,18). In these experiments, supplementation with ω-3 
PUFAs reversed the effect of the micronutrient imbalances(12). The PEMT pathway represents 
a major demand for methyl groups(19,20). Hence any factor that reduces the demand for 
methyl groups in the PEMT pathway (e.g. low PUFA intake) could in theory make more 
methyl groups available for DNA methylation, with potential consequences for epigenetic 
outcomes(21).  
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Fig 1: Formation of phosphatidylcholine by two metabolic pathways 
 
Abbreviations: CDP, cytidine diphosphocholine; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PEMT, phosphatidylethanolamine N-methyltransferase; PUFA,  
polyunsaturated fatty acids; SAM, S-adenosyl methionine. 
 
Amino acids: Several amino acids are thought to contribute 1-carbon units(22), and in turn 
deficiencies in 1-carbon-related analytes may affect amino acid metabolism(23–25). The most 
documented amino acids in this context are serine and glycine. Serine donates a 1-carbon 
unit at the stage of converting THF to methylene-THF through the action of Serine 
Hydroxymethyltransferase (SHMT) and PLP(26). In the process serine is converted to glycine. 
Serine is also involved in the transsulfuration pathway at the steps of converting 
homocysteine to cystathionine and then to cysteine. Glycine is not simply a by-product of 
reactions involving serine, however. For example, it accepts methyl groups from SAM via 
GNMT, especially when SAM concentrations are high(27). Its catabolism by the glycine 
cleavage system in the mitochondria generates methylene-THF with the involvement of THF, 
which is then used as a carbon donor in the 1C pathways(28). The catabolism of amino acids 
tryptophan and histidine is of also of particular interest within 1-carbon metabolism as this 
produces formate(22,29). Formate is produced in the mitochondria and then released into the 
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cytosol, forming formyl-THF by condensation with THF. Formyl-THF can then either be used 
in purine synthesis or be interconverted into other THF oxidation states as part of folate 
metabolism.  Taken together, formate, serine and glycine help link the mitochondrial and 
cytosolic folate pools(30).  
 
Methionine: Methionine is obtained from the diet or formed by the methylation of 
homocysteine. Its adenylation forms SAM, making it a key metabolite in the 1-carbon 
pathways. Methionine also upregulates glycine N-methyltransferase (GNMT) which can use 
excess SAM to methylate glycine to sarcosine. 
Homocysteine: Homocysteine is an intermediary metabolite that is hydrolysed from SAH. 
Since a build-up of SAH inhibits transmethylation reactions(2) homocysteine is often inversely 
associated with methylation. For example, van Mil et al. (2014) found an increase in maternal 
plasma homocysteine was associated with 0.04% lower methylation at NR3C1 in the infant 
epigenome (p=0.03)(31). Although it is not a nutritional exposure per se, nutritional inputs can 
influence the concentration of homocysteine. Trials that have aimed to decrease 
homocysteine as part of lowering blood pressure could therefore provide additional 
information as to exposures with the potential to influence the epigenome. For example, 
several studies indicate that increased consumption of ω-3 PUFAs is associated with reduced 
homocysteine levels(32), and that when combined with folic acid and other B vitamins the 
association is even stronger(33). Betaine supplementation has also been shown to reduce 
homocysteine levels(27) 
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ANNEX 3.2  Supplementary Material 2: Search terms used for narrative 
review 
 
Inclusion criteria for the review: 
1) Type of exposure: Nutrition-related, prioritising nutrients related to one-carbon 
metabolism 
2) Timing of study: Preconception and pregnancy 
3) Type of study: Human 
4) Type of study: Intergenerational  
5) Mechanism: DNA methylation  
6) Outcome: growth-related, cardio-metabolic, cognitive 
Databases searched: PubMed, Google Scholar. Search terms were applied to titles and 
abstracts. 
Example of PubMed search terms: 
1) Nutritional Exposure: (nutrition* OR micronutrient OR vitamin OR multivitamin OR 
folate OR “folic acid” OR B12 OR B6 OR B2 OR riboflavin OR “pyridoxal 5-
phosphate” OR cobalamin OR betaine OR choline OR PUFA* OR “polyunsaturated 
fatty acids” OR “UNIMMAP” OR “one carbon” OR “1-carbon” OR “methyl donor” 
OR famine OR carbohydrate OR protein OR fat OR “energy restriction” OR “energy 
intake” OR diet OR supplement*) 
 
2) Exposure timing: (pregnan* OR periconception* OR peri-conception* OR trimester 
OR “in utero”)  
 
3) Human study: (women OR woman OR maternal OR human) NOT (mouse OR mice 
OR rodent* OR rat OR rats OR pig OR pigs OR sheep) 
 
4) Intergenerational study: (offspring OR infant OR child OR children OR 
intergeneration*)  
 
5) Mechanism of DNA methylation: (epigenetic* OR epigenom* OR “DNA 
methylation” OR methylation)  
 
6) Outcome: (outcome OR phenotype OR cardio-metabolic OR “lipid profile” OR 
cholesterol OR “metabolic syndrome” OR “type-2 diabetes” OR “type-II diabetes” 
OR “body composition” OR “bone composition” OR adipos* OR obesity OR obese 
OR “body mass index” OR BMI OR growth OR anthropometr* OR “blood pressure” 
OR “mental health” OR cognit* OR ADHD OR “attention-deficit/hyperactivity 
disorder” OR “intelligence quotient”) 
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Search Strategy:  
 
 Search 1: For the review of nutritional exposures in pregnancy on infant DNA 
methylation search terms from 1) to 5) were linked together with ‘AND’. 
 
 Search 2: For the review of offspring methylation patterns and phenotypic 
outcomes there were two approaches. Firstly, the search terms from 4) to 6) were 
linked together with ‘AND’. Secondly, a nutrition-sensitive locus found in the first 
review ( e.g. ‘LEP’) was entered and linked with search terms 5) and 6) using ‘AND’. 
Only genes that had featured in the first search were included in the second search.  
 
 Search 3: To check for studies linking maternal nutritional exposure to offspring 
phenotype, mediated by DNA methylation, we ran the search terms from 1) to 6) 
linked by ‘AND’. 
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ANNEX 3.3  Supplementary Table 1: Studies investigating associations between maternal nutritional exposures and offspring 
DNA methylation (Search 1) 
 
 
 
Reference Exposure Exposure timing Study design Genes Investigated  Summary of results 
Amarasekera M, et 
al. FASEB J. 
2014;28: 4068–76(1)  
Maternal 
serum folate. 
High and low 
folate groups. 
 
3rd trimester 
 
Nested cohort study. 23 mother-infant pairs, 
Australia.  
 
Tissue: Cord blood CD4+ antigen presenting 
cells. 
Platform: Sequenom Epityper 
ZFP57 (main focus) 
 
Other DMRS:  
ACADM, C21orf56,  
FZD7, LASP1, 
LY6E,WNT9A 
High folate group: Hypomethylation at ZFP57 (mean 
differential methylation 19%), LY6E (8%) and 
C21orf56 (11%). 
Hypermethylation at LASP1 (8%), ACADM (13%), 
WNT9A (10%), FZD7 (8%)  
 
Amarasekera M, et 
al. Epigenetics. 
2014;9:1570–
1576(2) 
Maternal 
PUFA 
supplementat
ion 
2nd & 3rd 
trimesters 
Subset of randomised controlled trial study, 
(70 mother-infant pairs, 36 intervention, 34 
control). Trial was 3.7 g of fish oil (56.0% as 
DHA and 27.7% as EPA) from 20 weeks 
gestation to delivery vs. control.  
 
Tissue: Isolated CD4+ cells from cord blood  
Platform: Illumina Infinium 
HumanMethylation450 BeadChip 
Genome-wide Maternal docosahexaenoic acid (DHA), 
eicosapentaenoic acid (EPA), or total n-3 PUFAs 
showed dose-response effects on methylation at 
certain loci but none reached genome-wide 
significance.  
Azzi S, et al. 
Epigenetics. 2014;9: 
338–45(3) 
Maternal 
vitamins pre-
pregnancy 
BMI, vitamins 
B2, B3, B6, B9 
(folate), B12 
3 months before 
conception and 
last trimester 
Nested cohort study in France (254 mother-
infant pairs). Healthy infants from the ‘EDEN’ 
cohort. Maternal FFQs at 15 weeks gestation 
and post-delivery. Pre-pregnancy weight was 
by recall. 
 
Tissue: Infant cord blood measured  
Platform: Allele-specific methylated 
multiplex real-time quantitative PCR. 
PLAGL1 (ZAC1) Maternal B2 was positively correlated with ZAC1 DMR 
methylation index at pre-pregnancy (r = 0.14, p = 
0.04) and in the last trimester (r = 0.11, p = 0.09). Pre-
pregnancy BMI was positively associated with 
methylation at ZAC1 DMR. 
Ba Y, et al. Eur J Clin 
Nutr. 2011;65: 480–
5(4)  
Maternal 
serum folate 
and vitamin 
Delivery  Hospital-based cross-sectional study. 99 
mother-infant pairs, China.   
 
IGF2 Higher B12 associated with lower methylation at 
IGF2P3 (0.2% per SD). No association of folate with 
methylation.  
Intervention studies Studies using broader nutritional exposures KEY: No colour: observational studies involving one-carbon metabolites 
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Reference Exposure Exposure timing Study design Genes Investigated  Summary of results 
 B12 Tissue: Cord blood 
Platform: Power SYBR Green PCR Master Mix 
and real-time methylation specific PCR.  
Cooper WN,  et al. 
FASEB J. 2012;26: 
1782–90(5)  
 
UNIMMAP 
supplementat
ion 
Periconception Sub-sample from an RCT, The Gambia (58 
mother-infant pairs; 36 intervention, 22 
control). Intervention was one tablet of 
UNIMMAP vs. control from pre-pregnancy to 
mean 9.5 weeks gestation. UNIMMAP 
includes 15 micronutrients (vitamins A, D, E, 
B1, B2, B6, Bi 2, C, Niacin, Folic Acid, Fe, Zn, 
Cu, I, Se) at the Recommended Daily 
Allowance level, except for folic acid, which 
is included at a level of 400 µg 
 
Tissue: Infant cord blood and venous blood 
at 9 months 
Platform: mass spectrometry (SpectroCHIPs, 
Sequenom) 
GNASAS, IGF2, 
IGF2R, MEG3 
(GTL2), MEST 
(PEG1), PEG3, 
PLAGL1 (ZAC1) 
 
There were no overall effects of UNIMMAP 
supplementation. Cord blood results: In girls of 
supplemented mothers there was 8.6% lower 
methylation of IGF2R DMR compared to controls 
(p=0.023). In boys of supplemented mothers there 
was 6.5% lower methylation of GTL2 DMR2 compared 
to controls (p=0.044). 
 
9 month venous blood results:  In girls of 
supplemented mothers there was 7.7% lower 
methylation of PEG1 compared to controls (p=0.030), 
and 5.5% lower methylation of GNASAS (p=0.047). 
 
 
Dominguez-Salas P, 
et al.  Nat Commun. 
2014;5: 3746(6) 
1-carbon 
metabolites / 
season 
 
 
Periconception Cohort study, The Gambia. Followed 84 
women conceiving in peak of rainy season 
and 83 in peak of dry season and their 
infants. 
Maternal measurement: plasma folate, B6, 
B12, active B12, choline, betaine, 
methionine, homocysteine, SAM, SAH, 
dimethyl glycine and erythrocyte B2 back-
extrapolated to conception.  
 
Tissue: Infant venous blood taken at mean 
3.6 months of age. 
Platform: PSQTM HS 96 pyrosequencer 
(Biotage) 
RBM46, BOLA3, 
FLJ20433 (EXD3), 
LOC654433 (PAX8-
AS1), ZFYVE28, 
ZNF678 
 
Methylation potential in maternal plasma was higher 
during the rainy season compared to the dry season.  
 
Offspring of rainy season conceptions had higher 
levels of CpG methylation at the six metastable 
epialleles in peripheral blood monocytes when 
considered jointly. Individually only RBM46 
demonstrated a significant difference.  
Drake AJ, et al., Clin 
Endocrinol. 
2012;77:808-15(7). 
Maternal diet 
(food groups) 
‘Early’ (<20 
weeks) and ‘late’ 
(>20 weeks) 
Retrospective cohort study (‘Motherwell’). 
34 offspring at 40 years of age and mother’s 
dietary records looked up.  
HSD2, NR3C1, IGF2, 
H19 ICR, GR exon 1F 
Higher methylation at GR exon 1F was observed in 
mothers having higher meat/fish/vegetables and 
lower bread/potato intake in late pregnancy. Higher 
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Reference Exposure Exposure timing Study design Genes Investigated  Summary of results 
pregnancy Tissue: Whole blood 
Platform: Pyrosequencing using  PSQTM HS-
96A (Qiagen) 
 
methylation at HSD2 with increased meat and fish 
intake.  
Finer S, et al. BMJ 
Open. 
2016;6:e011768(8). 
Famine All trimesters Case-control study, Bangladesh. Cases: 
Offspring exposed to famine in utero for at 
least 7 months of gestation (n=13). Controls: 
unexposed (n=18).  
 
Tissue: Whole blood age 28-31 years 
Platform: Illumina Infinium 
HumanMethylation450 BeadChip 
VTRNA2-1, PAX8, 
PRDM9, HLA-DQB2, 
PLD6, near ZFP57, 
AKAP12, ATP5B, 
LRRC14B, SPG20, 
near BOLA, RBM46, 
ZFYVE28, EXD3, 
PARD6G, ZNF678 
and ZFYVE28 
Comparing cases with unexposed controls in 
Bonferroni- corrected post-hoc pairwise comparisons 
there was higher methylation at PAX8 (mean beta 
0.771 vs. 0.730, p<0.005), lower methylation at 
PRDM9 (0.656 vs 0.720, p<0.001) and lower 
methylation near ZFP57 (0.681 vs. 0.683, p<0.001). 
Godfrey KM, et al. 
Diabetes. 2011;60: 
1528–1534(9) 
Maternal 
carbohydrate 
intake 
2nd trimester Cohort, UK (78 mother-child pairs from 
Princess Anne Hospital and 239 mother-
infant pairs in replication cohort - 
Southampton Women's Study). Nutrition 
exposure measured by FFQ. 
 
Tissue: Infant cord blood  
Platform EpiTyper software v1.0 (Sequenom) 
 
RXRA,  NOS3, SOD1, 
IL8, PI3KCD 
 
RXRA methylation was inversely associated with 
maternal carbohydrate intake in early pregnancy. 
Gonseth S, et al. 
Epigenetics 
2015;10:1166–76(10) 
 
Maternal 
folate intake 
Periconception Used healthy controls from an existing case-
control study. N=343, USA. Maternal folate 
at conception assessed by retrospective 
FFQs, median 4 years later. Top hits were 
validated in an independent dataset. 
 
Tissue: Cord blood dried blood spots  
Platform: Illumina Infinium 
HumanMethylation450 BeadChip 
STX11, OTX2, 
TFAP2A, CYS1 
All CpG methylation in the four top hits showed an 
inverse relationship with folate intake. Lower 
methylation at these sites were associated with 
increased gene expression.  
 
When stratified by folate intake category, women 
with low intake (<200 µg/day) showed more positive 
associations between folate and methylation than 
inverse ones using epigenome-wide results. For 
women with high folate intakes (>600  µg/day) this 
trend reversed and more inverse associations were 
seen.  
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Reference Exposure Exposure timing Study design Genes Investigated  Summary of results 
Haggarty P, et al. 
Am J Clin Nutr 2013; 
97:94–9(11) 
 
Maternal 
folate and 
folic acid 
supplementat
ion 
Throughout 
pregnancy 
Cohort study. 913 mother-infant pairs, UK 
Maternal folic acid supplementation 
assessed by FFQ covering pre-conception, 
<12 weeks gestation and >12 weeks 
gestation. Maternal folate was measured 
using red blood cell folate at 19 weeks 
gestation.  
 
Tissue: Infant cord blood  
Platform: Pyrosequencing (PyroMark, 
Qiagen).  
PEG3, IGF2 DMR, 
SNRPN 
Maternal folic acid supplementation started after 12 
weeks gestation was associated with increased 
methylation in IGF2 (0.7%, p=0.044) and decreased 
methylation in PEG3 (-0.5%, p=0.018) compared to no 
supplementation. There was no effect of folic acid 
taken preconception or <12 weeks gestation. There 
was no association when the same analysis was done 
using maternal red blood cell folate.  
Heijmans BT, et al. 
Proc Natl Acad Sci 
USA. 2008;105: 
17046–9(12) 
Famine Throughout 
pregnancy 
Dutch hunger winter.  Retrospective case-
control study six decades after famine (cases 
n=60 exposed to famine periconceptionally, 
n=62 exposed in late gestation, each case 
had a same-sex, unexposed sibling control). 
 
Tissue: Adult whole blood 
Platform: a mass spectrometry–based 
method (Epi- typer, Sequenom).  
IGF2 In those offspring exposed to famine 
periconceptionally there was lower methylation at 
IGF2 DMR (-5.2%, p= 5.9 x 10-5) compared to controls. 
There was no association with those exposed during 
late gestation. 
Hoyo C, et al. 
Epigenetics. 2011;6: 
928–936(13) 
 
Maternal folic 
acid intake 
(‘none’, 
‘moderate’ 
and ‘high’ 
groups). 
Preconception & 
Prenatal (all 
trimesters)  
 
Cohort study (‘NEST’ cohort). 438 mother-
infant pairs, USA.  
 
Tissue: Cord blood leukocytes 
Platform: Pyromark Q96 MD Pyrosequencer 
(Qiagen).  
IGF2, H19 
 
No association of pre-conception folic acid intake 
with IGF2 DMR methylation.   
‘Moderate’ intake associated with 2% lower 
methylation at H19 compared with ‘none’ group. 
‘High’ intake associated with 2.8% lower methylation. 
Associations stronger in boys. Similar results for pre-
natal folate intakes.  
Hoyo C, et al. 
Epigenetics. 2014;9: 
1120–30(14) 
 
Maternal  
erythrocyte 
folate 
1st trimester 
(median 12 weeks 
gestation) 
Cohort study (‘NEST’ cohort). 496 mother-
infant pairs, USA. 
 
Tissue: Cord blood leukocytes.  
Platform: Pyromark Q96 MD Pyrosequencer 
(Qiagen). 
 
 
IGF2, H19, 
PEG1/MEST, PEG3, 
PLAGL1, MEG3-IG, 
PEG10/SGCE, NNAT, 
DLK1/MEG3  
Higher folate levels associated with decreased 
methylation at MEG3, PLAGL1 and PEG3 and 
increased methylation at IGF2. 
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Jiang X, et al. FASEB 
J. 2012;26: 3563–
74(15) 
Maternal 
serum choline 
3rd trimester  Randomised controlled trial, USA (24 
mother-infant pairs, 12 per arm). 480 vs. 930 
mg choline / day given from 26-29 weeks 
gestation for 12 weeks. 
 
Tissue: Placenta & cord blood leukocytes  
Platform: EpiTyper (Sequenom).  
 
CRH, GNASAS, IGF2, 
IL10, LEP, NR3C1 
 
CRH: Higher maternal choline intake associated with 
higher methylation of placental promoter (~4%, 
p=0.05) but lower methylation (~2.5%, p=0.04) of 
cord blood (effect size estimated from figure).  
 
GNASAS, IGF2, IL10, LEP: no effect 
 
NR3C1: Higher maternal choline intake associated 
with higher methylation of placental promoter (0.7%, 
p=0.002) but lower methylation (-0.6%, p=0.04) of 
cord blood. 
Joubert BR, et al. 
Nat Commun. 
2016;7: 10577(16) 
 
Maternal 
plasma folate 
2nd trimester 
(median 18 and 
13 weeks 
gestation for the 
two cohorts).   
Meta-analysis of two cohorts: Norwegian 
Mother and Child Cohort Study (‘MoBa’, 
N=1275); Generation R (Netherlands, 
N=713). 
 
Tissue: Infant cord blood 
Platform: Illumina Infinium 
HumanMethylation450 BeadChip 
APC2, GRM8, KLK4, 
LHX1, OPCML, 
PRPH, PRSS21, 
SLC16A12 
443 CpGs demonstrated differential methylation by 
folate levels using false discovery rate (FDR) of 5%.  
 
94% showed an inverse relationship between folate 
and methylation. 48 CpGs demonstrated differential 
methylation by folate levels after Bonferroni 
correction (P<1.17 x 10-7). The genes listed here 
represent the ones with the smallest p values.  
Kühnen P, et al. Cell 
Metab. 
2016;24:502–509(17) 
1-carbon 
metabolites / 
season 
Periconception Cohort study, The Gambia. 144 mother-child 
pairs from ‘MDEG’ cohort. 
 
Tissue: Infant venous blood taken at mean 
3.6 months of age. 
Platform: Illumina Infinium 
HumanMethylation450 BeadChip used for 
initial screen.  
POMC Lower methylation at the POMC VMR in children 
conceived in the dry season compared to those 
conceived in the rainy season (coefficient -0.152, 
p=0.034). 
  
Lee H-S, et al. 
Physiol Genomics. 
2014;46: 851–7(18) 
Maternal 
PUFA 
supplementat
ion 
2nd & 3rd 
trimester 
 
Randomised controlled trial. 261 mother-
child pairs (131 supplemented, 130 control) 
in Mexico. 400mg docosahexaenoic acid 
(DHA) vs. placebo given daily from 18-22wk 
gestation to birth. 
 
Tissue: Infant cord blood  
Platform: PyroMark ID system (Qiagen) 
H19, IGF2 No overall differences. The DHA supplemented group 
infants had lower H19 methylation (-1.66%, p=0.01) 
among mothers of BMI < 25 kg/m2. Methylation of 
IGF2 DMR was higher (1.35%, p=0.03) in the 
supplemented group for infants born to overweight 
mothers. DNA methylation levels in IGF2 P3 were 
higher (1.88%, p=0.04) in the DHA group than the 
control group in preterm infants.  
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Lin, X, et al. BMC 
Med. 
2017;15:50(19). 
Maternal BMI, 
glucose, 
plasma fatty 
acids, plasma 
vitamin D, 
serum B12, 
B6, folate, 
iron, zinc, 
magnesium 
3rd trimester 
(26-28 weeks) 
Cohort study (‘GUSTO’ cohort), 987 mother-
infant pairs, Singapore.  
 
Tissue: Infant cord blood 
Platform: Illumina Infinium 
HumanMethylation450 BeadChip 
EWAS  Methylation of cg25685359 (MIRLET7BHG) was 
inversely associated with maternal n-6 PUFA levels 
(P = 4.2 × 10–4). 
 
Methylation of cg23671997 (IGDCC4) was positively 
associated with maternal fasting glucose levels 
(P = 2.7 × 10–4). 
Marchlewicz EH, et 
al. Sci Rep. 
2016;6:34857(20).  
Maternal 
metabolomic 
profile, 
including 
PUFAs 
1st trimester Cohort study, USA (40 mother-infant pairs) 
 
Tissue: Infant cord blood  
Platform: PyroMark Q96 MD pyrosequencing 
(Qiagen). 
IGF2, H19, ESR1, 
PPARα 
Several derivatives of linoleic acid and α-linolenic acid 
were associated with candidate gene methylation, 
but direction of associations differed. Very Long Chain 
Fatty Acids were positively correlated with 
methylation at ESR1 and PPARα.  
 
McCullough LE, et 
al. Clin Epigenetics. 
2016;8: 8(21) 
Maternal 
plasma B12, 
B6, Hcy 
 
1st trimester  
(mean 12 weeks 
gestation) 
 
USA (496 mother-infant pairs), ‘NEST’ cohort 
 
Tissue: Infant cord blood  
Platform: Pyrosequencing (Pyromark Q96 
MD, Qiagen).  
H19, MEG3 (GTL2), 
PEG10 / SGCE, 
PLAGL1 (ZAC1) 
 
No association between maternal micronutrient 
levels and H19,  PEG10 / SGCE, PLAGL1 (ZAC1) 
 
Vitamin B6 (PLP) in quartiles positively associated 
with methylation at MEG3 DMR (βQuartile 3 = 2.01 
and βQuartile 4 = 3.24, p <0.05). 
McKay JA, et al. 
PLoS One. 2012;7: 
e33290(22) 
Maternal red 
blood cell 
folate, serum 
vitamin B12 
1st trimester 
(mean 10.6 weeks 
gestation) 
 
Nested cohort study, UK (121 mother-infant 
pairs). Also looked at genetic variants.  
 
Tissue: Infant cord blood  
Platform: Pyrosequencing (Pyromark MD, 
Qiagen).  
IGFBP3, IGF2 
 
Methylation of the IGFBP3 locus inversely correlated 
with infant cord vitamin B12 concentration 
(standardised β -0.345, p<0.001), but not maternal 
nutrient concentrations.   
 
Maternal B12 concentration inversely correlated with 
infant global DNA methylation. 
 
Maternal MTHFR C677T genotype associated with 
IGF2 methylation (but no association with 
micronutrients). 
 
 
 
 247 
 
Reference Exposure Exposure timing Study design Genes Investigated  Summary of results 
Pauwels S, et al. 
Clin Epigenetics 
2017;9:16(23) 
 
Maternal 
choline, 
betaine, 
folate, 
methionine, 
folic acid 
Throughout 
pregnancy, 
including 
periconception 
Cohort study (‘MANOE’ study). 114 mother-
infant pairs, Belgium. Maternal intakes 
assessed by food frequency questionnaires 
(FFQs) at different stages of pregnancy 
(periconception, 1st, 2nd, 3rd trimester) for 
different mothers.  
 
Tissue: Buccal epithelial cell in 6 months old 
infants  
Platform: Pyrosequencing (PyroMark Q24, 
Qiagen).  
IGF2 DMR, DNMT1, 
LEP, RXRA 
Periconceptional maternal intake (n=21): At RXRA (all 
CpGs) each increase in 100 μg folate was associated 
with 0.685% increase in methylation (p=0.027), and a 
0.875% increase in methylation per 100 mg increase 
in betaine. At LEP (all CpGs) each increase in 100 μg 
folate was associated with a decrease in 1.233% 
methylation (p=0.030). At IGF2 DMR (all CpGs) an 
increase in 100 μg folic acid was associated with a 
decrease of 0.706% methylation (p=0.010) 
 
2nd trimester intake (n=85): At DNMT1 (all CpGs) an 
increase in 100 μg folic acid was associated with a 
decrease of 0.027% methylation (p=0.020) 
 
3rd trimester intake (n= 82): At DNMT1 CpG1 an 
increase in 100mg choline was associated with an 
increase of 0.156% methylation (p=0.017). At DNMT1 
CpG3 an increase of 100 μg folate was associated 
with an increase of 0.131% methylation (p=0.026). 
Pauwels S, et al. 
Epigenetics 
2017;12:1–10(24) 
Maternal 
choline, 
betaine, 
folate, 
methionine, 
folic acid 
Throughout 
pregnancy, 
including 
periconception 
Cohort study (‘MANOE’ study). 115 mother-
infant pairs, Belgium. Maternal intakes 
assessed by FFQ at different stages of 
pregnancy (periconception, 1st, 2nd, 3rd 
trimester) for different mothers.  
 
Tissue: Cord blood  
Platform: Pyrosequencing (PyroMark Q24 
instrument, Qiagen).  
IGF2 DMR, DNMT1, 
LEP, RXRA 
Periconceptional maternal intake (n=24): At DNMT1 
CpG4 each increase in 100 mg betaine was associated 
with 0.675% increase in methylation (p=0.039). At LEP 
CpG each increase in 100 mg methionine was 
associated with 0.427% increase in methylation 
(p=0.048). 
 
2nd trimester (n=89): At LEP CpG2 each increase in 
100 mg betaine was associated with 0.575% decrease 
in methylation (p=0.05). Each increase in 100 μg 
folate was associated with 0.507% decrease in 
methylation (p=0.009). At DNMT1 CpG4 each 
increase in 100 mg choline was associated with 
0.301% decrease in methylation (p=0.031). Each 
increase in 100 μg folate was associated with 0.226% 
decrease in methylation (p=0.045). 
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3rd trimester (n=83): At DNMT1 CpG2 each increase in 
100 mg choline was associated with 0.291% increase 
in methylation (p=0.022). At RXRA CpG2 each 
increase in 100 μg folate was associated with 1.0% 
decrease in methylation (p=0.041).  
 
There was 2.3% higher methylation at LEP (mean of 
CpGs) when women had taken folic acid for 6 months 
prior to conception compared to those not taking any 
supplementation. Mean RXRA methylation was 1.2% 
higher in mothers who took folic acid 
supplementation throughout pregnancy compared to 
those who stopped in the 2nd trimester (p=0.01). 
Qian YY, et al., J 
Hum Nutr Diet. 
2016;29:643-51(25). 
Folic Acid Pregnancy – no 
details  
Case-control study.  39 small-for-gestational 
age (SGA) infants and 49 appropriate-for-
gestational-age (AGA) controls, China. 
Information on folic acid supplementation 
taken by mothers obtained through 
questionnaire responses.  
 
Tissue: Umbilical cord blood  
Platform: EpiTYPER, Sequenom. 
MEST,H19 Six sites in the H19 DMR were found to have 
significantly higher methylation in SGA when 
compared to AGA. The associations were stronger in 
males in the folic acid supplemented group. 
Rijlaarsdam J, et al., 
J Child Psychol 
Psychiatry. 
2017;58:19-27(26). 
High-fat and -
sugar diet 
3rd trimester (32 
weeks) 
Nested cohort study (‘ALSPAC’ cohort). 164 
youth with low conduct problems (CP) and 
early onset persistent (EOP) ADHD. FFQs 
administered to mothers. 
 
Tissue: Cord blood, peripheral blood at age 7 
Platform: Illumina Infinium 
HumanMethylation450 BeadChip 
IGF2 High-fat and -sugar diet taken prenatally was 
associated with higher IGF2 methylation. 
Silver MJ, et al. 
Genome Biol. 
2015;16: 118(27) 
1-carbon 
metabolites / 
season 
Periconception Cohort study, The Gambia. 110 children 
conceived in peak of dry season, 105 
conceived in peak of rainy season. Used an 
epigenome-wide screen to create a list of 
potential MEs susceptible to 
VTRNA2-1 The epigenome-wide screen top hit for differential 
methylation by season of conception was VTRNA2-1.  
Offspring conceived in the dry season had increased 
levels of hypomethylation (<40%) of VTRNA2-1 DMR 
(p=0.004).  
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periconceptional environment.  
 
Tissue: Infant venous blood taken at mean 
3.6 months of age. 
Platform: 450k (Illumina) used for initial 
screen.  
Steegers-
Theunissen RP, et 
al. PLoS One. 
2009;4: e784(28) 
Maternal folic 
acid  
Periconception Cross sectional study amongst controls for 
another study (‘HAVEN’). 120 mother-infant 
pairs, The Netherlands. Folic acid use 
ascertained from questionnaires at 17 
months post-delivery to determine two 
groups: 400 ug periconceptional 
supplementation (n=86) and 
unsupplemented (n=34).  
 
Tissue: Infant blood taken at 17 months.  
Platform: Mass spectrometry based platform 
(Epityper, Sequenom) 
IGF2 Relative methylation of IGF2 DMR (from 5 CpGs) 4.5% 
higher in children born to supplemented mothers 
(p=0.014).  
 
 
Tobi EW, et al. Hum 
Mol Genet. 
2009;18: 4046–
53(29) 
Famine Periconception, 
late gestation  
Dutch hunger winter.  Retrospective case-
control study six decades after famine (cases 
n=60 exposed to famine periconceptionally, 
n=60 same-sex, unexposed sibling controls). 
Also cases exposed to famine in late 
gestation (n=62) and controls (n=62). 
 
Tissue: Adult whole blood 
Platform: a mass spectrometry–based 
method (Epi- typer, Sequenom). 
 
ABCA1, CRH, 
GNASAS, IGF2R, 
IL10, INSIGF, LEP, 
MEG3 (GTL2) 
Famine exposure was significantly associated with 
methylation at INSIGF (↓), GNASAS (↑), MEG3 (↑), 
IL10 (↑), LEP (↑) and ABCA1 (↑). Effect sizes ranged 
from -1.6 % to + 2.4 % (all p values <0.017).  In 
addition, INSIGF, GNASAS and LEP demonstrated 
differences in methylation by sex. There was lower 
methylation at GNASAS for those exposed to famine 
in late gestation.  
Tobi EW, et al. PLoS 
One. 
2012;7:e37933(30) 
Famine Periconception Dutch hunger winter.  Retrospective case-
control study six decades after famine (cases 
n=60 exposed to famine periconceptionally, 
n=60 same-sex, unexposed sibling controls) 
 
Tissue: Adult whole blood 
INS, INSIGF, IGF2 
and H19 
Methylation at INSIGF was 1.5% lower in the cases 
compared to controls. Directions of associations with 
methylation at IGF2 varied according to the specific 
DMR.  
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Platform: a mass spectrometry–based 
method (Epi- typer, Sequenom). 
Tobi EW, et al. Int J 
Epidemiol. 2015 
May 5;44:1211–
1223(31) 
Famine Gestational weeks 
1–10, 11–20, 21–
30, or 31 to 
delivery 
Dutch hunger winter.  384 subjects exposed 
in the four timing windows.  
 
Tissue: Adult whole blood 
Platform: Illumina Infinium 
HumanMethylation450 BeadChip 
FAM150B, SLC38A2, 
PPAP2C, 
OSBPL5/MRGPRG, 
TMEM105, TACC1 
and ZNF385A 
Famine exposure in gestational weeks 1-10 had 
increased methylation at FAM150B, SLC38A2, 
PPAP2C, and lower methylation at OSBPL5/MRGPRG 
compared to later windows of exposure. 
 
Methylation of TACC1 and ZNF385A was increased 
after exposure during any time in gestation. 
Methylation at TMEM105 was lower when exposure 
was at periconception.  
Van Dijk SJ, et al. 
Clin Epigenetics. 
2016;8:114(32) 
Maternal 
PUFA 
supplementat
ion 
2nd & 3rd 
trimesters 
Subset of RCT trial, Australia (n= 369 at birth; 
190 intervention, 179 control). Trial was 800 
mg/day DHA vs. placebo from 20 weeks 
gestation to delivery. 
 
Tissue: Infant blood spots at delivery, and 
venepuncture at 5 years 
Platform: Illumina Infinium 
HumanMethylation450 BeadChip 
ESYT3,  SLC12A6, 
CCK,  MAD1L1,  
GTF2A1L, STON1,  
RPS6KA2,  
FAM110B,  
PWWP2B,  TRAK1, 
RAET1L 
The listed genes contained CpGs showing differential 
methylation according to intervention arm (p<5x10-5).  
 
Directions of associations changed, but mostly DHA 
was inversely associated with methylation. Maximum 
effect size was a difference of 4.5% methylation.  
 
These trends were still seen in the samples at 5 years, 
although they no longer reach genome-wide 
significance.  
van Mil NH, et al. 
Reproduction. 
2014;148: 581–
92(33) 
Maternal 
plasma folate, 
plasma 
homocysteine 
(Hcy) and folic 
acid intake 
1st trimester 
(mean 13 weeks) 
Nested cohort study (‘Generation R’). 463 
mother-infant pairs, The Netherlands. 
Questionnaires assessed periconceptional 
folic acid intake.   
 
Tissue: Infant cord blood  
Platform: Mass spectrometry based platform 
(Epityper, Sequenom) 
H19, NR3C1,  DRD4, 
5-HTT, IGF2 DMR, 
KCNQ1OT1, and 
MTHFR   
No association between maternal plasma folate and 
folic acid intake with infant DNA methylation when 
exposures treated as continuous variables.  
 
A 1 µmol/l increase in plasma homocysteine was 
associated with 0.04% lower methylation at NR3C1 
(p=0.03). 
 
In folate deficient mothers (<7 nmol/l) there was 
lower methylation at NR3C1 compared to folate 
replete mothers (≥7 nmol/l) (-0.60%, p<0.001).  
 
Mothers with elevated Hcy (>11 µmol/l) showed 
0.92% higher methylation at H19 compared to those 
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with low Hcy (≤11  µmol/l) (p=0.05).  
There were no significant associations at any other 
gene regions.  
Waterland RA, et al. 
PLoS Genet. 
2010;6:e1001252(34) 
Season 
 
Periconception Cross-sectional study taking samples from 30 
children conceived in the rainy season and 
30 conceived in the dry season, rural 
Gambia.  
 
Tissue: Venous blood taken at mean 8.9 
years. 
Platform: PSQTM HS 96 pyrosequencer 
(Biotage) 
BOLA3, FLJ20433, 
PAX8 ZFYVE28, 
SLITRK1 
 
Methylation at all 5 metastable epialleles was higher 
in children conceived in the rainy season compared to 
the dry season (all p<0.03). 
 
Abbreviations: DMR, differentially methylated region; EWAS, epigenome-wide association study; ME, metastable epiallele; RCT, randomised controlled trial; 
PUFA, polyunsaturated fatty acid; VMR, variably methylated region. 
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ANNEX 3.4  Supplementary Table 2: Studies investigating associations between nutrition-sensitive candidate genes and 
phenotypes (Search 2). 
Reference Study design Genes Implicated  Phenotype 
investigated 
Summary of results 
Azzi S, et al. Epigenetics. 
2014;9: 338–45(1) 
Nested cohort study in France. 254 mother-infant pairs. 
Healthy infants from the ‘EDEN’ cohort.  
 
Tissue: Cord blood  
Platform: Allele-specific methylated multiplex real-time 
quantitative PCR. 
PLAGL1 (ZAC1) Pre- and post-natal 
growth 
ZAC1 methylation index was positively correlated with 
estimated fetal weight at 32 weeks gestation (r=0.15, 
p=0.01). It was positively correlated with weight (r = 0.14, 
p=0.03) and BMI z-scores (r = 0.15, p=0.01) at age 1 year. 
Bens S, et al. Eur J Hum Genet. 
2013;21:838-43(2) 
Case-control study. 98 SGA infants and 50 AGA controls from 
centres of the BMBF consortium, Germany (range 0-18 
years).  
 
Tissue: Whole blood  
Platform: Pyrosequencer ID 
PLAGL1, IGF2R, 
GRB10, H19, IGF2, 
MEG3, NDN, 
SNRPN, NESP, 
NESPAS 
Size at birth  Cases showed hypomethylation at GRB10 (n=1) and H19 
2CTCF-binding site (n=1), and hypermethylation at NDN 
(n=1) and IGF2 (n=1). Note case study approach therefore 
not included in main narrative Table 2.  
Bouwland-Both MI, et al. PLoS 
One. 2013;8:e81731(3) 
Nested cohort study (‘Generation R’ cohort subset). 69 
small-for-gestational age (SGA) vs. 471 controls 
(appropriate-for-gestational-age; AGA).  
 
Tissue: Cord blood 
Platform: EpiTYPER, Sequenom 
IGF2, H19, MTHFR Birthweight and 
anthropometry. 
Weight gain at 3 
months 
Methylation at the MTHFR locus did not vary significantly 
between SGA and AGA infants. An inverse association was 
found between SGA and IGF2 DMR0 methylation (β =-1.07, 
p=0.015). SGA was not significantly associated with H19 
promoter DMR methylation. IGF2 DMR0 methylation was 
inversely associated with birth-three months weight gain 
(β=-0.46, p=0.022).  
Burris HH, et al., Epigenomics. 
2013; 5: 271–281(4) 
Cohort study. 219 infants, Mexico. 
 
Tissue: Cord blood. 
Platform: Pyrosequencing 
IGF2/H19, 
KCNQ1OT1, GCR, 
NR3C1, LINE-1, Alu 
Birthweight No significant methylation-birthweight associations were 
found for the studied loci.  
Córdova-Palomera A, et al. 
PLoS One. 2014;9:e103639(5) 
Nested cohort study. 34 monozygotic twin pairs of European 
descent, Spain. Age 22-56 years.  
 
Tissue: Whole blood  
Platform: Illumina Infinium HumanMethylation450 (450K) 
Bead-Chip. 
IGF2, IGF2BP1, 
IGF2BP2, IGF2BP3 
Birthweight, 
working memory 
Mean methylation at 2 CpG sites in IGF2BP1 was 
associated with birthweight (β=83.3 x 10-3, p=0.033) and 
working memory (β= -4.4 x 10-3, p=0.009). No variation in 
methylation was observed in other loci studied. 
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Deodati A, et al. Horm Res 
Paediatr. 2013;79:361-7(6) 
Cross-sectional study. 85 children, Italy. Mean age 11.6 
years. 
 
Tissue:  Whole blood 
Platform: Methyl-Profiler DNA Methylation qPCR Assay 
IGF2 Lipid profile Children with intermediate methylation at IGF2 had 
significantly higher levels of triglycerides (107.6 ± 41.99 vs. 
76.6 ± 30.18 mg/dl, p < 0.005) and higher triglyceride:high-
density lipoprotein-cholesterol ratio (2.23 ± 0.98 vs. 1.79 ± 
0.98, p < 0.02) in comparison with children showing 
hypomethylation at IGF2. 
Drake AJ, et al. Clin Endocrinol. 
2012;77:808-15(7) 
Retrospective cohort study (‘Motherwell’). 34 offspring at 40 
years of age. 
 
Tissue: Whole blood 
Platform: Pyrosequencing using  PSQTM HS-96A (Qiagen) 
IGF2, H19 ICR, 
HSD2, NR3C1 
Birthweight, current 
height, weight, 
waist 
circumference, 
blood pressure 
There was an inverse association between methylation at 
specific CpGs in HSD2 and neonatal ponderal index (Region 
2- CpG14 r=-0.38, CpG19 r=-0.34, p<0.05) and H19 ICR 
methylation and birth length (r=-0.36, p<0.05). HSD2 
methylation was positively associated with birthweight 
(r=0.49, p<0.05), adiposity measures and blood pressure in 
adulthood. H19 ICR methylation was not significantly 
associated with birthweight but was positively associated 
with weight in adulthood (β=0.37,p=0.03). Both H19 and 
NR3C1 Exon methylation were associated with waist 
circumference, BMI and blood pressure at age 40.  
Dunstan J, et al., Clin 
Epigenetics. 2017; 29:29(8) 
431 adolescents, USA. Age 10-15 years. 
 
Tissue: Saliva 
Platform: Pyromark Q24, Qiagen 
LEP, ICAM-1, CRH, 
LINE-1 
BMI, waist 
circumference, 
percent body fat 
In obese boys, LEP methylation was inversely associated 
with the obesity. No significant associations were found 
for ICAM-1, CRH and LINE-1. 
García-Cardona MC, et al. Int J 
Obes 2014;38:1457-65(9) 
Cross-sectional study, n=106 divided into lean and obese 
adolescents, Mexico. Age 10-16 years.  
 
Tissue: Whole blood 
Platform: Methylation-specific PCR  
LEP, ADIPOQ BMI, insulin 
resistance, glucose, 
cholesterol and 
triglycerides levels 
No significant variation in overall methylation of LEP, 
ADIPOQ. Lower methylation at both genes in obese 
subjects with insulin resistance.  
Godfrey KM, et al. Diabetes. 
2011;60: 1528–1534(10) 
Cohort study, UK (78 mother-child pairs from Princess Anne 
Hospital (PAH) and 239 mother-infant pairs in replication 
cohort - Southampton Women's Study(SWS)). Childhood 
adiposity measurements were made using dual energy X-ray 
absorptiometry DEXA (PAH study, age 9 years; SWS, age 6 
years). 
 
 
RXRA, eNOS 
 
Adiposity at age 9 
years 
RXRA methylation was associated with sex-adjusted 
childhood fat mass (exponentiated regression coefficient 
[β] 17% per SD change in methylation, p=0.009) and % fat 
mass (β=10%, p=0.023) at age 9 in the PAH cohort and also 
had similar association in the SWS cohort (Fat mass- β=6%, 
p=0.002; %fat mass-  β=4%, p=0.002).   
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Tissue: Cord blood  
Platform EpiTyper software v1.0 (Sequenom) 
 
Methylation at eNOS was associated with fat mass  
(β=20%, p<0.001) and %fat mass (β=12%, p=0.002) in the 
PAH cohort only.  
Harvey, NC et al. J Bone Miner 
Res. 2014; 29.3: 600–607(11)  
Cohort, UK (230 Southampton Women's Study and 64 
Princess Anne Hospital mother-infant pairs) 
 
Tissue: Cord blood  
Platform: Sequenom MassARRAY Compact System 
RXRA Bone mineral 
content at age 4 
years 
Methylation at four of six RXRA CpG sites inversely 
correlated with % bone mineral content. Note that 
maternal free 25(OH)-vitamin D index inversely associated 
with methylation at one RXRA CpG site (β=−3.3 SD/unit, 
p=0.03). 
Houde AA, et al. BMC Med 
Genet. 2015;16:29(12) 
Cross-sectional study. 73 severely obese adults, Canada. 
Mean age 34.7 years.  
 
Tissue: Blood, subcutaneous (SAT) and visceral adipose 
tissues (VAT).  
Platform: Pyrosequencing  
LEP, ADIPOQ BMI, 
anthropometry, 
blood pressure, 
lipid profile 
Higher ADIPOQ methylation levels in SAT were associated 
with higher BMI and waist circumference. Lower LEP 
methylation in blood was associated with higher BMI. A 
positive correlation was found between fasting LDL-C 
levels and LEP in blood and SAT, and with ADIPOQ in SAT 
and VAT. 
Hoyo C, et al. Cancer Causes 
Control. 2012;23:635-45(13) 
Cohort study (NEST cohort), USA. 300 mother-infant pairs.  
 
Tissue: Cord blood  
Platform: Pyromark Q96 MD (Qiagen) 
IGF2, H19 Birthweight IGF2 DMR0 methylation was inversely associated with 
IFG2 protein concentrations in cord blood (β = -9.87, 
p<0.01), having stronger associations in infants of obese 
women (β =-20.21, p<0.0001). Higher concentrations of 
IGF2 were related to higher birth weight (p<0.001). No 
associations found with H19 DMR. 
Hoyo C, et al. Epigenetics. 
2014;9: 1120–30(14) 
 
Cohort study (‘NEST’ cohort). 438 mother-infant pairs, USA.  
 
Tissue: Cord blood leukocytes 
Platform: Pyromark Q96 MD Pyrosequencer (Qiagen). 
H19, PEG10/SGCE, 
PLAGL1, MEG3 
 
Birth weight Higher methylation at H19, PEG10/SGCE and PLAGL1 
DMRs, and lower MEG3 methylation, associated with 
higher birth weight.  
Huang RC, et al. Clin 
Epigenetics. 2012;4:21(15) 
Cohort study (‘Raine’ Study). 315 children, Australia. 
Anthropometric parameters measured at birth and follow 
ups taken at 8 time points after birth.   
 
Tissue: Whole blood at age 17  
Platform: EpiTyper, Sequenom. 
IGF2/H19 BMI, 
anthropometry, 
birthweight 
No association was noted between IGF2/H19 ICR1 and 
anthropometric measures at birth. A 3.4% increase in 
methylation at 2 specific CpGs in the IGF2/H19 ICR was 
associated with 18 mm decrease in head circumference at 
age 17 (p= 0.006). 
Kappil MA, et al. Epigenetics. 
2015;10:842-9(16) 
Cohort study (Rhode Island Child Health Study (RICHS), USA). 
677 mother-infant pairs, subset of n=211 for methylation 
analysis.  
 
108 imprinted 
genes 
Size at birth Increased methylation of MEST observed in SGA infants. 
The paper focuses on gene expression data.   
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Tissue: Placenta 
Platform: Infinium HumanMethylation450 BeadChip. 
Kuehnen, P. et al. PLoS 
genetics. 2012; 8: 
p.e1002543(17)  
Case-control study, Germany. Normal weight controls (mean 
age 17.9 years, N=90), obese cases (mean age 11 years, 
N=171). 
 
Tissue: Peripheral blood 
Platform: Direct sequencing of bisulfite-converted DNA 
POMC Obesity at age 11 
years 
Increased methylation score at POMC in obese children 
compared to controls. Overall CpG methylation score from 
position -4 to +6 was 40% in cases and 25% in controls 
(p<0.001). 
Kühnen P, et al. Cell Metab. 
2016;24:502–509(18) 
Case-control study in German adults: 103 normal-weight 
and 125 obese, mean age 48.2 years.  
 
Tissue: Peripheral blood 
Platform: Pyromark Q24 (Qiagen)  
POMC BMI Positive correlation of average POMC VMR methylation 
with BMI (r = 0.18, p = 0.006).  
Lesseur C, et al. Mol Cell 
Endocrinol. 2013;381:160-7(19) 
Nested cohort study, USA. Rhode Island Child Health Study 
‘RICHS’ cohort, 81 mother-infant pairs, categorised by birth 
size.  
 
Tissue: Cord blood, placenta 
Platform: Pyromark MD (Qiagen)  
LEP Size at birth Higher LEP methylation levels were observed in SGA 
children (p=4.6×10−3). Infants born to pre-pregnancy obese 
mothers had lower cord blood methylation levels (p=0.03). 
There was an interaction between placental LEP 
methylation and sex (p=0.05).  
Lesseur C, et al. 
Psychoneuroendocrinology. 
2014;40:1-9(20) 
Nested cohort study, USA. Rhode Island Child Health Study 
‘RICHS’ cohort. N=444. NICU Network Neurobehavioral 
Scales (NNNS) used for neurobehavior testing. 
 
Tissue: Placenta 
Platform: Pyromark MD (Qiagen) 
LEP Neurobehavior In male infants increased LEP methylation a was 
associated with membership in the profile of increased  
lethargy and hypotonicity (OR = 1.9; 95% CI: 1.07–3.4), and  
reduced risk of membership in the profile of decreased 
lethargy and hypotonicity (OR = 0.54; 95% CI: 0.3–0.94). 
Lester BM, et al. Epigenomics. 
2015;7:1123-36(21) 
Cross-sectional study of 67 preterm infants, USA.  
 
Tissue: Buccal cells 
Platform: Pyrosequencing  
HSD2 and NR3C1 Neurobehaviour Infants with a high-risk neurobehavioral profile showed 
increased NR3C1 methylation and decreased HSD2 
methylation compared to infants with a low-risk 
neurobehavioral profile. 
Lin, X, et al. BMC Med. 2017 
Mar 7;15:50(22) 
Cohort study (‘GUSTO’ cohort), 987 mother-infant pairs, 
Singapore.  
 
Tissue: Cord blood.  
Platform: Illumina Infinium HumanMethylation450 BeadChip 
ANK3, CDKN2B, 
IGDCC4, P4HA3, 
MIRLET7BHG, 
CACNA1G and 
ZNF423 
Birthweight, size 
and adiposity at 4 
years 
Methylation at ANK3, CDKN2B, IGDCC4, P4HA3, 
MIRLET7BHG, CACNA1G and ZNF423 were associated with 
birth weight. MIRLET7BHG was the only ‘nutrition-
sensitive’ loci considered in this review, however.  
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Reference Study design Genes Implicated  Phenotype 
investigated 
Summary of results 
Murphy R, et al. BMC Med 
Genet. 2014;15:67(23) 
Cohort study (Auckland Birthweight Collaborative (‘ABC’) 
study) following 153 children out of which 80 were SGA. Age 
11 years 
 
Tissue: whole blood  
Platform: Methylation-specific multiplex-ligation-dependent 
probe amplification assay and pyrosequencing. 
IGF2, H19, 
KCNQ10T1 
Size at birth  IGF2 DMR0 methylation was 2.7% lower in SGA children. 
Methylation did not vary at H19 and KCNQ10T1 ICRs.  
Paquette AG, et al. 
Epigenomics. 2015;7:767-79(24) 
Rhode Island Child Health Study ‘RICHS’ cohort . N=547 
infants. NICU Network Neurobehavioral Scales (NNNS) used 
for neurobehavior testing. 
 
Tissue: Placenta 
Platform: Pyromark MD (Qiagen) 
NR3C1, HSD11B2, 
FKBP5, ADCYAP1R1 
Neurobehaviour Using maximum likelihood factor analysis, 3 factors were 
identified as explaining the maximum variability in DNA 
methylation. NR3C1 loaded strongly onto a factor that was 
associated with decreased quality of movement and self-
regulation, increased arousal and excitability, and 
increased non-optimal refluxes and stress abstinence 
scores, also referred to as a ‘poorly regulated’ profile. 
HSD11B2 methylation loaded onto factor associated with 
reducing risk of being in the poorly regulated profile. 
Qian YY, et al. J Hum Nutr Diet. 
2016;29:643-51(25) 
Case-control study.  39 small-for-gestational age (SGA) 
infants and 49 appropriate-for-gestational-age (AGA) 
controls, China.  
 
Tissue: Umbilical cord blood  
Platform: EpiTYPER, Sequenom. 
MEST,H19 Size at birth Methylation in SGA children was higher (p<0.05) than 
controls at 3 sites in the H19 DMR. Six sites in the H19 
DMR had higher methylation in SGA compared to AGA, but 
only in only males born to mothers who supplemented in 
pregnancy with folic acid. 
Rijlaarsdam J, et al. J Child 
Psychol Psychiatry. 
2017;58:19-27(26) 
Nested cohort study (‘ALSPAC’ cohort). 164 youth with low 
conduct problems (CP) and early onset persistent (EOP) 
ADHD.  
 
Tissue: Cord blood, peripheral blood at age 7 
Platform: Illumina Infinium HumanMethylation450 BeadChip 
IGF2 ADHD In the case of EOP individuals, IGF2 methylation was 
positively associated with ADHD symptoms. 
Souren NY, et al., Obesity. 
2011;19:1519-22(27) 
Monozygotic (MZ) twins study. 16 BMI discordant MZ twin 
pairs recruited from the East Flanders Prospective Twin 
Survey (EFPTS), Belgium. Mean age 30.9 years. 
Tissue: Saliva  
Platform:  PCR amplification followed by a single-nucleotide 
primer extension reaction 
KvDMR1, H19, 
IGF2, GRB10, 
MEST, SNRPN, 
GNAS  
BMI Methylation differences of the studied imprinted genes in 
salivary DNA did not account for the discordance in BMI 
between twins in this cohort. 
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Reference Study design Genes Implicated  Phenotype 
investigated 
Summary of results 
St-Pierre J, et al. Epigenetics. 
2012;7:1125-32(28) 
Cohort study. 50 mother-infant pairs, French-Canadian 
origin, Canada.  
 
Tissue: Placenta 
Platform: Pyromark Q24 (Qiagen) 
IGF2, H19 Birthweight IGF2 DMR2 mean methylation on the fetal placental side 
was positively correlated with birthweight (Spearman rank 
correlation=0.44, p< 0.01), height (r=0.40, p< 0.01), head 
(r=0.32, p< 0.05) and thorax (r=0.32,p < 0.05) 
circumference. 31% variance in birth weight could be 
accounted for by IGF2/H19 genotype and epigenotype 
jointly. 
Steegers-Theunissen RP, et al. 
PLoS One. 2009;4: e784(29) 
Cross sectional study amongst controls for another study 
(‘HAVEN’). 120 mother-infant pairs, The Netherlands.  
 
Tissue: Infant blood taken at 17 months.  
Platform: Epityper, Sequenom 
IGF2 Birth weight IGF2 methylation was inversely associated with 
birthweight ( -1.7% methylation per SD birthweight; 
p=0.034).   
Tobi EW, et al. Epigenetics. 
2011;6:171-6(30) 
Cohort study (The Dutch Project on Preterm and Small for 
Gestational Age Infants (‘POPS’)). 38 small for gestational 
age (SGA) and 75 appropriate for gestational age (AGA) 
individuals studied.  
 
Tissue: Whole blood at age 19. Methylation analysis by 
Platform: Epityper, Sequenom. 
IGF2, GNASAS, 
INSIGF, LEP 
Size at birth  Methylation levels of IGF2 DMR0, GNASAS, INSIGF and LEP 
did not significantly vary between SGA and AGA individuals 
at 19 years of age.  
Wijnands KP, et al. Nutr Metab 
Cardiovasc Dis. 2015;25:608-
14(31) 
Cohort study. 120 healthy children at 17 months of age, 
Netherlands.  
 
Tissue: Whole blood   
Platform: EpiTyper, Sequenom. 
TNFɑ, LEP Lipid profile High-density lipoprotein-cholesterol levels in the children 
were inversely associated with TNFɑ methylation (-6.1%, p 
=0.058) and LEP (-3.4%, p=0.021)  
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Abbreviations: ADHD, attention-deficit/hyperactivity disorder; BMI, body mass index; CI, 
confidence interval; DMR, differentially methylated region; ICR, imprinting control region; 
LDL-c, low-density lipoprotein cholesterol; OR, odds ratio; SD, standard deviation; VMR, 
variably methylated region. 
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22 Epigenetics, Nutrition, 
and Infant Health
Philip T. James, Matt J. Silver, 
and Andrew M. Prentice
INTRODUCTION
The field of epigenetics is currently garnering a great deal of interest, exploring 
how our very molecular makeup in the form of modifications to the genome can be 
altered by factors as diverse as aging, disease, nutrition, stress, alcohol, and exposure 
to pollutants. Epigenetic changes have previously been implicated in the etiology of 
a variety of diseases [1], notably in the development of certain cancers [2], and inher-
ited growth disorder syndromes [3], but the exploration of epigenetics’ role in fetal 
programming is still in its infancy. This chapter focuses on how nutritional expo-
sures during pregnancy may affect the infant epigenome, and the impact that such 
modifications may have on the long-term health of the child. We start by describing 
some keys concepts in epigenetics and discuss windows of epigenetic plasticity in 
the context of the developmental origins of health and disease (DOHaD) hypoth-
esis. We then review some of the key mechanisms by which nutrition can affect the 
epigenome, with a particular focus on the role of one-carbon metabolism. We finish 
by outlining some of the child health outcomes that have been linked to epigenetic 
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dysregulation, and discuss possible next steps that need to be realized if insights 
into the basic science of epigenetics are to be translated into tangible public health 
benefits.
A BRIEF PRIMER ON EPIGENETICS
Epigenetic processes describe changes to the genome that can alter gene expression 
without changing the underlying DNA sequence [4]. These changes are mitotically 
heritable, and involve the interplay of DNA methylation, histone modifications, and 
RNA-based mechanisms (Figure 22.1). DNA methylation most commonly occurs 
at loci where a cytosine is found next to a guanine on a DNA strand along its linear 
sequence, hence termed cytosine-phosphate-guanine or CpG sites. It involves the 
covalent bonding of a methyl (CH3) group to the cytosine at the 5′ carbon position 
to form 5-methylcytosine. CpGs found in high densities are termed CpG islands. 
Roughly two-thirds of human genes contain CpG islands in their promoter regions, 
although repetitive elements in the genome can also contain many CpG sites [5]. 
CpGs are generally methylated in nonpromoter regions and unmethylated at pro-
moter regions. Methylation at CpG sites in promoters is usually associated with tran-
scriptional silencing, although not consistently [6]. Although methylation is the most 
studied chemical alteration to date, others modifications (e.g., hydroxymethylation) 
can occur at cytosine bases [7].
DNA methylation is catalyzed by DNA methyltransferases (DNMTs). Mammals 
have three types of DNMT. DNMT1 recognizes hemimethylated DNA; therefore, 
after DNA replication and cell division, it methylates the newly synthesized strand to 
DNA methylation
1
Cytosine DNA
methylation
RNA strand
RNA-based mechanisms
3
2
Histone code
Nucleosome
H2B
H2A H4
H3
H1
FIGURE 22.1 An overview of epigenetic mechanisms. (From Yan MS-C, Matouk CC, 
Marsden PA, J Appl Physiol 2010, 109:916–26.)
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maintain methylation patterns of the original template strand (maintenance methyla-
tion). DNMT3a and 3b appear to primarily methylate fully unmethylated CpG sites 
(de novo methylation) [7]. DNA methylation is important for a host of biological 
processes, including transcriptional silencing, X-chromosome inactivation, genomic 
imprinting, and the maintenance of cellular identity by enabling tissue-specific gene 
expression [8].
DNA is tightly woven around histone proteins, forming compact complexes of 
DNA and protein called nucleosomes. Nucleosomes, in turn, are packed together 
to form chromatin. Within the nucleosomes, the histone proteins are arranged in an 
eight-part formation, comprising two copies each of histones H2A, H2B, H3, and 
H4. Histone modifications involve various posttranslational chemical alterations to 
the amino acids of the histone tails, including acetylation of lysine, methylation of 
lysine and arginine, phosphorylation of serine and threonine, and the ubiquitination 
of lysine [9]. There are several mechanisms by which chemical modifications of 
CpG sites and histones are thought to influence gene expression. The methyl group 
from 5-methylcytosine may block transcription factors either directly or through the 
recruitment of a methyl-binding protein. Alternatively, the DNMT enzymes acting 
on CpG sites may be physically linked to other enzymes, which bring about histone 
methylation and deacetylation [10]. Although chromatin remodeling is intricately 
controlled, a simplified summary is that the hyperacetylation of histones and hypo-
methylation of histones and CpGs is associated with a euchromatin (open) configu-
ration, generally associated with facilitation of transcriptional activity. Conversely, 
hypoacetylation of histones and hypermethylation of histones and CpGs is associ-
ated with a heterochromatin (closed) structure and transcriptional repression [11].
Although noncoding RNAs do not code for proteins, many are functional and 
may affect gene expression [12]. Of those that influence gene expression, microRNAs 
(miRNAs) have been the most studied to date. These are short pieces (~22 nucleo-
tides) of RNA that affect the epigenome through binding to target mRNAs control-
ling the expression of key regulators such as DMNTs and histone deacetylases [13]. 
In turn, CpG methylation and histone modifications can influence the transcription 
of certain miRNA classes [14]. MicroRNAs may also affect gene expression directly 
by binding to messenger RNAs, repressing their translation [14].
TIME POINTS OF PLASTICITY IN THE EPIGENOME
Times of increased cell turnover, such as during fetal development and infancy, may 
be particularly susceptible both to epigenetic errors and to environmental influences 
[15]. In this chapter, we focus on DNA methylation and the in utero period, to include 
periconception, since this falls within the first 1,000 days window, and is also a 
period of exceptionally rapid cell differentiation and complex epigenetic remodeling 
(Figure 22.2). In the first 48 hours after fertilization, there is rapid (active) demeth-
ylation of the paternal genome and a slower (passive) demethylation of the mater-
nal genome [16]. Erasing the epigenetic marks in the zygote prior to the blastocyst 
stage is important to enable pluripotency of the developing cells [8]. Imprinted genes 
and some retrotransposons (defined later) are known to resist demethylation at this 
stage [17]. Remethylation then occurs in tissue-specific patterns after implantation, 
D
ow
nl
oa
de
d 
by
 [P
hil
ip 
Ja
me
s] 
at 
10
:11
 12
 O
cto
be
r 2
01
7 
338 The Biology of the First 1,000 Days
during the process of gastrulation and differentiation of the somatic cells through-
out pregnancy. A second wave of demethylation occurs during the epigenetic repro-
gramming of primordial germ cells (PGCs) in the developing embryo at the point of 
their migration to the genital ridge [18]. Parental imprints are erased at this stage in 
preparation for the laying down of sex-specific imprints in the PGCs. Remethylation 
of sperm cells occurs before the birth of the child, and in oocytes over the duration 
of their maturation [18]. The periconceptional period is therefore one of huge dyna-
mism in the methylome, representing a window in which epigenetic errors could 
have significant consequences for the health of the child.
Which Parts of the ePigenome are most suscePtible 
to environmental influences?
There are some regions of the genome that demonstrate increased interindividual 
epigenetic variation, and may be particularly vulnerable to the impact of environ-
mental influences [19]. These include imprinted genes, metastable epialleles, and 
transposable elements. Imprinted genes show monoallelic expression, whereby only 
the maternally or paternally inherited allele is expressed [20]. If a gene is “paternally 
expressed” it means the expressed allele comes from the father and the maternal 
allele is imprinted (silenced). In regard to growth, paternally expressed genes tend 
to promote in utero growth, whereas maternally expressed genes restrict growth, 
and this forms the basis of the “parental conflict theory” [21]. Metastable epial-
leles (MEs) are genomic loci whose methylation state varies between individuals, 
but where variation is correlated across tissues originating from all germ layers in a 
single individual [22]. This indicates that the marks have been laid down in the first 
few days after conception before cell types start to specialize. MEs therefore provide 
a useful device to study the influence of the periconceptional environment, including 
maternal nutrition, on the offspring epigenome [23,24]. Transposable elements (TEs) 
are small pieces of DNA (usually of viral origin earlier in human history) that are 
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FIGURE 22.2 Epigenetic remodeling in embryogenesis. (From Perera F, Herbstman J, 
Reprod Toxicol 2011, 31:363–73.)
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mobile and can insert into new chromosomal locations throughout the genome. They 
are thought to make up more than half of the human genome [25]. TEs arise either 
through the use of RNA as an intermediate for transposition (DNA is transcribed to 
RNA, reverse transcribed to DNA, and then inserted by reverse transcriptase to form 
a retrotransposon), or through the complete DNA sequence being cut and pasted 
directly (forming DNA transposons, which are less common in the human genome). 
TEs are potentially functionally disruptive, for example, if transposed into a func-
tional gene or when increasing copy number, and this may be one reason why most 
are silenced epigenetically [26]. Some TEs are thought to be vulnerable to the influ-
ence of nutrition at key time points [27], and their variable methylation patterns have 
been shown to affect neighboring gene expression, most notably in the Agouti mouse 
experiments detailed later in this chapter.
EPIGENETICS AND THE DEVELOPMENTAL 
ORIGINS OF HEALTH AND DISEASE
The DOHaD hypothesis describes the idea that environmental insults experienced 
early in life can increase the risk of adverse health outcomes throughout the life 
course. DOHaD grew out of David Barker’s seminal work following a cohort born in 
Hertfordshire between 1911 and 1930. His early studies found an inverse relationship 
between birth weight and blood pressure at age 10, with a stronger association at age 
36 [28]. His findings soon expanded to identifying associations between low birth 
weight and adult-onset chronic disease [29], patterns that were also seen in different 
cohorts such as the Nurses’ Health Study I & II [30] and in Helsinki [31].
Although low birth weight provides a useful proxy for an adverse intrauterine 
environment, subsequent studies have attempted to pinpoint time points of vulner-
ability more precisely. Data from famine studies have been particularly useful in this 
respect. The Dutch Hunger Winter occurred toward the end of World War II, when 
the Western Netherlands was under German control from November 1944 to May 
1945. Nazi blockades cut off food and fuel, and the siege was coupled with a harsh and 
early winter. Calorie intake varied from 500 to 1,000 kcal per day, depending on the 
area and time period. An estimated 4.5 million people were affected, 20,000 of whom 
died [32]. Exposure to famine during pregnancy has been associated with a wide 
range of offspring phenotypes, from lower birth weight [33] to increased adult blood 
pressure [34], obesity [35], and risk of schizophrenia [36]. Furthermore the specific 
timing of famine exposure in utero appears to have different programming effects. 
For example, exposure in midgestation is associated with a doubling of the prevalence 
of obesity for men aged 18 to 19, yet exposure in the third trimester is associated with 
lower obesity [35]. Many of these associations are also found from records spanning 
the Chinese Great Leap Forward, where famine was particularly severe from 1959 
to 1961. For example, famine exposure in utero is associated with a doubled risk of 
schizophrenia in later life [37], as well as increased hyperglycemia at age 41 to 42, a 
trend that is exacerbated if an affluent diet was consumed later in life [38].
Although these two famine studies provide rich epidemiological evidence that 
nutritional exposures in early life are associated with later disease risk, they are 
unable to determine precise causal factors, for example, if the effects are driven by 
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depleted maternal energy, deficient levels of certain micronutrients, or a combination 
of both. The Pune Maternal Nutrition Study (PMNS) in the Maharashtra State of 
West-Central India sheds some light on more specific nutritional exposures that may 
be relevant for DOHaD mechanisms. PMNS is a prospective cohort of 797 women, 
followed pre- and throughout pregnancy, and their offspring. Higher maternal intake 
of green leafy vegetables, milk, and fruit, and higher erythrocyte folate concentra-
tions, were associated with larger size babies [39]. Higher maternal folate status at 
28 weeks gestation predicted higher offspring adiposity and insulin resistance at the 
age of 6, low maternal vitamin B12 status was associated with offspring insulin resis-
tance, and a combination of high maternal folate and low B12 produced the strongest 
associations [40].
Attention is now shifting to an investigation of the mechanisms that may mediate the 
observations above. In this respect, epigenetic modifications to the genome are emerg-
ing as a leading candidate that may, at least partially, explain some of the observations 
described in the DOHaD literature. For example, Heijmans et al. selected 60 individu-
als conceived during the Dutch Hunger Winter, and compared them with nonexposed 
siblings. Five CpG sites within IGF2 (a maternally imprinted gene controlling fetal 
growth) were less methylated in individuals exposed to famine at periconception, but 
there was no difference in methylation for individuals exposed to famine in late gesta-
tion [41]. Indeed, the most recent study from the same group confirms that exposure to 
famine in the first 10 weeks of gestation shows a greater signature in the adult blood 
methylome (58–59 years) compared to exposure later in gestation [42]. Whilst the exact 
mechanisms are so far unknown, one concept being debated is the “thrifty epigenome” 
hypothesis. This proposes that early life insults mold an epigenetic signature to pro-
gram a phenotype that is “adapted” to the intrauterine environment, which may be prob-
lematic if the environment into which the child is born then changes [43]. Under this 
hypothesis, malnutrition in pregnancy could program “thrifty” epigenotypes, designed 
to reduce metabolic rate and store energy in an attempt to adapt to a nutritionally poor 
environment, but may subsequently trigger symptoms of metabolic disease if the envi-
ronment changes to one of relative nutritional abundance.
MATERNAL NUTRITION EXPOSURES AND THE INFANT EPIGENOME
There are a variety of factors, both nutrition-related and otherwise, which may impact 
the infant epigenome in utero through maternal exposure (Figure 22.3). Of these 
exposures, particular attention has been paid to the role of one-carbon metabolites in 
the periconceptional period and during embryonic development [44]. In the follow-
ing section, we give an overview of one-carbon metabolism, and discuss evidence 
for the influence of one-carbon metabolites on the infant epigenome. We also briefly 
review other maternal nutrition exposures that have generated research in a human 
intergenerational setting: maternal BMI, polyunsaturated fatty acids, and vitamin C.
one-carbon metabolism
The one-carbon pool is composed of one-carbon units and the two main carriers that 
activate, transport, and transfer these units: tetrahydrofolate (THF) and S-adenosyl 
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methionine (SAM). One-carbon units are used as substrates for a whole range of 
intricate biochemical processes, including cellular biosynthesis, redox status regula-
tion, and genome maintenance through the regulation of nucleotide pools. However, 
it is their role in transmethylation reactions that is central to the notion of diet-
epigenome interplay, and this requires an understanding of how folate, methionine, 
homocysteine, transsulfuration, and transmethylation metabolic pathways interact 
(Figure 22.4).
S-adenosyl methionine (SAM) methylates a wide variety of acceptors in reactions 
catalyzed by methyl transferases. Over 200 methylation reactions are required for 
transcription, translation, protein localization, and signaling purposes [45], but it is 
the methylation of cytosine bases and amino acids on histone tails that play a role in 
epigenetics. The donation of SAM’s methyl group forms S-adenosyl homocysteine 
(SAH), which is further hydrolyzed to homocysteine (Hcy), where it is maintained in 
an equilibrium state that thermodynamically favors SAH over Hcy [46]. A buildup 
of Hcy results in an increase in SAH, which in turn impedes methylation reactions 
since SAH competes with SAM for the active site on methyl transferase enzymes 
[47]. The SAM:SAH ratio is therefore often used as a proxy indicator of methyla-
tion potential [48]. In order to maintain favorable methylation conditions, Hcy has 
to be removed from the system. One way in which this can happen is by accepting a 
methyl group to form methionine, which can then in turn be condensed with ATP to 
form SAM and continue the cycle. Hcy can also be removed through its irreversible 
degradation to cystathionine and cysteine in the transsulfuration pathway requiring 
vitamin B6.
The methylation of Hcy to methionine uses two distinct pathways. The major 
pathway is the vitamin B12-dependent reaction involving folate metabolic pathways. 
A stepwise reduction of dietary folates and folic acid forms tetrahydrofolate (THF). 
Exercise
Age, genetics
One-carbon
metabolism
BMI
PUFAs
Macronutrient
ratio
Individual
micronutrients and 
phytochemicals
Stress
Medication
Toxins
Smoking
Radiation
Infection
Nutrition related
Nonnutrition related
FIGURE 22.3 Potential maternal factors impacting the fetal epigenome.
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The one-carbon units attach to the N5 or N10 position, or bridge the two. THF can be 
converted into N5,10-methylene-THF using a methyl group primarily from serine with 
vitamin B6 as a cofactor. N5,10-methylene-THF is either used in the thymidylate syn-
thase pathway for DNA synthesis and repair, interconverted to N5,10-methenyl-THF, 
N10-formyl-THF (used in purine synthesis) and formate (an important one-carbon 
donor) forms, or irreversibly reduced to N5-methyl tetrahydrofolate (methyl-THF) 
through the action of 5,10-methylene THF reductase (MTHFR) and vitamin B2 as a 
cofactor. It is methyl-THF that then provides the methyl group for the methylation of 
Hcy, and in the process regenerates THF. The alternative pathway for the methyla-
tion of Hcy, predominantly used in the liver and kidneys, uses the methyl group from 
betaine, a product formed through the oxidation of choline. This description and 
Figure 22.4 give a very simplified overview of the complex and interlinking meta-
bolic pathways involved, some of which occur with different enzymes in different 
cellular compartments [49]. However, this brief overview helps explain why deficien-
cies in the key methyl donors of choline, betaine, or folate, alongside deficiencies 
in vitamins B2, B6, and B12, which play essential coenzyme roles, may disrupt the 
metabolic pathways that are responsible for DNA methylation. Genetic variants in 
proteins coding for enzymes used in key one-carbon metabolic processes can also 
affect activity at critical nodes and alter the flow of metabolites [50].
studies investigating one-carbon metabolites and ePigenetics
Perhaps the most famous animal experiments demonstrating how epigenetic changes 
driven by maternal diet in pregnancy can dramatically alter phenotype in the off-
spring come from the agouti mouse. In one experiment, pregnant dams were fed a 
diet that varied in methyl donor content (folic acid, choline, betaine, and vitamin 
B12). Their isogenic pups showed variable methylation at an intracisternal A particle 
(IAP), a retrotransposon upstream of the agouti gene that is a metastable epiallele. 
The degree of methylation at this locus altered expression of the agouti gene, result-
ing in permanent phenotypic differences. The most obvious change was in fur color, 
but differences were also found in appetite, adiposity, and glucose tolerance, factors 
highly relevant to life-long chronic disease risk [19,27]. A similar experiment in a 
different strain of kinky-tailed mice showed that methyl donor content of the mater-
nal diet also altered methylation at an IAP on the Axin gene, producing pups with 
varying levels of tail kink [51].
Human studies exploring associations between individual one-carbon metabolites 
and epigenetic effects are few and far between, especially those involving an inter-
generational study design. Homocysteine and vitamin B6 are two examples that are 
described in human cross-sectional studies assessing immediate effects on health at 
one time point within a single generation. Hyperhomocysteinemia has been associated 
with hypomethylation in several studies [52] supporting the hypothesis that epigenetic 
mechanisms may play a partial role in observed associations between hyperhomocys-
teinemia and decreased cardiovascular health via inflammation, free radical forma-
tion, and atherogenesis [53]. Low vitamin B6 levels may decrease N5,10-methenyl-THF 
through reduced serine hydroxymethyltransferase (SHMT) activity (Figure 22.4), 
stressing the thymidylate synthase pathway for DNA repair and incorporating more 
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uracil into DNA. This reduces genome stability through increased chromosome breaks, 
which, in turn, have been associated with increased levels of global DNA hypomethyl-
ation alongside a putative increased risk of tumor development [54].
Of the human studies using an intergenerational design, folate, vitamin B12, and 
choline have been most frequently investigated. Due to its role in preventing neural 
tube defects and involvement in some cancer therapies, folic acid has been extensively 
reviewed [55]. Increased periconceptional folic acid consumption has been associated 
with increased methylation in infants at a differentially methylated region (DMR) of 
the IGF2 gene, although these associations have not been established consistently [56]. 
Additional studies have found that maternal folate levels in late pregnancy influence 
offspring methylation patterns in the imprinting control region of IGF2 [57] and also 
in the imprinting regulator ZFP57 [58]. Despite the timing of maternal folate mea-
surements, these findings support the importance of nutritional status around concep-
tion, since many DMRs appear to have their methylation pattern established prior to 
gastrulation [59]. There are fewer studies assessing the effect of maternal vitamin B12 
status on the infant epigenome. However, preliminary evidence suggests that mater-
nal vitamin B12 levels at first antenatal visit are inversely correlated with infant cord 
blood global methylation levels [60]. For choline, one intervention study investigated 
the effect of supplementing mothers in the third trimester with daily choline of 480 mg 
versus 930 mg [61]. Higher maternal choline intake was associated with increased 
methylation of CRH and NR3C1 promoter regions within fetal placental tissue.
The complex interlinking metabolic pathways involved in one-carbon metabo-
lism may be more appropriately investigated by exploring the joint effects of relevant 
methyl donors and coenzymes. Researchers in The Gambia have been exploring 
human diet–epigenome interactions by exploiting a natural experimental design, in 
which fluctuations in energy balance and maternal nutritional exposures display a 
distinct bimodal seasonal pattern. The Gambia experiences a rainy (“hungry”) sea-
son from July to September (Figure 22.5a), a planting season with increased energy 
expenditure, depleted food stores, and peaks of malarial and diarrheal diseases. 
The dry (“harvest”) season occurs from February to April (Figure 22.5b), when 
(a) (b)
FIGURE 22.5 The Gambian (a) rainy/“hungry” and (b) dry/harvest seasons in Keneba, 
West Kiang. (Photo by Andrew M. Prentice.)
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harvesting takes place, leading to improved food security. Despite overall house-
hold food stores being more replete in the dry season, the rainy season offers the 
increased availability of certain micronutrients made available from rain-fed green 
leafy vegetables. It has been known for several decades that Gambian children born 
during the rainy season are up to 10 times more likely to die prematurely in young 
adulthood than those born during the dry season [62]. However, the processes under-
lying these findings have yet to be fully delineated, and nutrition-related epigenetic 
regulation in early embryonic development is emerging as one plausible contributory 
mechanism. A recent study compared women conceiving in the peak of the dry and 
the peak of the rainy season [24]. Maternal periconceptional plasma concentrations 
of folate, vitamin B2, methionine, betaine, and the SAM:SAH and betaine:dimethyl 
glycine ratios were higher in the rainy season, and concentrations of vitamin B12, 
homocysteine, and SAH were lower. This suggested that the maternal metabolome 
during the rainy season contained higher concentrations of methyl donors and exhib-
ited a higher methylation potential than the dry season metabolome. Indeed, off-
spring of these rainy season conceptions had higher levels of CpG methylation at six 
MEs in peripheral blood monocytes compared to the offspring of those conceived in 
the dry season, with similar patterns in hair follicle DNA [24]. A subsequent study 
details the genome-wide search for MEs susceptible to the periconceptional environ-
ment using two independent approaches [63]. Both found VTRNA2-1 as their top hit, 
an imprinted gene that was also found to exhibit increased hypomethylation among 
Gambian offspring conceived in the dry season compared to the rainy season. Taken 
together, the results support the hypothesis that maternal nutrition during the peri-
conceptional period can impact the infant epigenome in humans and has triggered 
further research into the possible phenotypic consequences.
Polyunsaturated fatty acids
Several studies indicate that increased consumption of ω-3 PUFAs is associated with 
reduced homocysteine levels [64]. In the context of early life nutrition, maternal fatty 
acid intake influences infant fatty acid composition via placental transfer and breast 
milk, with maternal PUFA intake potentially affecting infant appetite control, neuroen-
docrine function, and metabolic programming [65]. Investigating whether one-carbon 
pathways and epigenetic mechanisms are involved is of increasing interest. In rodent 
models, providing a maternal diet with excess folic acid and restricted vitamin B12 
(designed to reflect the nutritional situation in much of rural India) is associated with 
increased maternal oxidative stress, lower level of offspring placental and brain doco-
sahexaenoic acid, and decreased placental global methylation [66]. However, maternal 
supplementation with PUFAs seems to partially ameliorate the disrupted one-carbon 
metabolism associated with this diet [67]. One potential mechanism is through PUFAs 
upregulating enzymes responsible for the methylation of homocysteine to methionine 
[68], which in theory could increase the SAM:SAH ratio and help overcome the impact 
of reduced MTHFR activity brought about by the restricted vitamin B12. An additional 
recent hypothesis describes how a decreased maternal PUFA intake may increase the 
availability of methyl groups for DNA methylation since there would be reduced PUFAs 
for phosphatidylcholine synthesis and therefore less demand for methyl groups for this 
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pathway. The disruption to the one-carbon pathways brought about by low PUFA lev-
els is thought to alter epigenetic programming of placental genes, increasing the risk of 
aberrant methylation in offspring and adverse pregnancy outcome [69]. Human evidence 
at the intergenerational level, however, is currently limited to a study by Lee et al. [70]. 
Here, mothers were given either 400 mg of ω-3 PUFA (n = 131) or placebo (n = 130) 
daily from approximately 18 weeks gestation to birth. Among mothers supplemented 
with PUFAs, there was increased global methylation (measured at LINE-1 repetitive ele-
ments) in offspring of mothers who smoked (n = 26 case, 26 control) [71], and increased 
offspring IGF2 promoter 3 methylation in preterm infants (n = 16 case, 20 control) [70].
body mass index
Maternal body mass index (BMI) shows some association with infant epigenetic pat-
terns [72]. However, it can be difficult to define exactly what BMI represents as an 
exposure, since it does not always correlate well with body composition [73] and is a 
proxy for a wide range of potential metabolic disorders [74]. In an intergenerational 
setting, both maternal underweight and overweight is associated with epigenetic pat-
terns in infant cord blood [72]. The mechanism by which BMI influences epigenetics 
is so far unknown. Although SAM has been shown to be independently, positively 
associated with fat mass in older adults, alongside a higher rate of converting methio-
nine into SAM in obese individuals, the absence of a rise in the SAM:SAH ratio 
means conclusions are hard to draw [75]. Paternal BMI may also be a relevant expo-
sure to consider, since neonates born to obese fathers in a U.S. study showed hypo-
methylation at some loci within imprinted genes (MEST, PEG3, NNAT), independent 
of maternal obesity [76].
vitamin c and demethylation
As outlined earlier, the periconceptional period is a time of widespread remodel-
ing of the offspring epigenome, including rapid erasure (demethylation) of paren-
tal epigenetic marks and subsequent remethylation (Figure 22.2). In demethylation, 
5-methylcytosine (5mC) can be sequentially oxidized to different states by ten-
eleven translocation (TET) dioxygenases that use vitamin C (ascorbate) as a cofac-
tor [77]. In vitro studies, for example, indicate that adding vitamin C to mouse or 
human embryonic stem cells increases activity of TET enzymes, with active demeth-
ylation seen in the germline and associated gene expression changes [78]. Vitamin C is 
therefore  an  important factor to consider in epigenetic processes during early 
embryogenesis, although in vivo studies will be required to explore whether vitamin C 
deficiency could play a role in aberrant demethylation.
In this section we have identified some of the key ways that maternal nutrition 
might influence the offspring epigenome. Other exposures, both nutrition-related 
and otherwise, may also be involved. These include maternal stress [79], toxin expo-
sure [80], maternal hyperglycemia [81], the microbiome [82], dietary polyphenols 
[83], vitamin D [84], vitamin A [85], and infection [86]. As evidence builds, it will 
be necessary to explore how these multiple exposures work together to influence the 
D
ow
nl
oa
de
d 
by
 [P
hil
ip 
Ja
me
s] 
at 
10
:11
 12
 O
cto
be
r 2
01
7 
347Epigenetics, Nutrition, and Infant Health
infant epigenome and to more clearly define the potential consequences for human 
health. It is to the latter point that we now turn.
PHENOTYPES ASSOCIATED WITH THE IMPACT OF MATERNAL 
EXPOSURES ON THE INFANT EPIGENOME
Most population-based epigenetic studies to date have been limited to exploring 
either associations between maternal exposures and infant epigenetic patterns, or 
between infant epigenetic patterns and later phenotypes. Evidence linking maternal 
exposure to infant phenotypes with epigenetics as a mediating mechanism is scarce.
The first category of associations, linking maternal exposures to infant epigen-
etic patterns, was reviewed earlier. A number of studies linking infant epigenetic 
patterns with later phenotypes have focused on imprinted genes as candidate loci, 
due to their role in fetal growth [17] and a range of diseases [3,20]. It has been sug-
gested that imprinted genes may be more vulnerable to the effects of epigenetic 
dysregulation, since epigenetic mechanisms underpin their monoallelic expression. 
On chromosome region 11p15.5 there are two imprinting control regions (ICRs) of 
interest: the H19/IGF2 domain (ICR1) and the KCNQ1/CDKN1C domain (ICR2). 
Hypomethylation of ICR1 and hypermethylation of ICR2 are associated with 
Russell-Silver syndrome (RSS; an undergrowth disorder), whereas hypermethylation 
of ICR1 and hypomethylation of ICR2 are associated with Beckwith-Wiedemann 
syndrome (BWS; an overgrowth disorder) [3]. In addition to the aberrant methylation 
found at ICR1 and ICR2, some studies suggest patients with RSS and BWS show 
methylation defects at multiple gene loci [87]. Evidence for associations between 
growth-related phenotypes (other than RSS and BWS) and methylation patterns at 
several imprinted gene loci is slowly accumulating. Other phenotypes investigated to 
date include intrauterine growth restriction [88], small for gestational age [89], birth 
weight [90] and later adiposity [91].
Several studies describe associations between maternal one-carbon metabolites 
and infant growth-related outcomes, for example, vitamin B12 [92], folate [93], and 
homocysteine [94]. What then is the evidence that these associations are mediated 
through epigenetic mechanisms? Preliminary evidence from the Dutch Hunger 
Winter, as described earlier, suggests that exposure to famine in pregnancy, particu-
larly around conception, is associated with differential methylation in genes linked to 
growth, and development [41], and that famine exposure is also related to a wide range 
of offspring cognitive health and cardiometabolic risk factors six decades later [95]. 
It is, however, difficult to establish the direction of causality, since disease states can 
also influence the epigenome [96]. This issue of reverse causality is particularly per-
tinent to studies using a retrospective cohort design. Stronger evidence comes from 
prospective cohorts, such as the Newborn Epigenetics Study (NEST) in the United 
States. Hoyo et al. describe a positive association between maternal folate levels in 
the first trimester and birth weight [90]. Increased maternal folate was also associated 
with increased methylation at MEG3, PLAGL1, and PEG3 in infant cord blood, and 
decreased methylation at IGF2. Five differentially methylated sites were associated 
with birth weight, and it was speculated that the association seen between maternal 
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folate and birth weight could be mediated by differential methylation at MEG3, H19, 
and PLAGL1. In a more recent study from the same cohort, McCullough et al. found 
maternal plasma concentrations of homocysteine in the first trimester were inversely 
associated with birth weight, particularly in males [97]. Children born to mothers 
with the highest quartile of plasma B12 showed lower weight gain between birth and 
3 years. However, only maternal vitamin B6 was positively associated with cord meth-
ylation at a DMR from MEG3. A further example comes from Godfrey et al., who 
found that higher methylation of RXRA and eNOS in umbilical cord tissue was asso-
ciated with offspring adiposity at age 9, and that higher RXRA methylation was also 
associated with lower maternal carbohydrate intake in early pregnancy [91].
Given the scarcity of existing data and the many potential confounders in cohort 
studies, there is not yet any clear consensus on the extent to which epigenetics is 
involved in the etiology of suboptimal growth, particularly in the more widely inves-
tigated phenotypes of IUGR and SGA [98]. Similarly, although prepregnancy folic 
acid supplementation is known to prevent neural tube defects, the extent to which 
this protection is epigenetically mediated is not yet clear [56]. In the next few years, a 
number of prospective cohort studies should shed further light on the links between 
early life exposures and phenotypes, mediated by epigenetic mechanisms. In the 
meantime, we can use the literature from the range of studies described earlier to 
speculate that periconceptional nutritional insults may influence epigenetic mecha-
nisms in the infant, causing disruption at multiple loci and potentially leading to a 
broad spectrum of phenotypic consequences in later life.
NEXT STEPS
The field of epigenetic epidemiology is in its infancy. Future challenges include the 
need to consider a much larger number of candidate genetic regions (a challenge that 
will be met as rapid improvements in technology facilitate epigenome-wide associa-
tion studies with ever increasing genomic resolution); the need to focus on tissue 
types most appropriate to the phenotype of interest; and the need to integrate data 
on genetic variation, gene expression, and other epigenetic mechanisms such as his-
tone modifications and miRNAs. Investigations will also need to assess the extent 
to which postnatal exposures may interact with periconceptional effects. Finally, 
although we focus on the maternal periconceptional environment in this chapter, 
there is growing interest in the potential for paternal exposures to affect the infant 
epigenome transgenerationally via sperm methylation profiles [99]. Despite limited 
human evidence to date, this is an area of great potential public heath relevance.
Once disrupted epigenetic patterns can be better mapped onto phenotypes, the signifi-
cance for public health impact becomes more tangible. Can we design and test nutritional 
interventions to “correct” a suboptimal maternal metabolome, hence reducing patterns 
of aberrant methylation in the infant epigenome and reducing the burden of ill health? 
Despite the current complexities of disentangling the web of multiple exposures influenc-
ing the infant epigenome, as technology advances, collaborations grow, and knowledge 
is gained, the field of nutritional epigenetics has the potential to impact the health of 
children not only within the first 1,000 days but also across multiple generations.
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Imagine yourself at the scene of a crime where you need to de-
termine the age of a victim or perpetrator. If you are lucky, you 
will have access to skin or dental tissue, or perhaps anthropo-
metry measures, all of which may help determine an approxi-
mate age. However, recent research suggests that you could in-
stead obtain an astonishingly accurate measure of chronological 
age with an “epigenetic clock” that uses a very small number of 
epigenetic marks in the genome.1 This would allow you to pin 
down a sample's age to within a few months, irrespective of the 
tissue from which it was obtained.
 The field of epigenetics is currently attracting a lot of atten-
tion from scientists and the wider public. Epigenetic processes 
describe changes to the genome that can alter gene expression 
without changing the underlying DNA sequence2 (Figure 1). One 
such mechanism is DNA methylation of cytosine bases at CpG 
dinucleotide sites, and there is strong evidence that this can 
be influenced by a diverse array of intrinsic and environmental 
factors, including age, disease, stress, exposure to pollutants, 
and nutrition. Furthermore, epigenetic marks have been associ-
ated with a range of diseases affecting health throughout the 
life course, including cancers, and neurological and metabolic 
disorders.3 Together, these observations suggest that our epi- 
genomes carry a “cellular memory” of environmental insults, 
with the potential for lasting effects on health and disease. Epi-
genetic changes at certain locations are also believed to be her-
itable, raising the possibility of trans-generational effects that 
cannot be explained by standard Mendelian genetics.4 
Diet and epigenetics in The Gambia
Our group is exploring human diet-epigenome interactions by 
exploiting an “experiment of nature” in rural Gambia whereby 
Epigenetics, Nutrition  
and Human Health
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figure 1: Epigenetic mechanisms of DNA modification. Reproduced with permission from Yan MS-C, Matouk CC, Marsden PA.5
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fluctuations in energy balance and maternal nutrition show a dis-
tinct bimodal seasonal pattern (Figure 2). Our study population 
experiences a rainy (“hungry”) season from July to September, 
with increased energy expenditure through agricultural work, de-
pleted food stores, and peaks of malarial and diarrheal diseases. 
The dry (“harvest”) season occurs from February to April, when 
harvesting takes place, leading to improved food security. 
“ Epigenomes carry a ‘cellular memory’ 
of environmental insults, with the 
potential for lasting effects on health 
and disease”
 
 Almost 20 years ago, we uncovered strong evidence that the 
season when a child is born has a profound effect on lifelong 
health. Gambian children born during the rainy season are up 
to 10 times more likely to die prematurely in young adulthood.6 
Since then, pieces of the puzzle are starting to fall into place, 
with nutrition-related epigenetic regulation in the early embryo 
emerging as a highly plausible candidate mechanism. 
 Five years ago, in partnership with Rob Waterland at Baylor 
College of Medicine in Houston, we demonstrated that season 
of conception predicts DNA methylation at certain genomic 
loci known as metastable epialleles (MEs). These are CpG sites 
whose methylation state varies between individuals, but where 
variation is correlated across tissues originating from all germ 
layers in a single individual7 – indicating that the marks must 
have been laid down in the first few hours after conception be-
fore cell types start to specialize. This period in the very early 
embryo is when the methylome is globally reprogrammed – a pe-
riod crucial to development.8 We therefore use MEs as a device 
to study the influence of a mother’s nutrition on the epigenome 
of the baby at the time of conception.
“ We use metastable epialleles as  
a device to study the influence  
of a mother’s nutrition on the  
epigenome of the baby at the time  
of conception”
 We have since shown that a mother’s levels of several key nu-
trients vary by season and predict DNA methylation at six MEs in 
their offspring.9 These nutrients play a role in 1-carbon metabo-
lism, a biological pathway crucial for the provision of methyl 
(CH3) groups required for DNA methylation (Figure 3). The two 
main carriers that activate, transport and transfer these methyl 
groups are tetrahydrofolate (THF) and S-adenosylmethionine 
(SAM). While 1-carbon units are used as substrates for a whole 
range of intricate biochemical processes (including cellular 
biosynthesis, redox status regulation and genome maintenance 
through the regulation of nucleotide pools), it is their role in 
cytosine and histone methylation that is central to the interplay 
between diet and the epigenome. 
Linking diet, epigenetics and health
Our latest research has identified another ME that is sensitive to 
the periconceptional environment in Gambian infants.11 The as-
sociated gene has been implicated in the regulation of immune 
function and is a putative tumor suppressor, suggesting a potential 
epigenetic pathway linking a nutritional insult affecting the very 
early embryo to some serious outcomes in later life. This requires 
rigorous testing, but work in animal models has already demon-
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figure 2: Keneba in the rainy and dry seasons
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strated that maternal diet can influence the offspring epigenome, 
with subsequent dramatic effects on phenotype. In the case of the 
Agouti mouse, pregnant dams fed a diet rich in methyl donor mi-
cronutrients (vitamin B12, folic acid, betaine and choline) produced 
offspring with increased methylation at the agouti locus, leading to 
fewer obese yellow offspring and more lean brown offspring (Fig-
ure 4) – characteristics that persisted into adult life, with associ-
ated differences in appetite, adiposity and glucose tolerance.12,13
Implications for the future
Our Gambian studies offer the first-in-human evidence that peri-
conceptional nutrition can affect the epigenome of the fetus. Just 
as the epigenetic clock shows that our genome carries an epige-
netic signature of the ageing process, it seems that it also bears 
the hallmark of nutritional exposures at the very start of life. 
“ Our Gambian studies offer  
the first-in-human evidence that  
periconceptional nutrition can affect 
the epigenome of the fetus”
 The next task is to characterize more clearly how this af-
fects phenotype. To what extent does disrupted methylation 
affect gene expression? How might these effects influence life-
long risk of morbidity and mortality? Most importantly, from a 
translational perspective, can epigenetic errors be corrected by 
optimizing the maternal metabolome through periconceptional 
nutritional supplementation? 
 The best known periconceptional nutrition supplement to 
prevent neural tube defects is folic acid. While the mechanism in 
this particular example has not yet been conclusively described, 
epigenetics is a strong contender. Given current research, we 
believe it is possible to speculate that other forms of pericon-
ceptional supplementation might positively influence the epige-
nome of the unborn child, leading to lifelong health gains across 
a whole variety of phenotypes. 
 Clearly the process of validating key findings, further delin-
eating the mechanisms involved, and translating the science 
into practical public health policy requires a large collaborative 
effort, along with advances in technology and access to funding. 
While it is not possible to predict the precise direction research 
will take in this rapidly evolving field, it seems likely that nutri-
tional considerations will remain paramount in the development 
of epigenetic therapies to improve health over the life course. 
BHMT, betaine-homocysteine methyltransferase; B2, vitamin B2; B6, vitamin B6; B12, vitamin B12; CBS, cystathionine-β-synthase; CHDH,  
choline dehydrogenase; CTGL, cystathionine-γ-lyase; DMG, dimethylglycine; DNMT, DNA methyltransferases; GNMT, glycine N-methyltransferase;  
MAT, methionine adenosyltransferase; MTHFR, methylenetetrahydrofolate reductase; MS, methionine synthase; SAH, S-adenosylhomocysteine;  
SAHH, S-adenosylhomocysteine hydrolase; SAM, S-adenosylmethionine
figure 3: An overview of 1-carbon metabolism. Reproduced with permission from Dominguez-Salas P, Moore SE, Cole D et al.10
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ANNEX 4.1  Original methods overview and analysis plan of modelling 
Gambian maternal nutritional plasma concentration data using a 
constraint-based platform (RECON-III) 
 
The below provides information of the planned collaboration with Luxembourg Centre for 
Systems Biomedicine (discontinued as the model one-carbon pathways required some more 
development). Note that the model referred to in the text below, RECON-III, has since been 
made public and is termed Recon3D. Full details can be found in Brunk et al. (2018)(1). 
 
1. Introduction to constraint-based modelling 
1.1 Overview  
 
Systems biology is an integrative discipline that analyses complex datasets to help generate 
hypotheses which can be experimentally validated and used to improve computer modelling 
in an iterative fashion. It uses in silico analysis of reconstructed networks and ‘omics’ 
datasets. We will use Recon-III (Figure 1), the most comprehensive genome-wide 
reconstruction of human metabolism to date, representing over 80,000 reactions in more 
than 20 organs / cellular compartments.  
 
 
 
 
 
Figure 1: The Recon generation of metabolic modelling. Source: Aurich MK, Thiele I. Methods 
Mol Biol. 2016; 1386: 253–81(2). Reproduced with permission. 
 
The planned modelling approach uses flux balance analysis (FBA), a method within 
constraint-based modelling. Fundamental principles of this approach are outlined below.  
The planned analysis will generate a nuanced understanding of how the overall flow of 
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metabolites through 1C pathways varies across the year and help us predict how a potential 
nutritional supplement may impact the metabolome.  
 
1.2  Constraint-based modelling 
 
Constraint-based modelling approach uses stoichiometry and resulting mass balance 
equations to generate a map of the flux of metabolites through a network of reactions.  
Key concepts: 
 
 The law of mass conservation states that in an isolated system mass cannot be 
created or destroyed by reactions. 
 Stoichiometric coefficients in an equation represent the proportion of substrates 
and products involved in that reaction. They constrain mass balance to ensure the 
total amount of any compound being produced equals the total amount being 
consumed in a steady state. 
  ‘Flux’ can be defined as the rate that metabolites are consumed and produced in a 
metabolic pathway, regulated by enzymes. Each reaction is linked to a gene product 
via ‘gene-reaction-protein associations’, with Boolean rules determining whether 
multiple enzymes are required for a reaction (‘AND’) or whether the reaction can be 
catalysed by isozymes (‘OR’).  
 Since metabolic reactions are so fast in comparison to the timescale of cell growth 
or gene regulation a steady state assumption is adopted. 
Because FBA models metabolism in a steady state it is different from models requiring 
enzymatic kinetic data, which are difficult to obtain in vivo at the population level. The 
models using kinetic data involve series of differential equations which would be time-
consuming (if not impossible) to solve in the context of genome-wide metabolic 
reconstructions.  
 
Creating a stoichiometric matrix is a central step in flux balance analysis, notated as Matrix 
S (m metabolites x n reactions). Figure 2 below illustrates how a stoichiometric matrix is built 
up from information on metabolic reactions. Part a) represents the first few steps of 
glycolysis. Part b) shows how this can be portrayed in stoichiometric matrix form (matrix S). 
Each metabolite is given a row, and each reaction a column. If a metabolite participates in a 
reaction its stoichiometric coefficients are entered: negative coefficients if consumed and 
positive coefficients if produced. If one metabolite is present in different cellular 
compartments then each compartment is also given a separate row. Each reaction is given 
an upper and lower bound to limit flux rates and determine if the reaction is reversible or 
not (part c). As many reactions as possible are bounded to experimental data, to constrain 
the model to the most realistic context.  
The stoichiometric matrix can then be used to form flux balance equations using two vectors: 
Vector V detailing the flux of each metabolite through all its reactions (length n), and vector 
X with the concentration of metabolites (length m). The equations are arranged so that the 
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overall change in concentration of a metabolite per unit time is determined by calculating its 
net production or consumption (from matrix S) and associated flux (rate from vector V) for 
each reaction it participates in. Matrix algebra can be used to show that the change in 
concentration of metabolites over time (vector X) can be calculated by the dot product of 
matrix S with vector V (Figure 3). 
 
d[X] = S•V 
dt 
 
In a steady state dX/dt=0, so in a steady state model S•V = 0 
 
 
 
 
Figure 2: Creating a stoichiometric matrix. Adapted from Becker SA et al. Nat Protoc. 2007;2: 
727–38(3). Reproduced with permission. 
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Figure 3: Change in metabolite concentration as the dot product of matrix S with vector V. 
Adapted from Becker SA et al. Nat Protoc. 2007;2: 727–38(3). Reproduced with permission. 
 
We can therefore rearrange our mass balance equations so that S•V =0 and form a system 
of linear equations (Figure 4). These linear equations impose constraints on the flow of 
metabolites through the network. Note that in some models the equations also subtract a 
term describing the dilution of the metabolite due to biomass growth, but this is often 
ignored as it is usually very small.  
 
 
 
Figure 4: The creation of mass balance equations in a steady state 
Adapted from Becker SA et al. Nat Protoc. 2007;2: 727–38(3). Reproduced with permission. 
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Under a given set of constraints (stoichiometry and bounds) we can define the allowable flux 
distribution of the system. We then define our objective function (our ‘problem’ to 
investigate) e.g. maximise production of a certain metabolite. A collection of functions used 
within Matlab helps us solve the equations to predict our objective function. This produces 
a vector of weights describing how much each reaction contributes towards the objective. In 
complex metabolic models our system is under-determined, meaning we have more 
reactions than compounds (n>m), so there is (usually) never one unique solution. We 
therefore use linear programming to then identify the flux distribution that maximises or 
minimises the objective function within the allowable flux distribution space (Figure 5).  
 
Once we have solved the equations to achieve our objective function we can explore the 
solution space in more detail: 
 
 Flux variability analysis allows us to ascertain the minimum and maximum flux 
through each reaction that still helps us achieve our objective function under the 
given constraints. 
 Sampling analysis: this captures the solution space in higher resolution. Within the 
solution space generated under specific constraints random samples of flux 
distributions are taken, generating a histogram of flux distributions. The extremes of 
these histograms are what flux variability analysis (above) calculates.   
 
 
 
Figure 5:  Using linear programming to predict equations meeting the objective function. 
Adapted from Orth JD, et al. Nat Biotechnol. 2010;28: 245–8(4). Reproduced with permission. 
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2. Preparatory work 
2.1 Dietary input file 
 
RECON-III models nutrients available for absorption in the intestine. The nutrients are not 
forced to be taken up, but the model can decide what is required to achieve a specific 
objective function. The dietary input is a vector with a set of exchange reactions. Exchange 
reactions describe how a metabolite enters or exits a cell / compartment. In this case the 
exchange reactions allow the metabolites to move from the intestine model compartment 
to the portal vein compartment if required. We have already created a ‘Gambia diet’ based 
on foods known to be available from Gambian food tables. We restricted the calorie intake 
to 1830 kcal / day and corrected the intakes to represent the realistic macronutrients ratios 
found in the region (high carbohydrate intakes). We set intakes of 1-carbon related dietary 
inputs to those recorded in recent food intake calculations from Dominguez-Salas et al. 
(2013)(5).  
 
We decided to use a single diet based on mean annual dietary intakes rather than vary the 
diet by season. This is because for now we are more confident in the plasma concentration 
data as the more direct measures of nutritional status. We know that dietary intakes do not 
map onto plasma concentrations in simple ways, there are large measurement errors, and 
we also know the model has to simplify reality and does not model bioavailability, absorption 
rates, nutrient-nutrient interactions etc. Therefore at the outset we would prefer to see 
changes in flux by season / month based purely on plasma concentration data, rather than a 
combination of plasma with dietary input changes. We could manipulate the diet by season 
in later analysis to see the impact, but as a secondary objective.  
 
Ideally we need to add three additional metabolites as exchange reactions for the dietary 
exchange vector.  
 
 Methylcobalamin (VMH ID: C06453) 
 Betaine (VMH ID: glyb) 
 Choline (VMH ID: chol) 
All other metabolites are captured in the Virtual Metabolic Human (VMH) database1. 
Although these three metabolites are currently missing in the VMH dietary flux calculation, 
we can manually calculate them since we have data on intakes per day. We can convert these 
data into mmol/(human*day) using molecular mass information. 
 
The flux for methylcobalamin can be calculated by taking the overall vitamin B12 intake and 
splitting it between methylcobalamin and adenosylcobalamin. So far VMH only calculates 
exchange reactions for adenosylcobalamin (adocbl).  
 
 
                                                          
1 VMH is the Luxembourg university metabolic database which RECON-III draws from.  
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2.2 Plasma concentration file 
 
As the default the plasma nutrient metabolites represented in RECON-III will be constrained 
to average European concentrations. However, we will over-ride concentrations for the 
metabolites we have plasma concentration data on, inputting that laboratory plasma 
concentration data in micromole/L. All plasma concentration data will be forced into the 
model as constraints on uptake from the blood compartment. B12 and folate, however, 
involve an additional manipulation step: 
 
 Most B12 circulating in plasma is methylcobalamin(6), so we will map this onto 
C06453 (not onto adenosylcobalamin).  
 ‘Folate’ in plasma is a measure of total folate. However, we need to split this into the 
specific forms of folate in order for these to influence their specific biochemical 
pathways in the model. We therefore need to research the split between 10-fthf, thf 
and 5mthf and reflect this in the concentration input file.  
 
2.3 Imputation of flux values for reactions with nutritional cofactors 
 
The plasma metabolites acting as co-factors will not influence the flux distributions since 
they remain unchanged in the reactions. Fluxes can only be potentially altered if the plasma 
metabolites are substrates or products in a reaction. Attempting to model the co-factors in 
half equations would not change the flux distributions as they would simply cancel out. These 
co-factors relate to: 
 
o Vitamin B6 via pyridoxal 5’phosphate. This is a co-factor in GHMT (EC 
2.1.2.1), in CYSTS (EC 4.2.1.22) and in CYSTGL (EC 4.4.1.1). 
o Vitamin B12 via methylcobalamin. This is a co-factor for METS (EC 2.1.1.13).  
o Vitamin B2 via FMN and FAD. FAD is a co-factor for MTHFR (EC 1.5.1.20).  
Since these co-factors are a potentially key focus of interest we need to manually impute the 
fluxes based on the co-factor plasma concentration data.  
 
o Firstly using the overall population data determine the maximum and 
minimum flux of the reactions in question. We scale the range from 0-100%.  
o We then obtain the minimum and maximum concentration of the relevant 
co-factor metabolites and scale that range from 0-100%.  
o We finally impute the adjusted fluxes of the reactions based on the co-factor 
plasma concentration scale.  
 
2.4  Deciding how to measure methylation potential  
 
Currently the DNA methyltransferase reactions are not incorporated in the model. We might 
therefore choose to look at a variety of other reactions that use the SAM -> SAH (adomet -> 
ahcys) pathway and report the mean flux through these reactions as a proxy for ‘methylation 
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potential’. A caveat is that there is no guarantee an increased flux through other SAM -> SAH 
reactions would mirror an increase in the DNMT reaction. Indeed, it could be argued that 
more methyl groups being used for other transmethylation reactions could reduce the 
amount available for DNA methylation (indeed, that is the reason for some trials 
supplementing with choline and creatine – to have a methyl group sparing effect). Having an 
average flux from several transmethylation reactions might help at least talk of methylation 
potential broadly, and it might be the best we can do for now.   
 
2.5 Deciding the organ to isolate for detailed modeling work 
 
Many of the modelling tools will work best if we isolate one organ to explore. The overall 
model is simply too large for many of the techniques (detailed in section 3). We suggest 
choosing an organ a priori. The liver is our primary suggestion as: 
 
a) This is the organ that processes the nutrients contained in the plasma, coming from 
the intestine, before circulating onto other organs in the body. 
b) We know that BHMT is predominantly expressed in the liver, and to a much lesser 
extent in the kidney. This reaction uses a methyl group from betaine to methylate 
homocysteine. Betaine can also be formed through the oxidation of choline. 
Therefore choosing the liver means our choline and betaine data can be modelled 
more directly.  
 
2.6 Deciding key reactions of interest 
 
The main reactions of interest have been selected a priori based on them a) being core 
reactions to 1-carbon metabolism or b) involving more distal metabolites that we think could 
influence 1-carbon metabolism (Table 1). These are selected for each organ / compartment 
they are found in and number ~350 of the total 80,000 reactions present in RECON-III.  
 
Table 1: Key 1-carbon pathways chosen a priori for analysis 
 
Reaction in 
Recon-III  
Enzyme name 
Reaction  
(EC number) 
Nutrition-related hypothesis 
MTHFR3 
Methylenetetrahydrofolate 
Reductase 
1.5.1.20 Increased B2 increased flux 
METS Methionine synthase  2.1.1.13 Increased B12 increased flux 
METAT Methionine Adenosyltransferase 2.5.1.6 Increased methionine increased flux 
AHC Adenosylhomocysteinase 3.3.1.1 
Increased SAH increased flux and 
decreased flux of 2.1.1.37 
DHFR Dihydrofolate Reductase 1.5.1.3   Increased folate increase  flux 
GHMT2 Serine hydroxymethyltransferase, 2.1.2.1 Increased B6 increased flux 
BHMT 
Betaine Homocysteine 
Methyltransferase 
2.1.1.5 Increased choline & betaine increased flux 
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Reaction in 
Recon-III  
Enzyme name 
Reaction  
(EC number) 
Nutrition-related hypothesis 
CYSTS Cystathionine-Beta-Synthase 4.2.1.22 Increased B6 increased flux 
MTHFD / 
MTHFD2 
Methylenetetrahydrofolate 
Dehydrogenase 
1.5.1.5 
Decreased B2 increased flux? Increased B6 
increased flux? 
ADMDC Adenosylmethionine decarboxylase 4.1.1.50 
Increased flux here decreases flux of 
2.1.1.37? 
TMDS Thymidylate synthase 2.1.1.45 Decreased B6 decreases flux? 
PETOH 
Phosphatidylethanolamine N-
methyltransferase 
2.1.1.17 
PUFA intake increases flux? Decreases in 
turn flux of 2.1.1.37? 
CHOL Choline dehydrogenase 1.1.99.1 Increased choline increased flux? 
BETALD 
α-aminoadipic semialdehyde 
dehydrogenase  
1.2.1.8 Increased choline increased flux? 
Trans-
methylation 
Various Various 
Increased SAM:SAH ratio increased flux  
 
 
 
2.7  Decide what the objective function should be 
 
 The model is designed to enable maintenance of all essential physiological 
processes, and if a baby biomass component is added, to supply the needs of the 
growing baby.  
 If we change the objective to optimise the flux of one particular pathway, e.g. a SAM-
>SAH pathway, we risk obtaining an unrealistic solution. The model would simply try 
to solve the equation to maximise that flux, and then ignore the other pathways 
needing to be maintained for survival.  It is only when the objective is set to 
maintenance that we are more confident the plasma nutrients will be taken into the 
model.  
 Therefore to gain the benefits that this systems biology model offers we should keep 
to the original objective function of maintenance.   
 We then run different models according to months / seasons and see the flux results 
to identify the model that represents the best nutritional profile / flux through 
methylation reactions.  
 In this way we’re not actually saying one single reaction has to be optimized – which 
is beneficial as in reality we don’t necessarily want to maximize flux through one 
single reaction.  
 What will signpost us to the best model out there? From previous studies it would 
seem a higher methylation potential (higher SAM:SAH metabolite ratio) and higher 
levels of methyl donors & co-factors are associated with reduced loss of imprinting 
at certain genetic loci. We can use this as a starting point.  
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3 Preliminary analysis plan 
 
3.1  Key objectives 
 
Integrate maternal plasma biomarker data into RECON-III to: 
 
A. Describe the seasonal pattern of the 1C metabolome and related metabolic 
pathways to explore whether the observed patterns fit in with existing knowledge of 
metabolism.  Do the metabolites generally co-vary in ways that we expect? 
B. Identify key drivers of methylation potential.  
 
Then integrate the infant epigenomic data to: 
 
C. Explore the extent to which the maternal metabolome is associated with infant 
methylation patterns at key genomic regions.  
D. Model how a maternal metabolome can be optimised e.g. how do we move 
metabolomes associated with suboptimal epigenetic patterns (e.g. loss of 
imprinting) towards a more protective one? 
 
 
3.2  Objective A: Compare fluxes of key reactions by month and season 
 
 Input all the concentration data and obtain the distribution of fluxes through the 
metabolic pathways for each woman.   
 
3.2.1 Primary analysis 
 
 We can focus on main pathways of interest (section 2.6) and summarise the mean 
flux by month of plasma collection. We could initially report these by organ, 
however, our organ of interest (section 2.5) might be the only one we choose to 
finally publish based on the sheer volume of data we will get.  
 We could also repeat an analysis looking at the months corresponding to the peak 
of the dry (Feb – Apr) and peak of the rainy season (July-Oct) (e.g. Table 2).  
 We could test differences in fluxes by month / season using a one-way ANOVA for 
more than two groups (i.e. the months), or the t-test for two groups (i.e. the 
seasons). If the fluxes are not normally distributed we could consider the Kruskal 
Wallis and Wilcoxon Mann-Whitney tests respectively. Considering we have selected 
pathways a priori we could use a cut-off of p<0.05 to determine significant 
differences in fluxes.  
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Table 2:  Mean flux through key 1-carbon reactions in the liver by season  
 
Reaction Equation 
Mean Rainy  
season flux 
Mean Dry 
season flux  
P 
value 
'AHC'     'h2o[c] + ahcys[c]  <=> adn[c] + hcys_L[c] '    
'BHMT'     'hcys_L[c] + glyb[c]  -> dmgly[c] + met_L[c] '    
'CYSTS'     'hcys_L[c] + ser_L[c]  -> h2o[c] + cyst_L[c] '    
'DHFR'     'h[c] + nadph[c] + dhf[c]  <=> nadp[c] + thf[c] '    
'GHMT2r'     'thf[c] + ser_L[c]  <=> h2o[c] + gly[c] + mlthf[c] '    
'GNMT'     'amet[c] + gly[c]  -> h[c] + ahcys[c] + sarcs[c] '    
'METAT'     'h2o[c] + atp[c] + met_L[c]  -> pi[c] + amet[c] + ppi[c]     
'METS'     '5mthf[c] + hcys_L[c]  -> h[c] + thf[c] + met_L[c] '    
'MTHFD'     'nadp[c] + mlthf[c]  <=> nadph[c] + methf[c] '    
'MTHFR3'     '2 h[c] + nadph[c] + mlthf[c]  -> nadp[c] + 5mthf[c] '    
 
 We may also consider more complex multivariate approaches, for example using 
principal components to look at broader-scale flux changes across multiple reactions 
 We could consider taking the women in the two seasons separately and constraining 
two models based on population mean fluxes (i.e. one representative dry season and 
wet season model). We might need to pick more ‘extreme’ individuals to represent 
the seasonal differences. Then we could isolate one organ and perform a flux 
variability analysis (FVA) on our key reactions to see the range of possible fluxes for 
that reaction in the given constraints (Table 3).  
 
Table 3: Example of flux variability analysis to determine maximum and minimum fluxes 
through key 1-carbon reactions by season 
 
Reaction Equation 
Rainy season Dry season 
Min 
flux 
Max 
flux 
Min 
flux 
Max 
flux 
'AHC' 'h2o[c] + ahcys[c]  <=> adn[c] + hcys_L[c] '     
'BHMT' 'hcys_L[c] + glyb[c]  -> dmgly[c] + met_L[c] '     
'CYSTS' 'hcys_L[c] + ser_L[c]  -> h2o[c] + cyst_L[c] '     
'DHFR' 'h[c] + nadph[c] + dhf[c]  <=> nadp[c] + thf[c] '     
'GHMT2r' 'thf[c] + ser_L[c]  <=> h2o[c] + gly[c] + mlthf[c] '     
'GNMT'  'amet[c] + gly[c]  -> h[c] + ahcys[c] + sarcs[c] '     
'METAT' 
'h2o[c] + atp[c] + met_L[c]  -> pi[c] + amet[c] + 
ppi[c] ' 
  
  
'METS' '5mthf[c] + hcys_L[c]  -> h[c] + thf[c] + met_L[c]      
'MTHFD' 'nadp[c] + mlthf[c]  <=> nadph[c] + methf[c] '     
'MTHFR3' 
'2 h[c] + nadph[c] + mlthf[c]  -> nadp[c] + 
5mthf[c] ' 
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 Table 3 gives the range of fluxes but not a precise idea of the ‘true’ solution. We 
could therefore also perform a sampling frame on these reactions to generate 
density plots of the most likely fluxes and map the results to the main pathways 
using the example from Aurich et al. 2014(7) (Figure 7). 
 Due to the number of reactions involved and the redundancy of certain 
metabolic pathways, the flux distributions predicted by the FVA are not unique 
and there exist a large number of alternate optimal solutions. Hence, we use 
methods such as ‘sparseFBA’ to get a unique solution (sparseFBA limits the 
number of reaction fluxes). The idea is that this will produce a clearer signal of 
the effect of our constraints. When we predict a unique solution for each model, 
we can have increased confidence that the differences we see are real, rather 
than just due to the existence of alternative solutions.  This means we need to 
make sure the model is forced to use our key reactions of interest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: An example of how we could summarise the density plots generated by sampling 
analysis to show flux through key reactions by season. 
 
 Because of the limited number of constraints and because of the redundancy of  
Fig. 7: An example of how we could summarise the density plots generated by sampling 
analysis to show flux through key pathways by season. Photo credit: Andrew M Prentice.  
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3.3  Objective B: Identify drivers of methylation potential 
 
 For example, we could we create two representative seasonal models that have the 
mean plasma concentrations from those months, or otherwise choose the two most 
extreme individuals showing greatest variation by season.  
 We would then either optimise models according to our objective function, or just 
keep the fluxes as they are from the mean values (depending on decision from 
section 2.7).   
 If we did choose to optimise the models for an objective function, e.g. GNMT flux to 
represent methylation potential, we could end up with a flux balance analysis along 
the lines of Table 4 below, otherwise we just report the mean fluxes making up our 
models.  
 
Table 4: Example of optimizing a cell line model to maximize flux through GNMT and the 
resulting vector of fluxes through other key 1-carbon pathways to achieve that. 
 
Reaction Equation Flux when GNMT optimised  
‘AHC’     ‘h2o[c] + ahcys[c]   adn[c] + hcys_L[c] ‘ 4.749650462 
‘BHMT’     ‘hcys_L[c] + glyb[c]  -> dmgly[c] + met_L[c] ‘ 0 
‘CYSTS’     ‘hcys_L[c] + ser_L[c]  -> h2o[c] + cyst_L[c] ‘ 0 
‘DHFR’     ‘h[c] + nadph[c] + dhf[c]   nadp[c] + thf[c] ‘ 0.000370376 
‘GHMT2r     ‘thf[c] + ser_L[c]   h2o[c] + gly[c] + mlthf[c] ‘ 0.471297587 
‘GNMT’     ‘amet[c] + gly[c]  -> h[c] + ahcys[c] + sarcs[c] ‘ 4.749650462 
‘METAT’     ‘h2o[c] + atp[c] + met_L[c]  -> pi[c] + amet[c] + ppi[c]  4.749650462 
‘METS’     ‘5mthf[c] + hcys_L[c]  -> h[c] + thf[c] + met_L[c] ‘ 4.749650462 
‘MTHFD’     ‘nadp[c] + mlthf[c]   nadph[c] + methf[c] ‘ 4.080110894 
‘MTHFR3     ‘2 h[c] + nadph[c] + mlthf[c]  -> nadp[c] + 5mthf[c] ‘ 4.749650462 
 
 
 Regardless of whether we pick an objective function or just use the mean values 
from our chosen month / season / extreme individual, we can perform flux variability 
analysis on these models e.g. Table 5.  
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Table 5: Example of FVA using a cell line model where the flux through GNMT has been 
optimized 
 
Reaction Equation Min flux Max flux 
'AHC'     'h2o[c] + ahcys[c]  <=> adn[c] + hcys_L[c] ' 4.749650 4.764032 
'BHMT'     'hcys_L[c] + glyb[c]  -> dmgly[c] + met_L[c] ' 0 2.53E-13 
'CYSTS'     'hcys_L[c] + ser_L[c]  -> h2o[c] + cyst_L[c] ' 0 0 
'DHFR'     'h[c] + nadph[c] + dhf[c]  <=> nadp[c] + thf[c] ' 0.000370 0.000370 
'GHMT2r'     'thf[c] + ser_L[c]  <=> h2o[c] + gly[c] + mlthf[c] ' 0.027421 7.607178 
'GNMT'     'amet[c] + gly[c]  -> h[c] + ahcys[c] + sarcs[c] ' 4.749650 4.749650 
'METAT'     'h2o[c] + atp[c] + met_L[c]  -> pi[c] + amet[c] + ppi[c]  4.749650 4.764032 
'METS'     '5mthf[c] + hcys_L[c]  -> h[c] + thf[c] + met_L[c] ' 4.749650 4.764032 
'MTHFD'     'nadp[c] + mlthf[c]  <=> nadph[c] + methf[c] ' -500 500 
'MTHFR3'     '2 h[c] + nadph[c] + mlthf[c]  -> nadp[c] + 5mthf[c] ' 4.749650462 4.764032197 
 
3.4  Objective C and D: Integration of epigenetic data 
 
 How we integrate the epigenetic data remains an open question pending the 
methylation analysis.  
 We may keep the methylation and metabolome analyses separate, but use the 
former to inform the latter. For example, we could stratify the women as per 
epigenetic outcomes in their children and compare their metabolomes: 
o We could take total mean methylation across the whole genome, or across 
certain classes of gene, and categorise women into two or three groups. 
o We could take one imprinted gene and use a binary loss of imprinting / 
normal imprinting outcome to categorise the women. 
o To be developed.  
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ANNEX 4.2  A Primer on Fourier series regression models and how they 
will be used to back-extrapolate biomarkers 
Seasonal trends are periodic fluctuations around a mean that can be modelled using Fourier 
terms in linear regression models. These models introduce sine and cosine waves to 
represent the seasonal fluctuation of biomarker concentrations.   
Step 1: Calculate the date of measurement (‘booking’ / enrolment date) in radians (‘θ’) 
 The timespan 1st January to 31st December (365 days) can also be represented as 0 
to 2π radians. This is necessary in order to convert time into a cyclical variable, so 
that in a Fourier model, e.g. 31st December is ‘adjacent’ to 1st January: sinθ31/12 ~ 
sinθ1/1 
 The easiest way to do this is represent the date of booking as a value between 0 
and 1 (i.e. a fraction of 365) then multiply that by 2π to express that date in 
radians. 
 Take the example 01/03/2010 as an example of our measurement date. We 
subtract this date from the beginning of the year (01/01/2010) to get the number 
of days into the year our measurement date is: 01/03/2010 – 01/01/2010 = 59 days 
into the year.  
 We express this as a fraction of 365 to get a value between 0 and 1: 59/365 = 0.162 
 We multiply this by 2π to express this in radians (our θ value): 0.162 x 2π = 1.015 
radians 
Step 2: Create the Fourier terms  
 Fourier terms (FTs) take the sine and cosine of our θ values. 
 i.e. first pair of FTs (sin1, cos1) = sin(θ), cos(θ) 
 Second pair (sin2, cos2) = sin(2θ), cos(2θ) 
 Go up to 4 pairs of terms (sin4, cos4). 
 These FTs create cyclical patterns that we can use to describe our seasonal trends. 
Step 3: Decide on whether to transform the biomarker variable 
 Assess the normality of the biomarker data by performing a skewness-kurtosis test. 
 E.g. for folate the data is highly skewed, and log-transforming it creates a normally 
distributed variable. 
 We will therefore use log-transformed folate throughout the following steps. 
 Note in Chapter 4 we use the pre-adjusted log folate, after taking account of BMI, 
age, gestational age and inflammation. In this document we will just take log-folate 
and later adjust for gestational age, to keep the same methodology as  
Step 4: Decide on how many pairs to FTs to keep in the model 
We are going to regress our biomarker of interest (log folate) against the FTs (independent 
variables), successively adding in one pair of terms to find our best fit. E.g. Let us decide the 
seasonal trend for folate: 
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 Regress log folate (alone) to obtain the null model (i.e. no seasonal trend) 
 Store the estimates from this regression (‘estimates A’) 
 Regress log folate against the first pair of FTs (sin1, cos1) 
 Store the estimates (‘estimates B’). 
 Perform a likelihood ratio test (LRT) comparing estimates B with estimates A.  
 If p<0.05 we are justified in keeping that first pair of FTs.  
 If p>0.05 we have no evidence to suggest that adding in the FTs is any better than 
the null model. We would therefore declare there is no seasonal trend. 
 Assuming there is evidence for a seasonal trend we then regress log folate with the 
first two pairs of FTs and store the estimates (‘estimates C’). 
 Perform a LRT comparing estimates C with B to see whether two pairs of FTs fits 
better than one pair. 
 We keep going in this manner until the LRT is not significant (p>0.05), signalling 
there is no extra value in adding the additional pair of terms. 
 For each biomarker we suggest considering a maximum of 4 pairs of FTs.  
 For log folate in MDEG2 we find that 3 pairs of FTs gives us the best fit.  
Step 5: Visualise the seasonal trend 
 It can be helpful at this stage to plot the seasonal trend. 
 For example, with log folate we want to plot the fitted predictions with 3 pairs of 
FTs. 
 To do this regress log folate against 3 pairs of FTs, and store the predicted values. 
These predictions, when plotted against the booking date (θ) will give the 
smoothed seasonal trends.  
 Also store the standard error (SE) of the predicted values if you want to plot the 
95% CIs. Stata has a program to store the SE of the predictions with one command. 
You can then generate the upper and lower intervals using your predicted values ± 
1.96*SE.  
 This is what we get for 3 pairs of FTs for log folate with 95% CIs plotted: 
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This step is what we presented in Chapter 4. For future research we would like to back-
extrapolate the biomarker concentrations to predict their value at the time of 
conception. The following steps show how we use the above Fourier term regression 
models to do that.  
Step 6: Write the linear equation for the seasonal trend 
 Use the constant and coefficients from the linear regression model with the FTs 
to write the linear equations for the predicted values. 
 For example this is the output we get when we regress log folate against 3 pairs 
of FTs: 
 
Log folate Coefficient Std. Err. t P value Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
sin1 .0704035 .0459901 1.53 0.127 -0.0202481 0.1610552 
cos1 -.2125245 .0463401 -4.59 0.000 -0.303866 -0.1211829 
sin2 -.0415646 .0471592 -0.88 0.379 -0.1345207 0.0513915 
cos2 .1484138 .0453836 3.27 0.001 0.0589577 0.2378699 
sin3 .1437096 .0445225 3.23 0.001 0.0559508 0.2314684 
cos3 -.0529964 .0470574 -1.13 0.261 -0.1457518 0.039759 
constant 2.584036 .0326402 79.17 0.000 2.519698 2.648373 
 
 The equation for predicted folate with 3 pairs of FTs is therefore: 
Log Folate (predicted) = 2.584036 + 0.0704035*sin1 -0.2125245*cos1 -0.0415646*sin2 + 
0.1484138*cos2 + 0.1437096*sin3 - 0.0529964*cos3 
Where sin1 = sin(θ), sin2 = sin(2θ) etc. and θ is the date of booking in radians, as per Steps 1 
and 2.  
 This gives us the overall (mean) shape of the seasonal trend for the whole 
population. 
Step 7: Obtain the intercept for the individual values 
 Remember the above equation gives the overall population seasonal trend. The 
coefficients for the FTs describe the shape of the trajectory. 
 The constant (intercept) will shift that trajectory vertically up or down according to 
the individual woman’s actual folate concentration at the time of blood 
measurement (booking). 
 We therefore need to obtain the intercept (Ij) for woman j based on her measured 
concentration at booking (log folatebj).  
 We therefore re-arrange the equation: 
 Intercept (Ij) =  log folatebj - 0.0704035*sin(θbj) +0.2125245*cos(θbj)+ 
0.0415646*sin(2θbj) - 0.1484138*cos(2θbj) - 0.1437096*sin(3θbj) + 
0.0529964*cos(3θbj) 
where θj is the booking date (when folate was measured) for woman j. 
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Step 8: Obtain the date of conception in radians 
 First calculate the date of conception for woman j 
 This is done by subtracting the gestational age (days) from the date of booking. 
 Then follow the process outlined in Step 1 to obtain the date of conception 
expressed in radians (θcj). 
Step 9: Calculate the new Fourier terms 
 Now calculate the new FTs using the date of conception radians. 
o sin1cj = sin(θcj) 
o cos1cj = cos(θcj) 
o sin2 cj = sin(2θcj) etc.  
Step 10: Calculate the predicted biomarker concentration at the time of conception 
 Use the intercepts calculated for each individual (Ij) [step 7] , the coefficients from 
the linear equation [step 6] and the FTs using the date of conception radians [step 
9] to calculate the predicted biomarker concentration at conception: 
Predicted log folate at conception = Ij + 0.0704035*sin(θcj) -0.2125245*cos(θcj) -
0.0415646*sin(2θcj) +  0.1484138*cos(2θcj) + 0.1437096*sin(3θcj) - 0.0529964*cos(3θcj) 
 This takes the plasma concentration of log folate at blood measurement (booking) 
and then tracks back using the seasonal trajectory to the time of conception.  
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Checking the first few entries shows this has worked (using the graph in step 5 to help verify 
the changes make sense):  
     
Booking date Gestational age 
(days) 
Conception date Log folate at 
booking 
 
Predicted log 
folate at 
conception  
30 Jun 10 75 16 Apr 2010 2.901422 2.325179 
14 Jul 10 103 02 Apr 2010 3.091951 2.590727 
21 Jul 12 108 04 Apr 2010 3.468233 3.063819 
29 Jul 10 102 18 Apr 2010 2.861686 2.655936 
21 Jul 13 94 18 Apr 2010 2.183802 1.877994 
 
 Another way to check this has worked is to plot the predicted log folate (with 3 
pairs of FTs) at conception against conception date (θ), using the same method 
outlined in Step 5. If it has worked the graph (predicted conception concentration 
vs. conception date) should be almost identical to the graph in Step 5 (booking 
concentration vs. booking date).  
 
 Note that the shape of the curve is not exactly identical to the booking folate 
seasonal trend. This is because gestational age at booking varies slightly between 
women, so that there is not a straightforward translation of the means and CIs 
along the x-axis. (Strictly, mean gestational age at booking varies across the year). 
Step 11: Adjust the predicted values at conception for gestational age 
 Regress the predicted log folate at conception values against gestational age and 
store the residuals. This is because stage of pregnancy can influence biomarker 
concentrations through haemodilution and other physiological processes.  
 311 
 
Predicted 
folate at 
conception 
Coefficient Std. Err. t P value Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Gestational 
age (days) 
-.0001341 .0014913 -0.09 0.928 -0.0030732 0.002805 
Constant 2.593367 .1510821 17.17 0.000 2.295606 2.891128 
 
 Add the residuals to the intercept (2.593367) to give the final predicted values 
adjusted for gestational age.  
 Finally, calculate the exponentials (of natural log) of the predicted adjusted log 
folate at conception. 
 Example of first few entries below: 
Predicted 
folate at 
conception 
Residuals Intercept Predicted log folate at 
conception adjusted 
for gestational age 
Predicted folate at 
conception 
adjusted for 
gestational age 
(nmol/L) 
2.325179 -.2581314 2.593367 2.335236 10.33189  
2.590727 .0111711 2.593367 2.604538 13.52497  
3.063819 .4849338 2.593367 3.078301 21.72146  
2.655936 .0762461 2.593367 2.669613 14.43438  
1.877994 -.7027685 2.593367 1.890599 6.623332  
  
 Plotting the final shape of the seasonal trend of predicted log folate at conception 
adjusted for gestational age confirms that gestational age does not have a large 
effect on our biomarker concentrations.  
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A comparison with the MDEG Main Study 2014 method 
 For a simplified summary of the methodology refer to the Dominguez-Salas et al. 
(2014; PMID 24781383) paper where the first section of the methodology explains 
the back-extrapolation. In the words of the statistician: “To estimate biomarker 
concentrations at the time of conception we back-extrapolated along a trajectory 
parallel to the seasonal patterns (fitted by Fourier regression) …To account for 
pregnancy-mediated changes in biomarkers the values were further adjusted for 
the gestational age of the infant at the time of measurement.” 
 Note, however, for the paper the MDEG1 main study biomarkers were back-
extrapolated using the Fourier term coefficients from a separate dataset (the 
‘Indicator Group’). 
 The difference in this method is that we are using the seasonal trend from the 
same dataset (MDEG-2) to back-extrapolate the biomarkers; there is no indicator 
group. 
 This is mainly because we have an expanded set of biomarkers for MDEG-2, many 
of which were not included in the Indicator Group. 
 The Indicator Group comprises repeated monthly measures from a cohort of 30 
women followed for one year. The MDEG-2 dataset comprises cross-sectional 
information from different women each month over one year.  
 Why are we justified in back-extrapolating along a seasonal trend trajectory 
generated from the same dataset? 
o Firstly, when we compare the seasonal trends from the MDEG-2 data with 
the Indicator Group data the patterns are very similar, with the peaks and 
troughs of the curves corresponding fairly well (results in Chapter 4).  
o Secondly, inspecting the results of the Fourier term random effects linear 
regression models of the Indicator Group shows that the predicted fit 
explains a much greater proportion of intra-individual variation than inter-
individual variation. This suggests the seasonal differences within an 
individual are much stronger than the between-person differences. 
Therefore the MDEG2 data can still be used to capture seasonal differences 
even though we do not have repeated measures in the same person.  
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ANNEX 4.3  Core one-carbon biomarker details on metabolism and factors affecting plasma concentration 
 
Nutrient Main role in one-carbon pathways 
Correlation 
between plasma 
biomarker & 
intake data 
Do plasma levels 
change in pregnancy? 
Stability on storage and free-
thaw cycles 
Folate The folate assay provides information on 
tetrahydrofolate (THF), which is reduced to methylene-
THF, then to 5-methyl-THF, the form which donates its 
methyl group to homocysteine using vitamin B12(1).  
 
The assay used in MDEG-2 is a total folate assay.  Its 
limitation is that it shows a strong bias for 5-methyl-THF, 
so it does not perform well when the population in 
enriched with the MTHFR 677C->T genetic variant, but 
this allele is present in only 3.2% of the Gambian 
population (Keneba Biobank data). 
Conflicting views: 
some document no 
correlation(2) 
whereas others 
suggest it can 
reflect recent 
intake(3). 
Conflicting views: Slight 
decrease in serum folate 
over pregnancy, after 1st 
trimester(4). Slight increase 
in plasma folate 
gestational week (GW) 9-
16(5) 
 
Folate status alters the 
change in concentration 
during pregnancy in 
betaine, DMG and 
choline(6) 
Stable for storage at -70°C(7,8). 
Stable even at room temperature 
for 72 hours in serum(9). 
 
Degrades rapidly at room 
temperature at DT50 of 45.2 h(10), 
worst in EDTA compared to other 
matrices. 
 
Degrades at -25°C at DT50 of 23.6 
years(10) 
 
Vitamin B12 
(cobalamin) 
Required as a cofactor in the methylation of 
homocysteine by methyl tetrahydrofolate(11).  
Not influenced by 
recent intake(12) 
Decreases over 
pregnancy(4,5,13). 
Stable for storage at -70°C(7,8) 
Stable in EDTA at room 
temperature for 8 days and at -
25°C for 29 years(10) 
Pyridoxal (PL), 
pyridoxal-5’-
phosphate 
(PLP), and 
pyridoxic acid 
(PA). 
 
 
These are 3 of the 7 vitamers that exist for vitamin B6(14). 
In previous studies concentrations of these three 
vitamers have followed a very similar seasonal pattern(2). 
PLP is required to reduce THF to methylene-THF, and is 
also a cofactor in the transsulfuration pathway 
converting homocysteine to cysteine(11).  
Positive 
association(2) 
Gradual decline in PLP 
throughout pregnancy(4), 
especially in 3rd trimester 
(although may not be due 
to haemodilution)(3). 
PA is stable at room temperature 
for 8 days and at -25°C for 29 
years(10). PLP in serum degrades 
over time at -25°C at rate of DT50 = 
14.7 years(10). Note degraded PLP 
tends = recovery of PL, so PL+PLP 
relatively stable, and EDTA inhibits 
degradation(10) 
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Nutrient Main role in one-carbon pathways 
Correlation 
between plasma 
biomarker & 
intake data 
Do plasma levels 
change in pregnancy? 
Stability on storage and free-
thaw cycles 
Riboflavin 
(vitamin B2) 
Required as a precursor to FAD, which is used as 
cofactor for MTHFR to reduce methylene-THF to methyl-
THF(15). 
Erythrocyte 
glutathione 
reductase (EGRAC) 
is more common 
than plasma B2. 
Plasma B2 does not 
seem to vary much 
with intake(3). 
Minor changes only; slight 
increase in third 
trimester(4) 
Accumulates 3-4% per hour for first 
13 hours at room temperature in 
serum, but only marginally in 
EDTA(10) 
Choline Precursor to betaine (two-step oxidation reaction)(16). 
Synthesised endogenously or obtained from diet (good 
sources: red meat, poultry, milk, eggs, fish(17)). 
No 
correlation(2,18,19) 
Increases over pregnancy 
from maternal hepatic 
stores(5,18), used for 
increased 
phosphatidylcholine 
synthesis in favour of 
betaine synthesis(20). 
Concentration maintained 
to allow for active 
transport to foetus(16) 
Free choline in serum accumulates 
3-5% per hour at room 
temperature and 8.68% per year 
stored at -25°C but is stable in 
EDTA(10).  
Betaine Donation of methyl group to homocysteine via betaine-
homocysteine methyl transferase (BHMT)(16). Obtained 
in diet (good sources: wheat bran, wheat germ, spinach, 
beets(17)) or oxidation of choline. Eventually catabolised 
to glycine. 
No correlation(18) 
 
Positive 
association(2) 
Decreases over pregnancy 
to GW24(5,6,18,21) due to 
increased methyl donor 
demand in foetus(22) 
Stable in EDTA at room 
temperature for 8 days and at -
25°C for 29 years(10). 
 
Dimethylglycine 
(DMG) 
Product formed after the betaine has methylated 
homocysteine. Increased DMG levels then inhibit this 
reaction by reducing activity of BHMT(23). Also a 
derivative of glycine(16). 
N/A: an 
intermediary 
metabolite  
Decreases in early 
pregnancy(5), increases 
after GW16(6,18).  
Stable in EDTA at room 
temperature for 8 days and at -
25°C for 29 years(10) 
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Nutrient Main role in one-carbon pathways 
Correlation 
between plasma 
biomarker & 
intake data 
Do plasma levels 
change in pregnancy? 
Stability on storage and free-
thaw cycles 
Methionine Condensed with ATP to form SAM. It can be formed 
from the methylation of Hcy or gained directly from the 
diet. Increased methionine upregulates GNMT(24) 
No correlation(2) Increases over 
pregnancy(21) 
Oxidised to methionine sulfoxide 
over time at -25°C at rate of DT50 = 
5.5 years in serum, but more stable 
in EDTA(10) 
Cysteine An amino acid that can be formed from homocysteine, 
via cystathionine and PLP as a cofactor, through the 
transsulfuration pathway. 
Not assessed in(2) Undocumented Stable in EDTA at room 
temperature for 8 days and at -
25°C for 29 years(10) 
Homocysteine Held in equilibrium with SAH and is either degraded by 
the transsulfuration pathway or methylated by methyl-
THF or betaine to form methionine. 
N/A: an 
intermediary 
metabolite 
Slight decline in first 
trimester(4,5). 
Increase from GW 13-
delivery(21). 
Stable in EDTA at room 
temperature for 8 days and at -
25°C for 29 years(10). Particularly 
stable if plasma separated from 
cells quickly.  Repeated freeze-
thaw cycles may increase 
concentration(3). 
S-adenosyl 
methionine 
(SAM)  
Methylation of cytosine, facilitated by DNA methyl 
transferases (DNMTs), leading to epigenetic 
modifications. Elevated SAM inhibits MTHFR and 
BHMT(25) 
N/A: an 
intermediary 
metabolite 
Undocumented  Concentration after 2nd freeze-
thaw cycle is 3.53% lower than 
after 1st free-thaw cycle (UBC 
unpublished data).  
S-adenosyl 
homocysteine 
(SAH) 
Product formed after SAM methylates an acceptor. 
Increased SAH reduces the SAM methylation reaction 
rates. 
N/A: an 
intermediary 
metabolite 
Undocumented Concentration after 2nd freeze-
thaw cycle is 16.7% higher than 
after 1st free-thaw cycle (UBC 
unpublished data). 
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ANNEX 4.4:  Annotated 1-carbon pathway diagrams 
 
Chapter 3 provides a basic insight into the complexities of one-carbon pathways, but the 
summary remains extremely simplified. One-carbon metabolism is governed by intricately 
controlled feedback loops, which help protect the flux of metabolites through key reactions 
over a range of nutrient and co-factor concentrations(1,2). An example of these complex 
allosteric regulations come from considering what happens when levels of SAM increase, for 
example through increased methionine input. Elevated SAM a) increases SAH, which in turn 
inhibits methyl transferases, b) increases CBS activity (aiding removal of Hcy) and c) inhibits 
MTHFR and BHMT (decreasing the conversion of Hcy to methionine)(3). Since methyl-THF 
binds to (and deactivates) GNMT the reduced levels of methyl-THF brought about by MTHFR 
inhibition in c) help speed up  GNMT activity, decreasing levels of SAM and thus helping 
achieve SAM homeostasis(1). Even with these mechanisms helping to buffer impacts on SAM 
levels, it should be noted that different methyltransferases (MTs) have different Km values 
for SAM (Km: Michaelis constant; the concentration of substrate (SAM) required at half the 
maximum MT reaction velocity). Since DNMTs have low Km values for SAM their velocity 
reaches maximum at low SAM concentrations. Therefore higher SAM concentrations do not 
have as large as impact on DNMTs as for MTs with higher Km values(1). These few examples 
help illustrate why varying nutrient inputs may not impact the one-carbon metabolome in 
ways that might seem intuitive, and a mathematical modelling / systems biology approach 
may help to disentangle the complexities of human metabolism.  
 
The following diagrams show how the interlinking metabolic paths of: 
 
a) Transmethylation 
b) Methionine and homocysteine metabolism 
c) Folate metabolism  
d) Transsulfation pathway 
The subsequent diagrams then show where additional metabolites mentioned in Chapter 4 
(amino acids, formate, decarboxylated SAM) fit within one-carbon pathways: 
 
e) Decarboxylated SAM and the polyamine pathway 
f) The role of formate and its relationship with amino acids 
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Figure A: Transmethylation 
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Figure B: Methionine and homocysteine metabolism 
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Figure C: Folate metabolism 
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Figure D:  Transsulfuration 
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Figure E: Polyamine pathway 
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Figure F: Amino acids and formate 
 
 325 
 
ANNEX 7.1  Selection of B vitamin and folic acid trials detailing dosage and side effect information  
Study Design  Population Micronutrients 
Provided  
Outcome 
investigated 
Results Side effects 
Bhutta Z, et al. 
(2009)(1) 
RCT, daily 
supplementation in 
pregnancy. Fe-Fol 
vs. MMN 
2,378 
pregnant 
women, 
Pakistan 
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (1.4mg), B6, 
B12 (2.6µg), Zn, Cu, Se, 
I (UNIMMAP) 
Birthweight Increase of 70g birthweight in MMN 
arm.  
Comparable rates of self-
reported morbidities 
between arms. Minimal 
reported gastrointestinal 
side effects.  
Brough L, et al. 
(2010)(2) 
RCT, daily 
supplementation in 
pregnancy. MMN 
vs. placebo 
402 
pregnant 
women, UK 
β-carotene, B1, B2 
(2mg), B6, B12 (6µg), 
folic acid (400µg), C, D, 
E, K, Fe, Zn, Mg, I, Cu  
Maternal 
nutrient status, 
birth size 
↑ markers of Fe, folate, B1 and 
vitamin D in MMN arm in third 
trimester. In compliant subset MMN 
arm had ↓SGA infants (borderline 
significance) 
No difference in reported 
side effects.  
Christian P, et 
al. (2003)(3) 
Cluster RCT, daily 
supplementation in 
pregnancy. Vit A 
(control) vs. Vit A + 
FA vs. Vit A + FA + 
Fe vs. Vit A + FA + 
Fe + Zn vs. Vit A + 
Fe + MMN 
4926 
pregnant 
women, 
Nepal 
Vitamin A, folic acid 
(400µg), Fe, Zn, D, E, 
B1, B2 (1.8mg), B6, B12 
(2.6µg), C, K,  niacin, Cu, 
and Mg 
Foetal loss and 
infant mortality 
No effect of any arm on reduction of 
overall foetal loss. In stratified 
analyses the Vit A+FA arm and Vit A 
+ FA + Fe arms ↓ 3-month mortality 
amongst pre-terms compared to 
control. The MMN arm showed ↑ 
risk of mortality in term infants 
(borderline significance).   
No maternal side effects 
reported here.  
Dawson S, et al. 
(2016)(4) 
Meta-analysis of 
21 studies 
supplementing 
with either Omega-
3  or Omega-3 + FA 
+ B6 + B12 in daily 
supplementation 
Range of 
populations 
Folic acid (150 – 
2500μg), omega-3, B6, 
B12 (1.9 µg – 12mg) 
Plasma 
homocysteine 
Trials combining omega-3 with FA 
and B vitamins reduced plasma Hcy 
the most. 
Not reported. 
Ebbing M, et al. 
(2009)(5) 
RCT, daily 
supplementation 
for median 39 
months. 
FA+B12+B6 vs. 
6,837 
participants 
with 
ischaemic 
heart 
Folic acid (800µg), B12 
(400µg), B6 
Cancer 
incidence, 
mortality 
Increased lung cancer risk and cancer 
mortality in FA+B12 arm vs. control. 
No increased risks in B6 arms.  
No minor side effects 
reported but see results 
section for possible 
serious adverse events.  
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Study Design  Population Micronutrients 
Provided  
Outcome 
investigated 
Results Side effects 
FA+B12 vs. B6 vs. 
placebo 
disease, 
Norway 
Fawzi W, et al. 
(2007)(6) 
RCT, daily 
supplementation in 
pregnancy to 6 
weeks post-
partum. MMN + 
Fe-Fol vs. placebo 
+ Fe-Fol 
8,468 HIV-
negative 
pregnant 
women, 
Tanzania 
B1, B2 (20mg), B6, 
niacin, B12 (50 µg), C, E, 
folic acid (800µg) 
Low birth 
weight, 
prematurity, 
foetal death 
15% lower risk of LBW and 67g 
higher birthweight in MMN arm. No 
effect on preterm birth or foetal 
death.  
No difference in maternal 
mortality or miscarriages 
by arm.  
Friis H, et al. 
(2004)(7) 
RCT, daily 
supplementation in 
pregnancy until 
deliver. Fe-Fol + 
MMN vs. Fe-Fol 
1,106 
pregnant 
women, 
Zimbabwe. 
Folic acid, Fe, vitamins 
A, D, E, C, B1, niacin, B2 
(1.6mg), B6, B12 
(4.0µg), Zn, Cu, Se 
Birth outcomes 46g increase in the MMN + Fe-Fol 
arm but borderline significance.  
Maternal side effects not 
reported.  
Galan P, et al. 
(2010)(8) 
RCT, daily 
supplementation 
for median 4.7 
years. Omega 3 vs. 
omega 3 + B vits 
vs. B vits vs. 
placebo 
2,501 
patients 
with a 
history of 
myocardial 
infarction, 
unstable 
angina, or 
ischaemic 
stroke, 
France 
5-
methyltetrahydrofolate, 
B6, B12 (20 μg), omega-
3 fatty acids  
Prevention of 
cardiovascular 
events 
B vitamins arm ↓ plasma 
homocysteine concentrations by 19% 
compared with placebo, but had no 
effect on major vascular events. No 
effect of omega-3 on vascular events 
compared to placebo.  
2.1% of people 
experienced side effects 
(mainly gastrointestinal 
and nausea) in the B 
vitamins group, 
compared with 2.6% in 
the omega-3 fatty acids 
group, and 1.6% in the 
placebo group. 
Hall M, et al. 
(2016)(9) 
RCT, daily 
supplementation 
for 12 weeks. FA 
(800µg) vs. FA 
(400µg) vs. 
creatine vs. 
creatine + FA 
400µg vs. placebo 
622 arsenic-
exposed 
adults, 
Bangladesh 
Folic acid (800µg, 
400µg), creatine 
Plasma choline, 
betaine and 
dimethylglycine 
(DMG) 
concentrations 
FA groups ↑plasma betaine, ↓DMG 
and prevented a ↓ in choline. No 
difference when adding creatine.  
Not reported. 
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Study Design  Population Micronutrients 
Provided  
Outcome 
investigated 
Results Side effects 
Hininger I, et al. 
(2004)(10) 
RCT, daily 
supplementation 
for two months, 
MMN vs. placebo 
100 healthy 
pregnant 
women, 
France 
Folic acid (200µg), 
vitamin C, E, B1, B2 
(1.6mg), B6, B12 (1µg), 
pantothenic acid, β-
carotene, Zn, Mg, Ca 
Plasma 
micronutrient 
levels, oxidative 
stress 
parameters 
↑Folic acid, vitamin C, E, B2, B6 and 
β-carotene concentration in MMN 
arm. No difference in oxidative stress 
parameters. 
Not reported.  
Liu J, et al. 
(2013)(11) 
RCT, daily 
supplementation in 
pregnancy, FA 
(control) vs. FA + 
Fe vs. FA + Fe + 
MMNs 
18,775 
pregnant 
women, 
China  
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (1.4mg), B6, 
B12 (2.6µg), Zn, Cu, Se, 
I (UNIMMAP) 
Perinatal 
mortality, 
neonatal 
mortality, birth 
size, maternal 
nutrient status  
No effect of supplements on 
perinatal mortality. Supplement 
arms ↓ maternal anaemia in third 
trimester (~28% risk reduction). 
No serious adverse 
effects reported. 6% 
reported gastrointestinal 
discomfort in MMN 
group vs. only 2.2% in FA 
controls.  
Kaestel P, et al. 
(2005)(12) 
RCT, daily 
supplementation in 
pregnancy, Fe-Fol 
(control), vs. 15 
micronutrients at 
1xRDA (MMN1) vs. 
15 micronutrients 
at 2xRDA (MMN2) 
2,100 
pregnant 
women, 
Guinea 
Bissau 
Fe, folic acid (400µg, 
800µg), vitamins A, D, 
E, C, B1, niacin, B2 
(1.4mg, 2.8mg), B6, B12 
(2.6µg, 5.2µg), Zn, Cu, 
Se, I (UNIMMAP) 
Birthweight and 
birth outcomes 
MMN1 and MMN2 ↑ birthweight 
compared to control, 53g and 95g 
respectively. No difference in 
proportion of LBW. Larger effect 
with MMN2 in anaemic women (↑ 
birthweight by 218g and ↓LBW risk 
by 31%).  
Lower risk of miscarriage 
in MMN2 group (but not 
MMN1 group) compared 
to control. No difference 
in maternal mortality 
between arms.  
Kirke P, et al. 
(1992)(13) 
RCT, daily 
supplementation 
pre-conception for 
at least two 
months. FA vs. 
MMN vs. FA+MMN 
354 women, 
Ireland 
FA: Folic acid (0.36mg), 
MMN: Vitamins A, D, 
B1, B2 (1.5mg), B6, 
niacin, C, Ca, Fe 
Neural tube 
defects 
No statistical difference in 
prevention of NTDs per arm.  
No statistically significant 
differences in pregnancy 
outcome information by 
trial arm. 
Kumwenda N, et 
al. (2002)(14) 
RCT, daily 
supplementation in 
pregnancy. Fe-Fol 
vs. Fe-Fol + Vit A 
697 HIV-
positive 
pregnant 
women, 
Malawi 
 
 
 
Folic acid (400µg), Fe, 
Vit A 
Birthweight Fe-Fol plus Vit A arm ↑birthweight 
(90g). 
Not reported.  
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Study Design  Population Micronutrients 
Provided  
Outcome 
investigated 
Results Side effects 
Melse-Boonstra 
A, et al. 
(2005)(15) 
RCT, daily 
supplementation. 6 
incremental doses 
of FA vs. placebo 
308 adults 
(50-75y), 
The 
Netherlands 
Folic acid (50-800µg), Plasma betaine 
and 
homocysteine 
(Hcy) 
Plasma concentration of Hcy ↓ as 
↑folate and ↑ betaine. Plasma 
betaine ↑ as FA dose ↑.  
Not reported.  
Moore SE, et al. 
(2012)(16) 
RCT, daily 
supplementation in 
pregnancy. 
Protein-energy (PE) 
+ MMN, PE, MMN, 
Fe-Fol 
620 
pregnant 
women, The 
Gambia 
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (2.8mg), B6, 
B12 (5.2µg), Zn, Cu, Se, 
I, protein, lipids 
Thymic index Not yet reported for primary 
outcome. Secondary outcome 
analysis suggests no influence of 
supplementation on foetal 
growth(17). 
Not yet reported 
Wald N, et al. 
(1991)(18)  
RCT, daily 
supplementation 
pre-conception 
until week 12 of 
pregnancy. FA vs. 
FA + MMN vs. 
MMN vs. placebo 
1,817 
women in 7 
countries 
Folic acid (4mg), MMN:   
Vit A, D, B1, B2 (1.5mg), 
B6, C, nicotinamide  
Neural tube 
defects 
FA groups had ↓ risk of NTDs. No 
protection from MMNs without FA.  
No difference in self-
reported side effects 
between arms.  
Osrin D, et al. 
(2005)(19) 
RCT, daily 
supplementation in 
pregnancy. Fe-Fol 
(control) vs. MMN 
1,200 
pregnant 
women, 
Nepal 
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (1.4mg), B6, 
B12 (2.6µg), Zn, Cu, Se, 
I (UNIMMAP) 
Birthweight, 
gestational 
length 
MMN arm ↑ birthweight by 77g and 
↓ LBW by 25%.  
Fewer miscarriages in the 
MMN arm (5 vs. 2). No 
differences in 
gastrointestinal 
complaints.  
Ramakrishnan 
U, et al. 
(2003)(20) 
Double-blind RCT, 
6 days/week for at 
least two months, 
MMN vs. Fe-only 
873 
pregnant 
women, 
Mexico 
Vitamin A, B1, D, E, B2 
(1.87mg), niacin, folic 
acid (215µg), B6, B12 
(2.04µg), C, Zn, Fe, Mg 
Birth size No effect of multiple micronutrients 
versus iron alone 
None reported.  
Ramakrishnan 
U, et al. 
(2016)(21) 
RCT, daily 
supplementation 
pre-conception to 
conception (mean 
33 weeks). FA vs. 
FA + Fe vs. FA + FE 
+ MMNs 
1,813 
women, 
Vietnam 
Folic acid (2.8mg), Fe, 
A, D, E, C, B1, niacin, B2 
(1.4mg), B6, B12 
(2.6µg), Zn, Cu, Se, I  
Birth outcomes No difference in birthweight, 
gestational age, preterm delivery 
between arms. 
No difference in reported 
side effects by arm. 
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Study Design  Population Micronutrients 
Provided  
Outcome 
investigated 
Results Side effects 
Roberfroid D, et 
al. (2008)(22) 
RCT, daily 
supplementation in 
pregnancy. Fe-Fol 
(control) vs. MMN 
1,426 
pregnant 
women, 
Burkina 
Faso 
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (1.4mg), B6, 
B12 (2.6µg), Zn, Cu, Se, 
I (UNIMMAP) 
Fetal growth MMN arm ↑ birthweight by 52g, no 
difference in risk of LBW 
No difference in 
miscarriage between 
arms. No other maternal 
side effects reported.  
Rumiris D, et al. 
(2006)(23) 
RCT, daily 
supplementation in 
pregnancy. MMN 
vs. Fe-Fol (control) 
Pregnant 
women with 
low 
antioxidant 
status 
Vitamins A, B6, B12 (2.2 
µg), C, E, folic acid (400 
µg), N-acetylcysteine, 
Cu, Zn, Mn, Fe, Ca, Se  
Perinatal 
outcomes 
↓Preeclampsia in the MMN group 
compared to control  
Not reported. 
Rush D, et al. 
(1980)(24) 
RCT, daily 
supplementation in 
pregnancy, 
protein-energy (PE) 
+ MMN vs. MMN 
vs. standard care.  
1,051 
pregnant 
women, 
USA 
Ca, Mg, Fe, Zn, Cu, I, 
Vitamins A, D, E, C, B1, 
B2 (15mg), niacin, B6, 
pantothenic acid, 
biotin, folic acid 
(350µg), B12 (8µg), 
protein, carbohydrate, 
fat 
Birthweight, 
post-natal 
development 
PE+MMN prevented low birthweight 
in mothers who smoked heavily. 
Higher neonatal deaths in 
supplement group 
although not statistically 
significant (and note this 
was in the arm containing 
additional protein-
energy). 
Shankar AH, et 
al. (2008)(25) 
RCT, daily 
supplementation in 
pregnancy, Fe-Fol 
vs. MMN 
31,290 
pregnant 
women, 
Indonesia 
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (1.4mg), B6, 
B12 (2.6µg), Zn, Cu, Se, 
I (UNIMMAP) 
Infant mortality, 
foetal loss, 
birthweight 
↓Early infant mortality (18% 
reduction) in the MMN group 
compared to control. Combined 
foetal loss and neonatal mortality ↓ 
by 11% in the MMN arm. LBW ↓ by 
14% in MMN arm.  
Not reported. 
Tofail F, et al. 
(2008)(26) 
RCT, daily 
supplementation 
week 14 gestation 
to delivery. MMN 
(and early food) vs. 
Fe (30mg)-fol (and 
early food) vs. Fe 
(60mg)-fol (and 
early food) vs. 
2,853 
pregnant 
mothers, 
Bangladesh  
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (1.4mg), B6, 
B12 (2.6µg), Zn, Cu, Se, 
I (UNIMMAP) 
Infant 
development 
No intervention effects on whole 
group, but varying effects of the 6 
different groups for low BMI 
mothers.  
Not reported. 
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Study Design  Population Micronutrients 
Provided  
Outcome 
investigated 
Results Side effects 
MMN (normal 
food) vs. Fe 
(30mg)-fol (normal 
food) vs. Fe 
(60mg)-fol (normal 
food) 
Toole J, et al. 
(2004)(27) 
RCT, daily 
supplementation 
for mean 20 
months, high dose 
vs. low dose B6, 
B12, FA.  
3,680 adults 
with non-
disabling 
cerebral 
infarction, 
USA, 
Canada 
Scotland 
High dose: B6, B12 
(0.4mg), folic acid 
(2.5mg) 
 
Low dose: B6, B12 
(6µg), folic acid (20 µg) 
Plasma 
Homocysteine, 
stroke 
Plasma Hcy ↓ by 2µmol/L in high 
dose group compared to low dose 
group. No effect on stroke or death.   
No significant differences 
between groups for 
itching, skin rash, or 
gastrointestinal 
complaints. 
West K, et al. 
(2014)(28) 
RCT, daily 
supplementation in 
pregnancy to 12 
weeks postpartum, 
Fe-Fol vs. MMN. 
44,567 
pregnant 
women, 
Bangladesh 
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (1.4mg), B6, 
B12 (2.6µg), Zn, Cu, Se, 
I (UNIMMAP) 
Birth outcomes, 
6-month infant 
mortality 
No effect on 6-month infant 
mortality. MMN arm ↓ pre-term 
birth by 15% and ↓LBW  by 12%. 
No differences in 
morbidities between 
arms.  
Zagré N, et al. 
(2007)(29) 
RCT, daily 
supplementation in 
pregnancy, Fe-Fol 
vs. MMN. 
3,670 
pregnant 
women, 
Niger 
Fe, folic acid (400µg), 
vitamins A, D, E, C, B1, 
niacin, B2 (1.4mg), B6, 
B12 (2.6µg), Zn, Cu, Se, 
I (UNIMMAP) 
Birthweight Birthweight 67g higher in MMN arm 
compared to Fe-Fol arm.  
Miscarriages and 
maternal deaths were 
comparable in both 
groups 
Zeng, L et al. 
(2008)(30) 
Cluster RCT, daily 
supplementation in 
pregnancy. FA 
(control) vs. Fe-Fol 
vs. MMN 
5,828 
pregnant 
women in 
China  
Fe, folic acid (400 µg), 
Zn, Cu, Se, I, Vitamins A, 
B1, B2 (1.4 mg), B12 
(2.6µg), D, C, E, niacin. 
Birth size Birthweight 42g higher in MMN 
group compared to FA group. Fe-Fol 
reduced risk of pre-term delivery.  
No differences in 
perinatal mortality 
between groups.  
Abbreviations: BMI, body mass index; FA, folic acid; Fe-Fol, iron-folic acid supplement; Hcy, homocysteine; LBW, low birthweight; MMN, multiple micronutrient supplement; 
NTD, neural tube defect; RCT, randomised controlled trial; RDA, recommended daily allowance; UNIMMAP, United Nations International Multiple Micronutrient Preparation 
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ANNEX 9.1  Candidate exposures to consider in future epigenetic research 
in The Gambia 
 
Microbiome 
It is now well documented that the gut microflora influence a multitude of metabolic 
processes in the host(1), and that some of these processes are associated with a range of 
outcomes such as obesity, insulin resistance and glucose homeostasis(2,3). There is evidence 
that diet can affect microbiota composition(4–6). The intake of polysaccharides, 
oligosaccharides and other non-digestible carbohydrates are of particular interest, since 
these are the forms of carbohydrate that pass into the colon and can be fermented by the 
microbiota. In turn, the microbiota produce a number of metabolites that could influence 
one-carbon methyl donor concentrations(7) and possibly also histone acetylation 
processes(8,9). The most documented metabolites include short-chain fatty acids, choline and 
bile acid derivatives(10). However, some species of bacteria are also thought to be able to 
produce riboflavin (e.g. L. lactis, L. fermentum, L. plantarum) and folate (multiple strains of 
Lactobacillales)(7). There are several reviews that draw together animal and in vitro  
experimental data to explore how the metabolites produced by the microbiome could 
influence epigenetic processes in the host(11,12). However, there is a dearth of human in vivo 
evidence linking the microbiome with host epigenetic processes, although this research gap 
has been acknowledged and there are calls for more integrative research to address this(13). 
For example, there is preliminary evidence from a pilot study in humans that gut microflora 
composition may be associated with DNA methylation(14). However, this research has not 
been in the intergenerational setting, and further investigation is required as to whether the 
maternal microbiome can influence offspring epigenetics. 
 
Other nutritional influences 
Whilst a metabolomics approach outlined above would cover a wide breadth of metabolic 
networks, there are a two other specific nutrients of interest to consider: polyunsaturated 
fatty acids (PUFAs) and vitamin C. Several studies indicate that increased consumption of ω-
3 PUFAs is associated with reduced homocysteine levels(15) and there is increasing interest as 
to whether epigenetic mechanisms are affected. In rodent models, providing dams a diet 
with excess folic acid and restricted vitamin B12 (reflecting the nutritional status of many 
rural Indian mothers) is associated with increased maternal oxidative stress, lower offspring 
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placental and brain docosahexaenoic acid (DHA) concentration, and decreased placental 
global methylation(16). However, maternal dietary supplementation with PUFAs then partially 
ameliorates the disrupted one-carbon metabolism associated with this diet(17).  One potential 
mechanism is through PUFAs up-regulating enzymes responsible for the methylation of 
homocysteine to methionine(18), which in theory could increase the SAM:SAH ratio and help 
overcome the impact of reduced MTHFR activity brought about by the restricted vitamin 
B12. An additional hypothesis describes how a decreased maternal PUFA intake may increase 
the availability of methyl groups for DNA methylation. This is because there would be 
reduced PUFAs available for phosphatidylcholine (PC) synthesis through the 
phosphatidylethanolamine N-methyltransferase (PEMT) pathway, a process that requires 
three methyl groups from SAM for each molecule of PC formed. The disturbance to methyl 
balance brought about by low PUFA levels is therefore hypothesised to alter epigenetic 
programming of placental genes, increasing the risk of aberrant methylation in offspring and 
adverse pregnancy outcome(19). Human evidence at the intergenerational level, however, is 
currently limited to a study by Lee et al. (2013). Here 261 mothers were given either 400mg 
of ω-3 PUFA or placebo daily from approximately 18 weeks gestation to birth. Amongst 
mothers supplemented with PUFAs there was increased global methylation (measured at 
LINE-1 repetitive elements) in offspring of mothers who smoked(20) and increased offspring 
IGF2 promoter 3 methylation in pre-term infants(21).   
Vitamin C may be influential during the process of active erasure of methylation marks 
(demethylation), predominantly in the paternal genome immediately after fertilization 
between the zygote and blastocyst stage(22). In demethylation, 5-methylcytosine (5mC) can 
be sequentially oxidised to different states by ten-eleven translocation (TET) dioxygenases 
that use vitamin C (ascorbate) as a co-factor(23). 5mC is first oxidised to 5-
hydroxymethylcytosine (5hmC), and then in turn to 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC). Via a base excision repair mechanism 5fC or 5caC can be converted 
to an unmodified cytosine(23). Recent studies, however, have indicated that there may be 
several different mechanisms for demethylation, and that TET-mediated pathways may only 
account for 25% of paternal genome demethylation(22). Despite this, there is some 
preliminary evidence that vitamin C remains a potentially important contributing factor to 
consider in epigenetic processes during early embryogenesis. In vitro studies, for example, 
indicate that adding vitamin C to mouse or human embryonic stem cells increases activity of 
TET enzymes, with active demethylation seen in the germline and associated gene 
expression changes(24,25). In vivo studies will be required to validate these observations.  
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Oxidative stress 
Menezo et al. (2016)(26) make a strong case for considering the role of oxidative stress when 
considering exposures affecting DNA methylation. They summarise evidence suggesting that 
increased oxidative stress is associated with dysregulated DNA methylation.  This may be 
linked to the one-carbon cycle given that two of the most powerful antioxidants are 
glutathione and hypotaurine, products of the transsulfuration pathway, both of which are 
abundant in the genital tract. The authors suggest that it is particularly at the stage of 
maintaining the parental imprints post-fertilization when oxidative stress could affect 
methylation. Potential mechanisms for the association between oxidative stress and 
methylation are still being investigated, but one hypothesis is that guanine is the nucleotide 
most susceptible to oxidation, and therefore if not repaired could affect the methylation that 
would occur at a CpG site. Free-radical mediated oxidation of cytosine also occurs, forming 
5hmC, which as described above, can lead to demethylation. Together such alterations at 
the CpG level could affect the affinity of transcription factors with implications for chromatin 
organisation.  Another potential mechanism the authors present suggests the presence of 
reactive oxygen species (ROS) may directly affect the expression of DNA methyltransferase.  
The role of homocysteine in all this is complex. Homocysteine is required as a precursor along 
with serine to form cystathioinine, cysteine and then the anti-oxidant glutathionine in the 
transsulfuration pathway. However, excess homocysteine may increase oxidative stress, 
possibly through nitric oxide formation(27) or through several other routes to ROS production 
resulting from the oxidation of its thiol group(28,29). Despite the fact the mechanisms remain 
to be elucidated fully, collecting information on glutathione and species of ROS may help 
address the question of whether some of the methylation disturbances are due to oxidative 
stress mechanisms, and the role that imbalances in one-carbon metabolites may play in 
dysregulating homocysteine recycling(30).  
Inflammation and infection 
Claycombe et al. (2015)(31) review some of the intricate ways that infection, inflammation, 
nutrition and epigenetics can be interlinked. They describe existing animal and in vitro 
evidence suggesting the presence of certain pathogens can influence T cell differentiation, 
macrophage phenotype and cytokine production through mechanisms thought to involve 
DNA methylation and histone modifications. They hypothesise that inflammation during 
pregnancy may alter epigenetic regulation of immune function, which may contribute 
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towards inflammatory components of chronic diseases such as cardiovascular disease, 
obesity and asthma. Nutrition can modulate these relationships due to direct effects on 
inflammation, for example, the pro-inflammatory effects of a high saturated fat intake and 
the potential anti-inflammatory effects of vitamin D and folic acid. The authors highlight the 
fact that human in vivo evidence for causal relationships between maternal infection, 
offspring epigenetic effects and adverse phenotypes is scarce.  
Recent animal models, however, do suggest there is rationale for exploring these factors 
further. A mouse study subjected pups to bacterial infection in utero and found a number of 
methylation differences at genetic loci related to the toll-like receptor (TLR) signalling 
pathway, which correlated with gene expression(32). The TLR pathway is involved in innate 
immunity, promoting a pro-inflammatory response which could in turn be associated with 
phenotypes such as pre-term birth(32). There is also growing evidence to suggest that pups 
exposed to various viruses and bacteria in utero go on to develop neurodevelopmental 
disorders, potentially mediated by methylation at genes such as MECP2, reviewed in Weber-
Stadlbauer (2017)(33).  
Infection could also influence epigenetic mechanisms via oxidative stress (see above), since 
the presence of pathogens can trigger an inflammatory response in the host that affects 
redox balance, increasing oxidative stress(34,35).  
Toxin exposure 
There is a developing literature on maternal exposure to toxins and offspring DNA 
methylation effects, especially linked to arsenic exposure, tobacco smoke, air pollutants, 
phthalates and bisphenol A(36). In The Gambia maternal plasma markers of aflatoxin exposure 
divided into high and low exposure groups have been associated with offspring differential 
methylation at 71 CpGs, including genes associated with inflammatory  response(37). Of the 
toxins that may demonstrate a seasonal trend in The Gambia pesticide exposure may be the 
first choice to focus on, given it appears to affect DNA methylation not only in the person 
directly exposed(38) but potentially intergenerationally as well(39).  
Paternal influence 
There is growing interest in the potential for paternal exposures to affect the infant 
epigenome transgenerationally via sperm methylation profiles(40,41). Illum et al. (2018)(42) 
have reviewed mouse experiments altering paternal diet and detecting changes in either 
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sperm methylation or offspring methylation, which are also associated with offspring 
phenotype. To date there is preliminary, although conflicting, evidence to suggest that both 
paternal high-fat or low-protein diets may affect sperm methylation, and that these changes 
could contribute to adverse phenotypes such obesity and insulin resistance seen in the 
offspring(42). Despite the fact mechanisms and consistent patterns remain to be determined 
there is already a call for researchers to consider joint parental contribution in 
intergenerational and transgenerational epigenetics studies(43,44).  
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